

# Adherence to insulin in children and young people with Type 1 diabetes

Jordan Clarke  
September 2019

Department of Women's and Children's Health  
Institute of Translational Medicine

Thesis submitted in accordance with the requirement of the University of  
Liverpool for the degree of Master of Philosophy

Supervisors:  
Dr Daniel Hawcutt  
Dr Mark Deakin

# Abstract

## Introduction

Type 1 diabetes is an autoimmune condition that results in the inability of the pancreas to produce insulin. The mainstay of treatment for this disease is administration of exogenous insulin. Adherence to this therapy is vital in avoiding both life-threatening short-term complications and life-limiting long-term complications. Despite its importance, it is an area that many children and young people struggle with. While there are a huge number of studies that attempt to identify individual factors affecting adherence, to date there have been no studies that attempt to draw these factors together into a single systematic review.

## Aims

The aim of this project is to undertake a systematic review of insulin adherence in children and young people with T1DM, to understand what impact the factors studied have, and determine the areas that have/have not been researched with a view to guiding future research.

## Methods

A systematic review was undertaken following a search of five medical databases aided by extensive training on optimising searches. The PICO framework was used to create inclusion/exclusion criteria that was used to decide which studies to include in the review based on agreement of two reviewers. The key inclusion criteria stated that study participants must be humans, under the age of 18, with a diagnosis of T1DM and receiving insulin therapy. All study types that contained primary data were included.

Included studies had relevant information entered into a data extraction tool, which could then be used to perform quality assessments and thematic analysis.

## Results

One thousand three hundred and six studies were identified, of which 76 were included in the final analysis. Two hundred and thirty-six factors were assessed for association with adherence, using 38 different methods. Eleven factors were assessed by four or more studies. Age was the most commonly assessed factor (33 studies), followed by HbA1c/glycaemic control (20 studies), duration of diabetes (19 studies) and gender (15 studies). There were 210 factors (89%) that were only considered in a single study.

Overall, 9 969 children and young people have been included in studies assessing adherence to insulin (mean: 133, range: 28 to 1 028). Formal meta-analysis was not able to be performed due to the large number of different methods of measuring adherence, methods of data presentation and differences in populations studied. Amongst the factors that have been assessed by multiple studies, there were some that displayed good agreement between studies on the direction of the effect on insulin adherence. Increasing age, depression (in the child/young person) and smoking frequency showed good agreement between studies for decreased adherence. Higher self-efficacy, family support, exercise frequency, increased responsibility taken by the child, higher socio-economic status and better parent-child relationship showed good agreement between studies for improved insulin adherence.

Factors were divided into overarching themes: demographics, past medical history, diabetes management, psycho-social or family dynamics. Factors assigned to the demographics theme were the most frequently assessed by multiple studies. The most commonly assigned theme was the psycho-social theme, though the vast majority (93.1%) of these factors were assessed by a single study.

#### PENDANT Study

This prospective cohort study was designed with the aim of assessing the correlation between disease severity at diagnosis with a variety of psycho-social outcomes with a view to exploring their relationship with later adherence to insulin therapy. Recruitment for the study was interrupted by the COVID-19 pandemic after two patients had entered the study. The findings of this initial recruitment phase and the systematic review will be used to improve the study going forwards.

#### Conclusion

Insulin adherence has been assessed in multiple studies, but the variety of methods and heterogeneous populations make comparisons difficult. Harmonising methodologies for assessing adherence to insulin would enable improved assessment of factors affecting adherence to this critical medication and lead to the identification of potential barriers to target to improve adherence in T1DM in the future. Future studies could aim to assess modifiable factors that are currently under-researched, while also aiming to assess adherence in a way that considers the complex nature of adherence to insulin therapy.

## Acknowledgements

The author of this thesis would like to thank several individuals and groups of people, without whom, this work would not have been possible.

Firstly, to Mrs Fariba Bannerman of the Alder Hey Library and Knowledge Service, who provided invaluable training into conducting database searches and was instrumental in sourcing studies that were not freely available in the public domain. Without her contribution, the search upon which the quality of the entire review rests would have been much more difficult or even impossible to accomplish and would have included half the number of studies had she not tirelessly worked to find every study that was requested.

Next, to the foreign language data extractors/inclusion checkers. Their generous contribution allowed the study to broaden its scope as much as possible and their efforts in determining if the studies should be included and extracting the data when necessary allowed for a degree of accuracy and nuance that would have been impossible through any automated translation. These individuals are:

- Dr Anna Schugal (German)
- Mr Jordi Saez Dominguez (Spanish)
- Miss Amandine Charras (French)
- Dr Kalle Hoppu (Finnish)
- Dr Francine Verhoeff (Dutch)
- Mrs Maria Cursino (Portuguese)
- Dr Keiko Hikino (Japanese)
- Mrs Silvia Ravalli (Italian).

Next, to the second checker for the systematic review, Mr Dylan Griffiths, who kindly devoted hours of time to this essential role in ensuring the accuracy of this review.

To the entire Diabetes Team at Alder Hey Children's Hospital, who made me feel so welcome from the moment I arrived and who without hesitation took the time to help recruit patients to the PENDANT study. The things that I have learned from these individuals have undoubtedly contributed to my ability to write this thesis and have improved my insight into the clinical world of diabetes in children in general. To Miss Camilla Spengler and Miss Jacqueline Jones whose administrative help in



identifying patients for recruitment was invaluable. To Dr Lyndsey Carlson, whose expertise in all of the psycho-social measures in the PENDANT study and whose help in identifying the themes used in the systematic review was irreplaceable.

Lastly, to my supervisors, Dr Daniel Hawcutt and Dr Mark Deakin. The phrase “could not have managed without” does not adequately describe their contribution to this thesis as well as my development as clinician and academic as a whole. Their support and expertise frequently went beyond the remit of MPhil supervisors and this is something that I will always be grateful for.

## Contents

Abstract.....	2
Acknowledgements .....	4
List of tables .....	8
List of figures.....	11
List of abbreviations.....	13
1. Introduction .....	16
1.1. Pathophysiology.....	16
1.2. Epidemiology .....	21
1.3. Treatment .....	25
1.3.1. Treatment Adherence.....	33
1.4. Complications of T1DM.....	34
1.4.1. Short-Term – Hypoglycaemia.....	34
1.4.2. Short-Term – Hyperglycaemia and Diabetic Ketoacidosis .....	35
1.4.3. Long-Term – Retinopathy .....	38
1.4.4. Long-Term – Peripheral Neuropathy .....	40
1.4.5. Long-Term – Nephropathy.....	41
1.4.6. Long-Term – Cardiovascular .....	41
1.5. Burden of Diabetes .....	42
1.5.1. Economic.....	42
1.5.2. Psychological Impact.....	45
1.6. Aims of Thesis .....	46
2. Systematic Review Methodology.....	47
2.1. Background .....	47
2.2. Methods.....	47
2.2.1. Inclusion and Exclusion Criteria .....	47
2.2.2. Identification of Relevant Studies.....	50
2.2.3. Design of Search Strategy .....	50
2.2.4. Selecting Eligible Studies for Inclusion.....	51
2.2.5. Data Extraction .....	52
2.2.6. Quality Assessment of Studies.....	53
2.2.7. Grading of Evidence .....	54
2.2.8. Data Analysis.....	57
3. Results.....	58
3.1. Study Selection .....	58

3.2.	Quality of Included Studies .....	60
3.3.	Study Characteristics.....	60
3.4.	Methods of Measuring Adherence .....	61
3.5.	Range of Factors Assessed and Themes .....	67
3.6.	Primary Outcome: Factors Affecting Adherence to Insulin Therapy.....	75
3.6.1.	Age .....	75
3.6.2.	HbA1c/Glycaemic Control.....	89
3.6.3.	Duration of Diabetes.....	98
3.6.4.	Gender .....	105
3.6.5.	Perceptions of Family Conflict .....	111
3.6.6.	Depression .....	118
3.6.7.	Self-Efficacy.....	125
3.6.8.	Perceptions of Family Support.....	129
3.6.9.	Perceptions of Family Cohesion.....	133
3.6.10.	Diabetes Knowledge .....	137
3.6.11.	Exercise Frequency .....	139
3.6.12.	Less Frequently Assessed Factors .....	143
3.6.13.	Agreement of Studies .....	165
3.7.	Secondary Outcomes .....	169
3.7.1.	Reasons for Non-Adherence .....	169
4.	Thematic Analysis .....	171
5.	PENDANT Study .....	174
5.1.	Introduction .....	174
5.2.	Protocol.....	175
5.3.	Ethical Approval .....	178
5.4.	Ethical Amendments.....	178
5.5.	Aims .....	178
5.6.	Methods.....	179
5.7.	Psycho-social measures .....	180
5.8.	Recruitment .....	183
5.9.	Results.....	183
6.	Discussion .....	187
6.1.	Systematic Review .....	187
6.2.	PENDANT Study .....	191
7.	Conclusion.....	193
8.	References .....	195

## List of tables

*Table 1.1 Types and prevalence of different type of diabetes in children. Adapted from: Diabetes UK (9). Legend; T1DM: Type 1 Diabetes. T2DM: Type 2 Diabetes. MODY: Maturity-Onset Diabetes of the Young. CFRD: Cystic Fibrosis-Related Diabetes. \_\_\_\_\_ 22*

*Table 1.2 Incidence of Type 1 Diabetes throughout the world. Adapted from Diabetes UK (19). \_\_\_\_\_ 22*

*Table 1.3 Summary of types of insulin, their times of action and their roles in treatment of T1DM. Legend; insulin NPH: insulin Neutral Protamine Hagedorn. Adapted from (25,27). \_\_\_\_\_ 27*

*Table 1.4 Insulin pumps currently available in the UK and their features. Legend; U: units, U/h: units per hour, Y: yes, N: no. Adapted from (37). \_\_\_\_\_ 29*

*Table 1.5 Summary of core outcome measures for T1DM in children, adapted from (42). Legend; HbA1c: glycated haemoglobin, BMI: Body Mass Index \_\_\_\_\_ 32*

*Table 1.7 Prevalence of diabetic retinopathy over time. Adapted from Fong et al. (76) \_\_\_\_\_ 39*

*Table 1.8 Stages of diabetic retinopathy. Adapted from Fong et al. (76) \_\_\_\_\_ 39*

*Table 1.9 Healthcare costs associated with Type 1 Diabetes Mellitus. Adapted from Streisand et al. (90) \_\_\_\_ 44*

*Table 2.1 Inclusion and Exclusion Criteria for determining relevant studies. Legend; T1DM: Type 1 Diabetes, N/A: not applicable, PICO: framework used to construct criteria (Population, Intervention, Comparison and Outcomes). \_\_\_\_\_ 49*

*Table 2.2 Meanings of GRADE ratings. Legend; GRADE: Grading of Recommendations, Assessment, Development and Evaluations. Adapted from (115). \_\_\_\_\_ 56*

*Table 3.1 Different methods of adherence assessment used in the included studies and the number of studies that used them. SCI: Self-Care Inventory, SCI-R: Revised Self-Care Inventory, DSMP: Diabetes Self-Management Profile, DRAQ: Diabetes Regimen Adherence Questionnaire, MPR: Medication Possession Ratio, IDDM: Insulin Dependent Diabetes Mellitus, ChEDE: Child Health Eating Disorder Examination, DFRQ: Diabetes Family Responsibility Questionnaire, PedsQL: Paediatric Quality of Life Questionnaire, PAID: Problem Areas in Diabetes Questionnaire, SED: Self-Efficacy for Diabetes Questionnaire, DSCI: Diabetes Self-Care Inventory. \_\_\_\_\_ 64*

*Table 3.2 Changes made to the SCI to create the SCI-R. Legend; SCI: Self-Care Inventory, SCI-R: Revised Self-Care Inventory, N/A: not applicable. Adapted from (187,188). \_\_\_\_\_ 65*

*Table 3.3 List of factors checked for association for adherence and the number of studies that assessed them. Legend; DSMP: Diabetes Self-Management Profile, QoL: Quality of Life, DSS: Diabetes Social Support questionnaire, ADHD: Attention Deficit Hyperactivity Disorder, OCD: Obsessive Compulsive Disorder, PTSD: Post-Traumatic Stress Disorder, HbA1c: glycated haemoglobin, BMI: Body Mass Index, RCT: Randomised Control Trial, BGM: Blood Glucose Monitoring, GAD: Generalised Anxiety Disorder. \*Self-efficacy refers to the ability of the child/young person to complete a range of diabetes management tasks, as perceived by the child/young person. \_\_\_\_\_ 73*

*Table 3.4 Summary of results of studies that assessed the association between adherence and age. Legend: ADQ: Adherence in Diabetes Questionnaire, DRCQ: Diabetes Regimen Compliance Questionnaire, DFRQ: Diabetes Family Responsibility Questionnaire, MPR: Medication Possession Ratio, SCI: Self-Care Inventory, SCI-R: Revised Self-Care Inventory, Y: yes, N: No, r: Pearson correlation coefficient value,  $\beta$ : beta-value,  $R_2$ : multiple regression analysis value,  $R_{1,2}$ : zero order correlation value, HbA1c: glycated haemoglobin, MRA: Multiple Regression Analysis. Significant results indicating a positive relationship between increasing age and adherence are coloured green and significant results indicating a negative relationship between increasing age and adherence are coloured orange. Results that were not significant have been left white. \_\_\_\_\_ 88*

*Table 3.5 Studies that assessed the relationship between adherence and HbA1c/glycaemic control and their results. Legend; HbA1c: glycated haemoglobin, mmol/mol: millimoles per mole, DSMP: Diabetes Self-Management Profile, SCI: Self-Care Inventory, SCI-R: Revised Self-Care Inventory, r: Pearson correlation coefficient value, ADQ: Adherence in Diabetes Questionnaire, Y: yes, N: no. Statistically significant results that demonstrate HbA1c decreases/glycaemic or metabolic control improves with improved treatment adherence are coloured in green. Results that were not statistically significant have been left white. One study assessed correlations between 3 groups, with 1 of these correlations being significant and the others not significant; this result has been coloured yellow. \_\_\_\_\_ 97*

*Table 3.6 Studies assessing the relationship between disease duration and treatment adherence and their results. Legend; ADQ: Adherence in Diabetes Questionnaire, SCI-R: Revised Self-Care Inventory, DSMP: Diabetes Self-Management Profile, DFRQ: Diabetes Family Responsibility Questionnaire, MRA: Multiple Regression Analysis, MDI: Multiple Daily Injections, CSII: Continuous Subcutaneous Insulin Infusion, Y: yes, N: no, NK: Not Known, r: Pearson correlation coefficient value,  $R_{1,2}$ : zero order correlation value,  $R_2$ : Multiple Regression Analysis score. Statistically significant results suggestive of worsening adherence with increasing disease duration are coloured orange. Results left in white are not statistically significant. \_\_\_\_\_ 104*

*Table 3.7 Summary of results of studies that assessed the association between adherence and age. Legend; Y: yes, N: no, NK: not known, N/A: not applicable, PedsQL: Paediatric Quality of Life Inventory, DFRQ: Diabetes Family Responsibility Questionnaire, MPR: Medication Possession Ratio, ANOVA: Analysis of Variance, r: Pearson correlation coefficient value. Significant results where adherence was shown to be better in males have been highlighted in blue and significant results where adherence was shown to be better in females have been highlighted in orange. Result that were not statistically significant have been left in white. NB: whether the numerical value is positive or negative is not always consistent depending on the number each respective study assigned to which gender. \_\_\_\_\_ 110*

*Table 3.8 Studies assessing the relationship between family conflict and adherence and their results. Legend; Y: yes, N: no. r: Pearson correlation coefficient value,  $\beta$ : beta value. Statistically significant results suggesting that family conflict has a negative effect upon adherence are coloured orange. Insignificant results have been left white. \_\_\_\_\_ 117*

*Table 3.9 Studies assessing the relationship between depression in children and their mothers and treatment adherence, and their results. Legend; SCI: Self-Care Inventory, Y: yes, N: no, NK: Not Known, r: Pearson*

correlation coefficient value,  $R_2$ : multiple regression analysis value. Significant results suggesting that adherence worsens with depression are coloured in orange. Insignificant results have been left white. \_\_\_\_\_ 124

Table 3.10 Summary of studies assessing the relationship between the child's self-efficacy and adherence.

Legend; SCI: Self-Care Inventory, Y: yes, N: no,  $R_{1,2}$ : zero order correlation value,  $r$ : Pearson correlation coefficient value,  $\beta$ : beta value. Statistically significant results that suggest a positive relationship between self-efficacy and adherence are coloured green. Statistically insignificant results have been left white. \_\_\_\_\_ 128

Table 3.11 Summary of studies that assess the relationship between familial support and adherence. Legend; Y: yes, N: no,  $r$ : Pearson correlation coefficient value,  $R_{1,2}$ : zero order correlation value. Statistically significant results indicative of a positive relationship between familial support and adherence have been coloured green.

Results that were not statistically significant have been left white. \_\_\_\_\_ 132

Table 3.12 Studies assessing the relationship between perceptions of family cohesion and adherence. Legend; Y: yes, N: no,  $r$ : Pearson correlation coefficient value. Statistically significant results that suggest that adherence improves with increasing family cohesion are coloured in green and statistically significant results suggesting that adherence worsens with increasing family cohesion are coloured orange. Results that were not statistically significant have been left white. \_\_\_\_\_ 136

Table 3.13 Studies assessing the association between diabetes knowledge and treatment adherence. Legend; Y: Yes, N: No, NK: Not Known, DRAQ: Diabetes Regimen Adherence Questionnaire,  $r$ : Pearson correlation value,  $\beta$ : beta-value. Statistically significant results suggesting a positive relationship between diabetes knowledge and adherence have been coloured green. Results that were not statistically significant have been left white. \_\_\_\_\_ 138

Table 3.14 Studies assessing the association between exercise frequency and adherence. Legend; Y: Yes, N: No, T1: Time 1 (study entry), T2: Time 2 (follow-up), SCI: Self-Care Inventory, DSMP: Diabetes Self-Management Profile,  $r$ : Pearson correlation coefficient score. Statistically significant results that suggest adherence improves with exercise have been coloured green. Statistically insignificant results were left white. \_\_\_\_\_ 142

Table 3.15 Summary of factors that were assessed by 3 or fewer studies. Legend; N: sample size,  $n$ : number of studies, C: child, P: parent, N: nurse,  $r$ : correlation,  $\beta$ : beta-value, Y: yes, N: no, DSMP: Diabetes Self-Management Profile, HFS: Hypoglycaemia Fear Score, AG: Agreement Group, EG: Error Group, MG: Management Group, DRCQ: Diabetes Regimen Compliance Questionnaire, DSCQ: Diabetes Self-Care Activities Questionnaire, CCTI: Child Compliance Telephone Interviews, CSII: Continuous Subcutaneous Insulin Infusion, MDI: Multiple Daily Injections. Those in the "Agreement Group" were deemed as being compliant. Those in the "Error Group" were deemed as being intentionally non-compliant. Those in the "Management Group" were deemed as being unintentionally non-compliant. Groups A and B were statistically identical samples drawn from two different populations. \_\_\_\_\_ 164

Table 3.16 Factors assessed by multiple studies and the agreement of those studies. Legend; CSII: Continuous Subcutaneous Insulin Infusion, MDI: Multiple Daily Injections, BMI: Body Mass Index. Colour coding: dark green: predominant result suggests a positive relationship, light green: equal number of results suggesting a positive relationship and not significant/mixed significance results, white: predominant result is lack of statistical significance and/or mixed significance, orange: equal number of results suggesting a negative relationship and not significant/mixed significant results, red: predominant result suggests a negative relationship. \_\_\_\_\_ 168

<i>Table 3.17 Reported reasons for non-adherence. Legend; MDI: Multiple Daily Injection, CSII: Continuous Subcutaneous Insulin Infusion, A: group A, B: group B.</i>	170
<i>Table 5.1 Questionnaires to be completed by the child. Legend; TSCC: Trauma Symptoms Checklist for Children, PAID-C: Problem Areas in Diabetes – Child version, PAID-T: Problem Areas in Diabetes – Teen version, RSQ: Response to Stress Questionnaire.</i>	182
<i>Table 5.2 Questionnaires to be completed by the parent. Legend; TSCYC: Trauma Symptoms Checklist for Young Children, P-PAID-C: Problem Areas in Diabetes – Parent of Child version, P-PAID-T: Problem Areas in Diabetes – Parent of Teen version, RSQ: Response to Stress Questionnaire, GAD-7: General Anxiety Disorder 7, PHQ-9: Patient Health Questionnaire 9, PIP: Paediatric Inventory for Parents, WE-CARE: Wellbeing and Satisfaction of Caregivers of Children with Diabetes Questionnaire.</i>	182
<i>Table 5.3 Summary of questionnaire results completed by participants. Legend; TSCC: Trauma Symptoms Checklist for Children, TSCYC: Trauma Symptoms Checklist for Young Children, P-PAID-T: Problem Areas in Diabetes – Parent of Teen version, P-PAID-C: Problem Areas in Diabetes – Parent of Child version, PAID-C: Problem Areas in Diabetes child version, PAID-T: Problem Areas in Diabetes – teen version, GAD-7: General Anxiety Disorder 7, PHQ-9: Patient Health Questionnaire 9, PIP: Paediatric Inventory for Parents.</i>	186

## List of figures

<i>Figure 1.1 Pathophysiology of T1DM. Legend; CD4+ T cell: Helper T cell, CD8+ T cell: Cytotoxic T cell, <math>\beta</math>-cell: beta-cell, MHC: Major Histocompatibility Complex, BCR: B-cell receptor, TCR: T-cell receptor, DC: dendritic cell. Adapted from (10). A <math>\beta</math>-cell autoantigen is presented to the CD4+ and CD8+ T cells and the B cell via interface between T cell receptors and major histocompatibility complexes. This causes the CD8+ T cell to have direct cytotoxic effects upon the <math>\beta</math>-cells within the Islets of Langerhans, which are propagated by the effect of the CD4+ T cell and the islet cell autoantibodies produced by the B cell. The islet cell autoantibodies also have a direct damaging effect upon the <math>\beta</math>-cells.</i>	18
<i>Figure 1.2 Proposed mechanisms leading to Type 1 Diabetes following enterovirus infection. Legend; Anti-VP4 IgG: anti-Viral Protein 4 Immunoglobulin G, Fc<math>\gamma</math>RII: low-affinity IgG binding receptor, CAR: Chimeric Antigen Receptor, CD14: Cluster of Differentiation, IFN-<math>\alpha</math>: Interferon Alpha, IFN-<math>\beta</math>: Interferon Beta, MHC: Major Histocompatibility Complex, OAS1: Oligoadenylate Synthase 1, IFIH1: Interferon Induced with Helicase C Domain 1. Adapted from Hober et al. (16) Following enterovirus infection and the innate response of the immune system, the adaptive immune response begins with presentation of viral antigens and <math>\beta</math>-cell antigens from cells that have been infected with the virus. The viral antigen presentation is part of the desired immune response and ultimately contributes to the resolution of the infection, but the <math>\beta</math>-cell antigen presentation results in an autoimmune response via activation of T cells production of <math>\beta</math>-cell autoantibodies against the <math>\beta</math>-cells. This autoimmune response does not happen in all individuals who have an enterovirus infection. The</i>	

*exact reasons for this are incompletely understood, but certain genetic variations – particularly in some subtypes of HLA – have been closely associated.* \_\_\_\_\_ 20

*Figure 1.3 Age-related incidence rate of T1DM. Adapted from (10).* \_\_\_\_\_ 24

*Figure 1.4 Changes to diabetes management in England and Wales since 2005 and associated changes in median HbA1c. Legend; HbA1c: glycosylated haemoglobin, mmol/mol: millimoles per mole. Adapted from (41).*  
 \_\_\_\_\_ 32

*Figure 1.5 Pathophysiology of diabetic ketoacidosis, from Round, J (74).* \_\_\_\_\_ 37

*Figure 3.1 Flowchart of study identification process. Legend; n: number of studies.* \_\_\_\_\_ 59

*Figure 3.2 Graph showing the heterogeneity of methods used to assess adherence. Note that the “method used 10 times” was “questionnaire not otherwise specified”, so is likely composed of many different questionnaires.*  
 \_\_\_\_\_ 66

*Figure 3.3 Graph showing the heterogeneity of factors assessed for adherence. One factor was assessed in 32 studies while 158 factors were assessed in just 1 study.* \_\_\_\_\_ 74

*Figure 4.1 Variability between themes.* \_\_\_\_\_ 173

*Figure 5.1 Participant Information Sheet (PIS) for very young participants (aged 3-6).* \_\_\_\_\_ 176

*Figure 5.2 Participant Information Sheet (PIS) for parents.* \_\_\_\_\_ 177



## List of abbreviations

<b>ACE</b>	Angiotensin Converting Enzyme
<b>ADHD</b>	Attention Deficit Hyperactivity Disorder
<b>ADQ</b>	Adherence in Diabetes Questionnaire
<b>Anti-VP4</b>	Anti-Viral Protein 4
<b>APA</b>	American Psychological Association
<b>ARB</b>	Angiotensin Receptor Blocker
<b>AXIS</b>	Appraisal Tool for Cross-Sectional Studies
<b>β-cell</b>	Beta-cell
<b>BGM</b>	Blood Glucose Monitoring
<b>BMI</b>	Body Mass Index
<b>CAR</b>	Chimeric Antigen Receptor
<b>CBT</b>	Cognitive Behavioural Therapy
<b>CD14</b>	Cluster of Differentiation 14
<b>CD4+</b>	Helper T lymphocytes
<b>CD8+</b>	Cytotoxic T lymphocytes
<b>CFRD</b>	Cystic Fibrosis-Related Diabetes
<b>CGM</b>	Continuous Glucose Monitoring
<b>ChEDS</b>	Eating Disorders in Diabetes Questionnaire
<b>CIMT</b>	Carotid Intima-Media Thickness
<b>CSII</b>	Continuous Subcutaneous Insulin Infusion
<b>CTCA</b>	Computed Tomography Coronary Angiography
<b>CTLA</b>	Cytotoxic T Lymphocyte Antigen
<b>DFRQ</b>	Diabetes Family Responsibility Questionnaire
<b>DH-Data</b>	UK Department of Health's Library and Information Services
<b>DKA</b>	Diabetic Ketoacidosis
<b>DRAQ</b>	Diabetes Regimen Adherence Questionnaire
<b>DRCQ</b>	Diabetes Regimen Compliance Questionnaire
<b>DSMP</b>	Diabetes Self-Management Profile
<b>DSS</b>	Diabetes Social Support Questionnaire
<b>ECG</b>	Electrocardiogram
<b>EMBASE</b>	Excerpta Medica Database
<b>ESRD</b>	End-Stage Renal Disease
<b>exp</b>	Explode (database search function)
<b>FcyRII</b>	Low-Affinity IgG Binding Receptor
<b>GAD</b>	Generalised Anxiety Disorder
<b>GAD-7</b>	General Anxiety Disorder 7
<b>GI</b>	Gastro-Intestinal
<b>GP</b>	General Practitioner
<b>GRADE</b>	Grading of Recommendations, Assessment, Development and Evaluations
<b>HbA1c</b>	Glycated Haemoglobin
<b>HDAS</b>	Healthcare Databases Advanced Search
<b>HLA</b>	Human Leukocyte Antigen
<b>HMIC</b>	Healthcare Management Information Consortium
<b>IFIH1</b>	Interferon Induced with Helicase C Domain 1

<b>IFN-<math>\alpha</math></b>	Interferon-Alpha
<b>IFN-<math>\beta</math></b>	Interferon-Beta
<b>MDI</b>	Multiple Daily Injections
<b>MDT</b>	Multi-Disciplinary Team
<b>MeSH</b>	Medical Subject Headings
<b>MHC</b>	Major Histocompatibility Complex
<b>Mmol/mol</b>	Millimoles per Mole
<b>MODY</b>	Maturity-Onset Diabetes of the Young
<b>MPR</b>	Medication Possession Ratio
<b>NHS</b>	National Health Service
<b>NICE</b>	National Institute of Health and Care Excellence
<b>NOS</b>	Newcastle-Ottawa Scale
<b>OAS1</b>	Oligoadenylate Synthase 1
<b>OCD</b>	Obsessive Compulsive Disorder
<b>PAID</b>	Problem Areas in Diabetes Questionnaire
<b>PAID-C</b>	Problem Areas in Diabetes Questionnaire – Child Version
<b>PAID-T</b>	Problem Areas in Diabetes Questionnaire – Teen Version
<b>PedsQL</b>	Paediatric Quality of Life Questionnaire
<b>PGE<sub>2</sub></b>	Prostaglandin E <sub>2</sub>
<b>PGI<sub>2</sub></b>	Prostaglandin I <sub>2</sub>
<b>PHQ-9</b>	Patient Health Questionnaire 9
<b>PIP</b>	Paediatric Inventory for Parents
<b>PISs</b>	Participant Information Sheets
<b>P-PAID-C</b>	Problem Areas in Diabetes Questionnaire - Parent of Child Version
<b>P-PAID-T</b>	Problem Areas in Diabetes Questionnaire – Parent of Teen Version
<b>PROs</b>	Patient-Reported Outcomes
<b>PTSD</b>	Post-Traumatic Stress Disorder
<b>QoL</b>	Quality of Life
<b>RCPCH</b>	Royal College of Paediatrics and Child Health
<b>RCT</b>	Randomised Control Trial
<b>RoB 2</b>	Revised Cochrane Risk of Bias Tool for Randomised Trials
<b>RSQ</b>	Response to Stress Questionnaire
<b>SED</b>	Self-Efficacy for Diabetes Questionnaire
<b>SMBG</b>	Self-Monitoring of Blood Glucose
<b>SCI</b>	Self-Care Inventory
<b>SCI-R</b>	Revised Self-Care Inventory
<b>T1DM</b>	Type 1 Diabetes Mellitus
<b>T2DM</b>	Type 2 Diabetes Mellitus
<b>Tregs</b>	Regulatory T Cells
<b>TSCC</b>	Trauma Symptoms Checklist for Children
<b>TSCYC</b>	Trauma Symptoms Checklist for Young Children
<b>UK</b>	United Kingdom
<b>U/h</b>	Units per hour
<b>US/USA</b>	United States/United States of America
<b>VNTR</b>	Variable Number of Tandem Repeats

<b>WE-CARE</b>	Wellbeing and Satisfaction of Caregivers of Children with Diabetes Questionnaire
<b>WHO</b>	World Health Organisation

# 1. Introduction

## 1.1. Pathophysiology

Type 1 diabetes mellitus (T1DM) is a disease characterised by a complete lack of insulin production from the beta cells of the Islets of Langerhans within the pancreas (1). Though some remission of T1DM is common after following initiation of therapy, this “honeymoon phase” only lasts an average 7 months before insulin production ceases permanently (2).

In the majority of cases, this is caused by autoimmune destruction (type 1A) of the beta cells. In less than 10% of patients, the pathogenesis is idiopathic, with destruction/failure of the beta cells without any evidence of autoimmunity (type 1B) (3). The first clinical symptoms usually appear after approximately 80% of the total beta cell mass has been destroyed. This is often precipitated by a time of increased insulin demand, such as during stress or infection (4).

The exact underlying trigger of T1DM is a complicated interaction of genetic and environmental factors that is still not fully understood.

The main genetic component is attributed to certain haplotypes of the human leukocyte antigen (HLA) complex; specifically, HLA-DR3 and/or HLA-DR4 subtypes (5). Over 90% of T1DM patients possess one of these particular subtypes, versus around 40% of people without the disease (6). These HLA molecules are responsible for allowing helper T lymphocytes (CD4+) recognise antigens, thereby triggering an immune response (1).

Other contributing genes include the insulin gene promoter (insulin variable number of tandem repeats - VNTR) and the cytotoxic T lymphocyte antigen-4 (CTLA-4) (5).

There are three classes of insulin VNTRs, with the number on tandem repeats increasing from class 1, to 2, to 3 (7). Class I is associated with an increased risk of developing T1DM, whereas class III has a protective effect (7).

CTLA-4 is expressed by T cells and acts as an inhibitory receptor with certain alleles conferring to substantially increased risk of T1DM and other autoimmune conditions such as rheumatoid arthritis (7). Of particular interest is the contribution of CTLA-4 to the development of autoimmune thyroid

disease (7), which is the most common autoimmune disorder associated with T1DM, with a quarter of children with T1DM having thyroid autoantibodies at diagnosis (8).

The presence of specific genes alone is not sufficient to guarantee the development of T1DM, making the relationship between T1DM and family history a complicated one; 85% of T1DM patients have no family history (9). In fact, the population seeing the greatest increase in their incidence rate is the genetically low risk population, suggesting that the contribution of environmental factors to development of the disease is increasing, though the reasons for this are not currently clear (5).




Figure 1.1 Pathophysiology of T1DM. Legend; CD4+ T cell: Helper T cell, CD8+ T cell: Cytotoxic T cell,  $\beta$ -cell: beta-cell, MHC: Major Histocompatibility Complex, BCR: B-cell receptor, TCR: T-cell receptor, DC: dendritic cell. Adapted from (10). A  $\beta$ -cell autoantigen is presented to the CD4+ and CD8+ T cells and the B cell via interface between T cell receptors and major histocompatibility complexes. This causes the CD8+ T cell to have direct cytotoxic effects upon the  $\beta$ -cells within the Islets of Langerhans, which are propagated by the effect of the CD4+ T cell and the islet cell autoantibodies produced by the B cell. The islet cell autoantibodies also have a direct damaging effect upon the  $\beta$ -cells.

The risk of an individual with a positive family history developing T1DM varies depending on which other family member is affected. The maternal impact appears to be the least strong, with 2-4% of individuals with a mother with T1DM going on to develop the disease, compared with 6-9% of individuals with a father with T1DM (11). Concordance (the incidence of both siblings being affected) between non-monozygotic twin siblings is around 10% (11).

Monozygotic twin studies show a concordance rate of around 50% (12). Even in the studies that suggest higher concordance, this number is always significantly short of 100% (11).

One of the more extensively studied environmental factors is viral infection. The main viruses implicated in the development of T1DM are enteroviruses, such as coxsackievirus B. In a Finnish study (13), the appearance of islet autoantibodies correlated with the seasonal variance of enterovirus infection.

The mechanism by which these viral infections can trigger an autoimmune response is not clear, and there are multiple proposed mechanisms depending on the virus implicated (14).

In the case of coxsackievirus B, it produces an inflammatory response in the islets of Langerhans, which would lead to introduction of autoantigens as part of the inflammatory process. The virus also possesses proteins that molecularly strongly resemble an amino acid found within the pancreatic beta cells, causing an autoimmune response via molecular mimicry (14) (15). Other proposed mechanisms include direct destruction of beta cells by a virus or causing an imbalance between cytotoxic and regulatory T cells (Tregs), in favour of cytotoxic T cells (15) (Figure 1.2).

It is worth noting that no viral vaccine – even in individuals with high-risk alleles – has been shown to increase the risk of developing T1DM (14). In fact, there is some evidence in favour of the inverse relationship, with the early immune response granted by vaccination potentially reducing viral infection of the Islets of Langerhans within the pancreas, thereby protecting against inflammation and destruction (14).




Figure 1.2 Proposed mechanisms leading to Type 1 Diabetes following enterovirus infection. Legend; Anti-VP4 IgG: anti-Viral Protein 4 Immunoglobulin G, FcyRII: low-affinity IgG binding receptor, CAR: Chimeric Antigen Receptor, CD14: Cluster of Differentiation, IFN- $\alpha$ : Interferon Alpha, IFN- $\beta$ : Interferon Beta, MHC: Major Histocompatibility Complex, OAS1: Oligoadenylate Synthase 1, IFIH1: Interferon Induced with Helicase C Domain 1. Adapted from Hober et al. (16) Following enterovirus infection and the innate response of the immune system, the adaptive immune response begins with presentation of viral antigens and  $\beta$ -cell antigens from cells that have been infected with the virus. The viral antigen presentation is part of the desired immune response and ultimately contributes to the resolution of the infection, but the  $\beta$ -cell antigen presentation results in an autoimmune response via activation of T cells production of  $\beta$ -cell autoantibodies against the  $\beta$ -cells. This autoimmune response does not happen in all individuals who have an enterovirus infection. The exact reasons for this are incompletely understood, but certain genetic variations – particularly in some subtypes of HLA – have been closely associated.



## 1.2. Epidemiology

Type 1 diabetes mellitus (T1DM) accounts for 5-10% of all cases of diabetes worldwide, with the remainder being made up of type 2 diabetes mellitus (T2DM), maturity-onset diabetes of the young (MODY) or cystic fibrosis-related diabetes (CFRD) (9). In children however, around 95% of diabetes is type 1 (Table 1.1) (9).

Type 2 diabetes mellitus (T2DM) in children is a relatively new occurrence, with the first cases being officially diagnosed in the UK in 2000 (though earlier cases had been reported in the US in some Native American populations) (17). These first UK cases were all in overweight girls of Asian origin, who have a roughly 9-fold increased risk of developing T2DM when compared with their Caucasian counterparts (in whom the first diagnosis occurred two years later) (9). Even in this higher-risk group, T2DM is still comparatively rare in children (17).

T1DM is the most common metabolic disease in young people (18). Thirty thousand children in the UK are currently living with T1DM and incidence is increasing by about 4% every year. This gives the UK one of the highest rates of T1DM worldwide – only 4 countries have a higher incidence (Table 1.2) (19). Incidence is also increasing worldwide, at a rate of around 3% per year. Only one country – Sweden – has reported a steady incidence rate (5). If the worldwide trend were to continue at this rate for the next decade, the number of T1DM cases would nearly double (5).

There is a huge range of incidence worldwide, with the highest incidence of 57.6 per 100 000 children (in Finland) being nearly 600 times that of the lowest incidence of 0.1 per 100 000 (in Papua New Guinea and Venezuela) (19). Interestingly, there is even a huge variance in incidence between nearby countries. For example, the distance between Estonia and Finland is around 75 miles, but Finland has around 3 times the T1DM incidence rate of Estonia (where the incidence is 17.1 per 100 000) (5).

<u>Type of Diabetes</u>	<u>Percentage of Total Diabetes Cases in Children (under the age of 19)</u>
<b>T1DM</b>	95.1%
<b>T2DM</b>	1.9%
<b>MODY, CFRD and Undefined Diagnosis</b>	2.73%
<b>Other Types</b>	0.27%

Table 1.1 Types and prevalence of different type of diabetes in children. Adapted from: Diabetes UK (9). Legend; T1DM: Type 1 Diabetes. T2DM: Type 2 Diabetes. MODY: Maturity-Onset Diabetes of the Young. CFRD: Cystic Fibrosis-Related Diabetes.

<u>Country</u>	<u>Incidence per 100 000 Children Between the Ages of 0 and 14</u>
<b>Finland</b>	57.6
<b>Sweden</b>	43.1
<b>Saudi Arabia</b>	31.4
<b>Norway</b>	27.9
<b>UK</b>	24.5
<b>USA</b>	23.7
<b>Australia</b>	22.5
<b>Kuwait</b>	22.3
<b>Denmark</b>	22.2
<b>Canada</b>	21.7
<b>Netherlands</b>	18.6
<b>Germany</b>	18
<b>New Zealand</b>	18
<b>Poland</b>	17.3
<b>Czech Republic</b>	17.2
<b>Estonia</b>	17.1
<b>Puerto Rico</b>	16.8
<b>Ireland</b>	16.3
<b>Tanzania</b>	0.9
<b>Paraguay</b>	
<b>Zambia</b>	0.8
<b>China</b>	0.6
<b>Dominican Republic</b>	0.5
<b>Pakistan</b>	
<b>Peru</b>	
<b>Ethiopia</b>	0.3
<b>Thailand</b>	
<b>Papua New Guinea</b>	0.1
<b>Venezuela</b>	

Table 1.2 Incidence of Type 1 Diabetes throughout the world. Adapted from Diabetes UK (19).

One proposed reason for the increasing incidence of T1DM is the hygiene hypothesis, which suggests that exposure to a range of pathogens in early childhood decreases the incidence of immune-mediated diseases such as asthma and T1DM (20). This effect has been demonstrated in mice; individuals raised in sanitary conditions develop T1DM at a higher rate than those raised in less sanitary conditions (20).

Unlike other autoimmune conditions, which tend to affect women more often, T1DM appears to affect both males and females equally (5). Incidence tends to increase with age up until puberty, after which it begins to decline (Figure 1.3) (10).




Figure 1.3 Age-related incidence rate of T1DM. Adapted from (10).

### 1.3. Treatment

In the UK, NICE (National Institute of Health and Care Excellence) has published guidance on how T1DM should be managed in children (21).

The mainstay of T1DM treatment is insulin replacement, given via varying methods of subcutaneous injection (22).

The mechanism of action of insulin varies slightly in each of the tissues where it acts, but all have the net effect of reducing blood glucose levels (23). In skeletal muscle, insulin promotes storage of glucose as glycogen, as well as promoting use of glucose by the cells (23). In the liver, as with in skeletal muscle, insulin increases the storage of glucose as glycogen and additionally increases fat formation from glucose (lipogenesis) and decreases the formation of glucose from non-carbohydrate sources (gluconeogenesis) (23). It achieves this through mediation of gene expression (23). Lastly, in white adipose tissue (WAT), insulin decreases the breakdown of fat into glucose (lipolysis), while promoting its storage as fat via lipogenesis (23).

On a molecular level, all of these mechanisms are started when insulin binds to an insulin receptor on the cell surface membrane, triggering a cascade that ultimately results in the movement of glucose transport proteins (GLUT-4) to the cell surface (23). The concentration of glucose outside of the cell is greater than the concentration of glucose inside of the cell, and so glucose can enter the cell through the GLUT-4 proteins via facilitated diffusion (24).

The two main regimens of insulin therapy that are used in children are

- Multiple Daily Injection (MDI)
- Continuous Subcutaneous Insulin Infusion (CSII), commonly known as insulin pump therapy and

MDI consists of short or rapid-acting insulin before meals and snacks and long-acting insulin at least once per day (21).

There are 5 main types of insulin, separated according to their duration of action and time of onset (25). Table 1.3 details the 5 types of insulin and their role in the treatment of T1DM.

In CSII, insulin is delivered via an indwelling cannula that is connected to a programmable pump (21). These devices usually contain rapid or short-acting insulin that is delivered automatically at a programmable variable basal rate, with boluses for meals/snacks controlled manually by the patient (21). This method is often considered if the first-line MDI treatment is unsuitable for the patient's lifestyle or if their glycaemic control on MDI has been consistently poor (21).

There are currently 9 insulin pumps on the market in the UK, each with their own pros and cons. Most pumps are "tethered", meaning that the pump is connected to a thin section of plastic tubing that delivers the insulin to the patient, though some are "patch" pumps, which attach directly to the skin and as such, do not require any tubing (26). Pumps can also be "integrated", meaning that they can communicate directly with a CGM (26). Patients using pumps that lack this capability will either use SMBG or will have a separate CGM device (26). Table 1.4 summarises the 9 pumps currently available in the UK and some of their key features.

Type of Insulin	Examples (brand name)	Approximate time to onset	Approximate time to peak of action	Approximate duration of effect	Role in treatment
<b>Rapid-acting</b>	<ul style="list-style-type: none"> <li>Insulin lispro (Admelog, Humalog)</li> <li>Insulin aspart (Fiasp, NovoLog)</li> </ul>	15 minutes	1 hour	2-4 hours	Taken before meals
<b>Short-acting</b>	<ul style="list-style-type: none"> <li>Regular insulin (Humulin R, Novolin R, Velosulin R)</li> </ul>	30 minutes	2-3 hours	3-6 hours	Taken before meals
<b>Intermediate-acting</b>	<ul style="list-style-type: none"> <li>Insulin isophane/NPH (Humulin N, Novolin N, ReliOn)</li> </ul>	2-4 hours	4-12 hours	12-18 hours	Usually taken twice per day to cover elevations in glucose when rapid/short-acting insulin wears off. May be combined with rapid/short-acting insulin in a mixed insulin regimen.
<b>Long-acting</b>	<ul style="list-style-type: none"> <li>Insulin detemir (Levemir)</li> <li>Insulin glargine (Lantus)</li> </ul>	3-4 hours	No defined peak	Up to 24 hours	Usually taken once or twice per day to cover elevations in glucose when rapid-acting insulin wears off
<b>Ultra-long-acting</b>	<ul style="list-style-type: none"> <li>Insulin degludec (Tresiba)</li> <li>Insulin glargine u-300 (Toujeo)</li> </ul>	6 hours	No defined peak	Up to 36 hours	May be useful in patients for whom regular injections prove challenging

Table 1.3 Summary of types of insulin, their times of action and their roles in treatment of T1DM. Legend; insulin NPH: insulin Neutral Protamine Hagedorn. Adapted from (25,27).

	<b>Accu-Check Combo (28)</b>	<b>Accu-Chek Insight (29)</b>	<b>MiniMed Paradigm Veo (30)</b>	<b>Minimed 640G (31)</b>	<b>Mylife OmniPod (32)</b>	<b>Mylife YpsoPump (33)</b>	<b>DANA Diabecare R (34)</b>	<b>DANA Diabecare RS (35)</b>	<b>A6 TouchCare (36)</b>
<b>Features</b>	<ul style="list-style-type: none"> <li>Handset is both a blood glucose meter and a bolus calculator</li> </ul>	<ul style="list-style-type: none"> <li>Handset is a blood glucose meter, bolus calculator, data manager and remote control for the pump</li> </ul>	<ul style="list-style-type: none"> <li>Low glucose suspend feature</li> </ul>	<ul style="list-style-type: none"> <li>Algorithm that attempts to predict hypos and prevent them via suspension of basal insulin</li> </ul>	<ul style="list-style-type: none"> <li>Handset is also a blood glucose meter</li> </ul>	<ul style="list-style-type: none"> <li>Links to smartphone app to allow bolus calculation and data sharing</li> </ul>	<ul style="list-style-type: none"> <li>Handset is also a blood glucose meter</li> <li>Can connect to smartphones to act as a remote control for the pump</li> </ul>	<ul style="list-style-type: none"> <li>Can connect to smartphones to act as a remote control for the pump</li> </ul>	<ul style="list-style-type: none"> <li>Low glucose suspend feature</li> </ul>
<b>CGM integration? (Y/N)</b>	Y	Y	Y	Y	N	N	Y	Y	Y
<b>Tethered/patch</b>	Tethered	Tethered	Tethered	Tethered	Patch	Tethered	Tethered	Tethered	Patch
<b>Basal settings</b>	<ul style="list-style-type: none"> <li>Minimum 0.05U/h</li> <li>Maximum 50U/h</li> <li>Minimum adjustable increment of 0.01U</li> <li>Option for 5 different basal profiles</li> <li>Option for temporary basal</li> </ul>	<ul style="list-style-type: none"> <li>Minimum 0.02U/h</li> <li>Maximum 25U/h</li> <li>Minimum adjustable increment of 0.01U</li> <li>Option for 5 different basal profiles</li> <li>Option for TBR</li> </ul>	<ul style="list-style-type: none"> <li>Minimum 0.025U/h</li> <li>Maximum 35U/h</li> <li>Option for 48 basal rates over the day, between 3 different patterns</li> </ul>	<ul style="list-style-type: none"> <li>Minimum 0.025U/h</li> <li>Maximum 35U/h</li> <li>Option for 48 different basal rates over the day between 8 pre-set patterns</li> </ul>	<ul style="list-style-type: none"> <li>Minimum 0.05U/h</li> <li>Maximum 30U/h</li> <li>Option for 7 different basal programmes, with each programme having the option of 48 different basal rates over the day between 24 pre-set patterns</li> </ul>	<ul style="list-style-type: none"> <li>Minimum 0.02U/h</li> <li>Maximum 40U/h</li> <li>Minimum adjustable increment of 0.01U/h</li> <li>Option of 2 different basal programmes, with up to 24 rates over the day per programme</li> </ul>	<ul style="list-style-type: none"> <li>Minimum 0.04U/h</li> <li>Maximum 16U/h</li> <li>Minimum adjustable increment of 0.01U/h</li> <li>Option of 4 different basal programmes with each profile having adjustable hourly rates</li> </ul>	<ul style="list-style-type: none"> <li>Minimum 0.04U/h</li> <li>Minimum adjustable increment of 0.01U/h</li> <li>Option of 4 different basal programmes with each profile having adjustable hourly rates</li> </ul>	<ul style="list-style-type: none"> <li>Minimum 0.05U/h</li> <li>Maximum 10U/h</li> <li>Minimum adjustable increment of 0.05U/h</li> <li>Option for 5 different basal programmes, with each having the option of 48 different basal rates per day</li> </ul>



	<b>Accu-Check Combo (28)</b>	<b>Accu-Chek Insight (29)</b>	<b>MiniMed Paradigm Veo (30)</b>	<b>Minimed 640G (31)</b>	<b>Mylife OmniPod (32)</b>	<b>Mylife YpsoPump (33)</b>	<b>DANA Diabecare R (34)</b>	<b>DANA Diabecare RS (35)</b>	<b>A6 TouchCare (36)</b>
	rate (TBR)								
<b>Bolus settings</b>	<ul style="list-style-type: none"> <li>Up to 50U</li> <li>Can be delivered as quick, standard, extended or multiwave boluses</li> </ul>	<ul style="list-style-type: none"> <li>Up to 50U</li> <li>Can be delivered as standard, extended and multiwave boluses</li> </ul>	<ul style="list-style-type: none"> <li>Up to 75U</li> <li>Can be delivered as standard, square wave and dual wave boluses</li> </ul>	<ul style="list-style-type: none"> <li>Up to 75U</li> <li>Can be delivered as standard, dual and square wave boluses</li> </ul>	<ul style="list-style-type: none"> <li>Up to 30U</li> </ul>	<ul style="list-style-type: none"> <li>Up to 30U</li> </ul>	<ul style="list-style-type: none"> <li>Up to 80U</li> <li>Can be delivered as extended or dual pattern boluses</li> </ul>	<ul style="list-style-type: none"> <li>Up to 80U</li> <li>Can be delivered as extended or dual pattern boluses</li> </ul>	<ul style="list-style-type: none"> <li>Up to 25U</li> <li>Can be delivered as normal, extended and combo boluses</li> </ul>

Table 1.4 Insulin pumps currently available in the UK and their features. Legend; U: units, U/h: units per hour, Y: yes, N: no. Adapted from (37).

All insulin regimens require some sort of monitoring of blood glucose levels, which in the first instance is usually done with Self-Monitoring of Blood Glucose (SMBG), where the patient will take their own capillary blood glucose a recommended 5 times per day (21). Alternatively, patients may have Continuous Glucose Monitoring (CGM), where a sensor continually monitors the glucose levels in the interstitial fluid via a cannula just under the skin (38). These can be “standalone”, where the patient can view their glucose levels via a separate device or “integrated”, where the CGM is connected to a pump, which can display glucose levels in addition to delivering insulin (38).

Management of children with diabetes is typically done via a multi-disciplinary team (MDT) approach (21). Teams should comprise of diabetologists, dieticians, nurse educators/diabetes nurse specialists and clinical psychologists (21). It is recommended that children with diabetes be seen in an outpatient clinic at least 4 times per year (21).

As a part of the 4 clinic appointments each year, patients should also attend an annual review where they receive screening for autoimmune thyroid disease (21) at all ages, and screening for diabetic nephropathy and cardiovascular risk factors (including blood pressure, lipid levels, BMI and smoking status) from the age of 12 (21). Additionally, screening for diabetic retinopathy and peripheral vascular disease and neuropathy (via assessment of the feet) should also be done annually from the age of 12 (21). Most of these assessments will be done at the time of the annual review appointment (21) though the retinopathy screening is usually done by an optician (39).

HbA1c (glycated haemoglobin) is the primary outcome measure for diabetes with a target of 48mmol/mol or lower (40), and while this has improved significantly in over the past decade, from an average HbA1c of 72mmol/mol in the 2005-06 audit period, the average in 2018-19 was still 61.5mmol/mol (40). Figure 1.4 shows some of the improvements in diabetes care in the past decade have impacted HbA1c management (41).

Other outcome measures (as defined by the Royal College of Paediatrics and Child Health – RCPCH (42)) exist relating to microvascular disease (such as kidney and eye disease), large vessel disease and autoimmune disease. These are summarised in Table 1.5.

Most patients expect to transition from paediatric services to adult care between the ages of 17 and 19 years old, though in reality, the mean age of transition is 19.5-20.1 years of age (43). The transition process can be a challenging time for patients and healthcare providers alike with only 14% of transitioning patients meeting their targets for glycaemic control (44) and HbA1c rising from a mean of 58mmol/mol at their last paediatric appointment, to a mean of 77mmol/mol at their first adult visit (45). It has been suggested that the reasons for this worsening in glycaemic control can be attributed to the upheaval that young people often face in their lives around this age, as attendance at university takes them away from their families, as well as financial, educational and social issues which can affect young people whether they are at university or not, all of which can all have a detrimental effect on treatment adherence (46). Around a third of patients report feeling unsatisfied with their transition (47) and unprepared for it (48).




Figure 1.4 Changes to diabetes management in England and Wales since 2005 and associated changes in median HbA1c. Legend; HbA1c: glycosylated haemoglobin, mmol/mol: millimoles per mole. Adapted from (41).

Outcome	Measurement/assessment
Glycaemic control	HbA1c
Kidney disease	Albuminuria
Eye disease	Dilated eye examination
Large blood vessel disease	Blood pressure
	Cholesterol
	Body mass index (BMI)
	Smoking status

Table 1.5 Summary of core outcome measures for T1DM in children, adapted from (42). Legend; HbA1c: glycated haemoglobin, BMI: Body Mass Index

### 1.3.1. Treatment Adherence

How effective insulin therapy is in achieving good glycaemic control depends hugely on the adherence of the patient with said therapy (49), with the definition of adherence being “the extent to which a person’s behaviour coincides with medical or health advice” (50). The terms “compliance” and “adherence” may be used interchangeably, but modern medical literature tends to prefer the term “adherence” as it is seen as a more empowering term for the patient, as opposed to the more paternalistic view of “complying” (50) (51).

T1DM is not a condition where the patient takes their medicine once per day and then forgets about it; following advice on blood glucose monitoring (BGM), diet, exercise, hypoglycaemia management and regular clinic attendance are all required in order to optimise adherence and subsequent glycaemic control (52). Given this long list of tasks, it is perhaps not surprising that time constraints are a frequently reported barrier to adherence (52). Other reported barriers are numerous and wide-ranging and include lack of treatment understanding behavioural issues and fear of hypoglycaemia (53).

Frequency of Blood Glucose Monitoring (BGM) may be used as an objective marker of treatment adherence. When comparing BGM frequency in patients on MDI versus those using CSII, a 2019 study (54) found that CSII users had higher frequency of BGM, inferring better adherence, though this was only statistically different when including the readings registered by the CSII users’ CGM device.

The importance of the link between treatment adherence and better diabetes outcomes cannot be overstated; a meta-analysis of 21 studies (that included a total of 2492 adolescents) showed that better treatment adherence is strongly positively correlated with better glycaemic control, irrespective of any demographic variables (55). The impact of adherence is lasting, and children with suboptimal adherence (and subsequent suboptimal glycaemic control) have a higher risk of long-term complications, even if their glycaemic control improves as adults (52).

It is important to be able to assess treatment adherence, so that improved adherence can be promoted, resulting in better diabetes outcomes in both the short and long-term (50). However, unlike for glycaemic control, there is no objective biomarker to measure adherence, meaning that attempts to measure it can pose a challenge (50).

There have been many studies that examine factors that affect adherence, but to date there have been no systematic reviews that attempt to collate this information.

#### 1.4. Complications of T1DM

T1DM is therefore complex, and difficult. Furthermore, the disease has a range of short- and long-term complications that are related to underlying pathophysiology and adherence to treatment, which impacts the survival of patients. The life expectancy of a person with T1DM is reduced by an average of 20 years, when compared with people without T1DM. For T2DM, the average reduction in life expectancy is 10 years (56).

These complications of T1DM can be both short and long term. The long-term complications can be further classified into those that affect the small blood vessels in the body (microvascular) and the large blood vessels (macrovascular). Short-term complications are not classified in this way as their pathogenesis is systemic.

##### 1.4.1. Short-Term – Hypoglycaemia

Hypoglycaemia is generally said to occur when blood glucose is below 4mmol/L (57).

Administration of insulin will decrease the blood sugar. However, in T1DM, either the dose used, or the lack of a normal physiological feedback loop, can cause a hypoglycaemic episode. These are common, and potentially dangerous complications of insulin therapy (58). The average person with T1DM has two episodes of hypoglycaemia (that is serious enough to cause symptoms) per week and up to 40% of these patients will have at least one episode of severe hypoglycaemia (episodes that require treatment with glucagon) each year (58).

The risk of hypoglycaemia goes up with tight glycaemic control. Risk also tends to be higher in individuals who have had T1DM for longer (59). This is because the normal glucagon response to hypoglycaemia tends to become less effective over time, with almost all patients being unable to mount an adequate response after 5 years of the disease (60).

Signs and symptoms of early hypoglycaemia include dizziness, lethargy and sweating and if untreated can even progress to cause collapse and seizures (58). The vast majority of cases never

progress this far and are easily corrected, but it is still a huge worry of diabetic patients; studies have shown that the fear of hypoglycaemia is comparable to that of retinopathy and nephropathy (61). This creates a potential barrier to achieving good glycaemic control, as many patients would rather tolerate slightly higher blood glucose levels than risk having a hypoglycaemic episode (61).

The potential for hypoglycaemia can further negatively impact a patient's mental health and can restrict the activities that patients feel they are able to do, from sporting activities to driving (62).

#### 1.4.2. Short-Term – Hyperglycaemia and Diabetic Ketoacidosis

Like hypoglycaemia, there is some variability as to the precise value that constitutes hyperglycaemia, but it is generally considered to be blood glucose readings above 7.8mmol/L (63).

Some of the most common symptoms of T1DM (such as polydipsia and polyuria) (62) - are as a result of hyperglycaemia (64). The hyperglycaemia results in osmotic diuresis in the kidneys, resulting in dehydration and loss of electrolytes. Other earlier signs of hyperglycaemia include fatigue and headache (65).

If a person remains in untreated hyperglycaemia, they may enter into diabetic ketoacidosis (DKA) (66). Since people with undiagnosed diabetes are not receiving treatment, DKA can be their first presentation of the disease (67). 20% of DKA cases are in previously undiagnosed T1DM patients (68).

In the vast majority of cases, it occurs in people with T1DM, due to their absolute (as opposed to relative, as in T2DM) deficiency of insulin. This absolute deficiency results in an inability of glucose to enter the body's cells, leading to increased glycogenolysis and – more problematically – increased gluconeogenesis (production of glucose from non-carbohydrate sources, which takes place predominantly in the liver), which produces acidic ketone bodies (69). To try and compensate for this decrease in pH, the body attempts to get rid of acidic hydrogen ions by vomiting, which worsens the dehydration and electrolyte loss - initially resulting from polyuria - subsequently impairing renal function (70). With decreased renal function comes decreased glycosuria, worsening the hyperglycaemia, which is further worsened by increased cortisol and growth hormone production, which in turn worsens the polyuria, acidosis, vomiting and dehydration (70) (Figure 1.5).

The classical picture of polyuria, polydipsia and weight loss is seen less commonly in younger children, where it may be misdiagnosed as respiratory disease such as asthma or bronchiolitis (71). This can be an especially dangerous misdiagnosis, as the treatments for these conditions frequently involve the use of corticosteroids, which worsen hyperglycaemia (71).

Treated DKA across all stages of severity has a mortality rate of 2-5% (66), and if left untreated, is invariably fatal (67). In 60-90% of deaths in DKA, the cause of death is cerebral oedema, making it the most common cause of death (71). By the time cerebral oedema has occurred, the mortality rate is around 25% (71). For patients that survive this advanced stage, 10-25% will go on to develop pituitary insufficiency, which can be a significant cause of morbidity requiring lifelong treatment (71).

Around 1 in 10 T1DM patients reported at least one case of DKA in the previous year (69).

Along with the aforementioned polyuria, polydipsia and vomiting, abdominal pain and a history of weight loss are also common (69).

The most common cause of DKA is non-compliance with insulin therapy, accounting for just under half of all cases. Infection is the next most common cause (69).

NICE has published national guidance on how DKA in children should be managed under section 1.4 of their paediatric diabetes management guideline (21). The general principles of DKA management are:

- Rehydration
- Providing insulin
- Correcting electrolyte imbalances (21) (72).

In particular regarding electrolyte imbalances is the provision of potassium, with severe hypokalaemia being the most common derangement during treatment. This occurs due to one of the other effects of insulin, which causes potassium to enter the cells from the blood (73).

If untreated, hypokalaemia can result in potentially fatal cardiac arrhythmias (71). Electrocardiogram (ECG) changes can be seen in the earlier stages of hypokalaemia and as such patients will often have their ECG regularly monitored (71).






Figure 1.5 Pathophysiology of diabetic ketoacidosis, from Round, J (74).

### 1.4.3. Long-Term – Retinopathy

Diabetic retinopathy is the most common cause of new-onset blindness in people aged 20-74 (75). In one study, 3.6% of the T1DM patients sampled were legally blind, with diabetic retinopathy being the cause in 86% of cases (76). Though less affected, retinopathy still affects T2DM patients, with the same study finding that 1.6% of type 2 diabetics were blind and that diabetic retinopathy was the cause in around a third of cases (with the significantly lower proportion being due to the higher incidence of other eye diseases in older people) (76).

Presence and severity of diabetic retinopathy is best predicted by the duration of the diabetes diagnosis, with prevalence increasing with each year post-diagnosis (76). Almost all people with type 1 diabetes will have some form of diabetic retinopathy 20 years post-diabetes diagnosis (76).

It begins as mild non-proliferative retinopathy, progressing through to severe non-proliferative retinopathy, before finally becoming proliferative retinopathy (76).

There are multiple mechanisms by which retinopathy causes vision loss, including macular oedema and distortion of the retina itself by the growth of the new blood vessels (55).

The main way of limiting progression of diabetic retinopathy is by achieving good glycaemic control (77).

<u>Time Post-Diagnosis</u>	<u>Prevalence</u>
<b><u>Any Stage of Retinopathy</u></b>	
3 years	8%
5 years	25%
10 years	60%
15 years	80%
<b><u>Proliferative Retinopathy</u></b>	
3 years	0%
15 years	25%

*Table 1.6 Prevalence of diabetic retinopathy over time. Adapted from Fong et al. (76)*

<u>Stage of Diabetic Retinopathy</u>	<u>Characteristic Findings</u>
Mild non-proliferative	Increased vascular permeability
Moderate-severe non-proliferative	Vascular closure
Proliferative	Growth of new blood vessels

*Table 1.7 Stages of diabetic retinopathy. Adapted from Fong et al. (76)*

#### 1.4.4. Long-Term – Peripheral Neuropathy

Neuropathy is the most common complication of diabetes (78) and affects almost 1 in 10 children with T1DM (78). Prevalence increases significantly with age; almost 60% of T1DM patients over the age of 30 are affected (77).

Diabetic neuropathy can affect all nerves within the body, including both motor and sensory peripheral nerves (most common) and the autonomic nerves that supply the cardiovascular and gastrointestinal systems (77). Autonomic neuropathy is one of the contributing factors of diabetes-related sexual impotence in men, with the nerves that supply the urogenital system also becoming damaged (79). Damage to the autonomic nerves supplying the heart can result in unexplained bradycardia and tachycardia as well as silent myocardial ischaemia, which may then go untreated (77).

It usually has an insidious onset of a number of years and can manifest in several different ways, including loss of sensation, pain, or weakness (78).

Quality of life can be seriously negatively impacted by diabetic neuropathy, with 43% of patients reporting at least one of depression, anxiety, or sleep disturbance (78). The aforementioned sensory loss can result in injuries which go undetected, which can then lead to ulcers, affecting 50% of diabetic patients at some point (79). The healing of these ulcers is then further negatively impacted by the increased incidence of peripheral arterial disease in this population (79) (80). If left untreated, limb amputation can become necessary, with diabetic ulcers being the cause of 10% of all amputations (across all ages) (78).

It also carries a significant economic burden and is responsible for around a quarter of all costs related to diabetes treatment (78). Around 40% of people report it affecting their employment, with this group missing an average of 5.5 days of work every month due to pain (77).

The most effective method of prevention, much like other diabetic complications, is good glycaemic control (81) and patients should have a diabetic foot check at least annually (77). If neuropathy does occur, its management revolves around symptomatic relief with analgesia and mitigating further deterioration (82).

#### 1.4.5. Long-Term – Nephropathy

Diabetic nephropathy is the most common cause of kidney disease worldwide (82). Around half of all T1DM patients will be affected at some point in their life and around a quarter of these patients will progress to end-stage renal disease (ESRD), which requires potentially debilitating renal replacement therapy, such as dialysis or even renal transplant (83). Mortality after initiation of haemodialysis is high, with a 5-year survival rate of only 30% (83). Renal transplantation, despite increased short-term mortality, has much improves long-term mortality by around 70% (83). This is still not without its difficulties; hyperglycaemia increases the risk of infection and immunosuppressive drugs impair pancreatic beta-cell function and worsen peripheral insulin risk, which further worsens the hyperglycaemia (84).

The exact mechanism by which diabetes causes kidney damage is uncertain, (84) but much like other diabetic complications, it is significantly linked to glycaemic control (85). There is a demonstrable benefit to good glycaemic control, with just a 1% reduction in HbA1c potentially resulting in a 25% decrease in risk of diabetic complications such as nephropathy (85).

High blood pressure is also strongly correlated with incidence of nephropathy (85); this generally contributes less to the incidence of the disease in T1DM, who are usually younger and as such have not been subjected to years of potential hypertension-inducing factors such as smoking and obesity (82).

The early signs of the disease typically have no obvious symptoms (84) and as such, it is important for all diabetic patients to undergo annual screening (in the form of a urine test for albumin) (82) to increase the chance of early detection.

If nephropathy does occur, blood pressure controlling medications such as Angiotensin Converting Enzyme (ACE) inhibitors and Angiotensin-Receptor Blockers (ARBs) may have a protective effect (82). Young people, however, are severely undertreated, with only a third of people under the age of 20 who have diagnostic nephropathy receiving either of these clinical interventions (86).

#### 1.4.6. Long-Term – Cardiovascular

Cardiovascular complications represent a key factor in the reduction in life expectancy in patients with T1DM (79) (86).

Coronary heart disease, cerebrovascular disease, peripheral arterial disease, cardiomyopathy, and heart failure all fall under the general banner of “cardiovascular disease” and the incidence of all of them is higher in patients with T1DM (87).

While atherosclerotic cardiovascular disease in the general population is almost exclusively a problem of middle-age and above (87), this is not necessarily the case with T1DM patients; even in young adults with T1DM, the incidence of cardiovascular disease is about 1-2% annually (87). Incidence does still increase with age with 70% of men and 50% of women with T1DM showing signs of atherosclerosis by the age of 45 (87).

In addition to age and gender, glycaemic control also has a huge effect on the relative risk of cardiovascular disease, with the worst controlled patients having 10 times the risk of the best controlled patients (87) (though the risk in these patients is still double that of the general population (87). Though the correlation is strong, the underlying mechanism is not clear and is likely to have many contributing factors (87).

Presence of cardiovascular disease in T1DM patients is strongly predicted by the presence of diabetic retinopathy, so presence of this at the recommended annual check would likely prompt further cardiovascular investigation, initially by ECG (87). Additional investigations include Carotid Intima-Media Thickness (CIMT) assessed by ultrasound or Computed Tomography Coronary Angiography (CTCA) (87).

Reducing the risk of cardiovascular disease involves optimal blood glucose management, reduction of cholesterol with statins, blood pressure control and lifestyle measures such as smoking cessation (87). Interestingly, even when management is completely optimised in T1DM patients, they still have a markedly increased risk of cardiovascular disease than the general population; this is not true for T2DM, where optimal management brings the risk back to near baseline levels (88).

## 1.5. Burden of Diabetes

### 1.5.1. Economic

The current annual direct cost (with “direct cost” meaning treatment and management of the disease and its complications) of T1DM is estimated at £1 billion (88). It costs close to another £1

billion indirectly (through the effects of increased death and illness) (88). The breakdown of these costs is shown in Table 1.8.

By 2035 these costs are estimated to double to direct costs of £1.8 billion and indirect costs of £2.4 billion (89).

The total annual cost of caring for all forms of diabetes and their complications is £14 billion (89). To put that in perspective, that is the equivalent of:

- £1.5 million per hour
- £25 000 per minute or
- 10% of the entire annual budget of the NHS (53).

<b>Area of Cost</b>	<b>Percentage of Total Cost</b>
<b>Diabetes Medications</b>	7.8%
<b>Non-Diabetes Medications (to treat complications)</b>	15.2%
<b>Inpatient Care</b>	65.8%
<b>Outpatient Care (excluding medications)</b>	9.7%
<b>Other (e.g.- social service)</b>	1.7%

*Table 1.8 Healthcare costs associated with Type 1 Diabetes Mellitus. Adapted from Streisand et al. (90)*



### 1.5.2. Psychological Impact

Studies have shown that children with T1DM have higher incidences of emotional and behavioural problems (91).

The very routine required to manage T1DM can have a significant psychosocial impact upon patients and has been described by some researchers as “unrelenting” (92). Injections several times per day, counting of carbohydrates and anticipation and management of hypoglycaemia can combine to form a highly stressful routine; nearly 40% of people feel that their treatment interferes with their lives and over half worry about hypoglycaemia (92). The same study aimed to assess exactly which parts of life diabetes affects, and found that no part of life is immune to effect:

- Physical health (62.2%)
- Emotional well-being (45.2%)
- Finances (44%)
- Leisure activities (38.2%)
- Work-related activities (35.4%)
- Relationships with family and friends (20.5%) (93).

As mentioned above, the routine of diabetes management can be a central point in conflict between parents and children. (94) However, the relationship is a complex one. Addressing conflict through family therapy can improve treatment adherence and glycaemic control (95), but children with better glycaemic control report positive family dynamics even without intervention (92).

Up to 13.6% of family members of people with diabetes report a poor or very poor quality of life and up to 16.2% have WHO-5 scores indicative of depression (18). These figures are similar in the patients themselves (18).

Friends can also have a significant impact on T1DM outcomes. Many young people report that their friends are an important source of support (96). Young people with strong support networks tend to have greater treatment adherence and glycaemic control (96).

Psychological impact can have direct as well as indirect effects on a patient’s glycaemic control. If a patient becomes stressed, the effect of cortisol can lead to increased hyperglycaemia (97). It can also make it more difficult for the patient to complete the tasks required to manage their condition,

such as insulin injections or carbohydrate counting (18). Furthermore, another study showed that using CBT (Cognitive Behavioural Therapy) to treat stress-related depression in T1DM results in improved glycaemic control (98). This relationship is not clear-cut however, as other studies have found no direct relationship between stress and glycaemic control (though they do add that an indirect relationship is likely). This is an area where more work needs to be done; studies have demonstrated conflicting ideas and no study included more than 100 participants. Additionally, whilst several studies have looked at the psychological effect of diabetes as a whole, to date, no studies have assessed the specific impact of diagnosis.

Despite the evidence showing the importance of psychological factors in management of diabetes – whether it be through a direct or indirect effect - and the reflection of this is national management guidelines (99), it is recognised that psychological support for diabetic patients is under-resourced, with only around 10% of patients accessing psychological services (99). Care providers are identifying high numbers of people with diabetes-related psychological issues, but state that they lack the resources to provide these people with the support that they need (100).

Even when removing diabetes from the equation, the individual and societal impact of poor mental health is significant (101). Worldwide, depression is second only to lower back pain as a cause of years lived with disability (and is actually the most common cause in 26 countries) (101). Severe depression can lead to suicide, which is the second most common cause of death for people aged 15-29 (102).

## 1.6. Aims of Thesis

Despite the critical importance of adherence in long term complication free survival with T1DM, and the varied factors that affect it across childhood and adolescence, the range and impact of these factors has not been examined previously. Therefore, the initial aim of this project is to undertake a systematic review of insulin adherence in children and young people with T1DM, to understand what impact the factors studied have, and determine the areas that have/have not been researched.

The findings of this systematic review will then be used to find potential areas for future study.

## 2. Systematic Review Methodology

### 2.1. Background

This review was titled "Factors Affecting Adherence to Insulin in Children and Young People with Type 1 Diabetes".

With an ever-growing number of scientific studies, it can be difficult, if not impossible, for clinicians to keep up to date with every new study that is published (103). Systematic reviews are an effective way of collecting all available information on a particular topic, assessing the risk of bias and quality of the studies and thus summarising the scientific consensus, making them an important step between primary research and the application of it in clinical practice (103).

The PRISMA checklist (104) is an evidence-based system designed to provide structure to and improve the reporting of systematic reviews. It is primarily used for systematic reviews that report on RCTs but can also be used for reviews that use studies of other methodology (104) and as such, was used to guide the reporting of this review.

### 2.2. Methods

#### 2.2.1. Inclusion and Exclusion Criteria

This systematic review was undertaken in accordance with the PRISMA checklist on systematic reviews (105). The completed PRISMA checklist is shown in Appendix 1.

The eligibility criteria for the articles was described using the PICO framework, a full description of which can be found below in Table 2.1. The "comparison" aspect of the framework was not deemed relevant in the given context.

All study types and those published during any year were considered. Studies published in all languages were empirically considered, pending being able to find a translator for said language. Speakers of all foreign languages were found, so no articles were excluded on these grounds.

Studies were required to contain primary data and be published in writing in full. As such, reviews and conference abstracts were excluded. Theses were also not considered.

Regarding the participant population, studies were required to include children (participants under the age of 18) with type 1 diabetes. Studies that included some adults were not necessarily excluded, as long as inferences could be drawn specifically regarding children. Examples where this may be the case include:

- a) Adults were part of the study sample, but results were separated according to age.
- b) Adults were part of the study sample, but the mean participant age was below 18.

In terms of an intervention, it was required that participants be receiving insulin therapy. Given that no T1DM patients should ever not be receiving insulin therapy in some form, this part of the criteria was not expected to ever be utilised.

The outcome of interest was factors that affect adherence to insulin therapy. “Factors” could be quantitative (such as demographical correlations to adherence/non-adherence) or qualitative (such as patient-reported reasons for non-adherence/adherence). Studies were required to specifically assess insulin therapy in some way - whether it be through objective measures such as downloading of insulin pump data, or more subjective measures such as self-report questionnaires – but they were not required to separate the components of adherence out in results (i.e.- results being expressed as a composite measure of adherence were acceptable). Studies did not measure insulin adherence and instead inferred adherence by measuring of another aspect of care (such as BGM frequency) were excluded.

PICO	Inclusion Criteria	Exclusion Criteria
Population	<ul style="list-style-type: none"> <li>• Humans</li> <li>• Children (below the age of 18)</li> <li>• With type 1 diabetes</li> </ul>	<ul style="list-style-type: none"> <li>• Not humans</li> <li>• Adults (people aged 18 and over) <ul style="list-style-type: none"> <li>◦ Including papers where some children are included along with adults, but the results are not separated out into adults/children</li> </ul> </li> <li>• Do not have type 1 diabetes (including those with any form of diabetes other than type 1, e.g.- type 2 or cystic fibrosis-related)</li> </ul>
Intervention	<ul style="list-style-type: none"> <li>• Insulin treatment</li> </ul>	<ul style="list-style-type: none"> <li>• Not receiving insulin treatment (NB: this aspect of the exclusion criteria should theoretically never be met as every T1DM patient will receive insulin)</li> </ul>
Comparison	<ul style="list-style-type: none"> <li>• N/A</li> </ul>	<ul style="list-style-type: none"> <li>• N/A</li> </ul>
Outcomes	<ul style="list-style-type: none"> <li>• Primary data that relates to: <ul style="list-style-type: none"> <li>◦ Adherence to treatment</li> <li>◦ Non-adherence to treatment</li> </ul> </li> <li>• Results may show correlations (e.g.- “as children get older their adherence to insulin treatment gets worse”) or reasons for adherence/non-adherence (e.g.- “non-compliant children stated that they were fearful of hypos”)</li> </ul>	<ul style="list-style-type: none"> <li>• Any outcome not relevant to insulin treatment adherence</li> <li>• Outcomes that infer insulin adherence via measuring a different variable (e.g.- “we measured how often the patients performed blood glucose testing. Patients who measured more often we deemed as being more adherent to treatment.”)</li> <li>• Outcomes that relate to treatment adherence, but are not from primary data (e.g.- reviews)</li> <li>• Outcomes that relate to treatment adherence, but is not published in full (e.g.- conference papers that have not been fully published)</li> </ul>

Table 2.1 Inclusion and Exclusion Criteria for determining relevant studies. Legend; T1DM: Type 1 Diabetes, N/A: not applicable, PICO: framework used to construct criteria (Population, Intervention, Comparison and Outcomes).

### 2.2.2. Identification of Relevant Studies

To improve the chances of finding relevant studies, 5 databases were searched using the Healthcare Databases Advanced Search (HDAS) (106). HDAS is a search engine with access to 9 databases. Each database was researched to determine their predominant area of research and if it was likely to contain relevant studies. Based upon this, 5 of these 9 databases were searched:

- Excerpta Medica Database (EMBASE)
- Healthcare Management Information Consortium (HMIC)
- Medline
- PsychINFO
- PubMed

EMBASE is produced by Elsevier (107) and includes biomedical and pharmacological studies, including 32 million records across 8 500 journals, with the earliest dating to 1947.

HMIC (accessed only through HDAS (106)) is published by the UK Department of Health in association with the Nuffield Institute for Health and the King's Fund Library. It is a combination of the databases of the UK Department of Health's Library and Information Services (DH-Data) and the King's Fund Information and Library Service. It contains 214 000 articles between the two databases, dating back to 1979.

Medline is a component of PubMed, through which it is accessed (108). It contains over 26 million articles from a range of fields including medicine, nursing and pharmacy. Its records date back to 1946.

PsychINFO is produced by the American Psychological Association (APA) (109) and contains over 3.5 million articles, dating back to 1887 from the field of psychology.

PubMed is maintained by the United States National Library of Medicine (108) and has over 30 million articles dating back to 1966 from the fields of life science and biomedicine.

### 2.2.3. Design of Search Strategy

The search strategy was designed following training from a medical librarian with extensive experience in conducting medical literature searches. It was constructed with the main concepts of

the research question in mind and to maximise the number of potentially relevant results by including synonyms listed within the database thesauruses (MeSH – medical sub-heading – terms, accessed via the “explode” function within HDAS), as well as manually input synonyms added following discussions with experts in paediatrics and paediatric diabetology. The search strategy was largely similar across all databases, with small adjustments to cover potential omissions from each database’s in-built thesaurus and to account for the desired age of the population, where this was not part of the in-built search strategy.

The full search strategy can be found in Appendix 10. The core strategy first involved searching for articles relating to T1DM. Synonyms such as “insulin dependent diabetes” and “juvenile onset diabetes” were separated by the Boolean operator OR. The in-built search engine thesaurus specifically used the term “diabetes mellitus”, so additional search terms were manually added to exclude “mellitus”, to cover for the possibility of articles using the shortened name for the disease. All search terms were included in parentheses to ensure searching for that specific term, as opposed to all articles containing the word “type” and “one” et cetera.

The next step was to begin narrowing the search results by including the term insulin (separated from the first step of the strategy with the Boolean operator AND) followed by including the term “adherence” and its synonym “compliance” (again, separated from the previous steps with the Boolean operator AND). The final step of the strategy was to further refine to only include articles with children as subjects, which was done with each respective database’s “limits” function.

Terms relating to study types were not included as not all studies will state their design in their title, abstract or key words.

#### 2.2.4. Selecting Eligible Studies for Inclusion

All of these articles were then screened for eligibility by two independent reviewers (JC and DG). The results were passed through 3 times, first to exclude results based upon their title, then abstract and finally by full text.

If a result was excluded at any stage, the first point of the exclusion criteria that it satisfied was listed.

The two reviewers were required to agree on both the stage of screening that an article was excluded and the reason for exclusion. Any disagreement was first discussed between the reviewers. If a consensus could still not be reached, the article would be independently adjudicated by a third member of the research team (who was a consultant paediatrician and experienced academic - DH).

For the non-English language papers, the role of the second reviewer was fulfilled by the foreign language speaker.

For 1270 of the articles, agreement was already achieved. The remaining 36 were agreed upon after discussion. Adjudication was not required for any of the papers.

#### 2.2.5. Data Extraction

The first reviewer (JC) constructed a data extraction tool in correspondence with an experienced academic and consultant paediatrician (DH) and a consultant paediatric diabetologist (MD). This tool was then used to extract the following information:

- Mean age and duration of diabetes of the participants
- Method of measuring adherence
- Factors checked for association with adherence their effect on adherence
- Significance of the effect and the statistical test used.

The data extraction tool can be seen in full in Appendix 2.

Most study results were expressed as Pearson correlations. Pearson correlations (often abbreviated to “r”) measure the strength of a linear association between two variables and can be expressed as any value between -1 and +1 (110). The closer to -1 or +1 the value is, the stronger the relationship between the two variables, with a negative number indicating a negative relationship and vice versa (110). It is worth noting that Pearson correlation coefficients are not the same as a line of best fit; the Pearson correlation indicates how far all data points are from the line of best fit (110).

In some studies, the size of the effect was illustrated using the beta ( $\beta$ ) value. For every change of 1 unit in the predictor variable (for example, age) the outcome coefficient (adherence) changes by the value of  $\beta$ , either up or down, depending on if  $\beta$  is positive or negative (111).



### 2.2.6. Quality Assessment of Studies

Quality assessments of all English-language studies were performed by the first reviewer (JC). This assessment made it possible to determine if the results were valid and if proper conclusions could be drawn.

Quality assessment of foreign language studies were not performed as all tools used to assess quality were written in English, meaning that they would not necessarily translate appropriately and may lead to misleading comparisons.

A different validated quality assessment tool was used for each study design.

For cross-sectional cohort studies, the Appraisal Tool for Cross-Sectional Studies (AXIS) (112) was used. This tool has 20 questions across 5 domains: introduction, methods, results, discussion and other, with 1, 10, 5, 2 and 2 questions addressing each domain, respectively. All questions can be answered by the reviewer as yes, no or do not know. There is no defined, objective way of scoring the end results, so a total of the answers that would reduce the risk of bias has been added for the purposes of this review, to provide a quick way of comparing the quality of the included studies. For all questions apart from 13 and 19, an answer of “yes” would award 1 point and an answer of “no” would award 0 points. For questions 13 and 19, this was reversed. An answer of “do not know” for any question would award 0 points for that question. Appendix 3 includes the full tool as well as the answers and total score for all included cross-sectional cohort studies.

For case-control and longitudinal cohort studies, the Newcastle-Ottawa Scale (NOS) (113) was used. This system assesses studies across three domains: selection of study participants, comparability of the cohorts and outcome. A star rating system is used, with a possible maximum of 9 stars. The questions for cohort studies and case-control studies differ slightly, but still assess these 3 domains and still award a maximum of 9 stars. The full case-control study tool and responses can be found in Appendix 4 and Appendix 5, respectively. The full cohort study tool and responses can be found in Appendix 6 and Appendix 7, respectively.

For randomised control trials (RCTs), the short version of the Revised Cochrane risk of bias tool for randomised trials (RoB 2) (114) was used. This tool assesses studies across 5 domains:

1. Risk of bias arising from the randomisation process
2. Risk of bias due to deviations from the intended interventions

3. Risk of bias due to missing outcome data
4. Risk of bias in measurement of the outcome
5. Risk of bias in selection of the reported result.

The study is judged in each of these domains as “low risk”, “some concerns” or “high risk”.

The study is then given an overall rating with the same grading:

- Low risk: the study was judged as low risk across all 5 domains
- Some concerns: the study was judged to have some concerns in at least one domain, but was not high risk for any domain
- High risk: the study was judged to be high risk in at least one domain or to have some concerns across multiple domains.

The full tool and assessments for all included RCTs can be found in Appendix 8.

#### 2.2.7. Grading of Evidence

Evidence was graded using the validated GRADE (Grading of Recommendations, Assessment, Development and Evaluations) framework (115).

With this framework, the quality of evidence relating to each of the pre-defined outcomes is assessed and graded as either very low, low, moderate, or high (115). The meanings of each of these terms can be found in Table 2.2.

The methodology of studies provides the starting point for the GRADE rating, with RCTs beginning as “high” and observational studies beginning as “low” (115). The rating can then be moved down according to assessments made to 5 GRADE domains:

1. Risk of bias,
  - a. See section 2.2.6 regarding quality assessment of studies
2. Imprecision,
  - a. Usually assessed in relation to the 95% confidence interval
3. Inconsistency,
  - a. Whether consistent effects are shown across several studies or not
4. Indirectness,

- a. Whether the intervention of interest is occurring with the population of interest, or if assertions are being made based on a different intervention in a different population
5. Publication bias
- a. Requires making inferences about missing evidence to assess if the result of the study/studies influenced the decision to publish it/them (115).

Less frequently, evidence can have its rating increased if there is a large magnitude of effect, a dose-response gradient or if confounding factors would reduce the magnitude of an effect (115).

<b>GRADE Rating</b>	<b>Meaning</b>
<b>Very low</b>	True effect is probably markedly different from the estimated effect.
<b>Low</b>	True effect might be markedly different from the estimated.
<b>Moderate</b>	True effect is probably close to the estimated effect.
<b>High</b>	The authors (of the systematic review) have a lot of confidence that the true effect is similar to the estimated effect.

*Table 2.2 Meanings of GRADE ratings. Legend; GRADE: Grading of Recommendations, Assessment, Development and Evaluations. Adapted from (115).*

### 2.2.8. Data Analysis

Thematic analysis was performed on all included studies with each factor checked for association with adherence being sorted in to one of 5 themes:

1. Demographics
  - I. E.g.- age, gender and socio-economic status. Duration of diabetes was also placed within this theme as it is an innate, unidirectional characteristic and cannot fluctuate.
2. Past medical history
  - I. E.g.- number of hospital admissions.
3. Diabetes management and results
  - I. E.g.- insulin regimen, method of insulin delivery, HbA1c.
4. Psycho-social
  - I. E.g.- depression, lifestyle factors (such as exercise frequency).
5. Family dynamics.
  - I. E.g.- support from family members, family cohesion and conflict.

Factors considered to be related to family dynamics are distinct from psycho-social factors that involve family members. For example, family conflict would be considered to be related to family dynamics, whereas maternal depression would be a psycho-social factor, as how this actually affects the interactions between family members cannot be assumed.

Identification of these 5 themes was done following consultation with a consultant paediatric diabetologist and a clinical psychologist who works with children with diabetes.

## 3. Results

### 3.1. Study Selection

1799 studies were identified from the 5 databases using the search criteria, including 483 duplicates, leaving 1306 studies being screened for eligibility based on title or abstract. Of these studies, 1057 were deemed as being ineligible, leaving 249 studies to be screened by full text. 173 of these studies were ineligible, leaving 76 to be included for analysis. Four of these studies did not have an available full text after online searches, contacting the British Library and contacting the study authors, so were excluded for this reason. A list of all of the original 1306 studies can be found in Appendix 9, along with their reasons for exclusion at all stages. Figure 3.1 shows the flowchart illustrating the study selection process.




Figure 3.1 Flowchart of study identification process. Legend; n: number of studies.

### 3.2. Quality of Included Studies

Forty-four cross-sectional studies (116–159) were assessed for quality using the Appraisal Tool for Cross-Sectional Studies (AXIS) (as described in section 2.2.6). The mean score was 16/20 with a range of 13-19. The most common shortcoming of studies was relating to accounting for response bias, with just 7/44 (15.9%) of studies making any attempt to categorise non-responders. The full assessment of each study can be found in Appendix 3.

Two case-control studies (160,161) were assessed for quality using the case-control version of the Newcastle-Ottawa scale. Both of these studies earned the maximum number of 9 stars. The full assessment of both studies with individual answers can be found in Appendix 4.

Eighteen longitudinal cohort studies (162–179) were assessed for quality using the cohort study version of the Newcastle-Ottawa scale (as described in section 2.2.6). The maximum possible score for each study was 9 stars. The mean score (rounded to 1 decimal place) amongst the 18 studies was 6.8 stars with a range of 5-9 stars. The full assessment of each study with individual answers can be found in Appendix 6.

Seven Randomised Control Trials (RCTs) (180–186) were assessed for quality using the revised Cochrane Risk of Bias tool for randomised trials (RoB 2), as described in section 2.2.6. 3/7 (42.9%) of assessed studies were classed as having a high risk of bias, 2/7 (28.6%) as having “some concerns” and 2/7 (28.6%) as having a low risk of bias. The most common cause of a rating of high risk of bias was relating to domain 5: selection of reported result, with 5/7 (71.4%) of studies using multiple outcome measures. The full assessment of each study with individual answers can be found in Appendix 8.

The remaining five studies were foreign language studies and were not assessed.

### 3.3. Study Characteristics

The 76 included studies took place across 27 countries. The number of studies from each country were as follows: 44/76 (57.9%) from the USA, 4/76 (5.3%) from France, 3/76 (3.9%) from Canada and from across the UK (with a further 2 taking place specifically in Scotland and 1 in England), 2/76 (2.6%) from each of Austria, Denmark, Finland, Japan, the Netherlands and Spain respectively, and



1/76 (1.3%) from each of Australia, Egypt, Germany, Hong Kong, India, Iran, Israel, Kuwait, Malaysia, Norway, Poland, Portugal, Puerto Rico and Saudi Arabia.

For one study, the country where it took place could not be determined. The above numbers total to more than the total number of studies, as some studies took place across multiple countries.

Seventy-one of the included studies were published in English. One was published in French, 2 in Dutch and 2 in Spanish.

A total of 9 969 children and young people were included in all studies, with a mean of 133 children per study and a range of 28 to 1 028.

### 3.4. Methods of Measuring Adherence

The 76 publications contained 38 different methods of measuring adherence. Note that one of these methods is “questionnaire not otherwise specified”, so is likely composed of more methods. Table 3.1 Different methods of adherence assessment used in the included studies and the number of studies that used them. Table 3.1 lists the different methods used throughout the included studies and the numbers of studies that used each method. 69/76 (90.8%) of studies used 1 method of measuring adherence, 4/76 (5.3%) used 2 methods and 1/76 (1.3%) used 3 methods.

The contents of this table are summarised as a bar chart in Figure 3.2.

Questionnaires were the most common methods of assessing adherence, with 55/76 (72.4%) of the studies using some form of questionnaire either as a part of, or the as entirety of their adherence measure.

One of the most frequently used of the questionnaires was the Diabetes Self-Care Inventory (SCI) (187), with 10 of the studies using either the original questionnaire (183), the revised version (SCI-R) (128) (188), or creating their own questionnaire (173) based on the SCI. All versions of the SCI are self-reports on the patient’s perspective of their adherence to specific management tasks over the previous 1-2 months, asking them to grade each item from “never do it” to “always do this as recommended, without fail” (188). The original SCI contained 14 items that assessed adherence to blood glucose monitoring, insulin treatment, diet, exercise, and emergency precaution guidelines

(187). The SCI-R covered the same areas of adherence, but wording was updated to reflect the current practice recommendations and improve the efficiency of completion and clarity (188). Table 3.2 contains details of the changes that were made to items. Additionally, the response of “not applicable or N/A” was removed as an option from all items except those relating to ketones, insulin and pills; this is because the questionnaire is designed to be used by both patients with T1DM and T2DM and as such, items relating to these themes will not always be relevant (188).

The final result of the changes is a 15-item questionnaire consisting of:

- 4 regarding diet
- 3 regarding medication administration
- 3 regarding preventative measures/routine aspects of care
- 2 regarding glucose monitoring
- 2 regarding hypoglycaemia
- 1 regarding exercise (188).

The final score is calculated averaging the scores and converting to a 0-100-point scale, where higher scores indicate better adherence (188).

One of the few objective measures used to measure adherence was Medication Possession Ratio (MPR) (166) (167). This is calculated by dividing the number of days’ supply of a medication in a given period by the number of days that has elapsed between prescription collections (189). The ratio is always a positive number (including 0), with 0 being complete non-adherence (where no prescriptions have been collected) and 1 being perfect adherence (189). It is possible to get a number greater than one, if the patient has collected their prescription too early. This could infer medication overdosing but could also be a result of practical reasons such as lost medication, or changes in management (189).

The other objective measures are downloaded insulin pump data and BOLUS scores (138) (121). The length of time that can be assessed depends on the model of insulin pump, as does the data that can be collected from it. For example, the Medtronic pump (31) can store 2-3 months of data and captures carbohydrate inputs and doses of delivered insulin boluses, as well as blood glucose information by virtue of being an integrated pump (138). Other pumps such as the Omnipod (32) are not integrated with a CGM and as such cannot capture blood glucose data (190).

BOLUS scores range between 0-3, with 0 being the worst adherence and 3 being the best adherence (191). They are calculated by looking at the previous 14 days of downloaded insulin pump data: a point is awarded for any food-related bolus occurring at breakfast (6-10am), lunch (11am-3pm) and dinner (4-10pm), with a maximum of one point available at each time period (191). A mean of the 2 weeks of scores are then taken to give the final BOLUS score (191). Studies have shown that BOLUS scores are more closely associated with glycaemic control than frequency of SMBG, which was the standard objective diabetes adherence measure for many years (191).

Method of adherence assessment	Number of studies
Questionnaire (not otherwise specified)	11
Self-Care Inventory/Revised Self-Care Inventory (SCI/SCI-R; La Greca, 1994, 2004))	7
Downloaded pump data/BOLUS scores	7
Non-specified interviews	6
Barriers to Adherence Questionnaire	4
Diabetes Self-Management Profile (DSMP; Harris et al., 2000)	4
Questionnaire by Cerkoney and Hart, 1980	3
Diabetes Regimen Adherence Questionnaire (DRAQ)	2
Healthcare provider ratings	2
Interview by Hanson et al., 1992	2
Medication Possession Ratio (MPR)	2
Observation of injection technique	2
Questionnaire by Jacobson et al., 1987	2
Summary of Self-Care Activities Questionnaire	2
Adherence and IDDM Interview (Hanson et al., 1987)	1
Adherence in Diabetes Questionnaire (ADQ)	1
Child Eating Disorder Examination (ChEDE) version 12.0	1
Diabetes Adaptation Scale	1
Diabetes Family Responsibility Questionnaire (DFRQ)	1
Diabetes Management Questionnaire	1
Diabetes Self-Management Interview	1
General Self-Efficacy Scale	1
Insulin Adjustment Score	1
Insulin Required of Adherence Scale	1
Management Behaviours of Adolescents (Harris et al., 2000 and La Greca, 1995)	1
Paediatric Quality of Life Questionnaire (PedsQL)	1
Participant diaries	1
Problem Areas in Diabetes Questionnaire (PAID)	1
Questionnaire by Littlefield et al. 1992	1
Questionnaire on injection site rotation	1
Reported Adherence to Medication Scale (Horne, 1999)	1
Self-Care Questionnaire (Glasgow et al., 1987)	1
Diabetes Self-Care Inventory (DSCI; Kanematsu, 1997)	1
Self-Efficacy for Diabetes Questionnaire (SED)	1
Self-Report Questionnaire on Adherence (Almeida and Pereira, 2003)	1
Summary of Self-Care Activities Questionnaire (Schafer et al., 1983)	1

*Table 3.1 Different methods of adherence assessment used in the included studies and the number of studies that used them. SCI: Self-Care Inventory, SCI-R: Revised Self-Care Inventory, DSMP: Diabetes Self-Management Profile, DRAQ: Diabetes Regimen Adherence Questionnaire, MPR: Medication Possession Ratio, IDDM: Insulin Dependent Diabetes Mellitus, ChEDE: Child Health Eating Disorder Examination, DFRQ: Diabetes Family Responsibility Questionnaire, PedsQL: Paediatric Quality of Life Questionnaire, PAID: Problem Areas in Diabetes Questionnaire, SED: Self-Efficacy for Diabetes Questionnaire, DSCI: Diabetes Self-Care Inventory.*

<b>Item(s) in SCI</b>	<b>Change Made</b>	<b>Item in SCI-R</b>
<b>“eat meals on time” and “eat snacks on time”</b>	Items combined	<b>“eat meals/snacks on time”</b>
<b>“exercise strenuously”</b>	Item removed	N/A
<b>“testing blood glucose”</b>	Wording changed	<b>“check blood glucose with monitor”</b>
<b>“recording ketones”</b>	Wording changed	<b>“check ketones when blood glucose level is high”</b>
<b>N/A</b>	Item added	<b>“keeping food records”</b>
<b>N/A</b>	Item added	<b>“reading food labels”</b>
<b>N/A</b>	Item added	<b>“treating low blood glucose”</b>

*Table 3.2 Changes made to the SCI to create the SCI-R. Legend; SCI: Self-Care Inventory, SCI-R: Revised Self-Care Inventory, N/A: not applicable. Adapted from (187,188).*




Figure 3.2 Graph showing the heterogeneity of methods used to assess adherence. Note that the “method used 10 times” was “questionnaire not otherwise specified”, so is likely composed of many different questionnaires.

### 3.5. Range of Factors Assessed and Themes

Across the included studies there were 236 factors checked for association with adherence.

<b>Factor Checked for Association with Adherence</b>	<b>Number of Studies Assessing this Factor</b>	<b>Theme</b>
Age	33	Demographics
HbA1c/Glycaemic control	20	Diabetes management
Duration of diabetes	19	Demographics
Gender	15	Demographics
Family conflict	8	Family dynamics
Depression	7	Psycho-social
Self-Efficacy*	7	Psycho-social
Support from family	7	Family dynamics
Cohesion	5	Family dynamics
Diabetes knowledge	4	Diabetes management
Exercise frequency	4	Psycho-social
Child's increasing responsibility	3	Family dynamics
CSII vs MDI	3	Diabetes management
Household income	3	Demographics
Patient perceptions of family organisation	3	Family dynamics
Socio-economic status	3	Demographics
Stress	3	Psycho-social
Better parent-child relationship	2	Family dynamics
BGM frequency	2	Diabetes management
BMI SDS	2	Past medical history
Caregiver education level	2	Demographics
Diabetes adjustment	2	Psycho-social
Family stress	2	Psycho-social
Frequency of alcohol consumption	2	Psycho-social
Perceived impact	2	Psycho-social
Perceived threat	2	Psycho-social
Single parent household vs both parents	2	Family dynamics
Smoking frequency	2	Psycho-social
Social competence	2	Psycho-social
"Sweet talk" text message intervention	1	Psycho-social
Acceptance	1	Psycho-social
Achievement striving	1	Psycho-social
Activity level	1	Psycho-social
ADHD	1	Psycho-social
Adjustment disorder	1	Psycho-social
Adolescent diabetes technology index	1	Diabetes management
Adventurousness	1	Psycho-social
Agoraphobia	1	Psycho-social

Agreeableness	1	Psycho-social
Alcohol/drug abuse	1	Psycho-social
Altruism	1	Psycho-social
Amount of sleep	1	Psycho-social
Anger	1	Psycho-social
Anxiety	1	Psycho-social
Any psychiatric disorder	1	Psycho-social
Artistic interests	1	Psycho-social
Assertiveness	1	Psycho-social
Attitude	1	Psycho-social
Authoritarian family function	1	Family dynamics
Barriers to adherence	1	Psycho-social
Behavioural support	1	Family dynamics
Benefits - costs	1	Psycho-social
Binging	1	Psycho-social
Boluses delivered day before clinic visit (designed to assess white coat adherence)	1	Diabetes management
Cautiousness	1	Psycho-social
Cheerfulness	1	Psycho-social
Child's executive functioning	1	Psycho-social
Clinical/subclinical eating disorders	1	Psycho-social
Communication	1	Psycho-social
Compliance in the first 9 months' association with compliance in the second 9 months	1	Diabetes management
Conduct disorder	1	Psycho-social
Conscientiousness	1	Psycho-social
Consequences	1	Psycho-social
Control group vs intervention (trained by professionals who received a communication training plan) group	1	Psycho-social
Co-operation	1	Psycho-social
Coping measures: ego defense level	1	Psycho-social
Cues	1	Psycho-social
Cure-control	1	Psycho-social
Diabetes monitoring	1	Diabetes management
Diabetes Social Support Questionnaire: frequency	1	Psycho-social
Diabetes Social Support Questionnaire: individualised	1	Psycho-social
Discipline	1	Psycho-social
DSMP hypoglycaemia subscale: diet	1	Diabetes management
DSMP subscale: glucose testing	1	Diabetes management
DSMP subscale: hypoglycaemia management	1	Diabetes management
Dutifulness	1	Psycho-social
Dysthymia	1	Psycho-social
Eating Attitudes Test 26	1	Psycho-social
Eating disorders (clinical/subclinical)	1	Psycho-social



<b>Eating Disorders Inventory - Body Dissatisfaction Scale</b>	1	Psycho-social
<b>Education group vs positive affect (PA) text message group</b>	1	Psycho-social
<b>Education intervention</b>	1	Psycho-social
<b>Emergency (hypoglycaemia) precautions</b>	1	Diabetes management
<b>Emotional adjustment</b>	1	Psycho-social
<b>Emotionality</b>	1	Psycho-social
<b>Energy and willpower</b>	1	Psycho-social
<b>Excitement seeking</b>	1	Psycho-social
<b>Experience of results</b>	1	Psycho-social
<b>Expressiveness</b>	1	Psycho-social
<b>Externalising behaviour</b>	1	Psycho-social
<b>Extraversion</b>	1	Psycho-social
<b>Family relations</b>	1	Family dynamics
<b>Family support: affective</b>	1	Family dynamics
<b>Family support: control</b>	1	Family dynamics
<b>Family support: indirect</b>	1	Family dynamics
<b>Family support: no support</b>	1	Family dynamics
<b>Father negative</b>	1	Family dynamics
<b>Father-absent vs father-present</b>	1	Family dynamics
<b>Feel that diabetes affects their mental wellbeing</b>	1	Psycho-social
<b>Feel that diabetes affects their physical wellbeing</b>	1	Psycho-social
<b>Feel that they have support from nurses</b>	1	Psycho-social
<b>Feel that they have support from their physician</b>	1	Psycho-social
<b>Frequency of breakfast</b>	1	Psycho-social
<b>Frequency of dinner</b>	1	Psycho-social
<b>Frequency of evening snack</b>	1	Psycho-social
<b>Frequency of help</b>	1	Psycho-social
<b>Frequency of lunch</b>	1	Psycho-social
<b>Frequency of mid-afternoon snack</b>	1	Psycho-social
<b>Frequency of mid-morning snack</b>	1	Psycho-social
<b>Friendliness</b>	1	Psycho-social
<b>Functional enuresis</b>	1	Psycho-social
<b>General monitoring</b>	1	Psycho-social
<b>Generalised anxiety disorder</b>	1	Psycho-social
<b>Gregariousness</b>	1	Psycho-social
<b>HBM: Benefits</b>	1	Psycho-social
<b>HBM: costs</b>	1	Psycho-social
<b>HBM: cues to action</b>	1	Psycho-social
<b>HBM: Susceptibility</b>	1	Psycho-social
<b>Health Belief Model (HBM): Severity</b>	1	Psycho-social
<b>HFS: Behaviour</b>	1	Psycho-social
<b>HFS: worry/fear</b>	1	Psycho-social
<b>Identity</b>	1	Psycho-social
<b>Imagination</b>	1	Psycho-social
<b>Immigrant vs French Native mother: General insulin adherence</b>	1	Demographics

<b>Immigrant vs French Native mother: Percentage that adjust insulin dose during illness</b>	1	Demographics
<b>Impulsiveness</b>	1	Psycho-social
<b>Increased disease severity</b>	1	Past medical history
<b>Increased severity of risks</b>	1	Psycho-social
<b>Increased treatment complexity</b>	1	Diabetes management
<b>Increased vulnerability to risks</b>	1	Psycho-social
<b>Increasing lack of responsibility from mother or child</b>	1	Family dynamics
<b>Independence</b>	1	Psycho-social
<b>Independence and encouragement</b>	1	Psycho-social
<b>Insulin dosage calculator use: control group (manual calculations)</b>	1	Diabetes management
<b>Insulin dosage calculator use regularity</b>	1	Diabetes management
<b>Intellect</b>	1	Psycho-social
<b>Intensity of insulin regimen (2 vs 4 injections per day)</b>	1	Diabetes management
<b>Internalising behaviour</b>	1	Psycho-social
<b>Intervention group (12 play sessions) vs control group</b>	1	Psycho-social
<b>Intervention group (monthly diabetes education session) vs control group</b>	1	Diabetes management
<b>Intrusive support</b>	1	Psycho-social
<b>Liberalism</b>	1	Psycho-social
<b>Locus of control (internal/external etc.)</b>	1	Psycho-social
<b>Maternal Involvement</b>	1	Family dynamics
<b>Mean daily blood glucose</b>	1	Diabetes management
<b>Mean diabetes-specific stress (DSS) severity</b>	1	Psycho-social
<b>Method of insulin delivery</b>	1	Diabetes management
<b>Modesty</b>	1	Psycho-social
<b>Morality</b>	1	Psycho-social
<b>Mother negative</b>	1	Family dynamics
<b>Mother report of social functioning</b>	1	Psycho-social
<b>Mother's age</b>	1	Demographics
<b>Mother's education</b>	1	Demographics
<b>Mother's increasing responsibility for management of daily regimen tasks</b>	1	Family dynamics
<b>Mother's increasing responsibility for management of general health</b>	1	Family dynamics
<b>Mother's increasing responsibility for social presentation (talking to family and friends about disease etc.)</b>	1	Family dynamics
<b>Mother's sense of empowerment</b>	1	Psycho-social
<b>Motivation level</b>	1	Psycho-social
<b>Negative communication</b>	1	Psycho-social
<b>Negotiated Telephone Support</b>	1	Psycho-social

<b>Negotiated Telephone Support, yearly clinical review, 3-monthly measurement of HbA1c</b>	1	Diabetes management
<b>Neuroticism</b>	1	Psycho-social
<b>Non-supportive family</b>	1	Family dynamics
<b>Non-white adolescent</b>	1	Demographics
<b>Number of adverse life events</b>	1	Psycho-social
<b>Number of children in family</b>	1	Family dynamics
<b>Number of hospital admissions</b>	1	Past medical history
<b>OCD</b>	1	Psycho-social
<b>Openness to experience</b>	1	Psycho-social
<b>Oppositional defiant disorder</b>	1	Psycho-social
<b>Orderliness</b>	1	Psycho-social
<b>Overall QoL</b>	1	Psycho-social
<b>Parent perception of child's independence</b>	1	Family dynamics
<b>Parent perception of control</b>	1	Psycho-social
<b>Parent perception of family organisation</b>	1	Family dynamics
<b>Parental marital status</b>	1	Family dynamics
<b>Parents' health literacy</b>	1	Psycho-social
<b>Parents perceptions of expressiveness</b>	1	Psycho-social
<b>Parents' reading comprehension</b>	1	Psycho-social
<b>Patient perception of control</b>	1	Psycho-social
<b>Patient perception of independence</b>	1	Family dynamics
<b>Patient perceptions of expressiveness</b>	1	Psycho-social
<b>Perceived competence</b>	1	Psycho-social
<b>Perceived level of hope</b>	1	Psycho-social
<b>Presence of co-morbidities</b>	1	Past medical history
<b>Presence of threat to emotional well-being</b>	1	Psycho-social
<b>Presence of threat to physical well-being</b>	1	Psycho-social
<b>Presence of threat to social wellbeing</b>	1	Psycho-social
<b>Psychosis</b>	1	Psycho-social
<b>PTSD</b>	1	Psycho-social
<b>PTSD diagnosis of mother</b>	1	Psycho-social
<b>QoL (with number of injections per day)</b>	1	Psycho-social
<b>QoL: Diabetes worry</b>	1	Psycho-social
<b>QoL: Satisfaction</b>	1	Psycho-social
<b>QoL: Social worry</b>	1	Psycho-social
<b>Race</b>	1	Demographics
<b>Recent change in insulin dose</b>	1	Diabetes management
<b>Regular Use of I-Port</b>	1	Diabetes management
<b>Report of symptom severity</b>	1	Diabetes management
<b>Response costs</b>	1	Psycho-social
<b>Response efficacy</b>	1	Psycho-social
<b>School/work performance</b>	1	Psycho-social
<b>Self-consciousness</b>	1	Psycho-social
<b>Self-discipline</b>	1	Psycho-social

<b>Self-report on adherence to BGM</b>	1	Diabetes management
<b>Self-report on adherence to meals</b>	1	Diabetes management
<b>Self-report on adherence to snacks</b>	1	Diabetes management
<b>Sense of normality</b>	1	Psycho-social
<b>Separation anxiety disorder</b>	1	Psycho-social
<b>Sociability scores</b>	1	Psycho-social
<b>Social anxiety</b>	1	Psycho-social
<b>Social phobia</b>	1	Psycho-social
<b>Specific (isolated) phobias</b>	1	Psycho-social
<b>Support from friends</b>	1	Psycho-social
<b>Support from nurses</b>	1	Psycho-social
<b>Support from physicians</b>	1	Psycho-social
<b>Sympathy</b>	1	Psycho-social
<b>Teacher victimisation</b>	1	Psycho-social
<b>Threat</b>	1	Psycho-social
<b>Timeline</b>	1	Psycho-social
<b>Total DSMP score</b>	1	Diabetes management
<b>Total HFS</b>	1	Diabetes management
<b>Total meals</b>	1	Psycho-social
<b>Treatment effectiveness: control</b>	1	Psycho-social
<b>Treatment effectiveness: prevent</b>	1	Psycho-social
<b>Trust</b>	1	Psycho-social
<b>Type of insulin pen</b>	1	Diabetes management
<b>Uses diabetes apps</b>	1	Diabetes management
<b>Uses diabetes websites</b>	1	Diabetes management
<b>Uses meter/pump software</b>	1	Diabetes management
<b>Uses social networking</b>	1	Psycho-social
<b>Uses text messaging</b>	1	Psycho-social
<b>Utilising personal and interpersonal resources coping strategy</b>	1	Psycho-social
<b>Ventilation and avoidance coping strategy</b>	1	Psycho-social
<b>Vulnerability</b>	1	Psycho-social
<b>Warmth from family</b>	1	Family dynamics

Table 3.3 lists these factors, the number of studies that assessed them and the associated theme for thematic analysis (see section 4). A bar chart summarising the results of this table can be found in Figure 3.3.

<b>Factor Checked for Association with Adherence</b>	<b>Number of Studies Assessing this Factor</b>	<b>Theme</b>
Age	33	Demographics
HbA1c/Glycaemic control	20	Diabetes management
Duration of diabetes	19	Demographics
Gender	15	Demographics
Family conflict	8	Family dynamics
Depression	7	Psycho-social
Self-Efficacy*	7	Psycho-social
Support from family	7	Family dynamics
Cohesion	5	Family dynamics
Diabetes knowledge	4	Diabetes management
Exercise frequency	4	Psycho-social
Child's increasing responsibility	3	Family dynamics
CSII vs MDI	3	Diabetes management
Household income	3	Demographics
Patient perceptions of family organisation	3	Family dynamics
Socio-economic status	3	Demographics
Stress	3	Psycho-social
Better parent-child relationship	2	Family dynamics
BGM frequency	2	Diabetes management
BMI SDS	2	Past medical history
Caregiver education level	2	Demographics
Diabetes adjustment	2	Psycho-social
Family stress	2	Psycho-social
Frequency of alcohol consumption	2	Psycho-social
Perceived impact	2	Psycho-social
Perceived threat	2	Psycho-social
Single parent household vs both parents	2	Family dynamics
Smoking frequency	2	Psycho-social
Social competence	2	Psycho-social
"Sweet talk" text message intervention	1	Psycho-social
Acceptance	1	Psycho-social
Achievement striving	1	Psycho-social
Activity level	1	Psycho-social
ADHD	1	Psycho-social
Adjustment disorder	1	Psycho-social
Adolescent diabetes technology index	1	Diabetes management
Adventurousness	1	Psycho-social
Agoraphobia	1	Psycho-social
Agreeableness	1	Psycho-social
Alcohol/drug abuse	1	Psycho-social
Altruism	1	Psycho-social
Amount of sleep	1	Psycho-social

<b>Anger</b>	1	Psycho-social
<b>Anxiety</b>	1	Psycho-social
<b>Any psychiatric disorder</b>	1	Psycho-social
<b>Artistic interests</b>	1	Psycho-social
<b>Assertiveness</b>	1	Psycho-social
<b>Attitude</b>	1	Psycho-social
<b>Authoritarian family function</b>	1	Family dynamics
<b>Barriers to adherence</b>	1	Psycho-social
<b>Behavioural support</b>	1	Family dynamics
<b>Benefits - costs</b>	1	Psycho-social
<b>Binging</b>	1	Psycho-social
<b>Boluses delivered day before clinic visit (designed to assess white coat adherence)</b>	1	Diabetes management
<b>Cautiousness</b>	1	Psycho-social
<b>Cheerfulness</b>	1	Psycho-social
<b>Child's executive functioning</b>	1	Psycho-social
<b>Clinical/subclinical eating disorders</b>	1	Psycho-social
<b>Communication</b>	1	Psycho-social
<b>Compliance in the first 9 months' association with compliance in the second 9 months</b>	1	Diabetes management
<b>Conduct disorder</b>	1	Psycho-social
<b>Conscientiousness</b>	1	Psycho-social
<b>Consequences</b>	1	Psycho-social
<b>Control group vs intervention (trained by professionals who received a communication training plan) group</b>	1	Psycho-social
<b>Co-operation</b>	1	Psycho-social
<b>Coping measures: ego defense level</b>	1	Psycho-social
<b>Cues</b>	1	Psycho-social
<b>Cure-control</b>	1	Psycho-social
<b>Diabetes monitoring</b>	1	Diabetes management
<b>Diabetes Social Support Questionnaire: frequency</b>	1	Psycho-social
<b>Diabetes Social Support Questionnaire: individualised</b>	1	Psycho-social
<b>Discipline</b>	1	Psycho-social
<b>DSMP hypoglycaemia subscale: diet</b>	1	Diabetes management
<b>DSMP subscale: glucose testing</b>	1	Diabetes management
<b>DSMP subscale: hypoglycaemia management</b>	1	Diabetes management
<b>Dutifulness</b>	1	Psycho-social
<b>Dysthymia</b>	1	Psycho-social
<b>Eating Attitudes Test 26</b>	1	Psycho-social
<b>Eating disorders (clinical/subclinical)</b>	1	Psycho-social
<b>Eating Disorders Inventory - Body Dissatisfaction Scale</b>	1	Psycho-social
<b>Education group vs positive affect (PA) text message group</b>	1	Psycho-social

Education intervention	1	Psycho-social
Emergency (hypoglycaemia) precautions	1	Diabetes management
Emotional adjustment	1	Psycho-social
Emotionality	1	Psycho-social
Energy and willpower	1	Psycho-social
Excitement seeking	1	Psycho-social
Experience of results	1	Psycho-social
Expressiveness	1	Psycho-social
Externalising behaviour	1	Psycho-social
Extraversion	1	Psycho-social
Family relations	1	Family dynamics
Family support: affective	1	Family dynamics
Family support: control	1	Family dynamics
Family support: indirect	1	Family dynamics
Family support: no support	1	Family dynamics
Father negative	1	Family dynamics
Father-absent vs father-present	1	Family dynamics
Feel that diabetes affects their mental wellbeing	1	Psycho-social
Feel that diabetes affects their physical wellbeing	1	Psycho-social
Feel that they have support from nurses	1	Psycho-social
Feel that they have support from their physician	1	Psycho-social
Frequency of breakfast	1	Psycho-social
Frequency of dinner	1	Psycho-social
Frequency of evening snack	1	Psycho-social
Frequency of help	1	Psycho-social
Frequency of lunch	1	Psycho-social
Frequency of mid-afternoon snack	1	Psycho-social
Frequency of mid-morning snack	1	Psycho-social
Friendliness	1	Psycho-social
Functional enuresis	1	Psycho-social
General monitoring	1	Psycho-social
Generalised anxiety disorder	1	Psycho-social
Gregariousness	1	Psycho-social
HBM: Benefits	1	Psycho-social
HBM: costs	1	Psycho-social
HBM: cues to action	1	Psycho-social
HBM: Susceptibility	1	Psycho-social
Health Belief Model (HBM): Severity	1	Psycho-social
HFS: Behaviour	1	Psycho-social
HFS: worry/fear	1	Psycho-social
Identity	1	Psycho-social
Imagination	1	Psycho-social
Immigrant vs French Native mother: General insulin adherence	1	Demographics
Immigrant vs French Native mother: Percentage that adjust insulin dose during illness	1	Demographics
Impulsiveness	1	Psycho-social
Increased disease severity	1	Past medical history

<b>Increased severity of risks</b>	1	Psycho-social
<b>Increased treatment complexity</b>	1	Diabetes management
<b>Increased vulnerability to risks</b>	1	Psycho-social
<b>Increasing lack of responsibility from mother or child</b>	1	Family dynamics
<b>Independence</b>	1	Psycho-social
<b>Independence and encouragement</b>	1	Psycho-social
<b>Insulin dosage calculator use: control group (manual calculations)</b>	1	Diabetes management
<b>Insulin dosage calculator use regularity</b>	1	Diabetes management
<b>Intellect</b>	1	Psycho-social
<b>Intensity of insulin regimen (2 vs 4 injections per day)</b>	1	Diabetes management
<b>Internalising behaviour</b>	1	Psycho-social
<b>Intervention group (12 play sessions) vs control group</b>	1	Psycho-social
<b>Intervention group (monthly diabetes education session) vs control group</b>	1	Diabetes management
<b>Intrusive support</b>	1	Psycho-social
<b>Liberalism</b>	1	Psycho-social
<b>Locus of control (internal/external etc.)</b>	1	Psycho-social
<b>Maternal Involvement</b>	1	Family dynamics
<b>Mean daily blood glucose</b>	1	Diabetes management
<b>Mean diabetes-specific stress (DSS) severity</b>	1	Psycho-social
<b>Method of insulin delivery</b>	1	Diabetes management
<b>Modesty</b>	1	Psycho-social
<b>Morality</b>	1	Psycho-social
<b>Mother negative</b>	1	Family dynamics
<b>Mother report of social functioning</b>	1	Psycho-social
<b>Mother's age</b>	1	Demographics
<b>Mother's education</b>	1	Demographics
<b>Mother's increasing responsibility for management of daily regimen tasks</b>	1	Family dynamics
<b>Mother's increasing responsibility for management of general health</b>	1	Family dynamics
<b>Mother's increasing responsibility for social presentation (talking to family and friends about disease etc.)</b>	1	Family dynamics
<b>Mother's sense of empowerment</b>	1	Psycho-social
<b>Motivation level</b>	1	Psycho-social
<b>Negative communication</b>	1	Psycho-social
<b>Negotiated Telephone Support</b>	1	Psycho-social
<b>Negotiated Telephone Support, yearly clinical review, 3-monthly measurement of HbA1c</b>	1	Diabetes management
<b>Neuroticism</b>	1	Psycho-social
<b>Non-supportive family</b>	1	Family dynamics
<b>Non-white adolescent</b>	1	Demographics



<b>Number of adverse life events</b>	1	Psycho-social
<b>Number of children in family</b>	1	Family dynamics
<b>Number of hospital admissions</b>	1	Past medical history
<b>OCD</b>	1	Psycho-social
<b>Openness to experience</b>	1	Psycho-social
<b>Oppositional defiant disorder</b>	1	Psycho-social
<b>Orderliness</b>	1	Psycho-social
<b>Overall QoL</b>	1	Psycho-social
<b>Parent perception of child's independence</b>	1	Family dynamics
<b>Parent perception of control</b>	1	Psycho-social
<b>Parent perception of family organisation</b>	1	Family dynamics
<b>Parental marital status</b>	1	Family dynamics
<b>Parents' health literacy</b>	1	Psycho-social
<b>Parents perceptions of expressiveness</b>	1	Psycho-social
<b>Parents' reading comprehension</b>	1	Psycho-social
<b>Patient perception of control</b>	1	Psycho-social
<b>Patient perception of independence</b>	1	Family dynamics
<b>Patient perceptions of expressiveness</b>	1	Psycho-social
<b>Perceived competence</b>	1	Psycho-social
<b>Perceived level of hope</b>	1	Psycho-social
<b>Presence of co-morbidities</b>	1	Past medical history
<b>Presence of threat to emotional well-being</b>	1	Psycho-social
<b>Presence of threat to physical well-being</b>	1	Psycho-social
<b>Presence of threat to social wellbeing</b>	1	Psycho-social
<b>Psychosis</b>	1	Psycho-social
<b>PTSD</b>	1	Psycho-social
<b>PTSD diagnosis of mother</b>	1	Psycho-social
<b>QoL (with number of injections per day)</b>	1	Psycho-social
<b>QoL: Diabetes worry</b>	1	Psycho-social
<b>QoL: Satisfaction</b>	1	Psycho-social
<b>QoL: Social worry</b>	1	Psycho-social
<b>Race</b>	1	Demographics
<b>Recent change in insulin dose</b>	1	Diabetes management
<b>Regular Use of I-Port</b>	1	Diabetes management
<b>Report of symptom severity</b>	1	Diabetes management
<b>Response costs</b>	1	Psycho-social
<b>Response efficacy</b>	1	Psycho-social
<b>School/work performance</b>	1	Psycho-social
<b>Self-consciousness</b>	1	Psycho-social
<b>Self-discipline</b>	1	Psycho-social
<b>Self-report on adherence to BGM</b>	1	Diabetes management
<b>Self-report on adherence to meals</b>	1	Diabetes management

<b>Self-report on adherence to snacks</b>	1	Diabetes management
<b>Sense of normality</b>	1	Psycho-social
<b>Separation anxiety disorder</b>	1	Psycho-social
<b>Sociability scores</b>	1	Psycho-social
<b>Social anxiety</b>	1	Psycho-social
<b>Social phobia</b>	1	Psycho-social
<b>Specific (isolated) phobias</b>	1	Psycho-social
<b>Support from friends</b>	1	Psycho-social
<b>Support from nurses</b>	1	Psycho-social
<b>Support from physicians</b>	1	Psycho-social
<b>Sympathy</b>	1	Psycho-social
<b>Teacher victimisation</b>	1	Psycho-social
<b>Threat</b>	1	Psycho-social
<b>Timeline</b>	1	Psycho-social
<b>Total DSMP score</b>	1	Diabetes management
<b>Total HFS</b>	1	Diabetes management
<b>Total meals</b>	1	Psycho-social
<b>Treatment effectiveness: control</b>	1	Psycho-social
<b>Treatment effectiveness: prevent</b>	1	Psycho-social
<b>Trust</b>	1	Psycho-social
<b>Type of insulin pen</b>	1	Diabetes management
<b>Uses diabetes apps</b>	1	Diabetes management
<b>Uses diabetes websites</b>	1	Diabetes management
<b>Uses meter/pump software</b>	1	Diabetes management
<b>Uses social networking</b>	1	Psycho-social
<b>Uses text messaging</b>	1	Psycho-social
<b>Utilising personal and interpersonal resources coping strategy</b>	1	Psycho-social
<b>Ventilation and avoidance coping strategy</b>	1	Psycho-social
<b>Vulnerability</b>	1	Psycho-social
<b>Warmth from family</b>	1	Family dynamics

*Table 3.3 List of factors checked for association for adherence and the number of studies that assessed them. Legend; DSMP: Diabetes Self-Management Profile, QoL: Quality of Life, DSS: Diabetes Social Support questionnaire, ADHD: Attention Deficit Hyperactivity Disorder, OCD: Obsessive Compulsive Disorder, PTSD: Post-Traumatic Stress Disorder, HbA1c: glycated haemoglobin, BMI: Body Mass Index, RCT: Randomised Control Trial, BGM: Blood Glucose Monitoring, GAD: Generalised Anxiety Disorder. \*Self-efficacy refers to the ability of the child/young person to complete a range of diabetes management tasks, as perceived by the child/young person.*




Figure 3.3 Graph showing the heterogeneity of factors assessed for adherence. One factor was assessed in 32 studies while 158 factors were assessed in just 1 study.

### 3.6. Primary Outcome: Factors Affecting Adherence to Insulin Therapy

In the majority of cases, effects upon adherence were calculated using regression analysis with the strength of the relationship being expressed as Pearson correlations ( $r$ ). Some studies also quantified the size of the effect using beta ( $\beta$ ) values.

For Pearson correlation coefficients ( $r$ ) and beta values ( $\beta$ ), a positive value can be interpreted that adherence improved with the assessed factor and a negative value that adherence worsened with the assessed factor, unless otherwise specified.

If results are not published using Pearson correlations and/or  $\beta$  values, this will be explained alongside the result.

Due to the heterogeneity of the studies involved, as a result of the large number of different methods used to assess adherence and the different factors that were assessed for correlation with adherence, meta-analysis of the studies was not possible.

Due to the large number of factors that were only assessed by 1 study, only factors that were assessed by 4 or more studies have been discussed in detail below. A briefer summary of the remaining studies and factors can be found in Table 3.15.

#### 3.6.1. Age

Thirty-three studies (116,122,123,125,128,132–134,136–138,140,143–145,148,150,151,153,154,156,158,160,163,165–169,177,178,192,193) examined the effect of age upon treatment adherence. These studies are summarised in Table 3.4. To allow for a quick visual estimate of the overall message of the results, the “effect on adherence” column is coloured orange with significant results that suggest adherence worsens with age, and coloured green with significant results that suggest adherence improves with age. Results that are not statistically significant have been left white.

The studies contained a total of 6 134 children and young people with an average of 192 children per study and a range of 31 to 2011. Almost half (3 039/6 134; 49.4%) of these participants came from just two studies.

The 33 studies used 23 different methods of measuring adherence.

24/33 (73%) of these studies (122,123,125,132–134,136–138,140,143–145,151,153,158,163,166–169,177,178,192) had results showing a significant effect for age in at least one of their methods of measuring adherence.

All but two (66.66% of studies) (128) (193) of the papers with statistically significant results suggested that adherence became worse with age in childhood. In addition to demonstrating worsening adherence with advancing age through childhood, two studies (167,178) found that adherence begins to improve once participants exited adolescence into adulthood.

One study (126) found that the strength of the correlation ( $r$ ) between age and adherence was negative and statistically significant, but that when looking at the size of the effect ( $\beta$ ), this was not statistically significant.

The weighted mean (mean of means, taking into account sample size) of the two papers showing adherence improves with age was 11.4 years and the weighted mean of the papers (where both mean age and sample size was known) showing that adherence worsens with age was 13.4 years.

Seven of the studies used an objective measure of adherence (132,138,143,151,165–167), with the remaining 25 studies using a subjective measure; the majority of these were self-report measures, though one (178) had the participant's healthcare providers rating the adherence of the participant.

Of the studies that used objective measures to measure adherence, 2 used BOLUS scores (132,165), 2 used MPR (166,167) (with one of these (166) also using HbA1c and 3 used data retrospectively taken from insulin pumps (137,138,143). Note that BOLUS scores do require retrieving data from insulin pumps, but convert this data into a standardised score, so cannot be considered to be the same thing. Of the 2 studies that used MPR, each study expressed their results differently, with 1 (167) giving the individual scores for each group and the other (166) using Pearson scores. The heterogeneity of the methods of assessing and reporting adherence makes meta-analysis difficult. Just two studies (137,138) used the same method of measuring and reporting adherence (retrospectively collected pump data and Pearson correlations respectively). These two studies had slightly different outcomes, with one (137) assessing the effect of age on two different aspects of

adherence to insulin therapy and the other (138) assessing adherence at two different timepoints, again making meta-analysis not possible.

All of the studies assessing the relationship between age and adherence were observational studies, which according to the GRADE framework (see section 2.2.7), begins the body of evidence at “low certainty”. There were insufficient studies that demonstrated either a large magnitude of effect, a dose-response gradient, or a reduction in the effect size with additional confounders in order to increase the grading for this factor. Reduction of the grade by reason of risk of bias (including publication bias), imprecision, inconsistency or indirectness was also not considered necessary, leaving the body of evidence for this factor as “low certainty”.

Study	Mean age (range)	Sample size	Method of measuring adherence	Adherence to insulin therapy specifically assessed and presented separately in results? (Y/N)	Effect on adherence	Statistically significant? (Y/N)	P-value	Comments
Jacobson, 1990 (163)	NK	61	Self-created 4-point scale (1-4; poor-excellent), used by paediatricians or diabetes nurse specialists to make an assessment. Validated by Jacobson et al., 1987.	N	r= -0.4	Y	<0.007	
					β= -0.11	Y	0.0001	
Patton, 2017 (165)	5.2 (0.27-6.94)	116	BOLUS score	Y	r=-0.054	N	>0.05	

Study	Mean age (range)	Sample size	Method of measuring adherence	Adherence to insulin therapy specifically assessed and presented separately in results? (Y/N)	Effect on adherence	Statistically significant? (Y/N)	P-value	Comments
<b>Ying, 2017</b> (166)	14.39 (NK)	57	Medication Possession Ratio (MPR) and HbA1c	Y	$\beta = -0.435$	Y	<0.05	MPR equals the total number of days of supply for all claims during the study period divided by a total number of days elapsed during the period.
<b>Morris, 1997</b> (167)	16 (NK)	89	Medication Possession Ratio (MPR)	Y	<10 years old mean score: ~725 10-15 years old mean score: ~400 15-20 years old mean score: ~350 >20 years old mean score: 520	Y	0.0001	Results published were the raw scores calculated, with higher scores meaning better adherence. They are listed here as approximations as they were only published in graph form.



Study	Mean age (range)	Sample size	Method of measuring adherence	Adherence to insulin therapy specifically assessed and presented separately in results? (Y/N)	Effect on adherence	Statistically significant? (Y/N)	P-value	Comments
<b>Johnson, 1990</b> (168)	NK (6-19)	78	24-hour recall interviews	Y	r= 0.755	Y	<0.05	Higher scores conferred to worse adherence, hence this positive value indicating that adherence worsens with age.
<b>Palardy, 1998</b> (116)	14.07 (11-17)	101	Summary of Self-Care Activities Questionnaire	N	$R_{1,2} = -0.06$	N	>0.05	Used zero-order correlations ( $r_{1,2}$ ), indicating that no variables have been controlled for.
<b>Anderson, 1990</b> (169)	13.3 (6-21)	121	Diabetes Family Responsibility Questionnaire (DFRQ)	N	Mother's report: r= 0.26 Child's report: r= 0.29	Y	<0.01	Higher scores indicated worse adherence, so the positive relationship actually indicates poorer adherence with increasing age.

Study	Mean age (range)	Sample size	Method of measuring adherence	Adherence to insulin therapy specifically assessed and presented separately in results? (Y/N)	Effect on adherence	Statistically significant? (Y/N)	P-value	Comments
Hanson, 1989 (122)	NK	135	Self-report questionnaire based on Ceroney and Hart, 1980	N	r= -0.21	Y	0.008	
Nakamura, 2019 (128)	13.1 (NK)	123	Revised Diabetes Self-Care Inventory (SCI-R)	N	r= 0.21	Y	<0.05	Question was phrased as "regularity of insulin injections and snacks."
Hanson, 1995 (123)	15.2 (12-20)	157	Interview	N	r= -0.44	Y	<0.0001	
Calkins-Smith, 2018 (132)	13.68 (10-17)	90	BOLUS scores	Y	r= -0.27	Y	<0.01	
La Greca, 1995 (133)	14.2 (11-18)	74	Interview (developed by Hanson et al., 1992)	N	r= -0.24	Y	<0.05	

Study	Mean age (range)	Sample size	Method of measuring adherence	Adherence to insulin therapy specifically assessed and presented separately in results? (Y/N)	Effect on adherence	Statistically significant? (Y/N)	P-value	Comments
<b>Pereira, 2008</b> (136)	15 (10-18)	157	Self-Report Questionnaire on Adherence (Almeida & Pereira, 2003)	N	r= 0.221	Y	<0.01	Higher scores on the questionnaire used in this study indicated worse adherence, so this positive result should be interpreted as "adherence become worse with increasing age".
<b>Driscoll, 2013</b> (137)	13.11 (7-19)	31	Retrospectively taken from patients' insulin pumps	Y	Bolus delivering: r= -0.46	Y	<0.01	
					Carbohydrates being entered into calculator before calculating insulin dose: r= -0.46	Y	<0.05	

Study	Mean age (range)	Sample size	Method of measuring adherence	Adherence to insulin therapy specifically assessed and presented separately in results? (Y/N)	Effect on adherence	Statistically significant? (Y/N)	P-value	Comments
<b>Wiebe, 2011</b> (177)	12.79 (10-15.99)	82	Self-Care Inventory (SCI)	N	Parent's report at T1: R <sub>2</sub> = -0.28	Y	<0.01	Used Multiple Regression Analysis (MRA; R <sub>2</sub> ).
					Child's report at T1: R <sub>2</sub> = -0.17	N	>0.05	
					Parent's report at T2: R <sub>2</sub> = -0.23	Y	<0.05	
					Child's report at T2: R <sub>2</sub> = -0.05	N	>0.05	
<b>Hanson, 1987</b> (125)	14.4 (NK)	93	Self-report and observation (Cerkoney and Hart and Schlenk and Hart)	N	r= -0.21	Y	<0.05	
					β= -0.182	N	>0.05	
<b>Miller-Johnson, 1994</b> (140)	13 (8-18)	88	Self-report diary	N	Parent's report: r= -0.3	Y	<0.01	
					Child's report: r= -0.28	Y	<0.01	
					Nurse's report: r= -0.33	Y	<0.01	

Study	Mean age (range)	Sample size	Method of measuring adherence	Adherence to insulin therapy specifically assessed and presented separately in results? (Y/N)	Effect on adherence	Statistically significant? (Y/N)	P-value	Comments
<b>Stewart, 2000</b> (160)	Case: 15.08, control: 15.17 (9-21)	70	Questionnaire constructed based upon Littlefield et al., 1992	N	r= -0.2	N	>0.05	Specifically assessed the relationship with adherence to “pubertal stage”, with adherence non-significantly worsening with advancing pubertal stage (i.e.- increasing age)
<b>O’Connell, 2011</b> (143)	13.6 (NK)	100	Retrospectively taken from patients' insulin pumps	Y	r= -0.22 bolus events each day per year of age	Y	0.001	
<b>Schober, 2011</b> (144)	NK (10-21)	2011	Diabetes Self-Management Profile (DSMP;	Y	Mean age of compliant group: 14.00	Y	<0.01	Participants were placed in either the

Study	Mean age (range)	Sample size	Method of measuring adherence	Adherence to insulin therapy specifically assessed and presented separately in results? (Y/N)	Effect on adherence	Statistically significant? (Y/N)	P-value	Comments
			Harris et al., 2000)		Mean age of non-compliant group: 15.00			adherent or non-adherent group depending on the responses to the questionnaire, with the mean age of each group being calculated to try to assess the relationship of adherence with age.

Study	Mean age (range)	Sample size	Method of measuring adherence	Adherence to insulin therapy specifically assessed and presented separately in results? (Y/N)	Effect on adherence	Statistically significant? (Y/N)	P-value	Comments
Jacobson, 1987 (178)	12.8 (9-15)	57	Rated by healthcare providers	N	"Patients aged 10-20 years had... a lower adherence index when compared with patients younger than 10 years or older than 20 years" (no numerical value stated)	Y	<0.001	The results were published as quoted with no precise numerical effect.
Kristensen, 2012 (145)	12.3 (NK)	1028	Adherence in Diabetes Questionnaire (ADQ)	N	r= -0.31	Y	<0.001	
Ott, 2000 (148)	13.97 (11-18)	161	Summary of Self-Care Activities (Schafer et al. 1983)	N	R <sub>1,2</sub> = -0.04	N	>0.05	Used zero order correlations.
Patton, 2010 (150)	11.8 (2-17)	201	Self-created survey	Y	MDI users: r= 0.04	N	0.7	
					CSII users: r= -0.01	N	0.99	

Study	Mean age (range)	Sample size	Method of measuring adherence	Adherence to insulin therapy specifically assessed and presented separately in results? (Y/N)	Effect on adherence	Statistically significant? (Y/N)	P-value	Comments
<b>La Greca, 2002</b> (134)	14.2 (11-18)	74	Interview (developed by Hanson et al., 1992)	Y	r= -0.34	Y	<0.01	
<b>Bond, 1992</b> (153)	14.2 (10-19)	56	Diabetes Regimen Compliance Questionnaire (DRCQ; Brownlee-Duffeck et al., 1987)	Y	r= -0.28	Y	<0.05	Used several questionnaires, but only one of them had published results relating to age.
<b>Florian, 1998</b> (154)	15.11 (12-17)	88	Self-Care Questionnaire (Glasgow et al., 1987)	N	r= -0.16	N	>0.05	
<b>Maliszewski, 2017</b> (151)	13.64 (NK)	91	BOLUS scores	Y	r= -0.286	Y	<0.01	
<b>Brownlee-Duffeck, 1987</b> (156)	18 (13-26)	54	Diabetes Regimen Adherence Questionnaire (DRAQ)	N	r= -0.02	N	>0.05	
					$\beta$ = -0.58	N	>0.05	
<b>Vaala, 2015</b> (158)	14.47 (12-17)	174	Self-Care Inventory - Revised (SCI-R)	N	R <sub>2</sub> = -0.18	Y	<0.05	Used MRA.



Study	Mean age (range)	Sample size	Method of measuring adherence	Adherence to insulin therapy specifically assessed and presented separately in results? (Y/N)	Effect on adherence	Statistically significant? (Y/N)	P-value	Comments
<b>Driscoll, 2016</b> (138)	13.15 (7-19)	98	Retrospectively taken from patients' insulin pumps	Y	T1: r= -0.271	Y	<0.01	
					T2: r= -0.243	Y	<0.01	
<b>Moret, 1995</b> (193)	10.2 (7-13)	165	Insulin adjustment score	Y	r= 0.28	Y	<0.001	
<b>Van Dongen, 2005</b> (192)	12.7 (10-15)	53	Insulin Required of Adherence Scale	Y	r= -0.4	Y	<0.01	

Table 3.4 Summary of results of studies that assessed the association between adherence and age. Legend: ADQ: Adherence in Diabetes Questionnaire, DRCQ: Diabetes Regimen Compliance Questionnaire, DFRQ: Diabetes Family Responsibility Questionnaire, MPR: Medication Possession Ratio, SCI: Self-Care Inventory, SCI-R: Revised Self-Care Inventory, Y: yes, N: No, r: Pearson correlation coefficient value,  $\beta$ : beta-value,  $R_2$ : multiple regression analysis value,  $R_{1,2}$ : zero order correlation value, HbA1c: glycated haemoglobin, MRA: Multiple Regression Analysis. Significant results indicating a positive relationship between increasing age and adherence are coloured green and significant results indicating a negative relationship between increasing age and adherence are coloured orange. Results that were not significant have been left white.

### 3.6.2. HbA1c/Glycaemic Control

Twenty studies (121,123,125,126,128,132,135,137,139–141,144,145,151,154,155,159,160,173,176) assessed the correlation between treatment adherence and HbA1c. For one of these studies, the phrasing used was “glycaemic control”. A summary of the studies and their results can be found in Table 3.5. Statistically significant results that suggest HbA1c decreases/glycaemic control improves with improved adherence have been coloured green. Results that were not statistically significant have been left white. One result is yellow as 1 of the domains that it assessed was significant while the other was not significant.

All of the included studies suggested that HbA1c decreased/glycaemic control improved with better adherence. 15 studies (121,123,125,126,128,132,135,137,141,145,151,154,155,160,173) found the relationship to be statistically significant, unanimously across all of their assessed domains.

The studies included a total of 3 365 children and young people with diabetes with a mean of 168 children and a range of 31 to 1028.

The 20 studies used 15 different methods of measuring adherence.

One study (176) found that adherence at study entry was not significantly associated with HbA1c at follow-up, but that the relationship was significant across all other domains (adherence at study entry vs HbA1c at study entry and adherence at follow-up vs HbA1c at both study entry and follow-up).

Another study (159) found that the relationship was not significant when looking at specific age groups (aged 8-11 and 12-17) but was significant when looking at the total sample.

One study (144) found that the relationship was significant when comparing those that were compliant (group A) versus those that were intentionally non-compliant (group B), but not when comparing those that were unintentionally non-compliant (group C) with either of the other groups.

Two studies (139,140) found the relationship to be not significant in the one domain assessed (that being the sample as a whole). One of these studies (139) was approaching significance, with a p-value of 0.056.

No studies - significantly or not significantly - demonstrated that HbA1c increases with improved adherence.

Statistically significant results that demonstrate HbA1c decreases/glycaemic or metabolic control improves with improved treatment adherence are coloured in green. Results that were not statistically significant have been left white.

Studies differed considerably in their methods of measuring adherence and sample populations, so meta-analysis was not considered appropriate.

All of the studies assessing the relationship between HbA1c/glycaemic control and adherence were observational studies, which according to the GRADE framework (see section 2.2.7), begins the body of evidence at “low certainty”. There were insufficient studies that demonstrated either a large magnitude of effect, a dose-response gradient, or a reduction in the effect size with additional confounders in order to increase the grading for this factor. Reduction of the grade by reason of risk of bias (including publication bias), imprecision, inconsistency or indirectness was also not considered necessary, leaving the body of evidence for this factor as “low certainty”.

Study	Mean age (range)	Sample size	Method of measuring adherence	Adherence to insulin therapy specifically assessed and presented separately in results? (Y/N)	Effect on adherence	Statistically significant? (Y/N)	P-value	Comments
<b>Baucom, 2015</b> (173)	7.46 (NK)	175	Questionnaire based on the Self-Care Inventory (SCI)	N	r= -0.31	Y	<0.001	
<b>Kristensen, 2012</b> (145)	12.3 (NK)	1028	Adherence in Diabetes Questionnaire (ADQ)	N	Child's report: r= -0.36	Y	<0.001	
					Parent's report: r= -0.32	Y	<0.001	
<b>Allen, 1983</b> (139)	11.2 (8-17)	34	Rated by two members of clinic staff (5-point Likert-like scale)	N	r= 0.28	N (approaching significance)	0.056	Assessed "metabolic control" as opposed to HbA1c, so the positive correlation should be interpreted as "metabolic control improved as adherence improved".
<b>Nakamura, 2019</b> (128)	13.1 (NK)	123	Revised Diabetes Self-Care Inventory (SCI-R)	N	r= 0.266	Y	<0.01	Assessed "glycaemic control" as opposed to HbA1c, so the positive correlation should be interpreted as "glycaemic control improved as adherence improved".

Study	Mean age (range)	Sample size	Method of measuring adherence	Adherence to insulin therapy specifically assessed and presented separately in results? (Y/N)	Effect on adherence	Statistically significant? (Y/N)	P-value	Comments
Hanson, 1995 (123)	15.2 (12-20)	157	Interview	N	r= -0.3	Y	<0.0001	
Calkins-Smith, 2018 (132)	13.68 (10-17)	90	BOLUS scores	Y	r= -0.4	Y	<0.001	
Griva, 2000 (135)	20.6 (NK)	64	Questionnaire based on the Reported Adherence to Medication Scale (Horne et al. 1999)	N	r= -0.26	Y	<0.01	
McGrady, 2014 (176)	17.45 (15-20)	105	Self-Care Inventory	N	Adherence at entry vs HbA1c at entry: r= -0.28	Y	<0.01	
					Adherence at entry vs HbA1c at follow-up: r= -0.16	N	>0.05	
					Adherence at follow-up vs HbA1c at entry: r= -0.32	Y	<0.01	

Study	Mean age (range)	Sample size	Method of measuring adherence	Adherence to insulin therapy specifically assessed and presented separately in results? (Y/N)	Effect on adherence	Statistically significant? (Y/N)	P-value	Comments
					Adherence at follow-up vs HbA1c at follow-up: $r = -0.48$	Y	<0.01	
<b>Driscoll, 2013</b> (137)	13.11 (7-19)	31	Retrospectively taken from patients' insulin pumps	Y	Adherence to bolus frequency: $r = -0.37$	Y	<0.05	
					Adherence to carbohydrate input: $r = -0.34$	Y	<0.05	
<b>Hanson, 1987 [study 1]</b> (125)	14.4 (NK)	93	Self-report and observation (Cerkoney and Hart and Schlenk and Hart)	N	$r = -0.3$	Y	<0.01	One of two papers with this lead author written during this year and as such, this will be denoted as "Hanson, 1987 [study 1]".

Study	Mean age (range)	Sample size	Method of measuring adherence	Adherence to insulin therapy specifically assessed and presented separately in results? (Y/N)	Effect on adherence	Statistically significant? (Y/N)	P-value	Comments
<b>Miller-Johnson, 1994</b> (140)	13 (8-18)	88	Self-report diary	Y	r= -0.22	N	>0.05	Note that elsewhere where results of this paper have been published, it has not specifically reported insulin adherence; some of its assessed factors were reported as a composite index and others individually.
<b>Berg, 2011</b> (141)	12.49 (NK)	252	Self-Care Inventory (SCI)	N	r= -0.31	Y	<0.01	
<b>Stewart, 2000</b> (160)	Case: 15.08, control: 15.17 (9-21)	70	Questionnaire constructed based upon Littlefield et al., 1992	N	r= -0.41	Y	<0.001	
<b>Kyngäs, 2007</b> (121)	15.1 (NK)	289	Questionnaire (not otherwise specified)	N	Of the group who had a HbA1c below 53mmol/mol, 56% were classed as having good adherence.	Y	<0.0001	

Study	Mean age (range)	Sample size	Method of measuring adherence	Adherence to insulin therapy specifically assessed and presented separately in results? (Y/N)	Effect on adherence	Statistically significant? (Y/N)	P-value	Comments
					Of the group who had a HbA1c above 53mmol/mol, 9% were classed as having good adherence.			
<b>Schober, 2011</b> (144)	NK (10-21)	241	Diabetes Self-Management Profile (DSMP; Harris et al., 2000)	Y	Mean HbA1c of patients classed as being "compliant" (Group A) was 62mmol/mol Mean HbA1c of patients classed as "non-compliant" (Group B) was 72mmol/mol	N/A Y (A vs B), N for other correlations	N/A <0.01 (A vs B), >0.05 (for other correlations)	The study stated that "non-compliance" occurred when participants had deliberately been non-compliant with insulin therapy and "management problems" occurred when participants had unintentionally been non-compliant.



Study	Mean age (range)	Sample size	Method of measuring adherence	Adherence to insulin therapy specifically assessed and presented separately in results? (Y/N)	Effect on adherence	Statistically significant? (Y/N)	P-value	Comments
					Mean HbA1c of patients classed as having "management problems" (Group C) was 62mmol/mol	N for all correlations	>0.05 for all correlations	
<b>Hanson, 1987 [study 2]</b> (126)	14.5 (NK)	104	Self-Report and Observation (based on Cerkoney and Hart, 1980 and Schenk and Hart, 1984)	N	r= -0.28	Y	<0.001	One of two papers with this lead author written during this year and as such, this will be denoted as "Hanson, 1987 [study 2]".
<b>Florian, 1998</b> (154)	15.11 (12-17)	88	Self-Care Questionnaire (Glasgow et al., 1987)	N	r= -0.25	Y	<0.01	
<b>Maliszewski, 2017</b> (151)	13.64 (NK)	91	BOLUS scores	Y	r= -0.556	Y	<0.01	
<b>Kichler, 2008</b> (155)	14.1 (range 11-17)	75	Self-Care Inventory (SCI)	N	r= -0.54	Y	<0.01	
<b>Peters, 2008</b> (159)		167	Diabetes Self-Management	Y	Total sample: r= -0.159	Y	<0.05	

Study	Mean age (range)	Sample size	Method of measuring adherence	Adherence to insulin therapy specifically assessed and presented separately in results? (Y/N)	Effect on adherence	Statistically significant? (Y/N)	P-value	Comments
	12.8 (range 8-17)		Profile (DSMP; Harris et al., 2000)		Aged 8-11: r= -0.072	N	>0.05	
					Age 12-17: r= -0.154	N	>0.05	

Table 3.5 Studies that assessed the relationship between adherence and HbA1c/glycaemic control and their results. Legend; HbA1c: glycated haemoglobin, mmol/mol: millimoles per mole, DSMP: Diabetes Self-Management Profile, SCI: Self-Care Inventory, SCI-R: Revised Self-Care Inventory, r: Pearson correlation coefficient value, ADQ: Adherence in Diabetes Questionnaire, Y: yes, N: no. Statistically significant results that demonstrate HbA1c decreases/glycaemic or metabolic control improves with improved treatment adherence are coloured in green. Results that were not statistically significant have been left white. One study assessed correlations between 3 groups, with 1 of these correlations being significant and the others not significant; this result has been coloured yellow.

### 3.6.3. Duration of Diabetes

19 studies (116,120–123,128,131,133,136,144,145,148,150,154,158,160,163,169,178) assessed the association between the duration of diabetes and treatment adherence. Table 3.6 summarises these studies and their results.

The studies contained a total of 3 527 children and young people with diabetes, with a mean of 196 children per study and a range of 57 to 1 028. 29.1% of participants came from one study. One study did not indicate their sample size and was left out of this calculation.

The 19 studies used 16 different methods of measuring adherence.

Nine studies (120–123,128,131,136,145,154) had statistically significant results that suggested that adherence worsens with increasing disease duration, with the remainder of the studies reporting a relationship that was not significant.

No studies - significantly or not significantly - suggested that adherence improves with increased disease duration.

No studies with statistically significant results shared the same method of measuring and reporting adherence or had similar sample sizes and mean population ages, so meta-analysis was not possible.

All of the studies assessing the relationship between duration of diabetes and adherence were observational studies, which according to the GRADE framework (see section 2.2.7), begins the body of evidence at “low certainty”. There were insufficient studies that demonstrated either a large magnitude of effect, a dose-response gradient, or a reduction in the effect size with additional confounders in order to increase the grading for this factor. Reduction of the grade by reason of risk of bias (including publication bias), imprecision, inconsistency or indirectness was also not considered necessary, leaving the body of evidence for this factor as “low certainty”.

Study	Mean age (range)	Sample size	Method of measuring adherence	Adherence to insulin therapy specifically assessed and presented separately in results? (Y/N)	Effect on adherence	Statistically significant? (Y/N)	P-value	Comments
<b>Anderson, 1990</b> (169)	13.3 (6-21)	121	Diabetes Family Responsibility Questionnaire (DFRQ)	N	Mother's report: r= 0.17	N	>0.05	Higher scores in this questionnaire confer to worse adherence, so the positive relationship should be interpreted as "adherence decreased with increasing duration of diabetes".
					Child's report: r= 0.16	N	>0.05	
<b>Kyngäs, 2000</b> (120)	15.1 (NK)	289	Questionnaire (not otherwise specified)	N	36% of participants with a disease duration of 1-3 years were rated as having "good" compliance 17% of participants with a disease duration of 3-6 years were rated as having "good" compliance 12% of participants with a disease duration of longer than 6 years were rated as having "good" compliance	Y	<0.001	Study stated the percentages as written here but did not express this as a Pearson correlation. They did state that the relationship was significant.

Study	Mean age (range)	Sample size	Method of measuring adherence	Adherence to insulin therapy specifically assessed and presented separately in results? (Y/N)	Effect on adherence	Statistically significant? (Y/N)	P-value	Comments
<b>Jacobson, 1990</b> (163)	NK	61	Self-created 4-point scale (1-4; poor-excellent), used by paediatricians or diabetes nurse specialists to make an assessment. Validated by Jacobson et al., 1987.	N	No numerical value stated, but the relationship was stated as insignificant.	N	>0.05	Factor was specifically stated as “time between diagnosis and study entry”.
<b>Hanson, 1989</b> (122)	NK	135	Self-report questionnaire based on Cerkoney and Hart, 1980	N	r= -0.16	Y	0.032	
<b>Patton, 2010</b> (150)	11.8 (2-17)	201	Self-created questionnaire	Y	MDI users: r= -0.09	N	0.37	
					CSII users: r= -0.07	N	0.49	
<b>Nakamura, 2019</b> (128)	13.1 (NK)	123	Revised Diabetes Self-Care Inventory (SCI-R)	N	r= -0.162	Y	<0.05	

Study	Mean age (range)	Sample size	Method of measuring adherence	Adherence to insulin therapy specifically assessed and presented separately in results? (Y/N)	Effect on adherence	Statistically significant? (Y/N)	P-value	Comments
<b>Hanson, 1995</b> (123)	15.2 (12-20)	157	Interview	N	r= -0.38	Y	<0.0001	
<b>Smith, 2014</b> (131)	13.6 (NK)	NK	Diabetes Self-Management Profile (DSMP - Harris et al., 2000)	N	r= -0.42	Y	<0.001	
<b>La Greca, 1995</b> (133)	14.2 (11-18)	74	Interview (developed by Hanson et al., 1992)	N	NK (no value given, but relationship was stated as insignificant)	N	>0.05	
<b>Pereira, 2008</b> (136)	15 (10-18)	157	Self-Report Questionnaire on Adherence (Almeida & Pereira, 2003)	N	r= 0.308	Y	<0.001	Result was expressed as a t-test; these serve a similar purpose to Pearson correlations, indicating the direction of a relationship and the likelihood that the null hypothesis can be rejected, with results further from 0 in either direction increasing likelihood that it can be rejected. They are generally expressed between -3 and +3 (194) .

Study	Mean age (range)	Sample size	Method of measuring adherence	Adherence to insulin therapy specifically assessed and presented separately in results? (Y/N)	Effect on adherence	Statistically significant? (Y/N)	P-value	Comments
					$\beta = 0.273$	Y	<0.001	Higher scores in this questionnaire confer to worse adherence, so the positive relationship should be interpreted as "adherence decreased with increasing duration of diabetes".
<b>Stewart, 2000</b> (160)	Case: 15.08, control: 15.17 (9-21)	70	Questionnaire constructed based upon Littlefield et al., 1992	N	$r = 0.08$	N	>0.05	

Study	Mean age (range)	Sample size	Method of measuring adherence	Adherence to insulin therapy specifically assessed and presented separately in results? (Y/N)	Effect on adherence	Statistically significant? (Y/N)	P-value	Comments
<b>Kyngäs, 2007</b> (121)	15.1 (NK)	289	Questionnaire (not otherwise specified)	N	No numerical value was given, but it was stated within the body of text that those with 1-3 years disease duration had statistically significantly better adherence than those with more than 3 years disease duration.	Y	<0.0001	
<b>Schober, 2011</b> (144)	NK (10-21)	241	Diabetes Self-Management Profile (DSMP; Harris et al., 2000)	Y	<p>Mean disease duration in compliant patients was 6.2 years.</p> <p>Mean disease duration in non-compliant patients was 6.2 years.</p> <p>Mean disease duration in patients with management problems was 6.1 years.</p>	N	>0.05	The study stated that “non-compliance” occurred when participants had deliberately been non-compliant with insulin therapy and “management problems” occurred when participants had unintentionally been non-compliant.



Study	Mean age (range)	Sample size	Method of measuring adherence	Adherence to insulin therapy specifically assessed and presented separately in results? (Y/N)	Effect on adherence	Statistically significant? (Y/N)	P-value	Comments
Jacobson, 1987 (178)	12.8 (9-15)	57	Rated by healthcare providers	N	No value given, but relationship was stated as insignificant.	N	>0.05	
Kristensen, 2012 (145)	12.3 (NK)	1028	Adherence in Diabetes Questionnaire (ADQ)	N	$r = -0.17$	Y	<0.001	
Ott, 2000 (148)	13.97 (11-18)	161	Summary of Self-Care Activities (Schafer et al. 1983)	N	$R_{1,2}: -0.1$	N	>0.05	Used zero order correlations.
Florian, 1998 (154)	15.11 (12-17)	88	Self-Care Questionnaire (Glasgow et al., 1987)	N	$r = -0.19$	Y	<0.05	
Vaala, 2015 (158)	14.47 (12-17)	174	Self-Care Inventory - Revised (SCI-R)	N	$R_2: 0.08$	N	>0.05	Used multiple regression analysis (MRA).
Palardy, 1998 (116)	14.07 (11-17)	101	Summary of Self-Care Activities Questionnaire (Schafer et al. 1983)	N	$R_{1,2}: = -0.11$	N	>0.05	Used zero order correlations.

Table 3.6 Studies assessing the relationship between disease duration and treatment adherence and their results. Legend; ADQ: Adherence in Diabetes Questionnaire, SCI-R: Revised Self-Care Inventory, DSMP: Diabetes Self-Management Profile, DFRQ: Diabetes Family Responsibility Questionnaire, MRA: Multiple Regression Analysis, MDI: Multiple Daily Injections, CSII: Continuous Subcutaneous Insulin Infusion, Y: yes, N: no, NK: Not Known,  $r$ : Pearson correlation coefficient value,  $R_{1,2}$ : zero order correlation value,  $R_2$ : Multiple Regression Analysis score. Statistically significant results suggestive of worsening adherence with increasing disease duration are coloured orange. Results left in white are not statistically significant.

Table 3.7. Significant results suggesting that males have better adherence are coloured blue and significant results suggesting that females have better adherence are coloured orange. Results that were not statistically significant have been left white. Note that where Pearson correlations (r) or  $\beta$ -values have been used, results may be positive or negative even when showing the same relationship, depending upon the value assigned to each gender in the respective studies.

The studies contained a total of 2 647 children and young people with diabetes with a mean of 176 children in each study and a range of 34 to 1 028. 1 028/2 647 (38.8%) of these participants came from a single study.

The 15 studies used 15 different methods of measuring adherence; MPR was used twice, but one study used two different methods.

Of the 15 studies, 6 (136,144,154,161,166,168) found a significant association with gender. Five out of these 6 studies (136,144,154,166,168) (83.3%) suggested that males had better adherence and one (161) (17.7%) suggested that adherence was better in females.

Of the five studies that suggested adherence was better in males, three were European (Portuguese, Austrian and Dutch) studies, one was American and one was Malaysian with a weighted mean participant age of 14.9 years old (calculated from the 3 mean ages published). The study that suggested adherence was better in females took place in Kuwait and had a significantly lower mean age, with a mean age of 9.1 years old for the case group and 9.7 years old for the control group.

Studies differed considerably in their methods of measuring adherence and sample populations, so meta-analysis was not considered appropriate.

All of the studies assessing the relationship between gender and adherence were observational studies, which according to the GRADE framework (see section 2.2.7), begins the body of evidence at “low certainty”. There were insufficient studies that demonstrated either a large magnitude of effect, a dose-response gradient, or a reduction in the effect size with additional confounders in order to increase the grading for this factor. Reduction of the grade by reason of risk of bias (including publication bias), imprecision or indirectness was also not considered necessary. The inconsistency of the results warranted reducing the grading, leaving the body of evidence for this factor at “very low certainty”.

Study	Mean age (range)	Sample size	Method of measuring adherence	Adherence to insulin therapy specifically assessed and presented separately in results? (Y/N)	Effect on adherence	Statistically significant? (Y/N)	P-value	Comments
Jacobson, 1987 (178)	12.8 (9-15)	57	Rated by healthcare providers	N	NK	N	>0.05	No specific value for effect on adherence given, but it is stated as not statistically significant.
Schafer, 1983 (164)	13 (range 12-14)	34	Barriers to Adherence and Problem-Solving Questionnaire and Summary of Self-Care Activities Questionnaire	Y	“tendencies for boys to report taking more care when measuring insulin” (no numerical value stated)	N	>0.05	Adherence in this context is “care taken in measuring insulin”
Kristensen, 2012 (145)	12.3 (NK)	1028	Adherence in Diabetes Questionnaire (ADQ)	N	r= 0.07 (girls more adherent)	N	>0.05	
Ying, 2017 (166)	14.39 (NK)	57	Medication Possession Ratio (MPR)	Y	$\beta = -0.861$ (males had better adherence)	Y	<0.05	
Morris, 1997 (167)	16 (NK)	89	Medication Possession Ratio (MPR)	Y	NK	N	>0.05	No specific value for effect on adherence given, but it is stated as not statistically significant.
Johnson, 1990 (168)	NK (6-19)	78	24-hour recall interviews	Y	F=4.61 (males had better adherence)	Y	<0.04	Used Analysis of Variance (ANOVA).

Study	Mean age (range)	Sample size	Method of measuring adherence	Adherence to insulin therapy specifically assessed and presented separately in results? (Y/N)	Effect on adherence	Statistically significant? (Y/N)	P-value	Comments
<b>Anderson, 1990</b> (169)	13.3 (6-21)	121	Diabetes Family Responsibility Questionnaire (DFRQ)	N	Mothers' report: r= -0.17 (females had better adherence)	N	>0.05	
					Child's report: r= 0.02 (males had better adherence)	N	>0.05	
<b>Nakamura, 2019</b> (128)	13.1 (NK)	123	Revised Diabetes Self-Care Inventory	N	Males' mean score: 11.2, females' mean score: 10.7, with higher scores conferring to better adherence.	N	>0.05	Question where insulin adherence was assessed also assessed dietary adherence ("regularity of snacks and insulin injections").
<b>La Greca, 1995</b> (133)	14.2 (11-18)	74	Interview (developed by Hanson et al., 1992)	N	NK	N	>0.05	No specific value for effect on adherence given, but it is stated as not statistically significant.
<b>Pereira, 2008</b> (136)	15 (10-18)	157	Self-Report Questionnaire on Adherence (Almeida & Pereira, 2003)	N	$\beta = -0.198$ (males had better adherence)	Y	<0.01	
<b>Stewart, 2000</b> (160)	Case: 15.08, control: 15.17 (9-21)	70	Questionnaire constructed based upon Littlefield et al., 1992	N	r= -0.26 (females had better adherence)	N	>0.05	

Study	Mean age (range)	Sample size	Method of measuring adherence	Adherence to insulin therapy specifically assessed and presented separately in results? (Y/N)	Effect on adherence	Statistically significant? (Y/N)	P-value	Comments
<b>Schober, 2011</b> (144)	NK (10-21)	241	Diabetes Self-Management Profile (Harris et al., 2000)	Y	Group A (compliant): 56% male	N/A	N/A	The study stated that “non-compliance” occurred when participants had deliberately been non-compliant with insulin therapy and “management problems” occurred when participants had unintentionally been non-compliant.
					Group B (non-compliant): 22% male	Y	<0.01 (A vs B)	
					Group C (management problems): 25% male	Y	<0.05 (A vs C)	
<b>Abdul-Rasoul, 2013</b> (161)	Case: 9.1 (SD 3.7), control: 9.7 (SD 3.6)	Case group: 377, control group: 389	Paediatric Quality of Life Inventory (PedsQL) 3.0 Diabetes Module (of which 7 items out of 28 relate to adherence)	N	Males’ mean score: 69.7, females’ mean score: 76.6, with higher scores conferring to better adherence.	Y	<0.05	Gender was the only factor specifically assessed for adherence; this was still a composite index and not specifically regarding adherence to insulin therapy.
<b>Florian, 1998</b> (154)	15.11 (12-17)	88	Self-Care Questionnaire (Glasgow et al., 1987)	N	r= -0.24 (males had better adherence)	Y	<0.05	
<b>van Dongen, 2008</b> (192)	12.7 (10-15)	53	Insulin Required of Adherence Scale	Y	r= -0.2 (females had better adherence)	N	>0.05	

*Table 3.7 Summary of results of studies that assessed the association between adherence and age. Legend; Y: yes, N: no, NK: not known, N/A: not applicable, PedsQL: Paediatric Quality of Life Inventory, DFRQ: Diabetes Family Responsibility Questionnaire, MPR: Medication Possession Ratio, ANOVA: Analysis of Variance, r: Pearson correlation coefficient value. Significant results where adherence was shown to be better in males have been highlighted in blue and significant results where adherence was shown to be better in females have been highlighted in orange. Results that were not statistically significant have been left in white. NB: whether the numerical value is positive or negative is not always consistent depending on the number each respective study assigned to which gender.*

#### 3.6.4. Perceptions of Family Conflict

Eight studies (123,136,140,151,160,162,164,192) assessed the impact of perceived family conflict upon treatment adherence. These eight studies and their results are summarised in Table 3.8. Statistically significant results suggesting that family conflict has a negative effect upon adherence are coloured orange. Results that were not statistically significant have been left white.

The studies included a total of 702 children and young people with diabetes with a mean of 88 children per study and a range of 34 to 157.

The eight studies used nine different methods of measuring adherence; the number of methods is greater than the number of studies due to one study using two methods.

Five studies (123,140,151,162,192) assessed the perceptions of both the child and a parent of family conflict and 3 studies (136,160,164) assessed only the child's perception of conflict. Subjective reports of adherence are from the perspective of the child unless otherwise specified.

One study (140) assessed 12 correlations so is discussed separately here. This study had two participant groups: parents and children receiving treatment in private hospitals and parents and children receiving treatment in public hospitals. Both parents and children gave reports on their perceptions of family conflict and treatment adherence. The patients' nurses also gave a report on the adherence of the patient.

In the public hospital group, the parent's perceptions of family conflict were significantly negatively correlated with the parent's and nurse's report of adherence but was not correlated with the child's report of adherence. The child's perceptions of family conflict were significantly negatively correlated with the parent's and child's reports of adherence, but not the nurse's.

In the private hospital group, only the parent's report of family conflict with the parent's report of adherence was significantly negatively associated. All other correlations were insignificant. Of all the correlations assessed in this study, 5/12 (42%) of them suggested that adherence worsens with family conflict. The remaining 7/12 (58%) showed no significant interaction. Of the significant interactions, 4/5 (80%) were from the public hospital group.

Of the remaining studies that assessed the relationship between the child's perceptions of family conflict and adherence, 3/7 (43%) (123,162,192) had statistically significant results that suggest adherence worsens with family conflict. The remaining 4/7 (57%) (136,151,160,164), had results that were not statistically significant. One of these studies (160) assessed the frequency and intensity of conflict as separate domains (with both having insignificant results).

Of the remaining studies (123,151,162,192) that examined the effect of the parent's report of family conflict, 2/4 (50%) (151,192) had statistically significant results suggesting that adherence worsens with family conflict, with the other 2/4 (50%) (123,162) having statistically insignificant results.

When looking at the effect of whether the report of family conflict comes from the child or their parents, 42% of the results based on children's reports were statistically significant versus 50% when the report came from parents, with all suggesting that family conflict has a negative effect upon adherence.

As a composite analysis of all studies that assessed family conflict and its effect on adherence, including all parents' and children's reports of both conflict and adherence and nurses' reports of adherence, there were 24 correlations assessed. 10/24 (42%) of these correlations had statistically significant results suggesting that adherence worsens with family conflict, with the remaining 14/24 (58%) having statistically insignificant results. 0/24 (0%) of the correlations assessed had statistically significant results that suggested adherence improves with family conflict.

Studies differed considerably in their methods of measuring adherence and sample populations, so meta-analysis was not considered appropriate.

All of the studies assessing the relationship between family conflict and adherence were observational studies, which according to the GRADE framework (see section 2.2.7), begins the body of evidence at "low certainty". There were insufficient studies that demonstrated either a large magnitude of effect, a dose-response gradient, or a reduction in the effect size with additional confounders in order to increase the grading for this factor. Reduction of the grade by reason of risk of bias (including publication bias), imprecision, inconsistency or indirectness was also not considered necessary, leaving the body of evidence for this factor as "low certainty".



Study	Mean age (range)	Sample size	Method of measuring adherence	Adherence to insulin therapy specifically assessed and presented separately in results? (Y/N)	Effect on adherence	Statistically significant? (Y/N)	P-value	Comments
<b>Maliszewski, 2017</b> (151)	13.64 (NK)	91	BOLUS scores	Y	Child's perception of conflict: $r = -0.166$	N	>0.05	
					Parent's perception of conflict: $r = -0.293$	Y	<0.01	
					Composite index of conflict: $\beta = -0.235$	Y	<0.05	
<b>van Dongen, 2005</b> (192)	12.7 (10-15)	53	Insulin Required of Adherence Scale	Y	Child's perception of conflict: $r = -0.38$	Y	<0.01	
					Parent's perception of conflict: $r = -0.39$	Y	<0.01	
<b>Hauser, 1990</b> (162)	12.8	52	Questionnaire (validated by Jacobson et al., 1987)	Y	Child's perception of conflict: $r = -0.41$	Y	<0.004	
					Parent's perception of conflict: $r = -0.2$	N	>0.05	
<b>Schafer, 1983</b> (164)	13 (range 12-14)	34	Barriers to Adherence and Problem-Solving Questionnaire and	Y	Child's perception of conflict: $r = 0.1$	N	>0.05	Adherence in this context is "care

			Summary of Self-Care Activities Questionnaire					taken in measuring insulin"
<b>Hanson, 1995</b> (123)	15.2 (12-20)	157	Interview	N	Child's perception of conflict: $r = -0.3$	Y	<0.0001	Specifically assessed mother's perceptions, where other papers have been general in assessing "parents".
					Mother's perception of conflict: $r = -0.09$	N	>0.05	
<b>Pereira, 2008</b> (136)	15 (10-18)	157	Self-Report Questionnaire on Adherence (Almeida & Pereira, 2003)	N	Child's perception of conflict: $r = 0.053$	N	>0.05	
<b>Miller-Johnson, 1994</b> (140)	13 (8-18)	88	Self-report diary	N	Public hospital: parent's perception of conflict, parent's report of adherence: $r = -0.59, \beta = -0.54$	Y	<0.001	
					Public hospital: parent's perception of conflict, child's report of adherence: $r = -0.25, \beta = 0.22$	N	>0.05	
					Public hospital: parent's perception of conflict, nurse's report of adherence:	Y	<0.05	

					r= -0.3, $\beta$ = -0.3		
					Public hospital: child's perception of conflict, parent's report of adherence: r= -0.37, $\beta$ = -0.5	Y	r: <0.01 $\beta$ : <0.001
					Public hospital: child's perception of conflict, child's report of adherence: r= -0.5, $\beta$ = -0.52	Y	<0.001
					Public hospital: child's perception of conflict, nurse's report of adherence: r= -0.19, $\beta$ = -0.25	N	>0.05
					Private hospital: parent's perception of conflict, parent's report of adherence: r= -0.32, $\beta$ = 0.34	Y	<0.05
					Private hospital: parent's perception of conflict, child's	N	>0.05

					report of adherence: r= -0.02, $\beta$ = -0.01			
					Private hospital: parent's perception of conflict, nurse's report of adherence: r= -0.09, $\beta$ = -0.09	N	>0.05	
					Private hospital: child's perception of conflict, parent's report of adherence: r= -0.15, $\beta$ = -0.22	N	>0.05	
					Private hospital: child's perception of conflict, child's report of adherence: r= -0.25, $\beta$ = -0.31	N	>0.05	
					Private hospital: child's perception of conflict, nurse's report of adherence: r= -0.06, $\beta$ = -0.13	N	>0.05	

Stewart, 2000 (160)	Case: 15.08, control: 15.17 (9- 21)	70	Questionnaire constructed based upon Littlefield et al., 1992	N	Child's report, frequency of conflict: r= 0.07	N	>0.05	
					Child's report, intensity of conflict: r= 0.01	N	>0.05	

Table 3.8 Studies assessing the relationship between family conflict and adherence and their results. Legend; Y: yes, N: no. r: Pearson correlation coefficient value,  $\beta$ : beta value. Statistically significant results suggesting that family conflict has a negative effect upon adherence are coloured orange. Insignificant results have been left white.

### 3.6.5. Depression

Seven studies (117,132,142,146,151,173,195) assessed the relationship between depression/depressive symptoms in children and treatment adherence and one (177) assessed the relationship between depression in the child's mother and treatment adherence.

The studies contained a total of 3 527 children and young people with diabetes, with a mean of 196 children per study and a range of 57 to 1 028. 29.1% of participants came from one study. One study did not indicate their sample size and was left out of this calculation.

The seven studies used six different methods of measuring adherence and four different measures for assessing depression. These four methods were:

- Centre for Epidemiologic Studies – Depression Scale (132,151,173,177)
- Children's Diagnostic Interview for Psychiatric Disorders (117)
- M5-336 Questionnaire (142)
- Children's Depression Inventory (146)

All seven studies that assessed depression in the child had significant results that suggest adherence worsens with depression. Three of these studies (132,142,151) specifically assessed adherence to insulin treatment and presented this component of adherence separately with the others assessing adherence to insulin but presenting the results as a composite measure of all aspects of adherence.

Two of these studies (132,151) used the same measure of adherence, that being BOLUS scores, but did not control for the same variables, so meta-analysis was not possible.

No studies had results – significant or not significant – suggesting that treatment adherence improved with depression.

The study assessing maternal depression assessed depression and adherence at study entry (T1) and follow-up (T2) and tested for correlations between all of these variables and times. No relationships were statistically significant except the relationship between maternal depression at T2 and adherence at T2, which showed worsening adherence with depression.

Table 3.9 summarises all of the above studies and their results. Significant results that suggest adherence worsens with depression have been coloured orange. Results that were not statistically significant have been left white.

Studies differed considerably in their methods of measuring adherence and sample populations, so meta-analysis was not considered appropriate.

All of the studies assessing the relationship between depression and adherence were observational studies, which according to the GRADE framework (see section 2.2.7), begins the body of evidence at “low certainty”. There were insufficient studies that demonstrated either a large magnitude of effect, a dose-response gradient, or a reduction in the effect size with additional confounders in order to increase the grading for this factor. Reduction of the grade by reason of risk of bias (including publication bias), imprecision, inconsistency or indirectness was also not considered necessary, leaving the body of evidence for this factor as “low certainty”.

Study	Mean age (range)	Sample size	Method of measuring adherence	Adherence to insulin therapy specifically assessed and presented separately in results? (Y/N)	Effect on adherence	Statistically significant? (Y/N)	P-value	Comments
Berger, 2019 (117)	14.14 (NK)	322	Diabetes Self-Management Interview	N	<p>4.9% of the participants who were classed as being adherent had depression</p> <p>13.4% of the participants who were classed as unintentionally non-adherent had depression</p> <p>18.3% of the participants who were classed as intentionally</p>	Y	<0.005	



					manipulative non-adherent had depression			
<b>Baucom, 2015 (173)</b>	7.46 (NK)	175	Questionnaire based on the Self-Care Inventory (SCI)	N	r= -0.33	Y	<0.001	
<b>Calkins-Smith, 2018 (132)</b>	13.68 (10-17)	90	BOLUS scores	Y	r= -0.33	Y	<0.001	
<b>Wiebe, 2011 (177)</b>	12.79 (10-15.99)	82	SCI	N	Maternal depression at study entry with adherence at study entry: Child's report: R <sub>2</sub> : -0.04.	N	>0.05	Maternal depression.  Used multiple regression analysis (MRA).
					Maternal depression at study entry with adherence at study entry: Parent's report: R <sub>2</sub> : -0.06.	N	>0.05	
					Maternal depression at study entry with	N	>0.05	

					adherence at follow up: Child's report: R <sub>2</sub> : -0.15.			
					Maternal depression at study entry with adherence at follow up: Parent's report: R <sub>2</sub> : -0.09.	N	>0.05	
					Maternal depression at follow up with adherence at study entry: Child's report: R <sub>2</sub> : 0.01.	N	>0.05	
					Maternal depression at follow up with adherence at study entry: Parent's report: R <sub>2</sub> : -0.04.	N	>0.05	
					Maternal depression at follow up with adherence at follow up: Child's report:	N	>0.05	

					R <sub>2</sub> : -0.12			
					Maternal depression at follow up with adherence at follow up: Parent's report: R <sub>2</sub> : -0.29.	Y	<0.01	
<b>Wheeler, 2012</b> (142)	NK (13-18)	28	Questionnaire constructed by study authors	Y	r= -0.498	Y	<0.01	
<b>Littlefield, 1992</b> (146)	15.3 (13-18)	193	Questionnaire constructed by study authors	N	r= -0.5	Y	<0.001	
<b>Maliszewski, 2017</b> (151)	13.64 (NK)	91	BOLUS scores	Y	r= -0.28	Y	<0.01	
<b>Rossello, 2006</b> (195)	12.29 (8-17)	101	Questionnaire not otherwise specified	N	r= 0.342	Y	<0.01	"Adherence" in this case is actually the perceived difficulty of performing management tasks, so this result should be interpreted as "depressive state is associated with more

								difficulty in performing management tasks”.
--	--	--	--	--	--	--	--	---

Table 3.9 Studies assessing the relationship between depression in children and their mothers and treatment adherence, and their results. Legend; SCI: Self-Care Inventory, Y: yes, N: no, NK: Not Known, r: Pearson correlation coefficient value, R<sub>2</sub>: multiple regression analysis value. Significant results suggesting that adherence worsens with depression are coloured in orange.

Insignificant results have been left white.

### 3.6.6. Self-Efficacy

Seven studies (116,135,141,142,146,148,160) assessed the relationship between the child's self-efficacy and adherence. Self-efficacy in this context refers to a child's confidence in their abilities to perform various diabetes management tasks. These studies and their results are summarised in Table 3.10. Statistically significant results that suggest a positive relationship between self-efficacy and adherence are coloured green. Results that were not statistically significant have been left white.

The studies included 869 children and young people with diabetes with a mean of 124 children and a range of 28-252.

The seven studies used six different methods of measuring adherence. Self-efficacy was assessed within these methods.

5/7 (71%) (141,142,146,148,160) of these studies had statistically significant results that suggest increased self-efficacy is associated with improved adherence unanimously across all of their published results.

1/7 (14%) (116) found the relationship to be statistically significant when looking at the Pearson correlation ( $r$ ), but that the size of the effect ( $\beta$ ) was not significant.

1/7 (14%) (135) had results that were not statistically significant.

0/7 (0%) had results suggesting that increased self-efficacy is associated with worse adherence.

Studies differed considerably in their methods of measuring adherence and sample populations, so meta-analysis was not considered appropriate.

All of the studies assessing the relationship between self-efficacy and adherence were observational studies, which according to the GRADE framework (see section 2.2.7), begins the body of evidence at "low certainty". There were insufficient studies that demonstrated either a large magnitude of effect, a dose-response gradient, or a reduction in the effect size with additional confounders in order to increase the grading for this factor. Reduction of the grade by reason of risk of bias

(including publication bias), imprecision, inconsistency or indirectness was also not considered necessary, leaving the body of evidence for this factor as “low certainty”.

Study	Mean age (range)	Sample size	Method of measuring adherence	Adherence to insulin therapy specifically assessed and presented separately in results? (Y/N)	Effect on adherence	Statistically significant? (Y/N)	P-value	Comments
<b>Palardy, 1998</b> (116)	14.07 (11-17)	101	Summary of Self-Care Activities Questionnaire	N	$R_{1,2} = 0.24$	Y	<0.05	Used zero order correlations.
					$\beta = 0.1$	N	>0.05	
<b>Griva, 2000</b> (135)	20.6 (NK)	64	Questionnaire based on the Reported Adherence to Medication Scale (Horne et al. 1999)	N	$r = -0.25$	N	>0.05	Higher scores in the self-efficacy scale used by this study conferred to lower self-efficacy, so this result should be interpreted as “lower self-efficacy was negatively associated with adherence” (though the result is insignificant).
<b>Berg, 2011</b> (141)	12.49 (NK)	252	Self-Care Inventory (SCI)	N	$r = 0.4$	Y	<0.01	
<b>Stewart, 2000</b> (160)	Case: 15.08, control: 15.17 (9-21)	70	Questionnaire constructed based upon Littlefield et al., 1992	N	$r = 0.64$	Y	<0.001	
<b>Wheeler, 2012</b> (142)	NK (13-18)	28	Questionnaire constructed by study authors	Y	$r = 0.48$	Y	<0.01	
<b>Littlefield, 1992</b> (146)	15.3 (13-18)	193	Questionnaire constructed by study authors	N	$r = 0.57$	Y	<0.001	

<b>Ott, 2000</b> (148)	13.97 (11-18)	161	Summary of Self-Care Activities (Schafer et al. 1983)	N	$R_{1,2} = 0.21$	Y	<0.01	Used zero order correlations.
---------------------------	---------------	-----	---	---	------------------	---	-------	-------------------------------

Table 3.10 Summary of studies assessing the relationship between the child's self-efficacy and adherence. Legend; SCI: Self-Care Inventory, Y: yes, N: no,  $R_{1,2}$ : zero order correlation value,  $r$ : Pearson correlation coefficient value,  $\beta$ : beta value. Statistically significant results that suggest a positive relationship between self-efficacy and adherence are coloured green. Statistically insignificant results have been left white.



### 3.6.7. Perceptions of Family Support

Seven studies (120,126,133,134,136,148,164) assessed the relationship between support from family members and adherence. Their results are summarised in Table 3.11. Statistically significant results indicative of a positive relationship between familial support and adherence have been coloured green. Results that were not statistically significant have been left white.

The studies included a total of 882 children and young people with diabetes with a mean of 126 children in each study and a range of 34 to 289.

The seven studies used seven different methods of measuring adherence; the interview developed by Hanson et al., was used twice, but one study used two different methods. Perceptions of family support was assessed within these measures.

5/7 (71%) (120,126,133,136,148) of these studies had statistically significant results suggesting a positive relationship between familial support and adherence.

The remaining 2/7 (29%) (134,164) had statistically insignificant results.

The five studies that had results suggestive of a statistically significant positive relationship expressed the relationship of familial support to a composite index of all aspects of adherence. The two studies that did not have statistically significant results expressed the relationship of familial support to adherence to insulin therapy specifically.

0/7 (0%) of studies had statistically significant results suggestive of a negative relationship between familial support and adherence.

Studies differed considerably in their methods of measuring adherence and sample populations, so meta-analysis was not considered appropriate.

All of the studies assessing the relationship between family support and adherence were observational studies, which according to the GRADE framework (see section 2.2.7), begins the body of evidence at “low certainty”. There were insufficient studies that demonstrated either a large magnitude of effect, a dose-response gradient, or a reduction in the effect size with additional confounders in order to increase the grading for this factor. Reduction of the grade by reason of risk

of bias (including publication bias), imprecision, inconsistency or indirectness was also not considered necessary, leaving the body of evidence for this factor as “low certainty”.

Study	Mean age (range)	Sample size	Method of measuring adherence	Adherence to insulin therapy specifically assessed and presented separately in results? (Y/N)	Effect on adherence	Statistically significant? (Y/N)	P-value	Comments
Schafer, 1983 (164)	13 (range 12-14)	34	Barriers to Adherence and Problem-Solving Questionnaire and Summary of Self-Care Activities Questionnaire	Y	Supportiveness of mother: $r = -0.14$	N	>0.05	
					Supportiveness of father: $r = -0.07$	N	>0.05	
Kyngäs, 2000 (120)	15.1 (NK)	289	Questionnaire (not otherwise specified)	N	Children deemed to have parental support: 33% were classed as having "good" adherence, 67% "satisfactory" and 0% as "poor"	Y	<0.001	
					Children deemed to not have parental support: 2% were classed as having "good" adherence, 84% as "satisfactory" and 14% as "poor"			
La Greca, 1995 (133)	14.2 (11-18)	74	Interview (developed by Hanson et al., 1992)	N	$r = 0.37$	Y	<0.01	
Pereira, 2008 (136)	15 (10-18)	157	Self-Report Questionnaire on Adherence (Almeida & Pereira, 2003)	N	$r = 0.245$	Y	<0.01	

Ott, 2000 (148)	13.97 (11-18)	161	Summary of Self-Care Activities (Schafer et al. 1983)	N	$R_{1,2}: 0.36$	Y	<0.005	Used zero order correlations.
Hanson, 1987 (126)	14.4 (NK)	93	Self-report and observation (Cerkoney and Hart and Schlenk and Hart)	N	$r = 0.32$	Y	<0.005	
La Greca, 2002 (134)	14.2 (11-18)	74	Interview (developed by Hanson et al., 1992)	Y	$r = 0.11$	N	>0.05	

Table 3.11 Summary of studies that assess the relationship between familial support and adherence. Legend; Y: yes, N: no, r: Pearson correlation coefficient value,  $R_{1,2}$ : zero order correlation value. Statistically significant results indicative of a positive relationship between familial support and adherence have been coloured green. Results that were not statistically significant have been left white.

### 3.6.8. Perceptions of Family Cohesion

Five studies (123,134,136,162,164) assessed the correlation between the perceptions of family cohesion and treatment adherence. Their results are summarised in Table 3.12. Statistically significant results that suggest that adherence improves with increasing family cohesion are coloured in green. Results that are not statistically significant have been left white. Correlations are based upon the child's perceptions of family cohesion unless otherwise specified.

The studies included a total of 474 children and young people with a mean of 95 children and a range of 34 to 157.

The five studies used six different methods of measuring adherence; the number of methods used is greater than the number of studies due to one study using two methods to measure adherence.

All 5 studies assessed the association of the child's perception of family cohesion with adherence, with 2/5 (40%) (123,134) having statistically significant results that suggested that adherence improves as the child's perceptions family cohesion increases. 1/5 (20%) (162) had statistically significant results that suggested adherence worsens as the child's perceptions of family cohesion increases. The remaining 2/5 (40%) (136,164) had results that were not statistically significant.

Two of these studies (123,162) also assessed the associations between treatment adherence and a parent's perceptions of family cohesion. 2/2 (100%) had statistically significant results that suggested adherence improves as parent's perceptions of family cohesion increases. It is worth noting that 1 of these studies (162) suggested the inverse relationship when looking at the child's perceptions of family cohesion.

Studies differed considerably in their methods of measuring adherence and sample populations, so meta-analysis was not considered appropriate.

All of the studies assessing the relationship between family cohesion and adherence were observational studies, which according to the GRADE framework (see section 2.2.7), begins the body of evidence at "low certainty". There were insufficient studies that demonstrated either a large magnitude of effect, a dose-response gradient, or a reduction in the effect size with additional confounders in order to increase the grading for this factor. Reduction of the grade by reason of risk

of bias (including publication bias), imprecision, inconsistency or indirectness was also not considered necessary, leaving the body of evidence for this factor as “low certainty”.

Study	Mean age (range)	Sample size	Method of measuring adherence	Adherence to insulin therapy specifically assessed and presented separately in results? (Y/N)	Effect on adherence	Statistically significant? (Y/N)	P-value	Comments
<b>Hanson, 1995</b> (123)	15.2 (12-20)	157	Interview	N	Correlation with child's report of cohesion: r= 0.36	Y	<0.0001	
					Correlation with parent's report of cohesion: r= 0.24	Y	<0.0001	
<b>Pereira, 2008</b> (136)	15 (10-18)	157	Self-Report Questionnaire on Adherence (Almeida & Pereira, 2003)	N	r= -0.014	N	>0.05	Higher scores in the adherence questionnaire confer to worse adherence, so the negative relationship here should be interpreted as "increasing family cohesion was associated with improved adherence" (though it was not statistically significant).
<b>La Greca, 2002</b> (134)	14.2 (11-18)	74	Interview (developed by Hanson et al., 1992)	Y	r= 0.32	Y	<0.01	
<b>Hauser, 1990</b> (162)	12.8	52	Questionnaire (validated by Jacobson et al., 1987)	Y	Correlation with child's report of cohesion: r= -0.37	Y	<0.01	

					Correlation with parent's report of cohesion: r= 0.32	Y	<0.05	
<b>Schafer, 1983 (164)</b>	13 (range 12-14)	34	Barriers to Adherence and Problem-Solving Questionnaire and Summary of Self-Care Activities Questionnaire	Y	r= 0.11	N	>0.05	

Table 3.12 Studies assessing the relationship between perceptions of family cohesion and adherence. Legend; Y; yes, N: no, r: Pearson correlation coefficient value. Statistically significant results that suggest that adherence improves with increasing family cohesion are coloured in green and statistically significant results suggesting that adherence worsens with increasing family cohesion are coloured orange. Results that were not statistically significant have been left white.



### 3.6.9. Diabetes Knowledge

Four studies (125,156,193,196) assessed the association between diabetes knowledge and adherence. Table 3.13 summarises these studies and their results. Statistically significant results suggesting a positive relationship between diabetes knowledge and adherence have been coloured green. Results that were not statistically significant have been left white.

The studies included 348 children and young people with a mean of 87 children and a range of 36-165.

The four studies used each used a different method of measuring adherence.

2/4 (50%) (193,196) of the studies found that knowledge of diabetes was significantly positively associated with adherence, with one of these studies (193) being the only study that specifically assessed adherence to insulin therapy and expressed these results separately.

1/4 (25%) (125) of these studies found that the correlation ( $r$ ) between diabetes knowledge and adherence was positive and statistically significant, but the effect size ( $\beta$ ) was not statistically significant.

The remaining study (156) did not find a statistically significant association between diabetes knowledge and adherence.

No studies suggested that diabetes knowledge has a negative effect on treatment adherence.

Studies differed considerably in their methods of measuring adherence and sample populations, so meta-analysis was not considered appropriate.

All of the studies assessing the relationship between diabetes knowledge and adherence were observational studies, which according to the GRADE framework (see section 2.2.7), begins the body of evidence at “low certainty”. There were insufficient studies that demonstrated either a large magnitude of effect, a dose-response gradient, or a reduction in the effect size with additional confounders in order to increase the grading for this factor. Reduction of the grade by reason of risk of bias (including publication bias), imprecision, inconsistency or indirectness was also not considered necessary, leaving the body of evidence for this factor as “low certainty”.

Study	Mean age (range)	Sample size	Method of measuring adherence	Adherence to insulin therapy specifically assessed and presented separately in results? (Y/N)	Effect on adherence	Statistically significant? (Y/N)	P-value	Comments
<b>Hanson, 1987</b> (125)	14.4 (NK)	93	Self-report and observation (Cerkoney and Hart and Schlenk and Hart)	N	r=0.28,	Y	<0.01	
					$\beta$ = 0.227	N	>0.05	
<b>Brownlee-Duffeck, 1987</b> (156)	18 (13-26)	54	Diabetes Regimen Adherence Questionnaire (DRAQ)	N	r= 0	N	>0.05	
					$\beta$ = 0.02	N	>0.05	
<b>Moret, 1995</b> (193)	10.2 (7-13)	165	Insulin adjustment score	Y	r= 0.47	Y	<0.001	
<b>Olivares, 1994</b> (196)	10.29 (9.12)	36	Questionnaire (not otherwise specified)	N	t-score= 2.71	Y	<0.05	

Table 3.13 Studies assessing the association between diabetes knowledge and treatment adherence. Legend; Y: Yes, N: No, NK: Not Known, DRAQ: Diabetes Regimen Adherence Questionnaire, r: Pearson correlation value,  $\beta$ : beta-value. Statistically significant results suggesting a positive relationship between diabetes knowledge and adherence have been coloured green. Results that were not statistically significant have been left white.

### 3.6.10. Exercise Frequency

Four studies (120,121,159,176) assessed the association between exercise frequency and adherence. Table 3.14 summarises these studies and their results. Statistically significant results that suggest adherence improves with exercise frequency are coloured green. Results that were not statistically significant have been left white. Note that two of these studies (120,121) appeared to be from the same data set but have different publication years and methods of publishing their results. They have been included as a single row in the table below but referenced separately.

The four studies included 850 children and young people with a mean of 213 children per study and a range of 105-289. Note that two of these studies appeared to use the same sample; combining these two studies results in a mean of 187 children per study.

One of these studies (159) specifically reported the association with insulin adherence, with the other studies assessing insulin adherence, but reporting their results as a composite index.

3/4 of these studies (75%) (120,121,159) found that exercise was significantly positively associated across all of their assessed domains.

The one remaining study (176) found that exercise at study entry was significantly positively associated with adherence at study entry, but not statistically significant when assessing exercise frequency at study entry with adherence at follow-up and exercise frequency at follow-up with adherence at both study entry and follow-up.

0/4 (0%) studies suggested that exercise frequency was significantly negatively associated with adherence.

Studies differed considerably in their methods of measuring adherence and sample populations, so meta-analysis was not considered appropriate.

All of the studies assessing the relationship between age and adherence were observational studies, which according to the GRADE framework (see section 2.2.7), begins the body of evidence at “low certainty”. There were insufficient studies that demonstrated either a large magnitude of effect, a dose-response gradient, or a reduction in the effect size with additional confounders in order to increase the grading for this factor. Reduction of the grade by reason of risk of bias (including

publication bias), imprecision, inconsistency or indirectness was also not considered necessary, leaving the body of evidence for this factor as “low certainty”.

Study	Mean age (range)	Sample size	Method of measuring adherence	Adherence to insulin therapy specifically assessed and presented separately in results? (Y/N)	Effect on adherence	Statistically significant? (Y/N)	P-value	Comments
<b>Kyngäs, 2000, 2007</b> (120,121)	15.1 (NK)	289	Questionnaire (not otherwise specified)	N	Of the participants who regularly exercise, 90% were classed as having good adherence, 10% satisfactory adherence and 0% poor adherence	Y	<0.001	The way the levels of “good”, “satisfactory” and “poor” adherence were classified was not clear from the study manuscript.
					Of the participants who occasionally exercise, 68% were classed as having good adherence, 29% satisfactory adherence and 3% poor adherence			
					Of the participants who did not exercise at all, 5% were classed as having good adherence, 0% as having satisfactory adherence and 95% as having poor adherence			
<b>McGrady, 2014</b> (176)	17.45 (15-20)	105	Self-Care Inventory (SCI)	N	Exercise at study entry (T1) with adherence at T1: 0 .33	Y	<0.001	

					Exercise at T1 with adherence at follow-up (T2): $r = 0.11$	N	>0.05	
					Exercise at T2 with adherence at T1: $r = -0.04$	N	>0.05	
					Exercise at T2 with adherence at T2: $r = 0.11$	N	>0.05	
<b>Peters, 2008</b> (159)	12.8 (range 8-17)	167	Diabetes Self-Management Profile (DSMP; Harris et al., 2000)	Y	Sample age 8-11: 0.234	Y	<0.01	
					Sample age 12-17: $r = 0.219$	Y	<0.05	
					Total sample: $r = 0.245$	Y	<0.05	

Table 3.14 Studies assessing the association between exercise frequency and adherence. Legend; Y: Yes, N: No, T1: Time 1 (study entry), T2: Time 2 (follow-up), SCI: Self-Care Inventory, DSMP: Diabetes Self-Management Profile,  $r$ : Pearson correlation coefficient score. Statistically significant results that suggest adherence improves with exercise have been coloured green. Statistically insignificant results were left white.

### 3.6.11. Less Frequently Assessed Factors

Table 3.15 contains a summary of factors that were assessed by 3 or fewer studies and their correlation with/effect on adherence.

Factor Assessed (number of studies if n>1)	N	Effect on Adherence	Statistically Significant? (Y/N)	Ref
Acceptance	252	Male: r= 0.29	Y	(141)
		Female: r= 0.34	Y	
Achievement striving	28	r= 0.382	N	(142)
Activity level		r= 0.33	N	
ADHD	322	AG: 1.9%, EG: 3%, MG: 4.2%	N	(117)
Adjustment disorder		AG: 1%, EG: 0%, MG: 2.8%	N	
Adolescent diabetes technology index	174	$\beta$ = 0.23	Y	(158)
Adventurousness	28	r= 0.089	N	(142)
Agoraphobia	322	AG: 1.9%, EG: 4.5%, MG: 2.8%	N	(117)
Agreeableness	28	r= 0.46	N	(142)
Alcohol/drug abuse	322	AG: 0%, EG: 0%, MG: 0%	N/A	(117)
Altruism	28	r= 0.225	N	(142)
Amount of sleep	45	Every 1-minute increase/decrease in sleep resulted in 1.2% increase/decrease in the total number of daily boluses/20 minutes per bolus	Y	(149)
Anger	28	r= -0.542	Y	(142)
Anxiety		r= -0.441	N	
Any psychiatric disorder	322	AG: 17.5%, EG: 29.6%, MG: 46.5%	Y	(117)
Artistic interests	28	r= 0.009	N	(142)
Assertiveness		r= 0.09	N	
Attitude	289	Positive attitude: Good: 31%, satisfactory: 69%, poor: 0%	Y	(120)
		Negative attitude: Good: 0%, satisfactory: 85%, poor: 15%	Y	
Authoritarian family function	70	0.17	N	(160)
Barriers to adherence	34	-0.29	N	(164)



Factor Assessed (number of studies if n>1)	N	Effect on Adherence	Statistically Significant? (Y/N)	Ref
Behavioural intervention	37	Increase in questionnaire score by a mean of 1.0 from pre-test to follow-up	Y	(186)
Behavioural support (child report)	88	Public hospital sample: r=Parent's (P) report on adherence: 0.46, Child's (C) report on adherence: 0.18, Nurse's (N) report on adherence: 0.32. $\beta$ =P: 0.55, C: 0.23, N: 0.25	P and N reports: Y, C report: N	(140)
		Private hospital sample: r=P: 0.16, C: 0.14, N: 0.15. $\beta$ =P: 0.27, C: 0.09, N: 0.2.	N	
		Public hospital sample: r=P: 0.32, C: 0.4, N: 0.35. $\beta$ =P: 0.17, C:0.22, N: 0.23	Y	
		Private hospital sample: r=P: 0.05, C: 0.15, N: -0.12. $\beta$ =P: 0.12, C: 0.03, N: -0.03.	N	
Behavioural support (parent report)				
Benefits - costs	56	DRCQ: 0.17	N	(153)
		DSCQ: 0.31	Y	
		CCTI: -0.05	N	
		DRCQ: -0.38	Y	
		DSCQ: NK	N	
		CCTI: NK	N	
Benefits - costs and threat				
Better parent-child relationship (n=2)	101	r=0.23, $\beta$ =0.23	Y	(116)
	53	Child's report of adherence: r= 0.49	Y	(192)
		Parent's report of adherence: r= 0.38	Y	
BGM frequency	88	r= 0.24	N	(140)
BGM frequency T1	105	T1: r= 0.26, T2: r= 0.25	Y	(176)
BGM frequency T2		T1: r= 0.21, T2: r= 0.27	Y	
Binging	193	r= -0.36	Y	(146)
BMI (n=2)	241	Group A (compliant group):	N	(144)

Factor Assessed (number of studies if n>1)	N	Effect on Adherence	Statistically Significant? (Y/N)	Ref
		r= -0.19, Group B (intentionally non-compliant group): r= 0.18, Group C (unintentionally non-compliant): r= -0.06		
	75	r= -0.19	N	(155)
Boluses delivered day before clinic visit (designed to assess white coat adherence)	98	Visit 1: r= -0.06	Y	(138)
		Visit 2: r= -0.096	Y	
Boluses delivered day before clinic visit x age	98	Visit 1: r= 0.0027	Y	(138)
		Visit 2: r= 0.005	Y	
Caregiver education level (n=2)	1028	r= 0.05	N	(145)
	201	MDI: NK	N	(150)
CSII: NK		N		
Cautiousness	28	0.517	Y	(142)
Cheerfulness		0.156	N	
Child's executive functioning	NK	$\beta$ = -0.274 (child report of adherence)	Y	(131)
		$\beta$ = -0.191 (parent report of adherence)	N	
Child's increasing responsibility (n=3)	121	Mother's report of adherence report: r= 0.14	N	(169)
		Child's report of adherence: r= 0.2	Y	
	161	r= 0.19	Y	(148)
	34	r= 0.32	Y	(139)
Clinical/subclinical eating disorders	322	AG: 1.9%, EG: 6%, MG: 12.7%	Y	(117)
Communication	252	Male: r= 0.27	Y	(141)

Factor Assessed (number of studies if n>1)	N	Effect on Adherence	Statistically Significant? (Y/N)	Ref
		Female: r= 0.25	Y	
Compliance in the first 9 months' association with compliance in the second 9 months	57	r= 0.53-0.64	Y	(178)
Conduct disorder	322	AG: 1%, EG: 1.5%, MG: 2.8%	N	(117)
Conscientiousness	28	0.488	Y	(142)
Consequences	64	r= -0.12	N	(135)
Control group vs intervention (trained by professionals who received a communication training plan) group	208	-1.4 score difference control vs intervention group	N	(183)
Co-operation	28	r= 0.324	N	(142)
Coping measures: ego defence level	61	Mean change = -0.05 (with higher ego defence score)	Y	(163)
CSII vs MDI (n=3)	1028	r= 0.18 (CSII better adherence)	N	(145)
	123	Mean difference between scores, MDI vs CSII: 0	N	(128)
	34	"CSII patients had better compliance" (no numerical value stated)	Y	(197)
Cues	56	DRCQ: 0.2	N	(153)
		DSCQ: 0.34	Y	
		CCTI: 0.36	Y	
Cure-control	64	r= 0.41	Y	(135)
Diabetes adjustment (n=2)	57	0-9 months: r= 0.24	N	(178)
		10-18 months: 0.42	Y	

Factor Assessed (number of studies if n>1)	N	Effect on Adherence	Statistically Significant? (Y/N)	Ref
	52	Mean change of 0.27 in adherence score for those deemed to have better adjustment to diabetes	Y	(162)
Diabetes monitoring	252	Male: r= 0.38	Y	(141)
		Female: r= 0.38	Y	
Diabetes Social Support Questionnaire: frequency	74	r= 0.2	N	(134)
Diabetes Social Support Questionnaire: individualised		r= 0.27	Y	
Discipline (child's report)	88	Public: P: 0.23, C: 0.22, N: 0.23. b=P: 0.09, C: 0.14, N: 0.22	N	(140)
		Private: r=P: 0.03, C: 0.1, N: 0.08. b=P: 0.03, C: 0.13, N: 0.08.	N	
		Public hospital sample: r= P: 0.21, C: 0.08, N: 0.01. b=P: 0.08, C: -0.17, N: -0.22.	N	
		Private hospital sample: r=P: 0.05, C: 0.15, N: -0.12. b=P: -0.02, C:0.12, N: - 0.07.	N	
DSMP hypoglycaemia subscale: diet	167	Total sample: 0.403	Y	(159)
		Age 8-11: 0.407	Y	
		Age 12-17: 0.388	Y	
DSMP subscale: glucose testing	167	Total sample: 0.309	Y	(159)
		Age 8-11: 0.176	N	
		Age 12-17: 0.3	Y	

Factor Assessed (number of studies if n>1)	N	Effect on Adherence	Statistically Significant? (Y/N)	Ref
DSMP subscale: hypoglycaemia management		Total sample: 0.154	Y	
		Age 8-11: 0.061	N	
		Age 12-17: 0.185	Y	
Dutifulness	28	0.419	N	(142)
Dysthymia	322	AG: 0%, EG: 0%, MG: 4.2%	Y	(117)
Eating Attitudes Test 26	75	r= -0.45	Y	(155)
Eating disorders (clinical/subclinical)	322	AG: 1.9%, EG: 6%, MG: 12.7%	Y	(117)
Eating Disorders Inventory - Body Dissatisfaction Scale	75	r= -0.43	Y	(155)
Education group vs positive affect (PA) text message group	48	NK (insignificant)	N	(174)
Education intervention	40	Pre-intervention adherence score: 36.78 (SD 10.12), post -intervention adherence score: 37 (SD 10.26)	Y	(152)
Emergency (hypoglycaemia) precautions at study entry	105	T1: 0.23, T2: 0.12	T1: Y, T2: N	(176)
Emergency (hypoglycaemia) precautions at follow- up		T1: 0.26, T2: 0.33	Y	
Emotional adjustment	28	r= -0.28	Y	(142)
Emotionality	157	0.128	N	(123)

Factor Assessed (number of studies if n>1)	N	Effect on Adherence	Statistically Significant? (Y/N)	Ref
Energy and willpower	289	Has energy and willpower: Good: 39%, satisfactory: 61%, poor: 8%	Y	(120)
		No energy and willpower: Good: 3%, satisfactory: 86%, poor: 11%	Y	
Excitement seeking	28	r= -0.146	N	(142)
Experience of results	289	Positive experience: Good: 26%, satisfactory: 72%, poor: 3%	Y	(120)
		Negative experience: Good: 1%, satisfactory: 83%, poor: 16%	Y	
Expressiveness	NK	r= 0.02	N	(131)
Externalising behaviour	197	r= -0.24	Y	(175)
Extraversion	289	0.151	N	(120)
Family relations	93	r=0.32, $\beta$ =0.194	r=Y, b=N	(125)
	223	r= 0.64	NK	(127)
Family stress (n=2)	197	Maternal report: r= -0.24	Y	(175)
		Child's report: r= -0.09	N	
	322	Parent's report: $\beta$ : -0.333	Y	(117)
Family support: affective	157	r= 0.234	Y	(136)
Family support: control		r= 0.148	N	
Family support: indirect		r= 0.144	N	
Family support: no support		r= -0.095	N	
Father negative	34	r= -0.01	N	(164)
Father-absent vs father-present	60	F= 5.75 (better adherence in father- absent adolescents)	Y	(124)

Factor Assessed (number of studies if n>1)	N	Effect on Adherence	Statistically Significant? (Y/N)	Ref
Feel that diabetes affects their mental wellbeing	289	7.68 times more likely to be adherent than those who did not	Y	(121)
Feel that diabetes affects their physical wellbeing		2.95 times more likely to be adherent than those who did not	Y	
Feel that they have support from nurses		6.28 times more likely to be adherent than those who did not	Y	
Feel that they have support from their physician		6.69 times more likely to be adherent than those who did not	Y	
Frequency of alcohol consumption (n=2)	322	Regularly drinks alcohol: Good: 5%, satisfactory: 62%, poor: 33%	Y	(117)
		Occasionally drinks alcohol: Good: 9%, satisfactory: 78%, poor: 13%		
		Doesn't drink alcohol: Good: 68%, satisfactory: 31%, poor: 1%		
	28	NK (insignificant)	N	(142)
Frequency of breakfast	104	r= -0.369	Y	(129)
Frequency of dinner		r= -0.28	Y	
Frequency of evening snack		r= 0.01	N	
Frequency of help	252	Male: 0.04	N	(141)
		Female: 0.12	N (marginal)	
Frequency of lunch	104	r= -0.127	N	(129)
Frequency of mid- afternoon snack		r= -0.019	N	

Factor Assessed (number of studies if n>1)	N	Effect on Adherence	Statistically Significant? (Y/N)	Ref
Frequency of mid- morning snack		r= -0.095	N	
Friendliness	28	0.263	N	(142)
Functional enuresis	64	AG: 3.9%, EG: 1.5%, MG: 2.8%	N	(135)
General monitoring	252	Male: r= 0.46	Y	(141)
		Female: r= 0.26	Y	
Generalised anxiety disorder	28	AG: 0%, EG: 0%, MG: 1.4%	N	(142)
Gregariousness	34	r= 0.072	N	(164)
HBM: Benefits	54	r=0.02, $\beta$ =0.32	N	(156)
HBM: costs		r=0.25, $\beta$ =-1.19	N	
HBM: cues to action		r=0, $\beta$ =-0.43	N	
HBM: Susceptibility		r=0.01, $\beta$ =-0.29	Y	
Health Belief Model (HBM): Severity		r=0, $\beta$ =0.07	Y	
HFS: Behaviour	76	Boys: r= 0.12	N	(157)
		Girls: r= 0.15	N	
HFS: worry/fear		Boys: r= -0.5	Y	
		Girls: r= -0.02	N	
Household income (n=3)	101	r= 0.04	N	(116)
	1028	r= 0.18	Y	(145)
	174	$\beta$ = 0.08	N	(158)
Identity	28	r= -0.24	N	(142)
Imagination		-0.183	N	
Immigrant vs French Native mother: General insulin adherence	165	Immigrant mother score: 3.9, French native mother score: 4.6	Y	(147)
Immigrant vs French Native mother:		Immigrant mothers: 29.2%, Native French mother: 62%	Y	



Factor Assessed (number of studies if n>1)	N	Effect on Adherence	Statistically Significant? (Y/N)	Ref
Percentage that adjust insulin dose during illness:				
Impulsiveness	28	-0.348	N	(142)
Increased disease severity (n=3)	101	r= -0.22, b= -0.2	Y	(116)
	161	r= -0.16	N	(148)
	54	r=0, $\beta$ =0.07	N	(156)
Increased severity of risks	101	r=0.21, b=0.3	Y	(116)
Increased treatment complexity		r= -0.17	N	
Increased vulnerability to risks		r=-0.01, b=-0.14	N	
Increasing lack of responsibility from mother or child	121	Mother's (M) report of adherence: -0.23, Child's (C) report of adherence: -0.06	M report: Y, C report: N	(169)
Independence	70	r= -0.05	N	(160)
Independence and encouragement	252	Male: r= 0.27	Y	(141)
		Female: r= 0.28	Y	
Insulin dosage calculator use: control group (manual calculations)	83	Average adherence score change after 6 months: +0.29	Y	(182)
Insulin dosage calculator use: inconsistent		Average adherence score change after 6 months: +0.56	Y	
Insulin dosage calculator use: regular		Average adherence score change after 6 months: +0.12	N	
Intellect	28	r= 0.005	N	(142)

Factor Assessed (number of studies if n>1)	N	Effect on Adherence	Statistically Significant? (Y/N)	Ref
Intensity of insulin regimen (2 vs 4 injections per day)	89	No correlation	N	(167)
Internalising behaviour	252	r= -0.11	N (marginal)	(141)
Intervention group (12 play sessions) vs control group	30	Post-test: 0.156	N	(185)
Intervention group (monthly diabetes education session) vs control group	503	Intervention pre-test: 89.66	Y	(184)
		Intervention post-test: 94.4		
		Control pre-test: 63.9		
		Control post-test: 51.23		
Intrusive support	252	Male: 0.1	N	(141)
		Female: 0.14	Y	
Liberalism	161	0.21	N	(148)
Locus of control	57	0-9 months: r= 0.24	N	(178)
		10-18 months: r= 0.34	Y	
Locus of control: chance	174	r= -0.06	N	(158)
Locus of control: internal		r= 0.17	N	
Locus of control: powerful others		r= 0.18	N	
Maternal Involvement: child's report	82	P report T1: r= 0.09. C report T1: r= 0.05. P report T2: r= 0.18. C report T2: r= 0.04.	N	(177)

Factor Assessed (number of studies if n>1)	N	Effect on Adherence	Statistically Significant? (Y/N)	Ref
Maternal Involvement: Mother's report		P report T1: r= 0.03. C report T1: r= 0.01. P report T2: r= 0.17. C report T2: r= -0.06.	N	
Mean daily blood glucose	91	r= -0.428	Y	(151)
Mean diabetes- specific stress (DSS) severity	175	r= -0.11	N	(173)
Method of insulin delivery	207	Inhaled insulin usability score: 74.2, S/C insulin usability score: 67	Y	(179)
Modesty	28	r= 0.13	N	(142)
Morality		r= 0.603	Y	
Mother negative	34	-0.14	N	(164)
Mother report of social functioning	57	0-9 months: 0.45, 10.25	Y	(178)
		10-18 months: 0.43, 9.37	Y	
Mother's age	88	r= -0.07	N	(154)
Mother's education		0.13	N	
Mother's increasing responsibility for management of daily regimen tasks	121	Mother's report of adherence: r= -0.01, Child's report of adherence: r= 0.08	N	(169)
Mother's increasing responsibility for management of general health		Mother's report of adherence: r= 0, Child's report of adherence: r= 0.17	N	
Mother's increasing responsibility for social presentation (talking to family and		Mother's report of adherence: r=: -0.16, Child's report of adherence: r= -0.02	N	

Factor Assessed (number of studies if n>1)	N	Effect on Adherence	Statistically Significant? (Y/N)	Ref
friends about disease etc.)				
Mother's sense of empowerment	88	0.2	Y	(154)
Motivation level	289	Good motivation: Good: 39%, satisfactory: 61%, poor: 0%	Y	(120)
		No motivation: Good: 2%, satisfactory: 83%, poor: 15%	Y	
Negative communication	75	r= -0.39	Y	(155)
Negotiated Telephone Support	91	Adherence score mean change: 4.81 (SD 10.74). Barriers to Adherence mean change: 4.12 (SD 21.7)	N	(180)
Negotiated Telephone Support, yearly clinical review, 3-monthly measurement of HbA1c		Adherence score mean change: 7.32 (SD 9.1). Barriers to Adherence mean change: -0.64 (SD 11.9)	N	
Neuroticism	322	r= -0.505	Y	(117)
Non-supportive family		r= -0.29	Y	
Non-white adolescent		$\beta$ = -0.13	N	
Number of adverse life events	178	0-1 adverse life events: Mean adherence score, C report: 75. P report: 74. 2-3 adverse life events: Mean adherence score, C report: 71. P report: 71. 4+ adverse life events: Mean adherence score, C report: 68. P report: 68.	Y	(118)
Number of children in family	88	r= 0.03	N	(154)

Factor Assessed (number of studies if n>1)	N	Effect on Adherence	Statistically Significant? (Y/N)	Ref
Number of hospital admissions	89	No correlation	N	(167)
OCD	322	AG: 0%, EG: 3%, MG: 1.4%	N	(117)
Openness to experience	28	r= 0.051	N	(142)
Oppositional defiant disorder	57	AG: 1.9%, EG: 0%, MG: 5.6%	N	(178)
Orderliness	28	-0.018	N	(142)
Overall QoL	76	Boys: r= -0.44	Y	(157)
		Girls: r= -0.09	N	
Parent perception of control	52	r= -0.12	N	(162)
Parent perception of family organisation		r= 0.21	N	
Parent perception of independence		r= 0.04	N	
Parental marital status	201	MDI: NK	N	(150)
		CSII: NK	N	
Parents' health literacy	93	r = 0.2	N	(172)
Parents perceptions of expressiveness	52	0.16	N	(162)
Parents' reading comprehension (intensive insulin regimen); P report on adherence	93	Parents' report on adherence: r = 0.31, child's report on adherence: r = 0.32	Y	(172)
Patient perception of control	52	-0.05	N	(162)
	34	r= -0.1	N	(164)

Factor Assessed (number of studies if n>1)	N	Effect on Adherence	Statistically Significant? (Y/N)	Ref
Patient perceptions of family organisation (n=3)	157	r= 0.053	N	(136)
	52	r= 0.25	N	(162)
		r= 0.16	N	
		r= 0.17	N	
Patient perception of independence				
Patient perceptions of expressiveness				
Perceived barriers to site rotation	201	MDI: r= -0.28	Y	(150)
		CSII: r= -0.21	N	
Perceived competence	57	0-9 months: r= 0.22; 10-18 months: r= 0.3	N	(178)
Perceived impact (n=2)	105	T1: 0.01, T2: -0.03	N	(176)
	76	Boys: r= -0.38	Y	(157)
		Girls: r= -0.11	N	
Perceived level of hope	90	r= 0.26	Y	(132)
Perceived threat (n=2)	105	T1: r= -0.22, T2: r=-0.16	T1: Y, T2: N	(176)
	56	DRCQ: r= -0.08	N	(153)
		DSCQ: r= -0.05	N	
		CCTI: r= 0.09	N	
Presence of co- morbidities	57	Yes: 27.8% of non-adherence	N	(166)
		No: 72.2% of non-adherence	N	
Presence of threat to emotional well-being	289	No threat to emotional well-being: Good: 29%, satisfactory: 66%, poor: 5%	Y	(120)
		Threat to emotional well-being: Good: 7%, satisfactory: 85%, poor: 8%	Y	
Presence of threat to physical well-being		No threat to physical well-being: Good: 90%, satisfactory: 10%, poor: 0%	Y	

Factor Assessed (number of studies if n>1)	N	Effect on Adherence	Statistically Significant? (Y/N)	Ref
		Threat to physical well-being: Good: 2%, satisfactory: 143%, poor: 0%	Y	
Presence of threat to social wellbeing		No threat to social well-being: Good: 36%, satisfactory: 64%, poor: 0%	Y	
		Threat to social well-being: Good: 3%, satisfactory: 82%, poor: 15%	Y	
Psychosis	201	AG: 0%, EG: 0%, MG: 0%	N/A	(150)
PTSD		AG: 0%, EG: 4.5%, MG: 1.4%	N	
PTSD diagnosis of mother	60	Overall: r = -0.115, aged 0-8: r = -0.519, aged 9-16: r = 0.062	N	(171)
QoL (with number of injections per day)	503	chi-squared value: 6.73	Y	(184)
QoL: Diabetes worry	76	Boys: r= -0.24	N	(157)
		Girls: r= -0.14	N	
QoL: Satisfaction		Boys: r= -0.42	Y	
		Girls: r= -0.12	N	
QoL: Social worry		Boys: r= -0.3	N	
		Girls: r= 0	N	
Race	57	Malaysian: 35.2% of non-adherence	N	(166)
		Chinese: 51.9% of non-adherence	N	
		Indian: 11.1% of non-adherence	N	
		Other: 1.9% of non-adherence	N	
Recent change in insulin dose		Yes: 70.4% of non-adherence	N	
		No: 29.6% of non-adherence	N	
Regular Use of I-Port	55	Mean number of missed insulin doses in past three months down to 0.26 (SD 0.81) from 1.1 (SD 1.81)	Y	(170)

Factor Assessed (number of studies if n>1)	N	Effect on Adherence	Statistically Significant? (Y/N)	Ref
Report of symptoms (from child)	322	0-9 months: r= 0.22	N	(117)
		10-18 months: r= 0.32	Y	
Report of symptoms (from mother)		0-9 months: r= 0.3	Y	
10-18 months: r= 0.33		Y		
Response costs	101	r=-0.45, $\beta$ =- 0.36	Y	(116)
Response efficacy		r=0.3, $\beta$ = 0.18	Y	
School/work performance	223	r= 0.66	NK	(127)
Self-consciousness	28	r= -0.133	N	(142)
Self-discipline		r= 0.482	Y	
Self-report on adherence to BGM	88	r= 0.24	N	(140)
Self-report on adherence to meals		r= -0.27	N	
Self-report on adherence to snacks		r= 0.11	N	
Sense of normality	289	Strong sense of normality: Good: 29%, satisfactory: 71%, poor: 0%	Y	(120)
		Poor sense of normality: Good: 3%, satisfactory: 80%, poor: 17%	Y	
Separation anxiety disorder	88	AG: 1%, EG: 3%, MG: 4.2%	N	(154)
Single parent household vs both parents (n=2)	NK	t-score= -2.38 (worse adherence in single-parent households)	Y	(131)
	1028	r= 0.08 (better adherence in two-parent households)	N	(145)
Smoking frequency (n=2)	289	Regularly smokes: Good: 0%, satisfactory: 84%, poor: 16%	Y	(120)



Factor Assessed (number of studies if n>1)	N	Effect on Adherence	Statistically Significant? (Y/N)	Ref
		Occasionally smokes: Good: 2%, satisfactory: 91%, poor: 7%	Y	
		Doesn't smoke: Good: 64%, satisfactory: 35%, poor: 11%	Y	
	197	r= -0.08	Y	
Sociability scores	223	r= 0.46	NK	(127)
Social anxiety	76	Boys: r= -0.39	Y	(157)
		Girls: r= 0.21	N	
Social competence (n=2)	93	r=0.25, $\beta$ =-0.067	r=Y, b=N	(125)
	104	r= 0.2	Y	(126)
Social phobia	322	AG: 0%, EG: 1.49%, MG: 7%	Y	(117)
Socio-economic status (n=3)	104	Lower socioeconomic status related to poorer adherence; no numerical figure given	Y	(126)
	93	r= -0.14	N	(125)
	157	$\beta$ = 0.178 (higher class confers to better adherence)	Y	(136)
Specific (isolated) phobias	175	AG: 2.9%, EG: 9%, MG: 21.1%	Y	(173)
Stress (n=3)	56	r= -0.08	N	(153)
	64	r=-0.11, $\beta$ =-0.033	N	(135)
	174	r= -0.09	N	(158)
Support from friends	74	r= 0.05	N	(133)
Support from nurses	289	Has support from nurses: Good: 37%, satisfactory: 63%, poor: 0%	Y	(120)
		No support from nurses: Good: 1%, satisfactory: 85%, poor: 14%	Y	
Support from physicians		Has support from physicians: Good: 39%, satisfactory: 61%, poor: 0%	Y	

Factor Assessed (number of studies if n>1)	N	Effect on Adherence	Statistically Significant? (Y/N)	Ref
		No support from physicians: Good: 7%, satisfactory: 87%, poor: 12%	Y	
"Sweet talk" text message intervention (conventional insulin therapy)	90	Self-reported adherence score increased by 6.8 compared to the group receiving no intervention	Y	(181)
Sympathy	28	0.205	N	(142)
Teacher victimisation	167	Total sample: -0.135	N	(159)
		Age 8-11: -0.343	Y	
		Age 12-17: -0.112	N	
Threat	174	DRCQ: r= -0.08	N	(158)
		DSCQ: r= -0.05	N	
		CCTI: r= 0.09	N	
Timeline		r= 0.18	N	
Total DSMP score	167	Total sample: r= 0.65	Y	(159)
		Age 8-11: r= 0.667	Y	
		Age 12-17: r= 0.629	Y	
Total HFS	76	Boys: r= -0.38	Y	(157)
		Girls: r= 0.04	N	
Total meals	104	r= -0.332	Y	(129)
Treatment effectiveness: control	105	T1: r= 0.12, T2: r= 0.15	N	(176)
Treatment effectiveness: prevent		T1: r= 0.08, T2: r= 0.24	T1 : N, T2: Y	
Trust	28	r= 0.382	N	(142)
Type of insulin pen	116	Solostar pen: Percentage of participants completing all tasks successfully: 98%	Y	(119)
		FlexPen: Percentage of participants completing all tasks successfully: 97%	Y	

Factor Assessed (number of studies if n>1)	N	Effect on Adherence	Statistically Significant? (Y/N)	Ref
		Lilly Disposable Pen: Percentage of participants completing all tasks successfully: 72%	N	
		Pen X: Percentage of participants completing all tasks successfully: 79%	N	
Uses diabetes apps	174	$\beta = 0.12$	N	(158)
Uses diabetes websites		$\beta = 0.15$	Y	
Uses meter/pump software	88	$\beta = 0.15$	Y	(140)
Uses social networking	157	$\beta = 0.18$	Y	(136)
Uses text messaging	52	$\beta = 0.11$	N	(162)
Utilising personal and interpersonal resources coping strategy	135	$r = -0.055$	N	(122)
Ventilation and avoidance coping strategy		$r = -0.367$	Y	
Vulnerability	28	$r = -0.378$	N	(142)
Warmth (child's report)	34	Public hospital group: $r = \text{Parent's (P) report of adherence: 0.4, Child's (C) report of adherence: 0.35, Nurse's (N) report of adherence: 0.37. } b = P: 0.02, C: 0.11, N: 0.22.$	Y	(164)
		Private hospital group: $r = P: 0.03, C: 0.19, N: 0.03. } b = P: -0.16, C: 0.05, N: -0.13$	N	
Warmth (parent's report)		Public hospital group: $r = P: 0.55, C: 0.48, N: 0.35. } b = P: 0.35, C: 0.36, N: 0.29.$	Y	

Factor Assessed (number of studies if n>1)	N	Effect on Adherence	Statistically Significant? (Y/N)	Ref
		Private hospital group: r=P: 0.2, C: 0.13, N: -0.17. b=P: 0.11, C: 0.08, N: -0.14.	N	

*Table 3.15 Summary of factors that were assessed by 3 or fewer studies. Legend; N: sample size, n: number of studies, C: child, P: parent, N: nurse, r: correlation,  $\beta$ : beta-value, Y: yes, N: no, DSMP: Diabetes Self-Management Profile, HFS: Hypoglycaemia Fear Score, AG: Agreement Group, EG: Error Group, MG: Management Group, DRCQ: Diabetes Regimen Compliance Questionnaire, DSCQ: Diabetes Self-Care Activities Questionnaire, CCTI: Child Compliance Telephone Interviews, CSII: Continuous Subcutaneous Insulin Infusion, MDI: Multiple Daily Injections. Those in the "Agreement Group" were deemed as being compliant. Those in the "Error Group" were deemed as being intentionally non-compliant. Those in the "Management Group" were deemed as being unintentionally non-compliant. Groups A and B were statistically identical samples drawn from two different populations.*

### 3.6.12. Agreement of Studies

Table 3.16 contains the factors that were assessed more than once and summarises the agreement of the results of these studies.

Studies were deemed as having results of “mixed significance” if they assessed the factor in multiple domains (and published these domains separately), with some of them being statistically significant and others not significant. For example, they assessed the factor’s effect upon adherence in boys and girls, but the effect was only significant in boys. This includes studies with a significant correlation ( $r$ ) but a not significant effect size ( $\beta$ ). For a study’s results to be deemed as showing a positive or negative relationship, it would need to demonstrate this same relationship across all of its assessed domains; this includes studies that only assessed a single domain.

Each factor was colour coded according to the predominant result. If the predominant result suggested a positive relationship between the factor and adherence, it was coloured dark green (strong agreement of studies). If there were an equal number of results suggesting a positive relationship and not significant/mixed significance results, it was coloured light green (relative agreement of studies). If the predominant result was not statistically significant/of mixed significance, the result was left white. If there were an equal number of results suggesting a negative relationship and not significant/mixed significance results, it was coloured orange (relative agreement of studies). If the predominant result suggested a negative relationship, it was coloured red (strong agreement of studies).

There were no factors that had an even split of studies suggesting significant positive and negative relationships.

For single-parent versus dual-parent households, the light green colouration indicates an even number of studies suggesting adherence was better in dual-parent households and those suggesting a not significant/mixed significance relationship.

Factor	Number of Studies	Percentage	References
<b>Age</b>	Positive relationship: 2/33	6.06%	(116,122,123,125,128,132-134,136-138,140,143-145,148,150,151,153,154,156,158,160,163,165-169,177,178,192,193)
	Negative relationship: 22/33	66.66%	
	Results not statistically significant: 7/33	21.21%	
	Results of mixed significance: 2/33	6.06%	
<b>Glycaemic Control</b>	Positive relationship: 15/20	75%	(121,123,125,126,128,132,135,137,139-141,144,145,151,154,155,159,160,173,176)
	Negative relationship: 0/20	0%	
	Results not statistically significant: 3/20	15%	
	Results of mixed significance: 2/20	10%	
<b>Duration of Diabetes</b>	Positive relationship: 0/19	0%	(116,120-123,128,131,133,136,144,145,148,150,154,158,160,163,169,178)
	Negative relationship: 9/19	47.37%	
	Results not statistically significant: 10/19	52.63%	
	Results of mixed significance: 0/19	0%	
<b>Gender</b>	Better adherence in males: 5/15	33.33%	(128,133,136,144,145,154,160,161,164,166-169,178,192)
	Better adherence in females: 1/15	6.67%	
	Results not statistically significant: 9/15	60%	
	Results of mixed significance: 0/15	0%	
<b>Family Conflict</b>	Positive relationship: 0/8	0%	(123,136,140,151,160,162,164,192)
	Negative relationship: 1/8	12.5%	
	Results not statistically significant: 3/8	37.5%	
	Results of mixed significance: 4/8	50%	
<b>Depression (in the child/young person)</b>	Positive relationship: 0/7	0%	(117,132,142,146,151,173,195)
	Negative relationship: 7/7	100%	
	Results not statistically significant: 0/7	0%	
	Results of mixed significance: 0/7	0%	
<b>Self-Efficacy</b>	Positive relationship: 5/7	71.42%	(116,135,141,142,146,148,160)
	Negative relationship: 0/7	0%	
	Results not statistically significant: 1/7	14.29%	
	Results of mixed significance: 1/7	14.29%	
<b>Family Support</b>	Positive relationship: 5/7	71.42%	(120,126,133,134,136,148,164)
	Negative relationship: 0/7	0%	
	Results not statistically significant: 2/7	28.57%	
	Results of mixed significance: 0/7	0%	
<b>Family Cohesion</b>	Positive relationship: 2/5	40%	(123,134,136,162,164)
	Negative relationship: 0/5	0%	
	Results not statistically significant: 2/5	40%	
	Results of mixed significance: 1/5	20%	
<b>Diabetes Knowledge</b>	Positive relationship: 2/4	50%	(125,156,193,196)
	Negative relationship: 0/4	0%	
	Results not statistically significant: 1/4	25%	
	Results of mixed significance: 1/4	25%	
<b>Exercise Frequency</b>	Positive relationship: 3/4	75%	(120,121,159,176)
	Negative relationship: 0/4	0%	
	Results not statistically significant: 0/4	0%	
	Results of mixed significance: 1/4	25%	
	Positive relationship: 2/3	66.67%	(139,148,169)
	Negative relationship: 0/3	0%	

Factor	Number of Studies	Percentage	References
<b>Child's Increasing Responsibility</b>	Results not statistically significant: 1/3	33.33%	
	Results of mixed significance: 0/3	0%	
<b>CSII vs MDI</b>	Better adherence with MDI: 0/3	0%	(128,145,197)
	Better adherence with CSII: 1/3	33.33%	
	Results not statistically significant: 2/3	66.67%	
	Results of mixed significance: 0/3	0%	
<b>Disease Severity</b>	Positive relationship: 0/3	0%	(116,148,156)
	Negative relationship: 1/3	33.33%	
	Results not statistically significant: 2/3	66.67%	
	Results of mixed significance: 0/3	0%	
<b>Household Income</b>	Positive relationship: 1/3	33.33%	(116,145,158)
	Negative relationship: 0/3	0%	
	Results not statistically significant: 2/3	66.67%	
	Results of mixed significance: 0/3	0%	
<b>Socio-Economic Status</b>	Positive relationship: 2/3	66.67%	(125,126,136)
	Negative relationship: 0/3	0%	
	Results not statistically significant: 1/3	33.33%	
	Results of mixed significance: 0/3	0%	
<b>Stress</b>	Positive relationship: 0/3	0%	(135,153,158)
	Negative relationship: 0/3	0%	
	Results not statistically significant: 3/3	100%	
	Results of mixed significance: 0/3	0%	
<b>Better Parent-Child Relationship</b>	Positive relationship: 2/2	100%	(116,192)
	Negative relationship: 0/2	0%	
	Results not statistically significant: 0/2	0%	
	Results of mixed significance: 0/2	0%	
<b>BGM Frequency</b>	Positive relationship: 1/2	50%	(140,176)
	Negative relationship: 0/2	0%	
	Results not statistically significant: 1/2	50%	
	Results of mixed significance: 0/2	0%	
<b>BMI</b>	Positive relationship: 0/2	0%	(144,155)
	Negative relationship: 0/2	0%	
	Results not statistically significant: 2/2	100%	
	Results of mixed significance: 0/2	0%	
<b>Caregiver Education Level</b>	Positive relationship: 0/2	0%	(145,150)
	Negative relationship: 0/2	0%	
	Results not statistically significant: 2/2	100%	
	Results of mixed significance: 0/2	0%	
<b>Diabetes Adjustment</b>	Positive relationship: 1/2	50%	(162,178)
	Negative relationship: 0/2	0%	
	Results not statistically significant: 0/2	0%	
	Results of mixed significance: 1/2	50%	
<b>Family Relations</b>	Positive relationship: 0/2	0%	(125,127)
	Negative relationship: 0/2	0%	
	Results not statistically significant: 1/2	50%	
	Results of mixed significance: 1/2	50%	
<b>Family Stress</b>	Positive relationship: 1/2	50%	(117,175)
	Negative relationship: 0/2	0%	

Factor	Number of Studies	Percentage	References
	Results not statistically significant: 0/2	0%	
	Results of mixed significance: 1/2	50%	
Frequency of Alcohol Consumption	Positive relationship: 0/2	0%	(117,142)
	Negative relationship: 1/2	50%	
	Results not statistically significant: 1/2	50%	
	Results of mixed significance: 0/2	0%	
Perceived Impact	Positive relationship: 0/2	0%	(157,176)
	Negative relationship: 0/2	0%	
	Results not statistically significant: 1/2	50%	
	Results of mixed significance: 1/2	50%	
Perceived Threat	Positive relationship: 0/2	0%	(153,176)
	Negative relationship: 0/2	0%	
	Results not statistically significant: 1/2	50%	
	Results of mixed significance: 1/2	50%	
Single vs Dual-Parent Household	Adherence better in single-parent household: 0/2	0%	(131,145)
	Adherence better in dual-parent household: 1/2	50%	
	Results not statistically significant: 1/2	50%	
	Results of mixed significance: 0/2	0%	
Smoking Frequency	Positive relationship: 0/2	0%	(120,175)
	Negative relationship: 2/2	100%	
	Results not statistically significant: 0/2	0%	
	Results of mixed significance: 0/2	0%	
Social Competence	Positive relationship: 1/2	50%	(125,126)
	Negative relationship: 0/2	0%	
	Results not statistically significant: 0/2	0%	
	Results of mixed significance: 1/2	50%	

Table 3.16 Factors assessed by multiple studies and the agreement of those studies. Legend; CSII: Continuous Subcutaneous Insulin Infusion, MDI: Multiple Daily Injections, BMI: Body Mass Index. Colour coding: dark green: predominant result suggests a positive relationship, light green: equal number of results suggesting a positive relationship and not significant/mixed significance results, white: predominant result is lack of statistical significance and/or mixed significance, orange: equal number of results suggesting a negative relationship and not significant/mixed significant results, red: predominant result suggests a negative relationship.



### 3.7. Secondary Outcomes

#### 3.7.1. Reasons for Non-Adherence

One of the secondary outcomes of this study was to find some of the common reasons for non-adherence as reported by children and young people and/or their parents.

The 4 studies (117,130,139,140) reported 22 reasons for non-adherence. No two studies assessed the same reason.

Two studies (117,140) compared the reported reasons in CSII users versus MDI users. One of these 2 studies (140) was specifically asking for reasons that the child did not rotate their injection site.

One study (130) sorted participants into two groups (A and B) and asked for their reasons for non-adherence. There were no clear differences between these two groups.

One study (139) simply reported the percentage of their sample that reported a given reason.

Table 3.17 summarises the findings of these studies.

<b>Reported Reason</b>	<b>Percentage of Sample Reporting Given Reason</b>	<b>Ref</b>	
<b>Comfort with existing routine</b>	MDI users: 49%, CSII users: 64%	(117)	
<b>Counting exchanges difficulties</b>	A: 15%, B: 7%	(130)	
<b>Denial: wants to be like others, does not admit to being diabetic</b>	26.50%	(139)	
<b>Diabetes misunderstanding</b>	A: 23%, B: 36%	(130)	
<b>Eating many meals</b>	A: 18%, B: 28%		
<b>Estimation of food difficulties</b>	A: 23%, B: 28%		
<b>Fear of hypoglycaemia</b>	A: 50%, B: 39%		
<b>Feels bad; disease is responsible</b>	17.60%		
<b>Frequent blood monitoring</b>	A: 24%, B: 25%		
<b>Frequent infections</b>	A: 24%, B: 23%		
<b>Hedonism: Hungry or not hungry, concerned about weight, too much bother</b>	35.30%		(139)
<b>Interpersonal reasons: peer pressure, rebelling against parents</b>	17.60%		
<b>Lack of time</b>	A: 26%, B: 18%	(130)	
<b>New sites would be painful</b>	MDI: 49%, CSII: 64%	(140)	
<b>Parents' tiredness</b>	A: 50%, B: 55%	(130)	
<b>Poor material conditions</b>	A: 20%, B: 28%		
<b>Problems with care at kindergarten/school</b>	A: 32%, B: 37%		
<b>Shame of diabetes</b>	A: 6%, B: 3.5%		
<b>Snacking without parents' permission</b>	A: 17%, B: 43%		
<b>Stress related pain</b>	A: 36%, B: 39%		
<b>Stubborn, lazy, careless</b>	38.20%	(139)	
<b>Taking care of other children</b>	A: 17%, B: 16%	(130)	

*Table 3.17 Reported reasons for non-adherence. Legend; MDI: Multiple Daily Injection, CSII: Continuous Subcutaneous Insulin Infusion, A: group A, B: group B.*

## 4. Thematic Analysis

Across the 5 identified themes:

- 12 of the factors identified were relating to demographics
- 4 were related to past medical history.
- 32 were factors related to diabetes management and diabetes test results
- 159 were psycho-social factors and
- 29 were factors related to family dynamics.

Demographic factors were assessed in 38 studies with a total of 5 415 children and young people. This is a mean of 143 children per study, with a range of 31 to 1 028. The 38 studies used a total of 26 different measures of adherence.

Factors relating to past medical history were assessed in 2 studies with a total of 146 children and young people, with 57 in one study and 89 in the other. Both studies used MPR as their measure of adherence.

Factors relating to diabetes management were assessed in 31 studies with a total of 4 607 children and young people. This is a mean of 149 children per study, with a range of 31 to 1 028. The 31 studies used a total of 21 different measures of adherence.

Psycho-social factors were assessed in 54 studies with a total of 6 534 children and young people. This is a mean of 121 children per study with a range of 34 to 503. The 54 studies used a total of 33 different measures of adherence.

Factors relating to family dynamics were assessed in 21 studies with a total of 2 840 children and young people. This is a mean of 135 children per study with a range of 34 to 1 028. The 21 studies used a total of 16 different measures of adherence.

The variability between themes is illustrated as a bar chart in Figure 4.1.

Despite being the theme with the second-fewest number of individual factors (with 12), demographic factors were assessed in the second highest number of children. This is likely as a result of age being the most frequently assessed factor, being a variable in 33 studies. It is also the theme

with the greatest proportion of its factors being assessed by multiple studies, with 6/12 (50%) featuring in 2 or more studies.

Past medical history was the least assessed theme, with its four factors appearing between two studies. Just one of the four factors (BMI) was assessed in both studies, with both studies finding the effect upon adherence to be not statistically significant.

The second most commonly assessed factor across all studies was HbA1c/glycaemic control, which is in the diabetes management theme. Though it is a frequently assessed factor, it is the only factor that is definitively the result of adherence and not the other way around. While assessing HbA1c has limited usefulness when trying to identify factors that affect adherence, it may still be useful to measure to correlate improved adherence with improved glycaemic control, to highlight that this area of research can have significant physiological implications. The remaining factors were assessed fairly heterogeneously, with just 3/31 (9.7%) being assessed by multiple studies. Of these three factors, diabetes knowledge and BGM frequency had a potential positive correlation with adherence to insulin, with all studies finding a positive correlation, but only some of the studies finding the relationship to be statistically significant.

While the psycho-social theme was the most assessed theme, in terms of number of factors and total number of children, it was also the theme that had the lowest proportion of its factors assessed by multiple studies, with only 11/159 (6.9%) of psycho-social factors being assessed in 2 or more studies. Of these factors, exercise frequency and self-efficacy displayed some of the greatest agreement between studies regarding their effect, with 5/7 (71.42%) of studies assessing self-efficacy and 3/4 (75%) of studies assessing exercise frequency finding that they were significantly associated with adherence. The only factor with unanimous agreement between studies (assessed by 4 or more studies) was a psycho-social factor, that being depression.

Of the factors that were assessed multiple times, 6/7 (85.7%) of family dynamics factors were assessed by studies either in relative or strong agreement regarding the nature of the relationship between the factor and adherence (see section 3.6.12), which was the highest level of agreement of all themes.




Figure 4.1 Variability between themes.

## 5. PENDANT Study

### 5.1. Introduction

As explored in previous sections, there are many things that can affect treatment adherence in children and young people with diabetes, with many of the assessed factors relating to the psychology of children and young people. A new diagnosis of diabetes especially can have significant psychological effects on both the patient and the patient's parents (198) (199).

As well as the event of a new diagnosis being directly stressful to the patient and their parents, poor mental health in parents have been associated with increased risk of poor mental health in their children (200).

Mental health is an important consideration in the management of diabetes, as it can exert both direct effects upon their glycaemic control (199) as well as indirect effects through poorer adherence to treatment (201).

Glycaemic control is the best predictor of long-term outcomes in diabetes, with the risk of all complications being reduced with better glycaemic control (77).

This study was set-up prior to the development of the systematic review contained within sections 2, 3 and 4, based on an *a priori* hypothesis from the local diabetes and diabetes psychology team that the psychological impact of a new diagnosis of diabetes was correlated with later treatment adherence. As the systematic review carried out shows, there are currently no data on the psychological impact on children and their families of the diagnosis of T1DM, with current research examining those with already established disease, so this study was set up to try and support this hypothesis.

Given that the psychology of parents and their child can both directly affect glycaemic control and indirectly affect glycaemic control (through reduced treatment adherence) and that reduced treatment adherence can result in worse glycaemic control - which is the best predictor of long-term outcomes - a better understanding of the psychological stressors that children and their families face could not only improve their quality of life, but also have significant long-term physiological benefits.

## 5.2. Protocol

The study protocol was written by a consultant paediatrician with extensive academic experience (DH) and a consultant paediatric diabetologist (MD) with assistance from a paediatric clinical psychologist (LC) who works with children and young people with diabetes.

My contribution to the protocol was making the amendments to it and supporting documentation, including writing new patient information leaflets (PISs) for different age groups in order to gain the initial ethical approval, as well as making the later ethical amendments as detailed in section 5.4. The PIS for the youngest patients (aged 3-6) and the PIS for parents can be found in Figure 5.1 and Figure 5.2, respectively, to illustrate the different ways study information was communicated to prospective participants. There were also versions for older children, adolescents, and participants competent to consent (aged 16-18) which can be found in Appendix 11, Appendix 12 and Appendix 13, respectively. I was also responsible for creating the study master file, creation of the case record form (CRF), creation of the database to input data, recruiting patients, issuing the questionnaires, and analysing them once completed.

# PENDANT study

A study to establish if there is a relationship between how unwell children and young people are when diagnosed with Type 1 Diabetes, and how well they manage later on



Information leaflet for young participants (aged 3-6)

IRAS ID 264508  
PENDANT Study – Patient Information Leaflet for Children Aged 3-6 Years Old

## Do I have to take part?

No. If you don't want to take part, that is fine. Talk to your family or doctor if you are not sure.

## Can I change my mind?

Yes, this is not a problem. Just tell the nurse or doctor.



## What is this about?

We want to get you and your family's help. We don't yet understand how much your new condition (Diabetes) has changed your life. Or how it has changed your family's life. We want to learn about this.



## Why you?

You have recently found out that you have Type 1 Diabetes and go to Alder Hey.

## Who is doing this research?

Doctors at Alder Hey, and scientists at the University of Liverpool.

## Who do I ask about this?

Your family will have been given lots of information. If you or they are not sure, the doctor or nurse who gave you this information leaflet can tell you more.



IRAS ID 264508  
PENDANT Study – Patient Information Leaflet for Children Aged 3-6 Years Old

## What will happen?

We would like to ask you and your family some questions. This will be during your visit to Alder Hey.

Your family will have to agree to take part, and they can say no.



V3.0, 25<sup>th</sup> October 2019



Thank-you for taking part in the PENDANT study

V3.0, 25<sup>th</sup> October 2019

Figure 5.1 Participant Information Sheet (PIS) for very young participants (aged 3-6).



# PENDANT study

**A study to establish if there is a relationship between how unwell children and young people are when diagnosed with Type 1 Diabetes, and how well they manage later on**



## Information leaflet for parents/guardians

IRAS ID 264508  
PENDANT Study – Parent Information Leaflet

The information we collect may help us to improve the service we deliver to our newly diagnosed patients and help to inform a future screening protocol.

### How will we use information about your child?

We will need to use information from your child and their medical records for this research project.

This information will include your child's hospital number, name and contact details. People will use this information to do the research or to check your child's records to make sure that the research is being done properly.

People who do not need to know who you are will not be able to see your name or contact details. Your data will have a code number instead.

We will keep all information about you safe and secure.

Once we have finished the study, we will keep some of the data so we can check the results. We will write our reports in a way that no-one can work out that you took part in the study.

### What are your choices about how your child's information is used?

- You can stop being part of the study at any time, without giving a reason, but we will keep information about you that we already have.
- We need to manage your records in specific ways for the research to be reliable. This means that we won't be able to let you see or change the data we hold about you.

IRAS ID 264508  
PENDANT Study – Parent Information Leaflet

### What is this about?

We would like to invite you and your child to take part in our research study, to help understand the effects on families of a new diagnosis of Type 1 Diabetes. This leaflet will help you to understand why the research is being done, and what it will involve.

Our team will go through this information with you and answer any questions you may have.

### What do we know about how well children and families manage a Type 1 Diabetes Diagnosis?

For both children and young people diagnosed with Type 1 diabetes, and their families, the time around diagnosis can seem confusing and frightening.

There are many different ways of coping, but we do not know a lot about how individual children and young people, or their families, manage. How much extra stress does this put on them? Do they need any extra help?

### Why has your child been asked to take part in this study?

Your child has recently been diagnosed with Type 1 Diabetes and will be followed up by the team at Alder Hey.

### What will the study involve?

The study involves completing a series of questionnaires (maximum of 40 minutes) with a member of our team. The questionnaires will focus on the level of stress you and your child have experienced since diagnosis, how

### Where can you find out more about how your child's information is used?

You can find out more about how we use your child's information:

- at [www.hra.nhs.uk/information-about-patients/](http://www.hra.nhs.uk/information-about-patients/)
- by asking one of the research team
- by sending an email to [d.hawcutt@liv.ac.uk](mailto:d.hawcutt@liv.ac.uk), who can put you in contact with the sponsor's Data Protection Officer.

### Does my child have to take part?

No. If you are not happy then the doctors will keep looking after your child as normal. If you are sure then we can arrange for someone to talk to you and help you make up your mind.

### Can I change my mind?

Yes, this is not a problem. If you (or your child) change your mind, you can withdraw from the study at any time without giving reason (up to the point we publish the results).

### Who is doing this research?

This research is being organised by the doctors at Alder Hey Children's Hospital and scientists at the Department of Women's and Children's Health at the University of Liverpool. Part of the study is being undertaken by a University of Liverpool medical student who has taken an extra year in their degree to do a Masters degree (an MPhil). The student is closely supported by the doctors and scientists.

you have coped with this stress, and how the diagnosis has impacted on quality of life. There are separate questionnaires to be completed by you and your child. This will normally be done within the hospital before/after your child's diabetes clinic appointments. However, if for any reason we are unable to collect this information during this time we may need to contact you by phone or arrange to do a home visit.

### What will happen next?

If you agree to take part in this study, a member of our research team will ask you to sign a consent form. Once you have consented, we will arrange a time to see you before/after your child's diabetes clinic appointments to complete the series of questionnaires. If you are interested, we may ask you again in the future, but you can decide if you wish to take part in future.

### Are there any risks/ benefits to taking part?

The questionnaires will take about 40 minutes extra, in addition to your child's diabetes clinic appointment. Medical care will be unaffected, but if we do find something that may affect your child's health, we will discuss this with you.

Some parents or children find talking about an illness distressing. If at any time you or your child feels that the actual or perceived distress is too great, please do not hesitate to tell the researcher. We have clinical psychologists within our team that you might find helpful.

V3.0, 25<sup>th</sup> October 2019

As a student project, this research has no specific funding. The sponsor is Alder Hey Children's Hospital.

### Has the study been checked?

Yes. All research that involves NHS patients (like your child) must be approved by a Research Ethics Committee before it goes ahead. The Committee is satisfied that your rights will be respected, that any risks have been reduced to a minimum and balanced against possible benefits, and that you have been given sufficient information on which to make an informed decision to take part or not.

### Who do I ask about this?

The doctor or nurse who gave you this information leaflet can discuss the study with you more.

### What if something goes wrong?

If you are unhappy, or have concerns about any aspect of this study, or would like to make a complaint, you should speak to the PALS office on 0151 252 5374, or via email [PALS@alderhey.nhs.uk](mailto:PALS@alderhey.nhs.uk)

Alternatively, you can contact Dr Dan Hawcutt (the researcher in charge of the study) at [d.hawcutt@liv.ac.uk](mailto:d.hawcutt@liv.ac.uk).



V3.0, 25<sup>th</sup> October 2019

Figure 5.2 Participant Information Sheet (PIS) for parents.

### 5.3. Ethical Approval

Ethical approval for this study was granted by the West Midlands-South Birmingham Research Ethics Committee (REC) and the UK Health Research Authority (HRA) on the 25<sup>th</sup> October 2019 and 1<sup>st</sup> November 2019, respectively.

### 5.4. Ethical Amendments

Two ethical amendments were made to the initial study protocol. Amendment 1 was made on 13<sup>th</sup> December 2019 and amendment 2 on 11<sup>th</sup> March 2020. Full details of each amendment can be found in Appendix 14 and Appendix 15, respectively.

The original study protocol stated that participants would be consented and interviewed at their first clinic appointment, however, to be most in keeping with the study objectives, the appointment nearest to 3-months post-diagnosis was more appropriate. Thus, the first amendment was to reflect this change. A Notification of Non-Substantial/Minor Amendment(s) for NHS Studies was submitted to the HRA and was approved.

Most parents and children and young people had been willing to participate but were unable to take the extra time to complete the extensive number of questionnaires after/before their clinic appointment due to work or school commitments. Therefore, a second amendment was submitted with the aim of boosting recruitment rates. In version 2 of the study protocol, it was stated that parents and children who were willing to participate but were unable to due to time constraints could be contacted via telephone. However, early experience of issuing the large number of questionnaires in person suggested that completion would not be suitable over the phone. In order to try and recruit these patients, the option of a phone call was changed to the option of a home visit.

### 5.5. Aims

The majority of existing studies examine psychological factors in children who have been diagnosed for at least 6 months and often for over a year. Studies have shown that the adjustment period for children following a new diagnosis is 6-9 months (and 9-12 months for parents) (199), meaning that the time where psychological distress may be most prevalent is currently under-researched.

Therefore, the aim of this study was to assess the psychological impact of a new diagnosis of T1DM on children and young people.

## 5.6. Methods

The study has a prospective cohort design.

Newly diagnosed patients with T1DM have an outpatient hospital appointment within three months of diagnosis. Leading up to this appointment, there are also contacts with other members of the diabetes team, such as specialist nurses, to ensure that the disease is being appropriately managed.

Ideally, at one of these contacts, either as an outpatient or during the initial inpatient stay, the child/young person and their family will have the study discussed with them by one of the clinical members of the diabetes team. If they express interest, Participant Information Sheets (PISs) will be provided.

In some situations, if the young person and their family are willing, the study may be mentioned to them on the same day as the outpatient appointment where the questionnaires are being completed. Details on the questionnaires being issued can be found in section 5.7.

On the day of questionnaire completion, the young person and their family will give written informed consent/assent to a member of the study team. This includes permission to review historical health information on the hospital computer system. This will usually be at a clinic appointment within the first 3 months of diagnosis, but it may also be at a house visit previously arranged with the patient.

The questionnaires are estimated to take 30-45 minutes to complete.

After consent has been given and the questionnaires have been completed, a case record form for that participant is completed. The CRF was created by a postgraduate research Masters student (JC) in correspondence with a consultant paediatrician with extensive academic experience (DH), a consultant paediatric diabetologist (MD) and a paediatric clinical psychologist (LC) who works with children and young people with diabetes.

Families will have the opportunity to have follow-up questionnaires taken at subsequent clinic visits, but this is optional.

The normal pathway of care is maintained throughout the study.

The diabetes team will have had training on the study and so will know who to direct questions to in the event of queries from the family.

The completed questionnaires are reviewed by a trained clinical psychologist (LC) to identify any patients experiencing significant distress so that the appropriate support can be offered.

## 5.7. Psycho-social measures

Different questionnaires were issued to children/young people and parents depending on the age of their child to assess different psychological factors. Table 5.1 and Table 5.2 summarises the questionnaires that children and parents were expected to complete, respectively.

To assess trauma in the child, the Trauma Symptom Checklist for Children (TSCC) and the Trauma Symptom Checklist for Young Children (TSCYC) was used for participants aged 8-16 and 3-8 respectively. The TSCC is a 54 item self-report measure completed by the child, while the TSCYC contains 90 items and is completed by parents.

To assess trauma in the parent, the Paediatric Inventory for Parents (PIP) was used.

To assess diabetes distress, the Problem Areas in Diabetes (PAID) questionnaire is used. This questionnaire has a different version for children aged 8-12 (Problem Areas in Diabetes – Child; PAID-C) and young people aged 12-18 (Problem Areas in Diabetes – Teen; PAID-T). There is a corresponding parental version for parents of children in each age group (P-PAID-C and P-PAID-T, respectively).

To assess how the parent and child are coping with diabetes, the Response to Stress Questionnaire (RSQ) was used. This was a self-report measure for the child and was to be completed only by children aged 9 and over. For parents, there were two versions; one self-report regarding their own coping and one report on their perception of how the child is coping.

Quality of life was assessed only in the parent with the Wellbeing and Satisfaction of Caregivers of Children with Diabetes Questionnaire (WE-CARE).

Mental health was also assessed only in the parent. To assess depression, the Patient Health Questionnaire 9 (PHQ-9) was used and to assess anxiety the General Anxiety Disorder 7 (GAD-7) was used.

Factor Assessed	Age 3-8	Age 9-12	Age 12+
Trauma		TSCC	TSCC
Diabetes Distress		PAID-C	PAID-T
Coping		RSQ	RSQ

Table 5.1 Questionnaires to be completed by the child. Legend; TSCC: Trauma Symptoms Checklist for Children, PAID-C: Problem Areas in Diabetes – Child version, PAID-T: Problem Areas in Diabetes – Teen version, RSQ: Response to Stress Questionnaire.

Factor Assessed	Age 3-8	Age 9-12	Age 12+	Parent Measures
Child Trauma	TSCYC			
Diabetes Distress	P-PAID-C	P-PAID-C	P-PAID-T	
Child Coping	RSQ Type 1 Diabetes (parent report on child)	RSQ Type 1 Diabetes (parent report on child)	RSQ Type 1 Diabetes (parent report on child)	
Parental Coping				RSQ Type 1 Diabetes (Parent)
Parental Anxiety				GAD-7
Parental Depression				PHQ-9
Parental Trauma/Stress				PIP
Quality of Life				WE-CARE

Table 5.2 Questionnaires to be completed by the parent. Legend; TSCYC: Trauma Symptoms Checklist for Young Children, P-PAID-C: Problem Areas in Diabetes – Parent of Child version, P-PAID-T: Problem Areas in Diabetes – Parent of Teen version, RSQ: Response to Stress Questionnaire, GAD-7: General Anxiety Disorder 7, PHQ-9: Patient Health Questionnaire 9, PIP: Paediatric Inventory for Parents, WE-CARE: Wellbeing and Satisfaction of Caregivers of Children with Diabetes Questionnaire.

## 5.8. Recruitment

Contact was attempted with a view to recruitment into the study for 12 patients/their parents. 2/12 (16.7%) of the patients contacted agreed to participate in the study. 3/12 (25%) of the patients were not contactable by telephone after 3 attempts and answer phone messages. The remaining 7/12 (58.3%) of participants declined to participate. All of these patients cited a lack of time as their reason for not wishing to participate. They felt that the additional 30-45 minutes on top of the roughly an hour or more that they spend in the hospital for their clinic appointment was too much time due to work, school, and childcare commitments.

After the fourth patient had cited a lack of time on the day of the clinic visit as their reason for non-participation, an ethical amendment that would allow for home visits was submitted (see section 5.4 and Appendix 15).

The approval of this amendment coincided with the increasing number of COVID-19 cases in the UK and the resulting lockdown. As a result, for the safety of the participants and researchers, recruitment at this point was halted. The possibility of posting questionnaires to participants to complete at home was explored, but as this was not mentioned in the protocol submitted for ethical approval, this was not possible. It was also considered that this could reduce the quality of our data collection, as participants would not be able to immediately ask questions if they were unsure how to complete a section and may just complete a section incorrectly instead of spending more time attempting to get in touch with a member of the research team. Recruitment for this study will continue during the 2020-21 academic year, providing it is safe to do so.

## 5.9. Results

For the two recruited participants, patient A was a 14-year-old female and patient B was a 5-year-old male. Both participants had been diagnosed in the 3-months preceding their recruitment and for both participants, their mother was the person completing the parent measures. Table 5.3 contains the results of the measures for each participant and parent pairing.

Higher scores for each of the measures indicate increased severity in that domain. For the trauma measures (TSCC and TSCYC), the raw scores (which scale differently to each domain) have been converted into t-scores (which use the same scale) to aid interpretation.

Note that parents also completed the WE-CARE questionnaire to assess their quality of life and versions of the RSQ questionnaire to assess coping; these results have not been published here as for some questions, higher scores indicate a better quality of life and for others, higher scores indicate a worse quality of life. These questionnaires require more in-depth analysis that is not useful with such a small sample size.



Participant	Assessed Domain	Measure Used	Score
A	Child trauma	TSCC	Under-response: 47/111
			Hyper-response: 46/111
			Anxiety: 50/111
			Depression: 45/111
			Anger: 46/111
			Post-traumatic stress: 42/111
			Dissociation (general): 41/111
			Dissociation (overt): 40/111
			Dissociation (fantasy): 47/111
	Parent diabetes distress	P-PAID-T	57/90
	Child diabetes distress	PAID-T	35/84
	Parental anxiety	GAD-7	15/21
	Parental depression	PHQ-9	17/27
	Parental trauma/stress	PIP	Communication: frequency: 28/45
			Communication: difficulty: 27/45
			Medical care: frequency: 25/40
			Medical care: difficulty: 25/40
Emotional distress: frequency: 54/75			
Emotional distress: difficulty: 64/75			
Role function: frequency: 27/50			
Role function: difficulty: 31/50			
Frequency total: 134/210			
Difficulty total: 147/210			
B	Child trauma	TSCYC	Response level: 65/110
			Atypical response: 48/110
			Anxiety: 46/110
			Depression: 47/110
			Anger: 43/110
			Post-traumatic stress – intrusion: 47/110

			Post-traumatic stress – avoidance: 44/110
			Post-traumatic stress – arousal: 47/110
			Post-traumatic stress – total: 46/110
			Dissociation: 50/110
			Sexual concerns: 46/110
	Parent diabetes distress	P-PAID-C	57/90
	Child diabetes distress	PAID-C (completed by parent)	39/96
	Parental anxiety	GAD-7	3/21
	Parental depression	PHQ-9	2/27
	Parental trauma/stress	PIP	Communication: frequency: 16/45
			Communication: difficulty: 13/45
			Medical care: frequency: 18/40
			Medical care: difficulty: 13/40
			Emotional distress: frequency: 29/75
			Emotional distress: difficulty: 24/75
			Role function: frequency: 15/50
			Role function: difficulty: 16/50
			Frequency total: 78/210
			Difficulty total: 66/210

*Table 5.3 Summary of questionnaire results completed by participants. Legend; TSCC: Trauma Symptoms Checklist for Children, TSCYC: Trauma Symptoms Checklist for Young Children, P-PAID-T: Problem Areas in Diabetes – Parent of Teen version, P-PAID-C: Problem Areas in Diabetes – Parent of Child version, PAID-C: Problem Areas in Diabetes child version, PAID-T: Problem Areas in Diabetes – teen version, GAD-7: General Anxiety Disorder 7, PHQ-9: Patient Health Questionnaire 9, PIP: Paediatric Inventory for Parents.*

## 6. Discussion

### 6.1. Systematic Review

This study has identified many factors that are associated with adherence/non-adherence to insulin therapy. Studies were in strong agreement that age, depression, and smoking history were all negatively associated with adherence to insulin therapy and that glycaemic control, self-efficacy, family support, exercise frequency, increasing responsibility taken by the child/young person, socio-economic status and better parent-child relationship were all positively associated with adherence. Summaries of all assessed factors can be found in Table 3.15 and Table 3.16.

22/33 (66.66%) of the studies that assessed the association between age and treatment adherence found that adherence worsened with age. This is compared with just 2/33 (6.06%) that found adherence improves with age. The weighted mean age of participants in the studies suggesting that adherence worsens with age was 13.4 years, versus 11.4 years in the two studies suggesting that adherence improves with age. This supported the anecdotal hypothesis of the research team that the negative association between age and adherence begins during adolescence. There are several possible reasons for this association. When children are younger, more/the entirety of their care will be performed by their parents who are more likely to be able to maintain good adherence than just the child alone. As they become older, they will begin to take more responsibility for their care but will still likely be closely supervised by parents. As they enter adolescence, this supervision becomes more difficult and children will have times where they have the sole responsibility for their diabetes care, which they may not be accustomed to. Additionally, children and young people with diabetes still face all of the usual trials of adolescence, with increasing academic and personal life pressures potentially making adherence more difficult. The idea that it is the unique situation of adolescence that causes the decrease in adherence during this time is supported by the fact that adherence tends to improve again in the late teens/early twenties (167,178).

The strong negative association between depression and adherence could be of particular significance, as it is a modifiable factor with an established guideline for management (202). The reasons for the strong negative relationship between depression and adherence are likely linked to the symptoms of depression, which include a lack of motivation and even potentially a disregard for one's life (203).

The findings of the association between gender and adherence were somewhat surprising; the anecdotal hypothesis of the diabetes and research teams was that females generally have worse adherence than males in childhood, but this was only partially supported by the studies in this review, with 5/15 (33.33%) of studies finding that males had better adherence, 1/15 (6.67%) that females had better adherence and 9/15 (60%) having results that were non-significant. The weighted mean age of participants in the studies that suggested adherence was better in males was 14.9 years, versus 9.7 years in the study that suggested adherence was better in females. This difference in mean ages could indicate that it is not until adolescence that gender begins to play a part in adherence, but this cannot be assumed from such a small number of studies. Future studies could aim to clarify this relationship, perhaps via a longitudinal cohort study that assesses adherence, starting in pre-adolescence and continuing into adolescence. It is possible that the size of the effect of gender is reduced by the pre-adolescents in the samples, as during times of their life where most care is being performed by parents, it is less likely that their gender will make a difference.

The vast majority of studies that assessed glycaemic control found that better glycaemic control was associated with better treatment adherence. Despite its clear association, the inclusion of this factor in the study was a point of contention, due to the fact that improved glycaemic control is most likely a result of better adherence, not the other way around. The factor was ultimately included for several reasons. Firstly, it was felt that it was important to highlight the positive association between the two, to show that better adherence can indeed have dramatic physiological consequences. It was also included as while better adherence definitively results in improved glycaemic control, it could not be ruled out for glycaemic control to then have a knock-on effect upon further adherence. For example, if a patient had consistently good or improving HbA1c, this could motivate them to continue to have good adherence and vice versa. More research would need to be done that included questions on how HbA1c results affect the mindset of children and their parents, in order for this question to be definitively answered.

There are several limitations to this study. Firstly, as a result of the heterogeneity of the body of evidence, meta-analysis was not possible for any of the identified factors. Secondly, while all of the studies included in this review assess insulin adherence, they do not all express this aspect of adherence separately, with many studies presenting their results as a composite index. There were studies that were published in other languages, but we have overcome this by using fluent native speakers to extract these data, so no studies were excluded by reason of being written in a foreign

language. Any foreign language study that was screened and not included in the final data extraction was excluded due to not fitting the inclusion criteria.

Furthermore, one of the biggest issues facing studies that seek to identify factors associated with adherence is lack of an agreed and validated method of doing so. Many of the existing validated methods of measuring adherence to other medications are not appropriate when considering insulin use. For example, direct measurement of drug levels in the blood is invasive, unpopular with children and young people, technically difficult with the short half-life of insulin, as well as giving no indication of the patterns of adherence (204). Most general adherence questionnaires are predominantly designed to assess adherence to oral medications and as such do not factor in the additional difficulties a regular subcutaneous medication with such a potentially dangerous side effect (hypoglycaemia) may have. Medication Possession Ratio (MPR) is a validated measure used for all types of medication and has been used by some of the studies in this review, but even this assumes that all of the medication that the patient collects gets used and gets used in the correct way.

In the 76 studies contained within this review, there were 38 different methods used to assess adherence, with the most popular method being classed as “questionnaire not otherwise specified”, meaning that this figure itself is likely composed of multiple methods. Since the details of these questionnaires were not clear, this contributed to the difficulties in meta-analysis.

The next most common method of measuring adherence, being used by 7 studies, was the Self-Care Inventory (SCI). The SCI was first developed in 1988 (205) and was revised in 2005 (188). In 2009, a study (206) assessed the validity of the SCI for use as an adherence measure and found that it had both good internal consistency ( $\alpha=0.8$ ) and good test-retest reliability ( $r=0.77$ ,  $p<0.05$ ). In the 21 years from the development of the SCI in 1988, to its validation in 2009, no studies in this review used it as their measure of adherence. Since the validation of the tool in 2009, 7/30 (23.3%) of studies published in this time have used it as their measure of adherence, making it the joint most commonly used measure along with data from insulin pumps/BOLUS scores (both during this time period and overall). This suggests that the development of adherence measures without validation of those measures is largely not useful and that earlier validation of adherence measures could result in faster progression in this area of research.

Studies prior to 2009 were far more heterogenous in their method of adherence measuring, with the most common measure (aside from questionnaires and interviews that were not otherwise specified) being the Barrier to Adherence (BAQ) questionnaire, which was used by 4/46 (8.7%) of studies published in this time. This suggests that agreement on the best methods to use to assess adherence is slowly increasing with time.

Another issue when measuring adherence – particularly when relating to insulin adherence – is the number of components of taking insulin that are required to be correct in order to have good adherence. For example, in order to be fully adherent, a patient needs to take their insulin at the correct time, the correct amount of time before food, with the correct dose (often based on a calculation of the amount of carbohydrates in their food), into the correct site (rotating sites to avoid lipohypertrophy and malabsorption) and then perform the injection correctly. All of these steps are without even considering the changes made to insulin during hypoglycaemia management, which adds another layer of complexity. The systematic review has identified studies that have all measured these areas, but never all together.

To summarise the issues surrounding measuring adherence: self-report measures such as the SCI can result in reporting bias from the participants, objective measures such as MPR do not actually assess the use of the medication and observation of the patient administering their medication does not assess when the insulin is taken in their day-to-day life. Downloading of insulin pump data is perhaps the single method that solves most of these issues, however it does not account for all of the patients who receive treatment through MDI and so results in a sample that is not representative of the whole population. Each of these issues is solved by another method, but no studies have used these methods in combination with each other. Therefore, one of the recommendations for future research of this study is that multiple methods to measure adherence are used, but to ensure that each of these methods assesses a different component of adherence. For example, the SCI could be issued to measure the patient's general adherence in day-to-day life, MPR could be used to see if the patient's self-report is feasibly accurate, another questionnaire could be issued to assess the patient's competence in carbohydrate counting and insulin calculations, a third questionnaire or physical examination could assess the patient's rotation of the injection sites and lastly, the patient could be observed performing an injection to assess if they administer their injections correctly. This combination of methods would address the issues previously mentioned but has not been seen in any study to date.

While a large proportion of the factors identified in this study are only assessed by a single study, that does not diminish the usefulness of identification of the factors that have been assessed by greater number of studies. As seen in Table 3.16, there are clear groups of patients where additional resources could be directed to try and improve their adherence. For example, adherence has been shown to decrease with age in children; if interventions such as the “Sweet Talk” text messaging system (181), which was shown in an RCT to have a beneficial effect upon adherence, were targeted to this age group, it could mitigate the reduction in adherence. All seven studies assessing the effect of depression found that it had a statistically significant negative effect upon adherence, suggesting that investment in identification of these patients and psychological services to help them could be beneficial.

As well as trying to target the areas where adherence has shown to be worse, efforts could be directed to promote the factors that have shown to have a positive effect. For example, presence of family support was shown to have a statistically significant positive effect upon adherence, but none of the interventions proposed by the seven RCTs within this review were aimed at promoting supportive family environments.

The fact that only 7/76 (9.2%) of the studies included in this review are RCTs suggests that huge efforts are being devoted to identifying the factors that affect adherence to insulin therapy, but far less efforts are being directed towards addressing the issues that can be altered. Becoming a teenager is inevitable, as is longer duration of disease, but intervention studies should be developed for the modifiable factors, or around key times in the children and young people’s lives, to assess the potential to improve adherence.

There was no specific funding associated with this review.

## 6.2. PENDANT Study

As a result of the COVID-19 pandemic halting recruitment to this study, it is clearly grossly underpowered and no real conclusions regarding the data can be drawn. Despite this, there were still many learning points, from both the first stages of the study itself and from the systematic review, that can be taken forward that will improve this study overall.

Firstly, there were no issues regarding completion of the measures from either the child participants or their parents, suggesting good usability.

The early difficulties with recruitment due to time constraints on the day of the patient's outpatient appointments have hopefully been addressed with the implementation of ethical amendments.

With the benefit of hindsight as a result of the systematic review, there are some improvements that can be made. In its current form, the study assesses eight different domains between the child and their parent, with multiple reports for some measures such as the RSQ, which has a child report upon themselves, a parent report on themselves and a parent report on the child. This creates a huge mass of data, with many of the measures asking similar questions, making parts of the data somewhat redundant. The large number of measures could be another contributing factor to the poor response rate during this initial phase.

While the measures all assess a clearly defined area, for some of these measures, it is not clear how they would be best compared with each other when analysing the data as a whole. For example, the WE-CARE questionnaire (which assesses the quality of life of the parent) has some questions where a higher score would indicate a better quality of life and some questions where a higher score would indicate a worse quality of life. It is therefore difficult to find a way to make valid correlations between this method and methods such as the TSCC/TSCYC (which assess trauma in the child) or the GAD-7 and PHQ-9 (which assess anxiety and depression in the parent, respectively), where higher scores always confer to greater severity in the assessed domain.

Therefore, a possible change to this study going forwards would be to choose measures where the scores are always comparable or where the direction of individual questions is represented by a sub-scale. For example, the Stark QoL questionnaire (207) is consistent in higher scores conferring to better quality of life. The disadvantage to this questionnaire when compared to the WE-CARE is that the WE-CARE is specifically designed for parents of children with diabetes, whereas the Stark QoL is not.

In considering other methods, such as a structured interview, it is likely that questionnaires are more practical as they do not require as much training for researchers to deliver and are less time-consuming as both parents and children can complete their measures simultaneously, which is an important consideration when time constraints have been cited as a common reason for non-participation.



An anecdotal observation based on the small sample size to date is that the large number of questionnaires could result in reduced accuracy, particularly in the child measures. Participant A appeared to be getting somewhat bored by the final questionnaire, with some questions seeming to be completed without actually reading them. Since participant B was too young to complete any questionnaires, this meant that all measures needed to be completed by their mother, meaning that they took much longer to complete. While the mother was completing these questionnaires, her child was clearly getting bored and was becoming restless, again resulting in the questionnaires being completed in a hurried fashion.

It is possible that with such a small sample, these are not problems that would be seen in a significant capacity going forward. However, this possibility, combined with the aforementioned similarity of some questions between questionnaires suggests that in the future, a more focused approach to a smaller number of domains may be desirable. The time constraints of the questionnaires would be in-part addressed by the possibility of home visits.

If assessment of adherence was desired and needed to be done through a single measure, the SCI would likely be the best option, with it being a validated measure of adherence that is used in the greatest number of studies, which would contribute to creating a more homogeneous body of research.

## 7. Conclusion

To the best of our knowledge, at the time of writing, this is the first study that has attempted to review factors that affect adherence to insulin therapy.

This study has identified many factors that are associated with adherence, with many being modifiable factors that could be potential areas for future interventions. It has also highlighted that while adherence to insulin requires adherence to many individual components, it is frequently assessed in ways that do not necessarily reflect this complex nature. By virtue of collecting together such a large number of studies and the methods that these studies use, this study has been able to make suggestions for future research that combines methods in order to get the most accurate reflection of adherence.

It has also provided an opportunity to improve ongoing primary research, so that it may make a better contribution to the future body of evidence.



## 8. References

1. Peakman M, Leslie RDG, Vergani D. Immunological studies on type 1 diabetes in identical twins. *Archives of Disease in Childhood*. 1993.
2. Abdul-Rasoul M, Habib H, Al-Khouly M. "The honeymoon phase" in children with type 1 diabetes mellitus: Frequency, duration, and influential factors. *Pediatric Diabetes*. 2006;
3. Michels AW, Gottlieb P. Pathogenesis of Type 1A Diabetes [Internet]. 2015. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK279002/>
4. Hackett E, Jacques N, Gallagher A. Type 1 diabetes pathophysiology and diagnosis. *Clinical Pharmacist* [Internet]. 2013;5:69–72. Available from: <https://www.pharmaceutical-journal.com/download?ac=1065161&firstPass=false>
5. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. *The Lancet*. 2014.
6. Urcelay E, Santiago JL, de la Calle H. Type 1 Diabetes in the Spanish Population: additional factors to Class II HLA-DR3 and -DR4. *BMC Genomics* [Internet]. 2015;6(56). Available from: <https://bmcbgenomics.biomedcentral.com/articles/10.1186/1471-2164-6-56#citeas>
7. Jerram ST, Leslie RD. The genetic architecture of type 1 diabetes. *Genes*. 2017.
8. Orzan A, Novac C, Miha M, Tirgoviste CI, Balgradean M. Type 1 Diabetes and Thyroid Autoimmunity in Children. *Maedica*. 2016;
9. Diabetes UK. Facts and Stats [Internet]. 2016 [cited 2020 Jan 3]. Available from: [https://diabetes-resources-production.s3-eu-west-1.amazonaws.com/diabetes-storage/migration/pdf/DiabetesUK\\_Facts\\_Stats\\_Oct16.pdf](https://diabetes-resources-production.s3-eu-west-1.amazonaws.com/diabetes-storage/migration/pdf/DiabetesUK_Facts_Stats_Oct16.pdf)
10. Katsarou A, Gudbjörnsdóttir S, Rawshani A, Dabelea D, Bonifacio E, Anderson BJ, et al. Type 1 diabetes mellitus. *Nature Reviews Disease Primers*. 2017;
11. Jerram ST, Leslie RD. The Genetic Architecture of Type 1 Diabetes. *Genes* [Internet]. 2017;8(209). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5575672/>
12. Metcalfe KA, Hitman GA, Rowe RE, Hawa M, Huang X, Stewart T, et al. Concordance for Type 1 Diabetes in Identical Twins Is Affected by Insulin Genotype. *Diabetes Care*. 2001;
13. Kimpimäki T, Kupila A, Hämäläinen AM, Kukko M, Kulmala P, Savola K, et al. The first signs of  $\beta$ -cell autoimmunity appear in infancy in genetically susceptible children from the general population: The Finnish type 1 diabetes prediction and prevention study. *Journal of Clinical Endocrinology and Metabolism*. 2001;
14. Filippi CM, von Herrath MG. Viral trigger for type 1 diabetes: Pros and cons. *Diabetes*. 2008.
15. van der Werf N, Kroese FGM, Rozing J, Hillebrands JL. Viral infections as potential triggers of type 1 diabetes. *Diabetes/Metabolism Research and Reviews*. 2007.
16. Hober D, Sauter P. Pathogenesis of type 1 diabetes mellitus: Interplay between enterovirus and host. *Nature Reviews Endocrinology*. 2010.
17. Ehtisham S, Barrett TG. The emergence of type 2 diabetes in childhood. *Annals of Clinical Biochemistry*. 2004.
18. Ashraff S, Siddiqui MA, Carline TE. The psychosocial impact of diabetes in adolescents: A review. *Oman Medical Journal*. 2013.
19. Diabetes UK. List of countries by incidence of Type 1 diabetes ages 0 to 14 [Internet]. 2013 [cited 2020 Jan 3]. Available from: [https://www.diabetes.org.uk/about\\_us/news\\_landing\\_page/uk-has-worlds-5th-highest-rate-of-type-1-diabetes-in-children/list-of-countries-by-incidence-of-type-1-diabetes-ages-0-to-14](https://www.diabetes.org.uk/about_us/news_landing_page/uk-has-worlds-5th-highest-rate-of-type-1-diabetes-in-children/list-of-countries-by-incidence-of-type-1-diabetes-ages-0-to-14)
20. Bach JF, Chatenoud L. The hygiene hypothesis: An explanation for the increased frequency of insulin-dependent diabetes. *Cold Spring Harbor Perspectives in Medicine*. 2012;

21. NICE. Diabetes (type 1 and type 2) in children and young people: diagnosis and management [Internet]. NG18. 2015 [cited 2020 May 6]. Available from: <https://www.nice.org.uk/guidance/ng18/chapter/1-Recommendations#diabetic-ketoacidosis-2>
22. Hood KK, Peterson CM, Rohan JM, Drotar D. Association between adherence and glycemic control in pediatric type 1 diabetes: A meta-analysis. *Pediatrics*. 2009;
23. Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. *Physiological Reviews*. 2018.
24. Cooper GM. *The Cell: A Molecular Approach*. 2nd edition. [Internet]. 2000. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK9847/>
25. American Diabetes Association. Insulin Basics [Internet]. [cited 2020 May 12]. Available from: <https://www.diabetes.org/diabetes/medication-management/insulin-other-injectables/insulin-basics>
26. Diabetes.co.uk. Insulin pumps [Internet]. 2019 [cited 2020 May 14]. Available from: <https://www.diabetes.co.uk/insulin/Insulin-pumps.html>
27. Farinde A. Insulin Types [Internet]. 2020 [cited 2020 May 12]. Available from: <https://emedicine.medscape.com/article/2172166-overview>
28. Roche. Accu-Chek Combo Insulin Pump [Internet]. [cited 2020 May 16]. Available from: <https://www.accu-chek.co.uk/insulin-pumps/combo>
29. Roche. Accu-Chek Insight Insulin Pump [Internet]. [cited 2020 May 15]. Available from: <https://www.accu-chek.co.uk/insulin-pumps/insight>
30. Medtronic. MiniMed Paradigm Veo [Internet]. [cited 2020 May 15]. Available from: <https://www.medtronic-diabetes.co.uk/insulin-pump-therapy/minimed-paradigm-veo>
31. Medtronic. MiniMed 640G [Internet]. [cited 2020 May 15]. Available from: <https://www.medtronic-diabetes.co.uk/insulin-pump-therapy/minimed-640g-system>
32. YpsoMed Ltd. Omnipod [Internet]. [cited 2020 May 15]. Available from: <https://www.myomnipod.com/en-gb/about>
33. YpsoMed Ltd. mylife YpsoPump – The intuitive insulin pump system [Internet]. [cited 2020 May 15]. Available from: <https://www.mylife-diabetescare.com/en-GB/products/infusion-systems/mylife-ypsopump-insulin-pump.html>
34. Advanced Therapeutics UK Ltd. DANA Diabecare R [Internet]. [cited 2020 May 15]. Available from: <http://www.sooil.com/eng/product/dana-r.php>
35. Advanced Therapeutics UK Ltd. DANA Diabecare RS [Internet]. [cited 2020 May 15]. Available from: <http://www.sooil.com/eng/product/>
36. Medtrum. TouchCare System [Internet]. [cited 2020 May 15]. Available from: <https://www.medtrum.com/A6.html>
37. NHS Specialist Pharmacy Service. Comparative table of insulin pumps [Internet]. [cited 2020 May 15]. Available from: <https://www.sps.nhs.uk/wp-content/uploads/2018/05/Insulin-pump-table-May-2018.pdf>
38. Diabetes UK. Continuous glucose monitoring (CGM) [Internet]. [cited 2020 May 6]. Available from: <https://www.diabetes.org.uk/guide-to-diabetes/managing-your-diabetes/testing/continuous-glucose-monitoring-cgm>
39. Diabetes.co.uk. Diabetic Retinopathy Screening and Tests [Internet]. 2019 [cited 2020 May 9]. Available from: <https://www.diabetes.co.uk/diabetes-complications/retinopathy-screening.html>
40. Royal College of Paediatrics and Child Health. National Paediatric Diabetes Audit [Internet]. 2016. Available from: [https://www.rcpch.ac.uk/sites/default/files/2018-03/npda\\_parent\\_and\\_carers\\_report\\_2015-2016\\_0.pdf](https://www.rcpch.ac.uk/sites/default/files/2018-03/npda_parent_and_carers_report_2015-2016_0.pdf)

41. PENG MF, WARNER J, ROBINSON H, MUSZYNSKA K, EARDLEY S, CAMPBELL FM. 1299-P: The Paediatric Diabetes Service in England and Wales—An Improvement Journey. *Diabetes*. 2019;
42. Royal College of Paediatrics and Child Health. National Paediatric Diabetes Audit 2016-17 [Internet]. 2017. Available from: [https://www.rcpch.ac.uk/sites/default/files/2018-07/npda\\_annual\\_report\\_2016\\_-\\_2017\\_april\\_2018\\_final\\_updated\\_3.pdf](https://www.rcpch.ac.uk/sites/default/files/2018-07/npda_annual_report_2016_-_2017_april_2018_final_updated_3.pdf)
43. Iyengar J, Thomas IH, Soleimanpour SA. Transition from pediatric to adult care in emerging adults with type 1 diabetes: a blueprint for effective receivership. *Clinical Diabetes and Endocrinology*. 2019;
44. Miller KM, Foster NC, Beck RW, Bergensta RM, DuBose SN, DiMeglio LA, et al. Current state of type 1 diabetes treatment in the U.S.: Updated data from the t1d exchange clinic registry. *Diabetes Care*. 2015;
45. Lotstein DS, Seid M, Klingensmith G, Case D, Lawrence JM, Pihoker C, et al. Transition from pediatric to adult care for youth diagnosed with type 1 diabetes in adolescence. *Pediatrics*. 2013;
46. Garvey KC, Markowitz JT, Laffel LMB. Transition to adult care for youth with type 1 diabetes. *Current Diabetes Reports*. 2012;
47. Garvey KC, Wolpert HA, Rhodes ET, Laffel LM, Kleinman K, Beste MG, et al. Health care transition in patients with type 1 diabetes: Youngadult experiences and relationship to glycemic control. *Diabetes Care*. 2012;
48. Garvey KC, Foster NC, Agarwal S, DiMeglio LA, Anderson BJ, Corathers SD, et al. Health care transition preparation and experiences in a U.S. National sample of young adults with type 1 diabetes. *Diabetes Care*. 2017;
49. Modi AC, Pai AL, Hommel KA, Hood KK, Cortina S, Hilliard ME, et al. Pediatric self-management: A framework for research, practice, and policy. *Pediatrics*. 2012.
50. Gandhi K, Vu B-MK, Eshtehardi SS, Wasserman RM, Hilliard ME. Adherence in adolescents with Type 1 diabetes: strategies and considerations for assessment in research and practice. *Diabetes Management*. 2015;
51. Aronson JK. Compliance, concordance, adherence. *British Journal of Clinical Pharmacology*. 2007.
52. Datye KA, Moore DJ, Russell WE, Jaser SS. A Review of Adolescent Adherence in Type 1 Diabetes and the Untapped Potential of Diabetes Providers to Improve Outcomes. *Current Diabetes Reports*. 2015.
53. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. *Diabetic Medicine*. 2012;
54. Westen SC, Warnick JL, Albanese-O'Neill A, Schatz DA, Haller MJ, Entessari M, et al. Objectively Measured Adherence in Adolescents With Type 1 Diabetes on Multiple Daily Injections and Insulin Pump Therapy. *Journal of Pediatric Psychology*. 2019;
55. Nathan DM. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: Overview. *Diabetes Care*. 2014;
56. Diabetes.co.uk. Diabetes Prevalence [Internet]. 2019 [cited 2020 Jan 7]. Available from: <https://www.diabetes.co.uk/diabetes-prevalence.html>
57. Diabetes.co.uk. Diabetes and Hypoglycaemia [Internet]. 2019 [cited 2020 May 13]. Available from: <https://www.diabetes.co.uk/Diabetes-and-Hypoglycaemia.html>
58. McCrimmon RJ, Sherwin RS. Hypoglycemia in type 1 diabetes. *Diabetes*. 2010.
59. McCrimmon R. The mechanisms that underlie glucose sensing during hypoglycaemia in diabetes. *Diabetic Medicine*. 2008.

60. NHS. Low blood sugar (hypoglycaemia) [Internet]. 2017 [cited 2020 Feb 5]. Available from: <https://www.nhs.uk/conditions/low-blood-sugar-hypoglycaemia/>
61. Diabetes.co.uk. Fear of Hypoglycaemia [Internet]. 2019 [cited 2020 Feb 5]. Available from: <https://www.diabetes.co.uk/fear-of-hypoglycemia.html>
62. Institute for Quality and Efficiency in Health Care. Hyperglycemia and hypoglycemia in type 1 diabetes [Internet]. 2007. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK279340/>
63. JDRF. Signs and symptoms of type 1 diabetes [Internet]. [cited 2020 Feb 5]. Available from: <https://jdrf.org.uk/information-support/about-type-1-diabetes/what-are-the-signs-and-symptoms-of-type-1-diabetes/>
64. Diatribe. Type 1 diabetes [Internet]. [cited 2020 Feb 7]. Available from: <https://diatribe.org/type-1-diabetes>
65. Mayo Clinic Staff. Hyperglycemia in Diabetes [Internet]. 2018 [cited 2020 Feb 7]. Available from: <https://www.mayoclinic.org/diseases-conditions/hyperglycemia/symptoms-causes/syc-20373631>
66. Hardern RD, Quinn ND. Emergency management of diabetic ketoacidosis in adults. *Emergency Medicine Journal*. 2003.
67. Higgins C. Diabetic Ketoacidosis [Internet]. 2004 [cited 2020 Feb 10]. Available from: <https://acute-care-testing.org/en/articles/diabetic-ketoacidosis>
68. Freeman WH. Glucose Can Be Synthesized from Noncarbohydrate Precursors [Internet]. 5th ed. 2002. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK22591/>
69. Gosmanov A, Kitabchi A. Endotext [Internet]. 2018. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK279146/>
70. Umpierrez GE, Murphy MB, Kitabchi AE. Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar Syndrome. *Diabetes Spectrum*. 2002;
71. Wolfsdorf J, Glaser N, Sperling MA. Diabetic ketoacidosis in infants, children, and adolescents: A consensus statement from the American Diabetes Association. In: *Diabetes Care*. 2006.
72. Nguyen TQ, Maalouf NM, Sakhaee K, Moe OW. Comparison of Insulin action on glucose versus potassium uptake in humans. *Clinical Journal of the American Society of Nephrology*. 2011;
73. Wang W, Lo ACY. Diabetic retinopathy: Pathophysiology and treatments. *International Journal of Molecular Sciences*. 2018.
74. Round J. DKA [Internet]. 2017 [cited 2020 May 6]. Available from: <https://www.paediatricfoam.com/2017/02/diabetic-ketoacidosis-principles-behind-protocols/>
75. Klein R, Klein BEK, Moss SE, Davis MD, Demets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: III. Prevalence and Risk of Diabetic Retinopathy When Age at Diagnosis is 30 or More Years. *Archives of Ophthalmology*. 1984;
76. Fong DS, Aiello L, Gardner TW, King GL, Blankenship G, Cavallerano JD, et al. Retinopathy in Diabetes. *Diabetes Care*. 2004.
77. Quan D. Diabetic Neuropathy [Internet]. Medscape. 2020 [cited 2020 Feb 20]. Available from: <https://emedicine.medscape.com/article/1170337-overview>
78. Hicks CW, Selvin E. Epidemiology of Peripheral Neuropathy and Lower Extremity Disease in Diabetes. *Current Diabetes Reports*. 2019.
79. de Ferranti SD, de Boer IH, Fonseca V, Fox CS, Golden SH, Lavie CJ, et al. Type 1 diabetes mellitus and cardiovascular disease: A scientific statement from the American Heart Association and American Diabetes Association. *Diabetes Care*. 2014.

80. Gebreslassie B, Gebreselassie K, Esayas R. Patterns and Causes of Amputation in Ayder Referral Hospital, Mekelle, Ethiopia: A Three-Year Experience. *Ethiopian journal of health sciences*. 2018;
81. JDRF. Complications [Internet]. 2015 [cited 2020 Jan 12]. Available from: <https://jdrf.org.uk/information-support/about-type-1-diabetes/complications/>
82. Bjornstad P, Cherney D, Maahs DM. Early diabetic nephropathy in type 1 diabetes: New insights. *Current Opinion in Endocrinology, Diabetes and Obesity*. 2014.
83. Ghaderian SB, Hayati F, Shayanpour S, Beladi Mousavi SS. Diabetes and end-stage renal disease; a review article on new concepts. *Journal of renal injury prevention*. 2015;
84. Diabetes.co.uk. Diabetic Nephropathy - Kidney Disease [Internet]. 2019 [cited 2020 Feb 22]. Available from: <https://www.diabetes.co.uk/diabetes-complications/kidney-disease.html>
85. Ruggenti P, Remuzzi G. Nephropathy of type 1 and type 2 diabetes: Diverse pathophysiology same treatment? *Nephrology Dialysis Transplantation*. 2000.
86. Schofield J, Ho J, Soran H. Cardiovascular Risk in Type 1 Diabetes Mellitus. *Diabetes Therapy*. 2019.
87. Pahwa R, Ishwarlal J. Statpearls [Internet]. 2019. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK507799/>
88. Diabetes UK. NHS spending on diabetes “to reach £16.9 billion by 2035” [Internet]. 2012 [cited 2020 Jan 4]. Available from: [https://www.diabetes.org.uk/About\\_us/News\\_Landing\\_Page/NHS-spending-on-diabetes-to-reach-169-billion-by-2035](https://www.diabetes.org.uk/About_us/News_Landing_Page/NHS-spending-on-diabetes-to-reach-169-billion-by-2035)
89. Diabetes.co.uk. Cost of Diabetes [Internet]. 2019 [cited 2020 Jul 7]. Available from: <https://www.diabetes.co.uk/cost-of-diabetes.html>
90. Streisand R, Monaghan M. Young children with type 1 diabetes: Challenges, research, and future directions. *Current Diabetes Reports*. 2014.
91. Sullivan-Bolyai S, Deatrick J, Gruppuso P, Tamborlane W, Grey M. Constant vigilance: Mothers’ work parenting young children with type 1 diabetes. *Journal of Pediatric Nursing*. 2003;
92. Holt RIG, Kalra S. A new DAWN: Improving the psychosocial management of diabetes. *Indian Journal of Endocrinology and Metabolism* [Internet]. 2013;17. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3830378/>
93. Wysocki T. Randomized, Controlled Trial of Behavior Therapy for Families of Adolescents With Insulin-Dependent Diabetes Mellitus. *Journal of Pediatric Psychology*. 2000;
94. Ryden O, Nevander L, Johnsson P, Hansson K, Kronvall P, Sjoblad S, et al. Family therapy in poorly controlled juvenile IDDM: Effects on diabetic control, self-evaluation and behavioural symptoms. *Acta Paediatrica, International Journal of Paediatrics*. 1994;
95. Anderson BJ, Miller JP, Auslander WF, Santiago J v. Family characteristics of diabetic adolescents: Relationship to metabolic control. *Diabetes Care*. 1981;
96. Wiesli P, Schmid C, Kerwer O, Nigg-Koch C, Klaghofer R, Seifert B, et al. Acute psychological stress affects glucose concentrations in patients with type 1 diabetes following food intake but not in the fasting state. *Diabetes Care*. 2005;
97. van Esdonk MJ, Tai B, Cotterill A, Charles B, Hennig S. Prediction of glycaemic control in young children and adolescents with type 1 diabetes mellitus using mixed-effects logistic regression modelling. *PLoS ONE*. 2017;
98. Wei C, Allen RJ, Tallis PM, Ryan FJ, Hunt LP, Shield JPH, et al. Cognitive behavioural therapy stabilises glycaemic control in adolescents with type 1 diabetes—Outcomes from a randomised control trial. *Pediatric Diabetes*. 2018;

99. Peyrot M, Rubin RR, Lauritzen T, Snoek FJ, Matthews DR, Skovlund SE. Psychosocial problems and barriers to improved diabetes management: Results of the Cross-National Diabetes Attitudes, Wishes and Needs (DAWN) Study. *Diabetic Medicine*. 2005;
100. Mental Health Foundation. Mental health statistics: depression [Internet]. [cited 2020 Jan 11]. Available from: <https://www.mentalhealth.org.uk/statistics/mental-health-statistics-depression>
101. WHO. Depression [Internet]. 2020 [cited 2020 Jan 11]. Available from: <https://www.who.int/news-room/fact-sheets/detail/depression>
102. NICE. Type 1 diabetes [Internet]. 2015 [cited 2020 Feb 25]. Available from: <https://bnf.nice.org.uk/treatment-summary/type-1-diabetes.html>
103. Uman LS. Systematic reviews and meta-analyses. *Journal of the Canadian Academy of Child and Adolescent Psychiatry*. 2011;
104. PRISMA. PRISMA [Internet]. [cited 2020 Jun 1]. Available from: <http://prisma-statement.org/>
105. Moher D, Liberati A, Tetzlaff J, Altman DG, Altman D, Antes G, et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. *PLoS Medicine*. 2009.
106. NICE. HDAS [Internet]. Available from: <https://hdas.nice.org.uk/>
107. Elsevier. EMBASE [Internet]. Available from: <https://www.embase.com/login>
108. US National Library of Medicine, Health NI for. PubMed [Internet]. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/>
109. American Psychological Association. PsychINFO [Internet]. Available from: <https://www.apa.org/pubs/databases/psycinfo/>
110. Laerd Statistics. Pearson Product-Moment Correlation [Internet]. 2018 [cited 2020 May 22]. Available from: <https://statistics.laerd.com/statistical-guides/pearson-correlation-coefficient-statistical-guide.php>
111. StatisticsSolutions. Regression [Internet]. [cited 2020 Jun 17]. Available from: <https://www.statisticssolutions.com/directory-of-statistical-analyses-regression-analysis/regression/>
112. Downes MJ, Brennan ML, Williams HC, Dean RS. Development of a critical appraisal tool to assess the quality of cross-sectional studies (AXIS). *BMJ Open*. 2016;
113. Wells G, Shea B, O'Connell D, Peterson J. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa, ON: Ottawa Hospital Research Institute. 2000.
114. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H-Y, Corbett MS, Eldridge SM, Hernán MA, Hopewell S, Hróbjartsson A, Junqueira DR, Jüni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart HJ. RoB 2: A revised Cochrane risk-of-bias tool for randomized trials. *BMJ* (in press). 2019;
115. Siemieniuk R, Guyatt G. What is GRADE? [Internet]. *BMJ Best Practice*. [cited 2020 May 23]. Available from: <https://bestpractice.bmj.com/info/toolkit/learn-ebm/what-is-grade/>
116. Palardy N, Greening L, Ott J, Holderby A, Atchison J. Adolescents' Health Attitudes and Adherence to Treatment for Insulin-Dependent Diabetes Mellitus. *Journal of Developmental and Behavioral Pediatrics*. 1998;
117. Berger G, Waldhoer T, Barrientos I, Kunkel D, Rami-Merhar BM, Schober E, et al. Association of insulin-manipulation and psychiatric disorders: A systematic epidemiological evaluation of adolescents with type 1 diabetes in Austria. *Pediatric Diabetes*. 2019;
118. Commissariat P v., Volkening LK, Guo Z, ElBach JL, Butler DA, Laffel LM. Associations between major life events and adherence, glycemic control, and psychosocial characteristics in teens with type 1 diabetes. *Pediatric Diabetes*. 2018;



119. Haak T, Edelman S, Walter C, Lecointre B, Spollett G. Comparison of usability and patient preference for the new disposable insulin device solostar versus flexpen, lilly disposable pen, and a prototype pen: an open-label study. *Clinical Therapeutics*. 2007;
120. Kyngäs H. Compliance of adolescents with diabetes. *Journal of Pediatric Nursing*. 2000;
121. Kyngäs HA. Predictors of good adherence of adolescents with diabetes (insulin-dependent diabetes mellitus)1. Kyngäs HA. Predictors of good adherence of adolescents with diabetes (insulin-dependent diabetes mellitus). *Chronic Illn*. 2007; *Chronic Illness*. 2007;
122. Hanson CL, Cigrang JA, Harris MA, Carle DL, Relyea G, Burghen GA. Coping Styles in Youths With Insulin-Dependent Diabetes Mellitus. *Journal of Consulting and Clinical Psychology*. 1989;
123. Hanson CL, de Guire MJ, Schinkel AM, Kolterman OG. Empirical validation for a family-centered model of care. *Diabetes Care*. 1995;
124. Hanson CL, Henggeler SW, Rodrigue JR, Burghen GA, Murphy WD. Father-absent adolescents with insulin-dependent diabetes mellitus: A population at risk? *Journal of Applied Developmental Psychology*. 1988;
125. Hanson CL, Henggeler SW, Burghen GA. Model of associations between psychosocial variables and health-outcome measures of adolescents with IDDM. *Diabetes Care*. 1987;
126. Hanson CL, Henggeler SW, Burghen GA. Social Competence and Parental Support as Mediators of the Link Between Stress and Metabolic Control in Adolescents With Insulin-Dependent Diabetes Mellitus. *Journal of Consulting and Clinical Psychology*. 1987;
127. Galatzer A, Amir S, Gil R, Karp M, Laron Z. Crisis intervention program in newly diagnosed diabetic children. *Diabetes Care*. 1982;
128. Nakamura N, Yakushijin Y, Kanamaru T, Tani H, Ideno K, Nakai A. Development and validity testing of the revised diabetes self-care inventory for children and adolescents. *Diabetology International*. 2019;
129. Wisting L, Reas DL, Bang L, Skriverhaug T, Dahl-Jørgensen K, Rø Ø. Eating patterns in adolescents with type 1 diabetes: Associations with metabolic control, insulin omission, and eating disorder pathology. *Appetite*. 2017;
130. Piechowiak K, Zduńczyk B, Szybowska A. Environmental factors affecting management of type 1 diabetes in children below the age of 10. *Pediatric Endocrinology, Diabetes and Metabolism*. 2017;
131. Smith LB, Kugler BB, Lewin AB, Duke DC, Storch EA, Geffken GR. Executive functioning, parenting stress, and family factors as predictors of diabetes management in pediatric patients with type 1 diabetes using intensive regimens. *Children's Health Care*. 2014;
132. Calkins-Smith AK, Marker AM, Clements MA, Patton SR. Hope and mealtime insulin boluses are associated with depressive symptoms and glycemic control in youth with type 1 diabetes mellitus. *Pediatric Diabetes*. 2018;
133. la Greca AM, Auslander WF, Greco P, Spetter D, Fisher EB, Santiago J v. I get by with a little help from my family and friends: Adolescents' support for diabetes care. *Journal of Pediatric Psychology*. 1995;
134. la Greca AM, Bearman KJ. The Diabetes Social Support Questionnaire-Family Version: Evaluating adolescents' diabetes-specific support from family members. *Journal of Pediatric Psychology*. 2002;
135. Griva K, Myers LB, Newman S. Illness perceptions and self efficacy beliefs in adolescents and young adults with insulin dependent diabetes mellitus. *Psychology and Health*. 2000;
136. Pereira MG, Berg-Cross L, Almeida P, Machado JC. Impact of family environment and support on adherence, metabolic control, and quality of life in adolescents with diabetes. *International Journal of Behavioral Medicine*. 2008;

137. Driscoll KA, Johnson SB, Hogan J, Gill E, Wright N, Deeb LC. Insulin bolusing software: The potential to optimize health outcomes in type 1 diabetes mellitus. *Journal of Diabetes Science and Technology*. 2013;
138. Driscoll KA, Wang Y, Bennett Johnson S, Lynch R, Stephens H, Willbur K, et al. White Coat Adherence in Pediatric Patients with Type 1 Diabetes Who Use Insulin Pumps. *Journal of Diabetes Science and Technology*. 2016;
139. Allen DA, Tennen H, Mcgrade BJ, Affleck G, Ratzan S. Parent and child perceptions of the management of juvenile diabetes. *Journal of Pediatric Psychology*. 1983;
140. Miller-Johnson S, Emery RE, Marvin RS, Clarke W, Lovinger R, Martin M. Parent-Child Relationships and the Management of Insulin-Dependent Diabetes Mellitus. *Journal of Consulting and Clinical Psychology*. 1994;
141. Berg CA, King PS, Butler JM, Pham P, Palmer D, Wiebe DJ. Parental involvement and adolescents' diabetes management: The mediating role of self-efficacy and externalizing and internalizing behaviors. *Journal of Pediatric Psychology*. 2011;
142. Wheeler K, Wagaman A, McCord D. Personality Traits as Predictors of Adherence in Adolescents With Type I Diabetes. *Journal of Child and Adolescent Psychiatric Nursing*. 2012;
143. O'Connell M, Donath S, Cameron F. Poor adherence to integral daily tasks limits the efficacy of CSII in youth. *Pediatric Diabetes*. 2011;
144. Schober E, Wagner G, Berger G, Gerber D, Mengl M, Sonnenstatter S, et al. Prevalence of intentional under- and overdosing of insulin in children and adolescents with type 1 diabetes. *Pediatric Diabetes*. 2011;
145. Kristensen LJ, Thastum M, Mose AH, Birkebaek NH. Psychometric evaluation of the adherence in diabetes questionnaire. *Diabetes Care*. 2012;
146. Littlefield CH, Craven JL, Rodin GM, Daneman D, Murray MA, Rydall AC. Relationship of self-efficacy and bingeing to adherence to diabetes regimen among adolescents. *Diabetes Care*. 1992;
147. Tubiana-Rufi N, Moret L, Czernichow P, Chwalow J. Risk Factors for Poor Glycemic Control in Diabetic Children in France. *Diabetes Care*. 1995;
148. Ott J, Greening L, Palardy N, Holderby A, DeBell WK. Self-efficacy as a mediator variable for adolescents' adherence to treatment for insulin-dependent diabetes mellitus. *Children's Health Care*. 2000;
149. McDonough RJ, Clements MA, DeLurgio SA, Patton SR. Sleep duration and its impact on adherence in adolescents with type 1 diabetes mellitus. *Pediatric Diabetes*. 2017;
150. Patton SR, Eder S, Schwab J, Sisson CM. Survey of Insulin Site Rotation in Youth With Type 1 Diabetes Mellitus. *Journal of Pediatric Health Care*. 2010;
151. Maliszewski G, Patton SR, Midyett LK, Clements MA. The Interactive Effect of Diabetes Family Conflict and Depression on Insulin Bolusing Behaviors for Youth. *Journal of Diabetes Science and Technology*. 2017;
152. Cheraghi F, Shamsaei F. The Effect of Family-centered Care on Management of Blood Glucose Levels in Adolescents with Diabetes. *Endocrine Abstracts*. 2016;
153. Bond GG, Aiken LS, Somerville SC. The health belief model and adolescents with insulin-dependent diabetes mellitus. *Health psychology : official journal of the Division of Health Psychology, American Psychological Association*. 1992;
154. Florian V, Elad D. The impact of mothers' sense of empowerment on the metabolic control of their children with juvenile diabetes. *Journal of Pediatric Psychology*. 1998;
155. Kichler JC, Foster C, Opiari-Arrigan L. The relationship between negative communication and body image dissatisfaction in adolescent females with type 1 diabetes mellitus. *Journal of Health Psychology*. 2008;

156. Brownlee-Duffeck M, Peterson L, Simonds JF, Goldstein D, Kilo C, Hoette S. The Role of Health Beliefs in the Regimen Adherence and Metabolic Control of Adolescents and Adults With Diabetes Mellitus. *Journal of Consulting and Clinical Psychology*. 1987;
157. di Battista AM, Hart TA, Greco L, Gloizer J. Type 1 diabetes among adolescents: Reduced diabetes self-care caused by social fear and fear of hypoglycemia. *Diabetes Educator*. 2009;
158. Vaala SE, Hood KK, Laffel L, Kumah-Crystal YA, Lybarger CK, Mulvaney SA. Use of Commonly Available Technologies for Diabetes Information and Self-Management Among Adolescents With Type 1 Diabetes and Their Parents: A Web-Based Survey Study. *interactive Journal of Medical Research*. 2015;
159. Peters CD, Storch EA, Geffken GR, Heidgerken AD, Silverstein JH. Victimization of youth with type-1 diabetes by teachers: Relations with adherence and metabolic control. *Journal of Child Health Care*. 2008;
160. Stewart SM. Pathways From Emotional Adjustment to Glycemic Control in Youths With Diabetes in Hong Kong. *Journal of Pediatric Psychology*. 2000;
161. Abdul-Rasoul M, Alotaibi F, Abdulla A, Rahme Z, Alshawaf F. Quality of life of children and adolescents with type 1 diabetes in Kuwait. *Medical Principles and Practice*. 2013;
162. Hauser ST, Jacobson AM, Lavori P, Wolfsdorf JI, Herskowitz RD, Milley JE, et al. Adherence among children and adolescents with insulin-dependent diabetes mellitus over a four-year longitudinal follow-up: II. Immediate and long-term linkages with the family milieu. *Journal of Pediatric Psychology*. 1990;
163. Alan MJ, Hauser ST, Lavori P, Wolfsdorf JI, Herskowitz RD, Milley JE, et al. Adherence among children and adolescents with insulin-dependent diabetes mellitus over a four-year longitudinal foliow-up: I. The influence of patient coping and adjustment. *Journal of Pediatric Psychology*. 1990;
164. Schafer LC, Glasgow RE, McCaul KD, Dreher M. Adherence to IDDM regimens: Relationship to psychosocial variables and metabolic control. *Diabetes Care*. 1983;
165. Patton SR, Driscoll KA, Clements MA. Adherence to Insulin Pump Behaviors in Young Children with Type 1 Diabetes Mellitus. *Journal of Diabetes Science and Technology*. 2017;
166. Ying CL, Shah NM. Adherence to insulin treatment in children with type I diabetes mellitus at a hospital in Malaysia. *Asian Journal of Pharmaceutical and Clinical Research*. 2017;
167. Morris AD, Boyle DIR, McMahon AD, Greene SA, MacDonald TM, Newton RW. Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus. *Lancet*. 1997;
168. Johnson SB, Freund A, Silverstein J, Hansen CA, Malone J. Adherence-health status relationships in childhood diabetes. *Health psychology : official journal of the Division of Health Psychology, American Psychological Association*. 1990;
169. Anderson BJ, Auslander WF, Jung KC, Miller JP, Santiago J v. Assessing family sharing of diabetes responsibilities. *Journal of Pediatric Psychology*. 1990;
170. Khan AM. Benefits of using the I-port system on insulin-treated patients. *Diabetes Spectrum*. 2019;32:30–5.
171. Horsch A, McManus F. Brief report: Maternal posttraumatic stress symptoms are related to adherence to their child’s diabetes treatment regimen. *Journal of Health Psychology*. 2014;
172. Janisse HC, Naar-King S, Ellis D. Brief report: Parent’s health literacy among high-risk adolescents with insulin dependent diabetes. *Journal of Pediatric Psychology*. 2010;
173. Baucom KJW, Queen TL, Wiebe DJ, Turner SL, Wolfe KL, Godbey EI, et al. Depressive symptoms, daily stress, and adherence in late adolescents with type 1 diabetes. *Health Psychology*. 2015;

174. Zhang S, Hamburger E, Kahanda S, Lyttle M, Williams R, Jaser SS. Engagement with a Text-Messaging Intervention Improves Adherence in Adolescents with Type 1 Diabetes: Brief Report. *Diabetes Technology and Therapeutics*. 2018;
175. Lee Tracy E, Berg CA, Baker AC, Mello D, Litchman ML, Wiebe DJ. Health-risk behaviors and type 1 diabetes outcomes in the transition from late adolescence to early emerging adulthood. *Children's Health Care*. 2019;
176. McGrady ME, Peugh JL, Hood KK. Illness representations predict adherence in adolescents and young adults with type 1 diabetes. *Psychology and Health*. 2014;
177. Wiebe DJ, Gelfand D, Butler JM, Korbel C, Fortenberry KT, McCabe JE, et al. Longitudinal associations of maternal depressive symptoms, maternal involvement, and diabetes management across adolescence. *Journal of Pediatric Psychology*. 2011.
178. Jacobson AM, Hauser ST, Wolfsdorf JI, Houlihan J, Milley JE, Watt E. Psychologic predictors of compliance in children with recent onset of diabetes mellitus. *The Journal of Pediatrics*. 1987;
179. Testa MA, Simonson DC. Satisfaction and quality of life with premeal inhaled versus injected insulin in adolescents and adults with type 1 diabetes. *Diabetes Care*. 2007;
180. Howells L, Wilson AC, Skinner TC, Newton R, Morris AD, Greene SA. A randomized control trial of the effect of negotiated telephone support on glycaemic control in young people with Type 1 diabetes. *Diabetic Medicine*. 2002;
181. Franklin VL, Waller A, Pagliari C, Greene SA. A randomized controlled trial of Sweet Talk, a text-messaging system to support young people with diabetes. *Diabetic Medicine*. 2006;
182. Glaser NS, Iden SB, Green-Burgeson D, Bennett C, Hood-Johnson K, Styne DM, et al. Benefits of an insulin dosage calculation device for adolescents with type 1 diabetes mellitus. *Journal of Pediatric Endocrinology and Metabolism*. 2004;
183. Gregory JW, Robling M, Bennert K, Channon S, Cohen D, Crowne E, et al. Development and evaluation by a cluster randomised trial of a psychosocial intervention in children and teenagers experiencing diabetes: The DEPICTED study. *Health Technology Assessment*. 2011.
184. Abolfotouh MA, Kamal MM, El-Bourgy MD, Mohamed SG. Quality of life and glycemic control in adolescents with type 1 diabetes and the impact of an education intervention. *International Journal of General Medicine*. 2011;
185. Jones EM, Landreth G. The Efficacy of Intensive Individual Play Therapy for Chronically Ill Children. *International Journal of Play Therapy*. 2002;
186. Méndez FJ, Beléndez M. Effects of a behavioral intervention on treatment adherence and stress management in adolescents with IDDM. *Diabetes Care*. 1997;
187. Greco P, AM LG, S I, P W, C F, R A, et al. Assessing adherence in IDDM: A comparison of two methods. . 1990;40(Suppl 1):A165. *Diabetes*. 1990;40(Suppl 1(A165)).
188. Weinger K, Butler HA, Welch GW, la Greca AM. Measuring diabetes self-care: A psychometric analysis of the Self-Care Inventory-revised with adults. *Diabetes Care*. 2005;
189. Sperber CM, Samarasinghe SR, Lomax GP. An upper and lower bound of the Medication Possession Ratio. *Patient Preference and Adherence*. 2017;
190. Diabetes.co.uk. Omnipod Insulin Pump from Ypsomed [Internet]. 2019 [cited 2020 May 15]. Available from: <https://www.diabetes.co.uk/diabetic-products/pumps/omnipod-insulin-pump.html###>
191. Clements MA, DeLurgio SA, Williams DD, Habib S, Halpin K, Patton SR. Association of HbA1c to BOLUS Scores among Youths with Type 1 Diabetes. *Diabetes Technology and Therapeutics*. 2016;

192. van Dongen L, Westerlaken C, Verhaak C, Bazelmans E. Algemene ouder-kindrelatie en diabetesgerelateerde ouder-kindrelatie in de adolescentie: Relatie met glykemische controle en de rol van adherence. *Tijdschrift voor Kindergeneeskunde*. 2008;
193. Moret L, Chwalow J, Tubiana-Rufi N. [French version and validation of a scale evaluating compliance in diabetic children]. *Revue d'épidémiologie et de sante publique*. 1995;
194. BMJ. The t tests [Internet]. [cited 2020 May 20]. Available from: <https://www.bmj.com/about-bmj/resources-readers/publications/statistics-square-one/7-t-tests>
195. Rosselló J, Maysonet Guzmán M. Difficulties and concerns identified by Puerto Rican youth with insulin-dependent diabetes mellitus (IDDM): their relationship with metabolic control, hopelessness, social support, and depressive symptoms. *Puerto Rico health sciences journal*. 2006;
196. Olivares J. El cuidado de la diabetes mellitus insulino-dependiente: Efectos de un programa de modificación de conducta en padres. *Psicología Conductual Revista Internacional de Psicología Clínica de la Salud*. 1997;5:219–35.
197. Slijper FM, de Beaufort CE, Bruining GJ, de Visser JJ, Aarsen RS, Kicken DA, et al. Psychological impact of continuous subcutaneous insulin infusion pump therapy in non-selected newly diagnosed insulin dependent (type 1) diabetic children: evaluation after two years of therapy. *Diabete et Metabolisme*. 1990;
198. Talakoub S, Nasiri M. Affective responses of the parents after diagnosis of type 1 diabetes in children. *Iranian journal of nursing and midwifery research*. 2012;
199. Guthrie DW, Bartsocas C, Jarosz-Chabot P, Konstantinova M. Psychosocial Issues for Children and Adolescents With Diabetes: Overview and Recommendations. *Diabetes Spectrum*. 2003;
200. Karimzadeh M, Rostami M, Teymouri R, Moazzen Z, Tahmasebi S. The association between parental mental health and behavioral disorders in pre-school children. *Electronic Physician*. 2017;
201. Stentzel U, van den Berg N, Schulze LN, Schwaneberg T, Radicke F, Langosch JM, et al. Predictors of medication adherence among patients with severe psychiatric disorders: Findings from the baseline assessment of a randomized controlled trial (Tecla). *BMC Psychiatry*. 2018;
202. NICE. Depression in children and young people: identification and management [Internet]. 2019 [cited 2020 Aug 15]. Available from: <https://www.nice.org.uk/guidance/ng134>
203. NHS. Symptoms Clinical Depression [Internet]. 2019 [cited 2020 Aug 15]. Available from: <https://www.nhs.uk/conditions/clinical-depression/symptoms/>
204. Lam WY, Fresco P. Medication Adherence Measures: An Overview. *BioMed Research International*. 2015.
205. la Greca A, Swales T, Klemp S, Madigan S. Self care behaviors among adolescents with diabetes. *Ninth Annual Sessions of the Society of Behavioral Medicine*. 1988;A42.
206. Lewin AB, Lagreca AM, Geffken GR, Williams LB, Duke DC, Storch EA, et al. Validity and reliability of an adolescent and parent rating scale of type 1 diabetes adherence behaviors: The self-care inventory (SCI). *Journal of Pediatric Psychology*. 2009;
207. Hardt J. A new questionnaire for measuring quality of life - the Stark QoL. *Health and Quality of Life Outcomes*. 2015;

## 9. Appendix

Section/topic	#	Checklist item	Reported on page #
<b>TITLE</b>			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	50
<b>ABSTRACT</b>			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2-3
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of what is already known.	49
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	49
<b>METHODS</b>			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	51
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	52
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	53
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	54, 374-376
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	54-55
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	55
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	51

Section/topic	#	Checklist item	Reported on page #
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	56-57
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	55
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., $I^2$ ) for each meta-analysis.	60
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	57-58
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	N/A
<b>RESULTS</b>			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	61-62
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	63-64
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	63, 235-238, 240, 242-243, 244-249
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	78-167, 172-173
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	70, 174-175

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	80, 93, 101, 108-109, 115, 122, 128, 131-132, 135-136, 139-140, 142-143
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	N/A
<b>DISCUSSION</b>			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	168-171, 190-192
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	192
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	194
<b>FUNDING</b>			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	192

Appendix 1 PRISMA Checklist



Study Title	Lead Author	Year	Country	Setting (dropdown of inpatient, outpatient, intensive care, primary care, healthy participants)	Mean Age of Participants (include range or SD if given)	Mean duration of diabetes at start of study	Prospective, Retrospective, not known	Study Design (RCT, Cohort, Case report)	Sample (Y/N)	Adherence to insulin therapy assessed	Primary, secondary outcome or not known	Over what time did they assess the patients' adherence (days/weeks/months)	How did they measure adherence?	Factor assessed for association with adherence (please list all captured by study team). Please use a new row for each variable tested for association with adherence	Effect on adherence - how did each factor alter the use of insulin (numerical)	Statistical test	P value	Statistically significant (Y/N)
A randomized control trial of the effect of negotiated telephone support on glycaemic control in young people with Type 1 diabetes	Howells	2002	UK	Outpatient	16.8 (SD 3.4, range 12.3-24.8)	7.0y (SD 4.5, range 1.0-19.3)	Prospective	RCT	91	Y	Secondary	365 days	Self-efficacy for diabetes (SED) questionnaire, environmental barriers to adherence (BA) questionnaire	Group 2: Negotiated Telephone Support	SED mean change: 4.81 (SD 10.74). BA mean change: 4.12 (SD 21.7)	ANOVA	NK	N
														Group 3: Negotiated Telephone Support, yearly clinical review, 3-monthly measurement of HbA1c	SED mean change: 7.32 (SD 9.1). BA mean change: -0.64 (SD 11.9)	ANOVA	NK	N
A randomized controlled trial of Sweet Talk, a text-messaging system to support young people with diabetes	Franklin	2006	Scotland	Outpatient	NK	NK	Prospective	RCT	90	Y	Primary	365 days	Self-efficacy for diabetes (SED) questionnaire, environmental barriers to adherence (BA) questionnaire, self-reported	"Sweet talk" text message intervention (conventional insulin therapy)	SED increased by 6.1 when compared with group 1 (no intervention). Self-reported adherence score increased by 6.8.	ANCOVA	SED = 0.003. Self-reported adherence = 0.042	Y
Adherence among children and adolescents with insulin-dependent diabetes mellitus over a four-year longitudinal follow-up: I. The influence of patient coping and adjustment	Jacobson	1990	USA	Outpatient	NK	NK	Prospective	Cohort study	61	Y	Primary	1 460 days (4 years)	Self-created 4 point scale (1-4; poor-excellent). Validated by Jacobson et al., 1987.	Gender	NK	NK	NK	N
														Time between Dx and study entry	NK	NK	NK	N
														Age	Mean change = -0.11 (with increasing age).	F test	0.0002	Y
														Initial adjustment to diabetes	Mean change = +0.27 (with better adjustment)	F test	0.0001	Y
														Coping measures: ego defense level	Mean change = -0.05 (with higher ego defense score)	F test	0.02	Y
														Patient perceptions of family conflict	-0.41 NK		<0.004	Y
														Parent perceptions of family cohesion	-0.2 NK		>0.05	N
														Patient perceptions of family cohesion	-0.37 NK		<0.01	Y
														Parent perceptions of family cohesion	0.32 NK		<0.05	Y
														Patient perceptions of expressiveness	0.17 NK		>0.05	N
Adherence among children and adolescents with insulin-dependent diabetes mellitus over a four-year longitudinal follow-up: II. Immediate and long-term linkages with the family milieu	Hauser	1990	USA	Outpatient	12.8 (SD 1.9)	4.79 months (SD 3.97 months)	Prospective	Cohort study	52	Y	Primary	1 460 days (4 years)	Self-created 4 point scale Validated by Jacobson et al., 1987.	Parent perceptions of family independence	0.16 NK		>0.05	N
														Parent perception of independence	0.04 NK		>0.05	N
														Parent perception of control	-0.05 NK		>0.05	N
														Parent perception of control	-0.12 NK		>0.05	N
														Patient perception of independence	0.16 NK		>0.05	N
														Parent perception of independence	0.04 NK		>0.05	N
														Parent perception of control	-0.05 NK		>0.05	N
														Parent perception of control	-0.12 NK		>0.05	N
														Patient perception of independence	0.16 NK		>0.05	N
														Parent perception of independence	0.04 NK		>0.05	N

Study Title	Lead Author	Year	Country	Setting (dropdown of inpatient, outpatient, intensive care, primary care, healthy participants)	Mean Age of Participants (include range or SD if given)	Mean duration of diabetes at start of study	Prospective, Retrospective, not known	Study Design (RCT, Cohort, Case Control, Case report)	Sample (Y/N)	Adherence to insulin therapy assessed (Y/N)	Primary, secondary outcome or not known	Over what time did they assess the patients' adherence (days/weeks/months)	How did they measure adherence?	Factor assessed for association with adherence (please list all captured by study team). Please use a new row for each variable tested for association with adherence	Effect on adherence - how did each factor alter the use of insulin (numerical)	Statistical test	P value	Statistically significant (Y/N)	
<i>Adherence to IDDM regimens: relationship to psychosocial variables and metabolic control.</i>	Schafer	1983	USA	Outpatient	13; self-calculated (range 12-14)	4.61 years; self-calculated (range 1-11 years)	Prospective	Cohort study	34	Y	Primary	7 days	questionnaire	Gender	"non-significant tendencies for boys to report taking more care when measuring insulin" (no numerical value)	NK	<0.1	N	
														Family Environment Scale (FES): Cohesion	0.11	NK	>0.05	N	
														FES: Expressiveness	0.02	NK	>0.05	N	
														FES: Conflict	0.1	NK	>0.05	N	
														FES: Independence	-0.05	NK	>0.05	N	
														FES: Organisation	-0.1	NK	>0.05	N	
														Barriers to adherence and problem solving questionnaire and summary of self-care activities	Family Behaviour Checklist (FBC): Mother supportive	-0.14	NK	>0.05	N
															FBC: Mother negative	-0.14	NK	>0.05	N
															FBC: Father supportive	-0.07	NK	>0.05	N
															FBC: Father negative	-0.01	NK	>0.05	N
	Barriers to adherence	-0.29	NK	<0.1	N														
<i>Adherence to Insulin Pump Behaviors in Young Children with Type 1 Diabetes Mellitus</i>	Patton	2017	USA	Outpatient	5.2 (SD 1.4, range 0.2-11.62 (SD 1.77))	1.62 (SD 1.77)	Retrospective	Cohort study	116	Y	Primary	NK	Data retrospectively taken from patients' insulin pumps, looking at whether they corrected for high	Age	Number of days with 3 or more boluses given, r =	Means, SDs, frequency counts	0.01	Y	
														Female: 57.4% of non-adherence	Fisher's exact test		1	N	
														Non-adherent: n = 54 (94.7%)	Mann-Whitney U-test		0.339	N	
														Malaysian: 35.2% of non-adherence	Fisher's exact test			1	N
														Chinese: 51.9% of non-adherence	Fisher's exact test			1	N
														Indian: 11.1% of non-adherence	Fisher's exact test			1	N
														Other: 1.9% of non-adherence	Fisher's exact test			1	N
														Yes: 27.8% of non-adherence	Fisher's exact test			0.209	N
														No: 72.2% of non-adherence	Fisher's exact test			0.209	N
														Insulin aspart penfill + insulin glargine: 46.3% of non-adherence	Fisher's exact test			0.171	N
														Insulin aspart penfill + insulin detemir: 16.7% of non-adherence	Fisher's exact test			0.171	N
														Insulin lispro kwikpen + insulin glargine: 3.7% of non-adherence	Fisher's exact test			0.171	N
														Insulin aspart penfill only: 5.6% of non-adherence	Fisher's exact test			0.171	N
														Insulin aspart flexpen + insulin detemir: 1.9% of non-adherence	Fisher's exact test			0.171	N
														Insulin aspart flexpen + insulin glargine: 16.7% of non-adherence	Fisher's exact test			0.171	N
														Insulin aspart penfill + soluble insulin penfill + insulin glargine: 1.9% of non-adherence	Fisher's exact test			0.171	N
														Insulin aspart penfill + soluble insulin penfill + insulin detemir: 1.9% of non-adherence	Fisher's exact test			0.171	N
														30% soluble insulin/70%	Fisher's exact test			0.171	N

Study Title	Lead Author	Year	Country	Setting (dropdown of inpatient, outpatient, intensive care, primary care, healthy participants)	Mean Age of Participants (include range or SD if given)	Mean duration of diabetes at start of study	Prospective, Retrospective, not known	Study Design (RCT, Cohort, Case report)	Sample (Y/N)	Adherence to insulin therapy assessed	Primary, secondary outcome or not known	Over what time did they assess the patients' adherence (days/weeks/months)	How did they measure adherence?	Factor assessed for association with adherence (please list all captured by study team). Please use a new row for each variable tested for association with adherence	Effect on adherence - how did each factor alter the use of insulin (numerical)	Statistical test	P value	Statistically significant (Y/N)										
<i>Adherence to insulin treatment in children with type 1 diabetes mellitus at a hospital in Malaysia</i>	Ying	2017	Malaysia	Outpatient	14.39 (SD 3.41)	8.05 (SD 3.83)	Retrospective	Cohort study	57	Y	Primary	365 days	MPR	Type of insulin	Soluble insulin + isophane insulin: 1.9% of non-adherence Insulin aspart flexpen + insulin glargine + isophane insulin: 1.9% of non-adherence	Fisher's exact test	0.171	N										
														Adjustment in insulin dose?	Yes: 70.4% of non-adherence No: 29.6% of non-adherence	Fisher's exact test	0.171	N										
																Fisher's exact test	1	N										
																Fisher's exact test	1	N										
<i>Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus</i>	Morris	1997	Scotland	Outpatient	16 (SD 7)	7 (SD 4)	Retrospective	Cohort study	89	Y	Primary	365 days	MPR	Age	Under 10, mean adherence score approx 725 (best)	Change in log-likelihood from each variable (degree of freedom for each	0.0001	Y										
															10-15, mean adherence score approx 400	Change in log-likelihood from each variable (degree of freedom for each	0.0001	Y										
															15-20, mean adherence score approx 350 (worst)	Change in log-likelihood from each variable (degree of freedom for each	0.0001	Y										
															20+, mean adherence score approx 520	Change in log-likelihood from each variable (degree of freedom for each	0.0001	Y										
														Intensity of insulin regimen (2 vs 4 injections per day)	No correlation	Change in log-likelihood from each variable (degree of freedom for each	NK	N										
																			Gender	No correlation	Change in log-likelihood from each variable (degree of freedom for each	NK	N					
																								Number of hospital admissions	No correlation	Change in log-likelihood from each variable (degree of freedom for each	NK	N

Study Title	Lead Author	Year	Country	Setting (dropdown of inpatient, outpatient, intensive care, primary care, healthy participants)	Mean Age of Participants (include range or SD if given)	Mean duration of diabetes at start of study	Prospective, Retrospective, not known	Study Design (RCT, Cohort, Case Control, Case report)	Sample (Y/N)	Adherence to insulin therapy assessed (Y/N)	Primary, secondary outcome or not known	Over what time did they assess the patients' adherence (days/weeks/months)	How did they measure adherence?	Factor assessed for association with adherence (please list all captured by study team). Please use a new row for each variable tested for association with adherence	Effect on adherence - how did each factor alter the use of insulin (numerical)	Statistical test	P value	Statistically significant (Y/N)														
<i>Adherence-health status relationships in childhood diabetes</i>	Johnson	1990	USA	Outpatient	NK (range 6-19)	NK (range 1-16.5)	Retrospective	Cohort study	78	Y	Primary	9 x separate 24 hour recall interviews to both the patient and their	24 hour recall interviews to both the patient and their	Gender	F=4.61 (boys more compliant than girls)	ANOVA	<0.04	Y														
														Age	-0.4	ANOVA	<0.007	Y														
														Age	-0.06	Zero order	NK	N														
														Duration of diabetes	-0.11	Zero order	NK	N														
														Household income	0.04	Zero order	NK	N														
														Better parent-child relationship	r=0.23, b=0.23	Zero order	<0.05	Y														
														Increased disease severity	r=-0.22, b=-0.2	Zero order	<0.05	Y														
														Increased treatment complexity	-0.17	Zero order correlations	NK	N														
														Increased vulnerability to risks	r=-0.01, b=-0.14	Zero order correlations	NK	N														
														Increased severity of risks	r=0.21, b=0.3	Zero order correlations	r=<0.05, b=<0.01	Y														
														Self-efficacy	r=0.24, b=0.1	Zero order correlations	r=<0.05, b=>0	Y														
														Response efficacy	r=0.3, b=0.18	Zero order correlations	<0.01, b=>0.05	Y														
														<i>Adolescents' health attitudes and adherence to treatment for insulin-dependent diabetes mellitus</i>	Palardy	1998	USA	Outpatient	14.07 (range 11-17, SD 3.04)	4.79 (range 5 months-11.67 years, SD 3.04)	Retrospective	Cross-sectional	101	Y	Primary	NK	Summary of self-care activities questionnaire, completed by children and their parents	Response costs	r=-0.45, b=-0.36	Zero order correlations	r=<0.001, b=<0.001	Y
Age	M report: 0.26, C report: 0.29	Zero order	<0.01	Y																												
Gender	M report: -0.17 (better female adherence), C report: 0.02 (better male adherence)	Zero order correlations	NK	N																												
Duration of diabetes	M report: 0.17, C report: 0.16	Zero order	NK	N																												
Mother's increasing responsibility for management	M report: 0, C report: 0.17	Zero order correlations	NK	N																												
Mother's increasing responsibility for management of daily regimen tasks	M report: -0.01, C report: 0.08	Zero order correlations	NK	N																												
Mother's increasing responsibility for social presentation (talking to family and friends about disease etc.)	M report: -0.16, C report: -0.02	Zero order correlations	NK	N																												
Child's increasing overall responsibility	M report: 0.14, C report: 0.2	Zero order correlations	M report: NK, C report: <0.05, C report: Y	M report: N, report: Y																												
Diabetes Family Responsibility Questionnaire (DFRQ)																																
Increasing lack of responsibility from mother or child	M report: -0.23, C report: -0.06	Zero order correlations	M report: <0.05, C report: NK	M report: Y, report: N																												
<i>Assessing family sharing of diabetes responsibilities.</i>	Anderson	1990	USA	Inpatient	13.3 (range 6-21, SD 5.5)	(range 1-15, SD 3)	Retrospective	Cohort study	121	Y	Secondary	1 week	Diabetes Family Responsibility Questionnaire (DFRQ)															Increasing lack of responsibility from mother or child	M report: -0.23, C report: -0.06	Zero order correlations	M report: <0.05, C report: NK	M report: Y, report: N

Study Title	Lead Author	Year	Country	Setting (dropdown of inpatient, outpatient, intensive care, primary care, healthy participants)	Mean Age of Participants (include range or SD if given)	Mean duration of diabetes at start of study	Prospective, Retrospective, not known	Study Design (RCT, Cohort, Case report)	Sample (Y/N)	Adherence to insulin therapy assessed	Primary, secondary outcome or not known	Over what time did they assess the patients' adherence (days/weeks/months)	How did they measure adherence?	Factor assessed for association with adherence (please list all captured by study team). Please use a new row for each variable tested for association with adherence	Effect on adherence - how did each factor alter the use of insulin (numerical)	Statistical test	P value	Statistically significant (Y/N)
														ADHD	AG: 1.9%, EG: 3%, MG: 4.2%	Bonferroni correction	0.974	N
														Conduct disorder	AG: 1%, EG: 1.5%, MG: 2.8%	Bonferroni correction	0.358	N
														Oppositional defiant disorder	AG: 1.9%, EG: 0%, MG: 5.6%	Bonferroni correction	0.168	N
														Functional enuresis	AG: 3.9%, EG: 1.5%, MG: 2.8%	Bonferroni correction	0.625	N
														Depression (all subtypes)	AG: 4.9%, EG: 13.4%, MG: 18.3%	Bonferroni correction	<0.005	Y
														Dysthymia	AG: 0%, EG: 0%, MG: 4.2%	Bonferroni correction	0.019	Y
														Separation anxiety disorder	AG: 1%, EG: 3%, MG: 4.2%	Bonferroni correction	0.168	N
														Agoraphobia	AG: 1.9%, EG: 4.5%, MG: 2.8%	Bonferroni correction	0.671	N
														Specific (isolated) phobias	AG: 2.9%, EG: 9%, MG: 21.1%	Bonferroni correction	<0.001	Y
														Social phobia	AG: 0%, EG: 1.49%, MG: 7%	Bonferroni correction	0.004	Y
														OCD	AG: 0%, EG: 3%, MG: 1.4%	Bonferroni correction	0.333	N
														Clinical/subclinical eating	AG: 1.9%, EG: 6%, MG: 12.7%	Bonferroni correction	0.004	Y
														Generalised anxiety disorder	AG: 0%, EG: 0%, MG: 1.4%	Bonferroni correction	0.176	N
														PTSD	AG: 0%, EG: 4.5%, MG: 1.4%	Bonferroni correction	0.358	N
														Adjustment disorder	AG: 1%, EG: 0%, MG: 2.8%	Bonferroni correction	0.333	N
<i>Association of insulin-manipulation and psychiatric disorders: A systematic epidemiological evaluation of adolescents with type 1 diabetes in Austria</i>	Berger	2019	Austria	Outpatient	14.14 (SD 2.67)	NK	Retrospective	Cross-sectional	322	Y	Primary	NK	Interview	Adjustment disorder	AG: 1%, EG: 0%, MG: 2.8%	Bonferroni correction	0.333	N
														Alcohol/drug abuse	AG: 0%, EG: 0%, MG: 0%	Bonferroni correction	N/A	N/A
														Psychosis	AG: 0%, EG: 0%, MG: 0%	Bonferroni correction	N/A	N/A
<i>Associations between major life events and adherence, glycemic control, and psychosocial characteristics in teens with type 1 diabetes.</i>	Commissariz	2018	Denmark	Outpatient	14.9 (SD 1.3)	7.3 years (SD 3.7)	Prospective	Cross-sectional	178	Y	Primary	28 days	Diabetes Management Scale	Any psychiatric disorder	AG: 17.5%, EG: 29.6%, MG: 46.5%	Bonferroni correction	<0.001	Y
														0-1 adverse life events	Mean adherence score, C report: 75. P report: 74.	ANOVA and chi-squared	C: 0.002, P: 0.02	Y
														2-3 adverse life events	Mean adherence score, C report: 71. P report: 71.	ANOVA and chi-squared	C: 0.002, P: 0.02	Y
														4+ adverse life events	Adherence score, C report: 68. P report: 68.	ANOVA and chi-squared	C: 0.002, P: 0.02	Y
<i>Benefits of an insulin dosage calculation device for adolescents with type 1 diabetes mellitus</i>	Glaser	2004	USA	Outpatient	14.25 (self-calculate)	5.1 years (self-calcul)	Prospective	RCT	83	Y	Secondary	365 days	Diabetes Regimen Adherence Questionnaire (DRAQ)	Inconsistent Insulin Dosage Calculator Usage	Average adherence score change after 6 months: +0.12	chi-squared	0.27	N
														Consistent Insulin Dosage Calculator Usage	Average adherence score change after 6 months: +0.56	chi-squared	0.07	Y
														Control Group (manual calculations)	Average adherence score change after 6 months: +0.29	chi-squared	<0.001	Y
<i>Benefits of using the I-port system on insulin-treated patients</i>	Khan	2019	Saudi Arabia	Outpatient	14.96 (SD 8.95)	4.6 years (SD 4.25)	Prospective	Cohort study	55	Y	Primary	"equal to or greater than 3 months"	Interviews	Regular Use of I-Port	Non-compliance down to 11.1% at follow up, from 50% at baseline Mean number of missed insulin doses in past three months down to 0.26 (SD 0.81) from 1.1 (SD 1.81)	chi-squared	0.032	Y
																	0.028	Y
<i>Brief report: Maternal posttraumatic stress symptoms are related to adherence to their child's diabetes treatment regimen.</i>	Horsch	2014	England	Outpatient	NK	NK	Prospective	Cohort study	60	Y	Secondary	NK	The Adherence and IDDM Interview (Hanson et al., 1987)	PTSD diagnosis of mother overall	r = -0.115	Pearson correlation	0.19	N
														PTSD diagnosis of mother of children aged 0-8 at diagnosis	r = -0.519	Pearson correlation	0.008	Y
														PTSD diagnosis of mother of children aged 9-16 years at diagnosis	r = 0.062	Pearson correlation	0.354	N
														PTSD diagnosis of mother vs no PTSD diagnosis: younger children	U = 4.500	Mann-Whitney U-test	0.009	Y
														PTSD diagnosis of mother vs no PTSD diagnosis: older children	U = 30.500	Mann-Whitney U-test	0.35	N

Study Title	Lead Author	Year	Country	Setting (dropdown of inpatient, outpatient, intensive care, primary care, healthy participants)	Mean Age of Participants (include range or SD if given)	Mean duration of diabetes at start of study	Prospective, Retrospective, not known	Study Design (RCT, Cohort, Case Control, Case report)	Sample (Y/N)	Adherence to insulin therapy assessed	Primary, secondary outcome or not known	Over what time did they assess the patients' adherence (days/weeks/months)	How did they measure adherence?	Factor assessed for association with adherence (please list all captured by study team). Please use a new row for each variable tested for association with adherence	Effect on adherence - how did each factor alter the use of insulin (numerical)	Statistical test	P value	Statistically significant (Y/N)
<i>Brief report: Parent's health literacy among high-risk adolescents with insulin dependent diabetes</i>	Janisse	2010	USA	Outpatient	14.2 (SD 2.2)	4.5 years (SD 2.8)	Prospective	Cohort study	93	Y	Primary	NK	Diabetes Management Scale	Parents' health literacy (total sample)	r(91) = 0.2	NK	<0.1	N
														Parents' reading comprehension (intensive insulin regimen); P report on adherence	r(63) = 0.31	NK	<0.01	Y
														Parents' reading comprehension (intensive insulin regimen); C self-report on adherence	r(63) = 0.32	NK	<0.01	Y
<i>Comparison of usability and patient preference for the new disposable insulin device solostar versus flexpen, lilly disposable pen, and a prototype pen: an open-label study</i>	Haak	2007	Multiple : USA, Japan, France, Germany	Outpatient	NK (adults included too, but results separated out. Explicitly assessed paediatric age range: 11-15 years old).	NK	Prospective	Cross-sectional	510 over a II, 116 11-15 year olds	Y	Secondary	NK	Watched users delivery an injection into a receptacle using each of the pens to assess usability	SoloStar pen vs all other pens	Percentage of participants completing all tasks successfully: 98%	chi-squared	<0.05	Y
														FlexPen vs Lilly and Pen X	Percentage of participants completing all tasks successfully: 97%	chi-squared	<0.05	Y
														Lilly Disposable Pen	Percentage of participants completing all tasks successfully: 72%	chi-squared	NK	N
														Pen X	Percentage of participants completing all tasks successfully: 79%	chi-squared	NK	N

Study Title	Lead Author	Year	Country	Setting (dropdown of inpatient, outpatient, intensive care, primary care, healthy participants)	Mean Age of Participants (include range or SD if given)	Mean duration of diabetes at start of study	Prospective, Retrospective, not known	Study Design (RCT, Cohort, Case Control, Case report)	Sample (Y/N)	Adherence to insulin therapy assessed	Primary, secondary outcome or not known	Over what time did they assess the patients' adherence (days/weeks/months)	How did they measure adherence?	Factor assessed for association with adherence (please list all captured by study team). Please use a new row for each variable tested for association with adherence	Effect on adherence - how did each factor alter the use of insulin (numerical)	Statistical test	P value	Statistically significant (Y/N)
														Disease duration 1-3 years	Good compliance: 36%, satisfactory: 58%, poor: 6%	chi-squared	<0.001	Y
														Disease duration 3-6 years	Good: 17%, satisfactory: 79%, poor: 4%	chi-squared	<0.001	Y
														Disease duration more than 6 years	Good: 12%, satisfactory: 80%, poor: 4%	chi-squared	<0.001	Y
														Exercise frequency regular	Good: 90%, satisfactory: 10%, poor: 0%	chi-squared	<0.001	Y
														Exercise occasionally	Good: 68%, satisfactory: 29%, poor: 3%	chi-squared	<0.001	Y
														Exercises not at all	Good: 5%, satisfactory: 0%, poor: 95%	chi-squared	<0.001	Y
														Regularly smokes	Good: 0%, satisfactory: 84%, poor: 16%	chi-squared	<0.001	Y
														Occasionally smokes	Good: 2%, satisfactory: 91%, poor: 7%	chi-squared	<0.001	Y
														Doesn't smoke	Good: 64%, satisfactory: 35%, poor: 11%	chi-squared	<0.001	Y
														Regularly drinks alcohol	Good: 5%, satisfactory: 62%, poor: 33%	chi-squared	<0.001	Y
														Occasionally drinks alcohol	Good: 9%, satisfactory: 78%, poor: 13%	chi-squared	<0.001	Y
														Doesn't drink alcohol	Good: 68%, satisfactory: 31%, poor: 1%	chi-squared	<0.001	Y
														Good motivation	Good: 39%, satisfactory: 61%, poor: 0%	chi-squared	<0.001	Y
														No motivation	Good: 2%, satisfactory: 83%, poor: 15%	chi-squared	<0.001	Y
														Strong sense of normality	Good: 29%, satisfactory: 71%, poor: 0%	chi-squared	<0.001	Y
														Poor sense of normality	Good: 3%, satisfactory: 80%, poor: 17%	chi-squared	<0.001	Y
														Positive experience of results	Good: 26%, satisfactory: 72%, poor: 3%	chi-squared	<0.001	Y
														Negative experience of results	Good: 1%, satisfactory: 83%, poor: 16%	chi-squared	<0.001	Y
														Have energy and willpower	Good: 39%, satisfactory: 61%, poor: 8%	chi-squared	<0.001	Y
														No energy and willpower	Good: 3%, satisfactory: 86%, poor: 11%	chi-squared	<0.001	Y
														Has support from parents	Good: 33%, satisfactory: 67%, poor: 0%	chi-squared	<0.001	Y
														No support from parents	Good: 2%, satisfactory: 84%, poor: 14%	chi-squared	<0.001	Y
														Has support from physicians	Good: 39%, satisfactory: 61%, poor: 0%	chi-squared	<0.001	Y
														No support from physicians	Good: 7%, satisfactory: 87%, poor: 12%	chi-squared	<0.001	Y
														Has support from nurses	Good: 37%, satisfactory: 63%, poor: 0%	chi-squared	<0.001	Y

Study Title	Lead Author	Year	Country	Setting (dropdown of inpatient, outpatient, intensive care, primary care, healthy participants)	Mean Age of Participants (include range or SD if given)	Mean duration of diabetes at start of study	Prospective, Retrospective, not known	Study Design (RCT, Cohort, Case Control, Case report)	Sample (Y/N)	Adherence to insulin therapy assessed (Y/N)	Primary, secondary outcome or not known	Over what time did they assess the patients' adherence (days/weeks/ months)	How did they measure adherence?	Factor assessed for association with adherence (please list all captured by study team). Please use a new row for each variable tested for association with adherence	Effect on adherence - how did each factor alter the use of insulin (numerical)	Statistical test	P value	Statistically significant (Y/N)	
<i>Compliance of adolescents with diabetes</i>	Kyngas	2000	Finland	Outpatient	15.1 (SD 1.51)	6.1 years (SD 3.8)	Prospective	Cross-sectional	289	Y	Primary	NK	Questionnaire	No support from nurses	Good: 1%, satisfactory: 85%, poor: 14%	chi-squared	<0.001	Y	
														Positive attitude	Good: 31%, satisfactory: 69%, poor: 0%	chi-squared	<0.001	Y	
														Negative attitude	Good: 0%, satisfactory: 85%, poor: 15%	chi-squared	<0.001	Y	
														No threat to social well-being	Good: 36%, satisfactory: 64%, poor: 0%	chi-squared	<0.001	Y	
														Threat to social well-being	Good: 3%, satisfactory: 82%, poor: 15%	chi-squared	<0.001	Y	
														No threat to emotional well-being	Good: 29%, satisfactory: 66%, poor: 5%	chi-squared	<0.001	Y	
														Threat to emotional well-being	Good: 7%, satisfactory: 85%, poor: 8%	chi-squared	<0.001	Y	
														No threat to physical well-being	Good: 90%, satisfactory: 10%, poor: 0%	chi-squared	<0.001	Y	
<i>Compliance of adolescents with diabetes</i>													Threat to physical well-being	Good: 2%, satisfactory: 143%, poor: 0%	chi-squared	<0.001	Y		
<i>Coping styles in youths with insulin-dependent diabetes mellitus</i>	Hanson	1989	USA	Outpatient	NK	NK	Prospective	Cross-sectional	135	Y	Primary	NK	Self-report questionnaire based on Cerkoney and Hart, 1980	Utilising personal and interpersonal resources coping	-0.055	chi-squared	NK	N	
														Ventilation and avoidance coping strategy	-0.367	chi-squared	<0.0001	Y	
														Age	-0.21	chi-squared		0.008	Y
														Duration of diabetes	-0.16	chi-squared		0.032	Y
<i>Crisis intervention program in newly diagnosed diabetic children.</i>	Galatzer	1982	USA	Outpatient	15 (range 7-24)	NK	Prospective	Cross-sectional	223	Y	Secondary	NK	Interviews	Family relationship scores	0.64	Pearson correlation	NK	NK	
														Sociability scores	0.46	Pearson correlation	NK	NK	
														School/work performance	0.66	Pearson correlation	NK	NK	
<i>Depressive symptoms, daily stress, and adherence in late adolescents with type 1 diabetes.</i>	Baucom	2015	USA	Outpatient	17.7 (SD 0.38)	7.46 years (SD 3.76)	Prospective	Cohort study	175	Y	Secondary	14 days	Questionnaire based on the diabetes Self-Care Inventory (La Greca, 2004)	Glycaemic control	Improved glycaemic control (-0.31)	NK	<0.001	Y	
														Depressive symptoms	-0.33	NK	<0.001	Y	
														Mean general stress (GS)	-0.09	NK		NK	N
														Mean diabetes-specific stress (DSS) severity	-0.11	NK		NK	N
<i>Development and validity testing of the revised diabetes self-care inventory for children and adolescents</i>	Nakamura	2019	Japan	Outpatient	13.1 (SD 2.7)	6.8 years (SD 4.2)	Prospective	Cross-sectional	123	Y	Primary	NK	Revised Diabetes Self-Care Inventory (R-DSCI; Kanematsu, 1997). Note that this is not the same measure as the SCI made by La Greca.	Gender	Question F2: male: 11.2 (SD 2.7), female 10.7 (SD 2.2)	t-test		NK	N
														Insulin delivery method	Question F2: MDI: 10.9 (SD 2.4), CSII: 10.9 (SD 2.8)	t-test		NK	N
														Age	F2: 0.21	Pearson correlation	<0.05	Y	
														Duration of diabetes	F2: -0.162	Pearson correlation	<0.05	Y	
														HbA1c	F2: 0.266	Pearson correlation	<0.01	Y	
<i>Eating patterns in adolescents with type 1 diabetes: Associations with metabolic control, insulin omission, and eating disorder pathology.</i>	Wisting	NK	Norway	Outpatient	15.7 (SD 1.8, range 12-15.6)	12.5.6 years (SD 3.6)	Prospective	Cross-sectional	104	Y	Secondary	NK	Child Eating Disorder Examination v. 12.0 (ChEDE), in which insulin omission is assessed.	Frequency of breakfast	-0.369	chi-squared	<0.01	Y	
														Frequency of mid-morning snack	-0.095	NK		NK	N
														Frequency of lunch	-0.127	NK		NK	N
														Frequency of mid-afternoon	-0.019	NK		NK	N
														Frequency of dinner	-0.28	chi-squared	<0.05	Y	
														Frequency of evening snack	0.01	NK		NK	N
														Total meals	-0.332	chi-squared	<0.01	Y	
<i>Effects of a behavioral intervention on treatment adherence and stress management in adolescents with IDDM</i>	Mendez	1997	Spain	Outpatient	13.36 (SD 1.89; control group), 13.83 (SD 2; experimental group)	4.46 (SD 3.52; control), 3.73 (SD 3.93; experimental)	Prospective	RCT	37	Y	Primary	13 months	Barriers to adherence questionnaire	Control group	Mean score of 13 at pre-test, post-test and follow up	NK		0	Y
														Intervention group	Mean score of 14 at pre-test, post-test and follow up	NK		0	Y



Study Title	Lead Author	Year	Country	Setting (dropdown of inpatient, outpatient, intensive care, primary care, healthy participants)	Mean Age of Participants (include range or SD if given)	Mean duration of diabetes at start of study	Prospective, Retrospective, not known	Study Design (RCT, Cohort, Case Control, Case report)	Sample	Adherence to insulin therapy assessed (Y/N)	Primary, secondary outcome or not known	Over what time did they assess the patients' adherence (days/weeks/months)	How did they measure adherence?	Factor assessed for association with adherence (please list all captured by study team). Please use a new row for each variable tested for association with adherence	Effect on adherence - how did each factor alter the use of insulin (numerical)	Statistical test	P value	Statistically significant (Y/N)
<i>Empirical validation for a family-centered model of care</i>	Hanson	1995	USA	Outpatient	15.2 (range 12-20)	6.1 years (range 0.83	Prospective	Cross-sectional	157	Y	Primary	NK	Interviews	Age	-0.44	chi-squared	<0.0001	Y
														Duration of diabetes	-0.38	chi-squared	<0.0001	Y
														HbA1c	-0.3	chi-squared	<0.0001	Y
														Youth report on family cohesion	0.36	chi-squared	<0.0001	Y
														Maternal report on family	0.24	chi-squared	<0.0001	Y
														Youth report on family conflict	-0.3	chi-squared	<0.0001	Y
														Maternal report on conflict	-0.09	chi-squared	NK	N
														Youth report on family life stress	-0.09	chi-squared	NK	N
Maternal report on family life	-0.24	chi-squared	<0.0001	Y														
<i>Engagement with a Text-Messaging Intervention Improves Adherence in Adolescents with Type 1 Diabetes: Brief Report.</i>	Zhang	2018	NK	Outpatient	14.7 (SD 1.3, range 13	5.83 years (SD 3.4, range 1-14)	Prospective	Cohort study	48	Y	Secondary	8 weeks	Self-Care Inventory	Education group vs positive affect (PA) text message group	NK (insignificant)	NK	NK	N
														Low engagement with text	NK (insignificant)	NK	NK	N
														Good engagement with text message	NK (insignificant)	NK	NK	N
														High engagement with text	F = 8.75	NK	0.008	Y
<i>Environmental factors affecting management of type 1 diabetes in children below the age of 10.</i>	Piechowiak	2017	Poland	Outpatient	Group A: 6.8 (SD 2), group B: 7.5 (SD 1.7)	Group A: 3 years (SD 1.8 years), group B: 3.4 years (SD 2.2 years)	Prospective	Cross-sectional	165	N	N/A	N/A	Questionnaire to look for factors that could potentially affect it.	Lack of time	A: 26%, B: 18%	N/A	>0.05	N
														Poor material conditions	A: 20%, B: 28%	N/A	>0.05	N
														Fear of hypoglycaemia	A: 50%, B: 39%	N/A	>0.05	N
														Counting exchanges difficulties	A: 15%, B: 7%	N/A	>0.05	N
														Stress related pain	A: 36%, B: 39%	N/A	>0.05	N
														Frequent blood monitoring	A: 24%, B: 25%	N/A	>0.05	N
														Shame of diabetes	A: 6%, B: 3.5%	N/A	>0.05	N
														Snacking without parents	A: 17%, B: 43%	N/A	0.0008	Y
														Diabetes misunderstanding	A: 23%, B: 36%	N/A	>0.05	N
														Frequent infections	A: 24%, B: 23%	N/A	>0.05	N
														Estimation of food difficulties	A: 23%, B: 28%	N/A	>0.05	N
														Eating many meals	A: 18%, B: 28%	N/A	>0.05	N
														Taking care of other children	A: 17%, B: 16%	N/A	>0.05	N
Parents' tiredness	A: 50%, B: 55%	N/A	>0.05	N														
Problems with care at kindergarten/school	A: 32%, B: 37%	N/A	>0.05	N														
<i>Executive functioning, parenting stress, and family factors as predictors of diabetes management in pediatric patients with type 1 diabetes using intensive regimens</i>	Smith	2014	USA	Outpatient	13.6 (SD 3.1)	4.8 years (SD 3.2 years)	Prospective	Cross-sectional	NK	Y	Primary	NK	Diabetes Self-Management Profile (Harris et al., 2000)	Single parent household vs both parents	-2.38 (worse adherence in single-parent households; child report)	t-test	0.03	Y
														Duration of diabetes	-0.42 (parent report)	pearson	<0.001	Y
														Child's executive functioning	-0.274 (child report)	beta	0.007	Y
														Parenting stress	-0.191 (parent report)	beta	0.07	N
															-2.96 (parent report; PIP-F)	t-test	0.004	Y
<i>Father-absent adolescents with insulin-dependent diabetes mellitus: A population at risk?</i>	Hanson	1988	USA	Outpatient	14.4	5.4 years	Prospective	Cross-sectional	60	Y	Primary	NK	Interviews	Father-absent vs father-present	5.75 (better adherence in father-absent adolescents)	ANOVA	0.02	Y
<i>Health-risk behaviors and type 1 diabetes outcomes in the transition from late adolescence to early emerging adulthood</i>	Lee Tracy	2019	USA	Outpatient	NK (range 17-18)	7.35 years (SD 3.88 years)	Prospective	Cohort study	197	Y	Primary	2 years	Questionnaire (single question about frequency of insulin withholding, 1-5 Likert-type scale and Diabetes Behaviour Rating Scale)	Smoking frequency	-0.08	Multilevel modelling	0.004	Y
														Alcohol consumption frequency	NK (insignificant)	Multilevel modelling	NK	N
														Insulin withholding frequency	-0.03	Multilevel modelling	<0.001 within persons, 0.002 between	Y

Study Title	Lead Author	Year	Country	Setting (dropdown of inpatient, outpatient, intensive care, primary care, healthy participants)	Mean Age of Participants (include range or SD if given)	Mean duration of diabetes at start of study	Prospective, Retrospective, not known	Study Design (RCT, Cohort, Case Control, Case report)	Sample	Adherence to insulin therapy assessed (Y/N)	Primary, secondary outcome or not known	Over what time did they assess the patients' adherence (days/weeks/months)	How did they measure adherence?	Factor assessed for association with adherence (please list all captured by study team). Please use a new row for each variable tested for association with adherence	Effect on adherence - how did each factor alter the use of insulin (numerical)	Statistical test	P value	Statistically significant (Y/N)
<i>Hope and mealtime insulin boluses are associated with depressive symptoms and glycemic control in youth with type 1 diabetes mellitus</i>	Calkins-Smit	2018	USA	Outpatient	13.68 (SD 1.76, range	6.01 (SD 3.11)	Prospective	Cross-sectional	90	Y	Primary	NK	BOLUS scores	Age	-0.27	Pearson correlation	<0.01	Y
														Perceived level of hope	0.26	Pearson correlation	<0.01	Y
														Depression	-0.33	Pearson correlation	<0.001	Y
														HbA1c	-0.4	Pearson correlation	<0.001	Y
<i>I get by with a little help from my family and friends: Adolescents' support for diabetes care</i>	La Greca	1995	USA	Outpatient	14.2 (SD 2.3, range 11	5.2 years (SD 3.5 years, range 0.5-14 years)	Prospective	Cross-sectional	74	Y	Secondary	NK	Interview (developed by Hanson et al., 1992)	Support from family	0.37	chi-squared	<0.01	Y
														Support from friends	0.05	chi-squared	>0.05	N
														Age	-0.24	chi-squared	<0.05	Y
														Gender	NK (insignificant)	chi-squared	>0.05	N
														Duration of diabetes	NK (insignificant)	chi-squared	>0.05	N
														Identity	-0.24	Pearson correlation	NK	N
														Timeline	0.18	Pearson correlation	NK	N
														Consequences	-0.12	Pearson correlation	NK	N
													Self-report questionnaire based on the Reported Adherence to Medication Scale, Horne et al., 1999)	Cure-control	0.41	Pearson correlation	<0.001	Y
<i>Illness perceptions and self efficacy beliefs in adolescents and young adults with insulin dependent diabetes mellitus</i>	Griva	2000	UK	Outpatient	20.6 (SD 3.29; total sample, comprised of 26 adolescents, mean age 17.19, SD 1.12)	7.91 years (SD 4.67 years; total sample), 7.62 years (SD 4.36 years; adolescents)	Prospective	Cross-sectional	64	Y	Primary	NK		Diabetes self-efficacy	-0.25	Pearson correlation	NK	N
														General self-efficacy	0.21	Pearson correlation	NK	N
														HbA1c	-0.26	pearson correlation	<0.01	Y

Study Title	Lead Author	Year	Country	Setting (dropdown of inpatient, outpatient, intensive care, primary care, healthy participants)	Mean Age of Participants (include range or SD if given)	Mean duration of diabetes at start of study	Prospective, Retrospective, not known	Study Design (RCT, Cohort, Case report)	Sample (Y/N)	Adherence to insulin therapy assessed	Primary, secondary outcome or not known	Over what time did they assess the patients' adherence (days/weeks/months)	How did they measure adherence?	Factor assessed for association with adherence (please list all captured by study team). Please use a new row for each variable tested for association with adherence	Effect on adherence - how did each factor alter the use of insulin (numerical)	Statistical test	P value	Statistically significant (Y/N)
<i>Illness representations predict adherence in adolescents and young adults with type 1 diabetes</i>	McGrady	2014	USA	Outpatient	17.45 (range 15-20, SD 1.8)	8.16 years (SD 3.86)	Prospective	Cohort study	105	Y	Primary	3 months (two cross-sectional surveys)	Self-Care Inventory	Treatment effectiveness: control	T1: 0.12, T2: 0.15	Multivariate hierarchical regression	Both >0.05	N
														Treatment effectiveness: prevent	T1: 0.08, T2: 0.24	Multivariate hierarchical regression	T1: >0.05, T2: <0.05	T1: N, T2: Y
														Perceived impact	T1: 0.01, T2: -0.03	Multivariate hierarchical regression	Both >0.05	N
														Perceived threat	T1: -0.22, T2: -0.16	Multivariate hierarchical regression	T1: <0.05, T2: >0.05	T1: Y, T2: N
														BGM frequency T1	T1: 0.26, T2: 0.25	Multivariate hierarchical regression	Both <0.05	Y
														BGM frequency T2	T1: 0.21, T2: 0.27	Multivariate hierarchical regression	Both <0.05	Y
														SCI: BGM T1	T1: 0.49, T2: 0.35	Multivariate hierarchical regression	Both <0.01	Y
														SCI: BGM T2	T1: 0.3, T2: 0.55	Multivariate hierarchical regression	Both <0.01	Y
														SCI: exercise T1	T1: 0.33, T2: 0.11	Multivariate hierarchical regression	T1: <0.01, T2: >0.05	T1: Y, T2: N
														SCI: exercise T2	T1: -0.04, T2: 0.17	Multivariate hierarchical regression	Both >0.05	N
														SCI: emergency precautions T1	T1: 0.23, T2: 0.12	Multivariate hierarchical regression	T1: <0.05, T2: >0.05	T1: Y, T2: N
														SCI: emergency precautions T2	T1: 0.26, T2: 0.33	Multivariate hierarchical regression	<0.01	Y
														HbA1c T1	T1: -0.28, T2: -0.32	Multivariate hierarchical regression	Both <0.01	Y
														HbA1c T2	T1: -0.16, T2: -0.48	Multivariate hierarchical regression	T1: <0.05, T2: <0.01	T1: N, T2: Y
<i>Impact of family environment and support on adherence, metabolic control, and quality of life in adolescents with diabetes.</i>	Pereira	2008	Portugal	Outpatient	15 (range 10-18, SD 2.6)	6.4 years	Prospective	Cross-sectional	157	Y	Primary	Cross-sectional	Self-Report Questionnaire on Adherence (Almeida & Pereira, 2003)	Age	0.221	Pearson	<0.01	Y
														Duration of diabetes	0.308	Pearson	<0.001	Y
														Social class	3.46 (higher social class better adherence). B=0.178 (lower class)	de Fisher	de Fisher=<0.05, b=<0.05	Y
														Gender	2.52 (males better adherence)	t-test	<0.05	Y
														FES: cohesion	-0.014	Pearson	>0.05	N
														FES: conflict	0.053	Pearson	>0.05	N
														FES: Organisation	0.053	Pearson	>0.05	N
														Family Social Support (FSS)	0.245	Pearson	<0.01	Y
														FSS: affective	0.234	Pearson	<0.01	Y
														FSS: indirect	0.144	Pearson	>0.05	N
														FSS: control	0.148	Pearson	>0.05	N
FSS: no support	-0.095	Pearson	>0.05	N														

Study Title	Lead Author	Year	Country	Setting (dropdown of inpatient, outpatient, intensive care, primary care, healthy participants)	Mean Age of Participants (include range or SD if given)	Mean duration of diabetes at start of study	Prospective, Retrospective, not known	Study Design (RCT, Cohort, Case Control, Case report)	Sample (Y/N)	Adherence to insulin therapy assessed (Y/N)	Primary, secondary outcome or not known	Over what time did they assess the patients' adherence (days/weeks/months)	How did they measure adherence?	Factor assessed for association with adherence (please list all captured by study team). Please use a new row for each variable tested for association with adherence	Effect on adherence - how did each factor alter the use of insulin (numerical)	Statistical test	P value	Statistically significant (Y/N)
<i>Insulin bolusing software: The potential to optimize health outcomes in type 1 diabetes mellitus</i>	Driscoll	2013	USA	Outpatient	13.11 (range 7-19, SD 1.37-12.4 years, SD 3.21 years)	6.16 years (range 1.37-12.4 years, SD 3.21 years)	Prospective	Cross-sectional	31	Y	Primary	Previous 10-319 days (mean 102.52)	Downloaded data from insulin pump (hence hugely variable assessment range)	HbA1c	Bolus: -0.37, carbs: -0.34	pearson	Bolus: <0.05, carbs: <0.058	Bolus: Y, carbs: N (marginal)
														Age	Bolus: -0.46, carbs: -0.46	pearson	Bolus: <0.01, carbs: <0.05	Both Y
														Maternal Depression at T1	P report T1: -0.06. C report T1: -0.04. P report T2: -0.09. C report T2: -0.15.	Multiple regression analysis	All >0.05	All N
														Maternal Depression at T2	P report T1: -0.04. C report T1: 0.01. P report T2: -0.29. C report T2: -0.12.	Multiple regression analysis	P report T2: <0.01. Rest >0.05.	P report T2: Rest N.
														Maternal Involvement at T1: Mother's report	P report T1: 0.03. C report T1: 0.01. P report T2: 0.17. C report T2: -0.06.	Multiple regression analysis	All >0.05	All N
														Maternal Involvement at T1: child's report	P report T1: 0.09. C report T1: 0.05. P report T2: 0.18. C report T2: 0.04.	Multiple regression analysis	All >0.05	All N
														Maternal Involvement at T2: Mother's report	P report T1: 0.14. C report T1: 0.12. P report T2: 0.14. C report T2: 0.07.	Multiple regression analysis	All >0.05	All N
<i>Longitudinal associations of maternal depressive symptoms, maternal involvement, and diabetes management across adolescence.</i>	Wiebe	2011	USA	Outpatient	12.79 (SD 1.7, range 10-15.99)	5.4 years	Prospective	Cohort study	82	Y	Primary	Previous 2 weeks (T2 16 months after T1)	Self Care Inventory (La Greca, 1994, 2004)	Age	P report T1: 0.27. C report T1: 0.19. P report T2: 0.27. C report T2: 0.11.	Multiple regression analysis	C report T2: >0.05. Rest <0.1	All N; P report T1/T2 and C report T1 marginal.
														Age	P report T1: -0.28. C report T1: -0.17. P report T2: -0.23. C report T2: -0.05.	Multiple regression analysis	P report T1: <0.01. P report T2: <0.05. Both C report >0.05	P reports: Y. reports: N.

Study Title	Lead Author	Year	Country	Setting (dropdown of inpatient, outpatient, intensive care, primary care, healthy participants)	Mean Age of Participants (include range or SD if given)	Mean duration of diabetes at start of study	Prospective, Retrospective, not known	Study Design (RCT, Cohort, Case Control, Case report)	Sample (Y/N)	Adherence to insulin therapy assessed	Primary, secondary outcome or not known	Over what time did they assess the patients' adherence (days/weeks/months)	How did they measure adherence?	Factor assessed for association with adherence (please list all captured by study team). Please use a new row for each variable tested for association with adherence	Effect on adherence - how did each factor alter the use of insulin (numerical)	Statistical test	P value	Statistically significant (Y/N)
<i>Model of associations between psychosocial variables and health-outcome measures of adolescents with IDDM</i>	Hanson	1987	USA	Outpatient	14.4 (SD 2.45)	NK	Prospective	Cross-sectional	93	Y	Primary	Cross-sectional	Self-report and observation (Cerkoney and Hart and Schlenk and Hart)	HbA1c	-0.3	Pearson	<0.01	Y
														Chronic stress	r=-0.11, b=-0.033	Multiple regression analysis & pearson	>0.05	N
														Social competence	r=0.25, b=-0.067	Multiple regression analysis & pearson	r=<0.01, b=>0.05	r=Y, b=N
														Family relations	r=0.32, b=0.194	Multiple regression analysis & pearson	r=<0.001, b=>0.05	r=Y, b=N
														Diabetes knowledge	r=0.28, b=0.227	Multiple regression analysis & pearson	r=<0.01, b=>0.05	r=Y, b=N
Age	r=-0.21, b=-0.182	MRA and Pearson	r=<0.05, b=>0.05	r=Y, b=N														
<i>Parent and child perceptions of the management of juvenile diabetes</i>	Allen	1983	USA	Outpatient	11.2 (SD 2.6, range 8-	NK	Prospective	Cross-sectional	34	Y	Primary	Cross-sectional	Rated by two members of clinic staff (5-point Likert-like scale)	Child's responsibility	0.32	NK	0.038	Y
														Glycaemic control	0.28	NK	0.056	N (marginal)
														Personality traits: stubborn, lazy, careless	38.20%	N/A	N/A	N/A
														Physical reasons: feels bad, disease is responsible	17.60%	N/A	N/A	N/A
														Denial: wants to be like others, doesn't admit to being diabetic	26.50%	N/A	N/A	N/A
														Hedonism: Hungry or not hungry, concerned about weight, too much bother	35.30%	N/A	N/A	N/A
														Interpersonal reasons: peer pressure, rebelling against	17.60%	N/A	N/A	N/A

Study Title	Lead Author	Year	Country	Setting (dropdown of inpatient, outpatient, intensive care, primary care, healthy participants)	Mean Age of Participants (include range or SD if given)	Mean duration of diabetes at start of study	Prospective, Retrospective, not known	Study Design (RCT, Cohort, Case report)	Sample (Y/N)	Adherence to insulin therapy assessed (Y/N)	Primary, secondary outcome or not known	Over what time did they assess the patients' adherence (days/weeks/months)	How did they measure adherence?	Factor assessed for association with adherence (please list all captured by study team). Please use a new row for each variable tested for association with adherence	Effect on adherence - how did each factor alter the use of insulin (numerical)	Statistical test	P value	Statistically significant (Y/N)	
														Age	P report: -0.3, C report: -0.28, N (nurse) report: -0.33	Zero order correlations	All <0.01	Y	
															C report: worse adherence in mid-puberty vs pre/post; F(1, 82) = 6.4	Zero order correlations	<0.05	Y	
															Mother's report: worse adherence with advanced pubertal maturation; F(1, 37) = 4.9	Zero order correlations	<0.05	Y	
															Girl's report: worse adherence in mid-puberty;	Zero order correlations	<0.05	Y	
															Lower SES related to poorer adherence; no numerical figure given	NK	NK	NK	
															HbA1c	-0.22	Zero order	>0.05	N
															Parent report of general	0.29	Zero order	>0.05	N
															Child report of general	0.25	Zero order	>0.05	N
															Nurse report of general	0.18	Zero order	>0.05	N
															Self-report on adherence to BGM	0.24	Zero order	>0.05	N
															Self-report on adherence to	-0.27	Zero order	>0.05	N
															Self-report on adherence to	0.11	Zero order	>0.05	N
															Public hospital sample: r= P: 0.21, C: 0.08, N: 0.01. b=P: 0.08, C: -0.17, N: -0.22.	Zero order correlations	>0.05	N	
															Private hospital sample: r=P: 0.05, C: 0.15, N: -0.12. b=P: -0.02, C: 0.12, N: -0.07.	Zero order correlations	>0.05	N	
															Parent rating: discipline		r=P and N: <0.05, C: <0.01, b=>0.05.	>0.05	All Y
															Public: r=P: 0.32, C: 0.4, N: 0.35 b=P: 0.17, C: 0.22, N: 0.23 Private: r=P: 0.05, C: 0.15, N: -0.12. b=P: 0.12, C: 0.03, N: -0.03.	Zero order correlations	>0.05	N	
															Parent rating: behavioural support		r=P: <0.05, C: <0.001, N: <0.01. b=C:<0.05, P and N: >0.05	>0.05	All Y
															Public: r=P: 0.55, C: 0.48, N: 0.35. b=P: 0.35, C: 0.36, N: 0.29. Private: r=P: 0.2, C: 0.13, N: -0.17. b=P: 0.11, C: 0.08, N: -0.14.	Zero order correlations	>0.05	N	
															Parent rating: warmth		P: =<0.001, C: >0.05, N: <0.05	>0.05	P and N: Y, C N
															Public: r=P: -0.59, C: -0.25, N: -0.3. b=P: -0.54, C: -0.22, N: -0.3. Private: r=P: -0.32, C: -0.02, N: -0.09. b=P: 0.34, C: -0.01, N: -0.09.	Zero order correlations	P: <0.05, C and N: >0.05	>0.05	P: Y, C and N
															Parent rating: conflict		P: <0.05, C and N: >0.05	>0.05	N
															Public: P: 0.23, C: 0.22, N: 0.23. b=P: 0.09, C: 0.14, N: 0.22	Zero order correlations	>0.05	N	
															Private: r=P: 0.03, C: 0.1, N: 0.08. b=P: 0.03, C: 0.13, N: 0.08.	Zero order correlations	>0.05	N	
															Child rating: discipline		P: r and b=<0.001, C: r and b=>0.05, N: r=<0.05, b=>0.05	>0.05	P and N: Y, C N
															Public: r=P: 0.46, C: 0.18, N: 0.32. b=P: 0.55, C: 0.23, N: 0.25	Zero order correlations	>0.05	N	
															Private: r=P: 0.16, C: 0.14, N: 0.15. b=P: 0.27, C: 0.09, N: 0.2.	Zero order correlations	>0.05	N	
															Child rating: behavioural support		r=P: <0.01, C and N: >0.05	>0.05	All Y
															Public: r=P: 0.4, C: 0.35, N: 0.37. b=P: 0.02, C: 0.11, N: 0.22. Private: r=P: 0.03, C: 0.19, N: 0.03. b=P: -0.16, C: 0.05, N: -0.13	Zero order correlations	>0.05	N	
													Asked participants to	Child rating: Warmth		Zero order correlations	>0.05	N	

Study Title	Lead Author	Year	Country	Setting (dropdown of inpatient, outpatient, intensive care, primary care, healthy participants)	Mean Age of Participants (include range or SD if given)	Mean duration of diabetes at start of study	Prospective, Retrospective, not known	Study Design (RCT, Cohort, Case Control, Case report)	Sample (Y/N)	Adherence to insulin therapy assessed	Primary, secondary outcome or not known	Over what time did they assess the patients' adherence (days/weeks/ months)	How did they measure adherence?	Factor assessed for association with adherence (please list all captured by study team). Please use a new row for each variable tested for association with adherence	Effect on adherence - how did each factor alter the use of insulin (numerical)	Statistical test	P value	Statistically significant (Y/N)
<i>Parent-child relationships and the management of insulin-dependent diabetes mellitus</i>	Miller-Johnson	1994	USA	Outpatient	Public hospital group: 13 (SD 2.6, range 8-18). Private hospital: 13 (SD 2.9, range 8-18)	NK	Prospective	Cross-sectional	88	Y	Primary	7 days	fill out a list of care tasks and the time of day that they completed them; this was then scored against the expected times, as rated by a nurse	Child rating: conflict	Public: r=P: -0.37, C: -0.5, N: -0.19. b=P: -0.5, C: -0.52, N: -0.25 Private: P: -0.15, C: -0.25, N: -0.06. b=P: -0.22, C: -0.31, N: -0.13.	Zero order correlations	P: r=<0.01, b=<0.001, C: r and b=<0.001, N: r and b=>0.05.	P and C: Y, N
														Acceptance	Male: 0.29 Female: 0.34	Bootstrapped standard errors	<0.01	Y
<i>Parental involvement and adolescents' diabetes management: the mediating role of self-efficacy and externalizing and internalizing behaviors.</i>	Berg	2011	USA	Primary Care	12.49 (SD 1.53)	4.13 years (SD 3 year)	Prospective	Cross-sectional	252	Y	Secondary	Preceding month	Self-Care Inventory (La Greca et al., 1995) and Self-Efficacy for Diabetes Self-Management Scale (SEDMS; Ianotti, 2009)	Independence and encouragement	Male: 0.27 Female: 0.28	Bootstrapped standard errors	<0.01	Y
														Communication	Male: 0.27 Female: 0.25	Bootstrapped standard errors	<0.01	Y
														Intrusive support	Male: 0.1 Female: 0.14	Bootstrapped standard errors	>0.05	N
														Frequency of help	Male: 0.04 Female: 0.12	Bootstrapped standard errors	>0.05	N
														General monitoring	Male: 0.46 Female: 0.26	Bootstrapped standard errors	<0.01	Y
														Externalising behaviour	Male: 0.38	Bootstrapped standard errors	<0.01	Y
														Internalising behaviour	-0.24 -0.11	Bootstrapped standard errors	<0.01	Y
														Self-efficacy	0.4	Bootstrapped standard errors	<0.01	Y
														HbA1c	-0.31	Bootstrapped standard errors	<0.01	Y
														HbA1c	-0.41	NK	<0.001	Y
														Pubertal stage	-0.2	NK	>0.05	N
														Duration of diabetes	0.08	NK	>0.05	N
														Self-efficacy	0.64	NK	<0.001	Y
														Frequency of conflict	0.07	NK	>0.05	N
Intensity of conflict	0.01	NK	>0.05	N														
Authoritarian family function	0.17	NK	>0.05	N														
Locus of control: powerful others	0.18	NK	>0.05	N														
Locus of control: chance	-0.06	NK	>0.05	N														
Locus of control: internal	0.17	NK	>0.05	N														
<i>Pathways from emotional adjustment to glycaemic control in youths with diabetes in Hong Kong</i>	Stewart	2000	Hong Kong	Outpatient	15.08 (diabetic patients) 15.17 (controls), range 9-21	6.67 years (SD 4.04 years, range 1-17 years)	Prospective	Case-control	70	Y	Primary	NK	Questionnaire constructed based upon Littlefield et al., 1992	Emotional adjustment	-0.28	NK	<0.05	Y
														Gender	-0.26	Multiple regression analysis	>0.05	N

Study Title	Lead Author	Year	Country	Setting (dropdown of inpatient, outpatient, intensive care, primary care, healthy participants)	Mean Age of Participants (include range or SD if given)	Mean duration of diabetes at start of study	Prospective, Retrospective, not known	Study Design (RCT, Cohort, Case Control)	Sample (Y/N)	Adherence to insulin therapy assessed	Primary, secondary outcome or not known	Over what time did they assess the patients' adherence (days/weeks/months)	How did they measure adherence?	Factor assessed for association with adherence (please list all captured by study team). Please use a new row for each variable tested for association with adherence	Effect on adherence - how did each factor alter the use of insulin (numerical)	Statistical test	P value	Statistically significant (Y/N)
Personality traits as predictors of adherence in adolescents with type 1 diabetes	Wheeler	2012	USA	Outpatient	NK (range 13-18)	NK	Prospective	Cohort study	28	Y	Primary	Previous 6 months	Questionnaire	Neuroticism	-0.505 Domain level	<0.01	Y	
														Extraversion	0.151 Domain level	>0.01	N	
														Openness to experience	0.051 Domain level	>0.01	N	
														Agreeableness	0.46 Domain level	>0.01	N	
														Conscientiousness	0.488 Domain level	<0.01	Y	
														N1: anxiety	-0.441 Facet level correlation	>0.01	N	
														N2: anger	-0.542 Facet level correlation	<0.01	Y	
														N3: depression	-0.498 Facet level correlation	<0.01	Y	
														N4 self-consciousness	-0.133 Facet level correlation	>0.01	N	
														N5: impulsiveness	-0.348 Facet level correlation	>0.01	N	
														N6 vulnerability	-0.378 Facet level correlation	>0.01	N	
														E1: friendliness	0.263 Facet level correlation	>0.01	N	
														E2: gregariousness	0.072 Facet level correlation	>0.01	N	
														E3: assertiveness	0.09 Facet level correlation	>0.01	N	
														E4: activity level	0.33 Facet level correlation	>0.01	N	
														E5: excitement seeking	-0.146 Facet level correlation	>0.01	N	
														E6: cheerfulness	0.156 Facet level correlation	>0.01	N	
														O1: Imagination	-0.183 Facet level correlation	>0.01	N	
														O2: artistic interests	0.009 Facet level correlation	>0.01	N	
														O3: emotionality	0.128 Facet level correlation	>0.01	N	
														O4: adventurousness	0.089 Facet level correlation	>0.01	N	
														O5: intellect	0.005 Facet level correlation	>0.01	N	
														O6: liberalism	0.21 Facet level correlation	>0.01	N	
														A1: trust	0.382 Facet level correlation	>0.01	N	
														A2: morality	0.603 Facet level correlation	<0.01	Y	
														A3: altruism	0.225 Facet level correlation	>0.01	N	
														A4: co-operation	0.324 Facet level correlation	>0.01	N	
A5: modesty	0.13 Facet level correlation	>0.01	N															
A6: sympathy	0.205 Facet level correlation	>0.01	N															
C1: self-efficacy	0.48 Facet level correlation	<0.01	Y															
C2: orderliness	-0.018 Facet level correlation	>0.01	N															
C3: dutifulness	0.419 Facet level correlation	>0.01	N															
C4: achievement striving	0.382 Facet level correlation	>0.01	N															
C5: self-discipline	0.482 Facet level correlation	<0.01	Y															
C6: cautiousness	0.517 Facet level correlation	<0.01	Y															
Poor adherence to integral daily tasks limits the efficacy of CSII in youth	O'Connell	2011	Australia	Outpatient	13.6 (SD 3.2)	6.1 years (SD 3.1)	Retrospective	Cross-sectional	100	Y	Primary	Previous 14 days	Downloaded data from insulin pump	Age	-0.22 bolus events per day with per year of age.	logistic regression	0.001	Y
Predictors of good adherence of adolescents with diabetes (insulin-dependent diabetes)														Feel that diabetes affects their mental wellbeing	7.68 times more likely to be adherent than those who didn't	chi-squared	0.0001	Y
														Feel that they have support from their physician	6.69 times more likely to be adherent than those who didn't	chi-squared	0.0008	Y
														Feel that they have support from nurses	6.28 times more likely to be adherent than those who didn't	chi-squared	0.0006	Y
														Have good motivation	5.52 times more likely to be adherent than those who didn't	chi-squared	0.0004	Y
														Have energy and willpower	3.69 times more likely to be adherent than those who didn't	chi-squared	0.0007	Y
														Feel that diabetes affects their physical wellbeing	2.95 times more likely to be adherent than those who didn't	chi-squared	0.0032	Y
														1-3 years disease duration vs 3 years + duration	No value given; shorter disease better adherence	NK	<0.0001	Y
														Regularly exercises	90% good adherence, 10% satisfactory	NK	<0.0001	Y
														Doesn't smoke	64% good adherence	NK	<0.0001	Y
														Doesn't consume alcohol	68% good adherence	NK	<0.0001	Y
HbA1c below 7%	56% good adherence	NK	<0.0001	Y														



Study Title	Lead Author	Year	Country	Setting (dropdown of inpatient, outpatient, intensive care, primary care, healthy participants)	Mean Age of Participants (include range or SD if given)	Mean duration of diabetes at start of study	Prospective, Retrospective, not known	Study Design (RCT, Cohort, Case report)	Sample (Y/N)	Adherence to insulin therapy assessed	Primary, secondary outcome or not known	Over what time did they assess the patients' adherence (days/weeks/months)	How did they measure adherence?	Factor assessed for association with adherence (please list all captured by study team). Please use a new row for each variable tested for association with adherence	Effect on adherence - how did each factor alter the use of insulin (numerical)	Statistical test	P value	Statistically significant (Y/N)
<i>mellitus)</i>	Kyngas	2007	Finland	Outpatient	15.1 (SD 1.51)	6.1 years (SD 3.8)	Prospective	Cross-sectional	289	Y	Primary	NK	Questionnaire	HbA1c above 7%	9% good adherence	NK	<0.0001	Y
<i>Prevalence of intentional under- and overdosing of insulin in children and adolescents with type 1 diabetes</i>	Schober	2011	Austria	Outpatient	Ages given as medians. Group A (compliant): 14, group B (non-compliant): 15, group C (management problems): 14, all range 10=21)	Group A: 6.2 (SD 3.9), group B: 6.2 (SD 3.4), group C: 6.1 (SD 3.4)	Prospective	Cross-sectional	241	Y	Primary	NK	Diabetes Self-Management Profile (Harris et al., 2000; German version, translated by the authors)	Age	A: 14 B: 15 C: 14	chi-squared, t and U test	<0.01 (A vs Y) N/A N/A	N/A Y N/A
														Age at disease onset	A: 8.3 B: 9.5 C: 8.6	chi-squared, t and U test	N/A <0.05 (A vs Y) <0.05 (B vs Y)	N/A Y Y
														Duration of diabetes	A: 6.2 B: 6.2 C: 6.1	chi-squared, t and U test	N/A N/A N/A	N/A N/A N/A
														Gender	A: 56% boys B: 22% boys C: 25% boys	chi-squared, t and U test	<0.01 (A vs Y) <0.05 (A vs Y)	Y N N
														BMI SDS	A: -0.19 B: +0.18 C: -0.06	Bonferroni correction	>0.05 >0.05 >0.05	N N N
														HbA1c	A: 7.8 B: 8.7 C: 7.8	Bonferroni correction	N/A <0.01 (A vs Y) >0.05	N/A Y N
														CIT insulin regimen	A: 5% B: 1%	chi-squared, t and U test	0.1	N
														FIT insulin regimen	A: 64% B: 51%	chi-squared, t and U test	0.23	N
														CSII insulin regimen	A: 29% B: 15%	chi-squared, t and U test	<0.05	Y
														Unknown regimen	A: 5% B: 4%	chi-squared, t and U test	0.6	N
														0-9 months post-follow up	mean compliance: 3.3 (SD 10-18 months post-follow up mean compliance: 3 (SD 0.5)	ANOVA	<0.005	Y
														Compliance in the first 9 months' association with compliance in the second 9 months	0.53-0.64	Pearson	<0.001	Y
														Duration of diabetes	NK (insignificant)	Pearson	>0.05	N
														Age	F = 6.57 (increasing age associated with worse adherence)	ANOVA	<0.01	Y
														Self-esteem	0-9 mo: 0.27, 4.77 10-18 mo: 0.36, 12.5	ANOVA	<0.04 <0.0008	Y Y
Perceived competence	0-9 mo: 0.22, 1.12 10-18 mo: 0.3, 6.44	ANOVA	>0.05 <0.04	N Y														
Locus of control	0-9 mo: 0.24, 2.56 10-18 mo: 0.34, 11.28	ANOVA	>0.05 <0.0008	N Y														
Child report of symptoms	0-9 mo: 0.22, 1.07 10-18 mo: 0.32, 10.5	ANOVA	>0.05 <0.005	N Y														
Mother report of symptoms	0-9 mo: 0.3, 8.86 10-18 mo: 0.33, 6.19	ANOVA	<0.005 <0.04	Y Y														
Mother report of social functioning	0-9 mo: 0.45, 10.25 10-18 mo: 0.43, 9.37	ANOVA	<0.005 <0.005	Y Y														
Diabetes adjustment	0-9 mo: 0.24, 2.75 10-18 mo: 0.42, 14.8	ANOVA	>0.05 <0.0008	N Y														
<i>Psychologic predictors of compliance in children with recent onset of diabetes mellitus</i>	Jacobson	1987	USA	Outpatient	12.8 (SD 2.1, range 9-17)	greater: 17.7%	Prospective	Cohort study	57	Y	Primary	18 months	Health-provider ratings	Age	-0.31	Pearson, cronbach's, t	<0.001	Y
														Duration of diabetes	-0.17	Pearson, cronbach's, t	<0.001	Y
														Household income	0.18	Pearson, cronbach's, t	<0.001	Y
														Caregiver education level	0.05	Pearson, cronbach's, t	<0.18	N

Study Title	Lead Author	Year	Country	Setting (dropdown of inpatient, outpatient, intensive care, primary care, healthy participants)	Mean Age of Participants (include range or SD if given)	Mean duration of diabetes at start of study	Prospective, Retrospective, not known	Study Design (RCT, Cohort, Case report)	Sample (Y/N)	Adherence to insulin therapy assessed	Primary, secondary outcome or not known	Over what time did they assess the patients' adherence (days/weeks/months)	How did they measure adherence?	Factor assessed for association with adherence (please list all captured by study team). Please use a new row for each variable tested for association with adherence	Effect on adherence - how did each factor alter the use of insulin (numerical)	Statistical test	P value	Statistically significant (Y/N)
<i>Psychometric evaluation of the adherence in diabetes questionnaire</i>	Kristensen	2012	Denmark	Outpatient	12.3 (SD 3.69)	5.2 years (SD 3.31)	Prospective	Cohort study	1028	Y	Primary	Previous month	Adherence in Diabetes Questionnaire (ADQ)	Two-parent vs single parent household	0.08 (better adherence in two-parent households)	Pearson, cronbach's, t	>0.05	N
														Gender	0.07 (girls better adherence)	Pearson, cronbach's, t	>0.05	N
														CSII vs MDI	0.18 (CSII better adherence)	Pearson, cronbach's, t	>0.05	N
														HbA1c	-0.36 (C report), -0.32 (P report)	Pearson, cronbach's, t	<0.001	Y
<i>Quality of life and glycemic control in adolescents with type 1 diabetes and the impact of an education intervention</i>	Abolfotouh	2011	Egypt	Outpatient	14.63 (SD 2.23, range 12-20)	NK	Prospective	RCT	503	Y	Secondary	Previous month	Questionnaire	QoL (with number of injections per day)	chi-squared value: 6.73	Kruskal-Wallis test	<0.001	Y
														Intervention pre-test: 89.66	Wilcoxon test	<0.001	Y	
														Intervention post-test: 94.4				
														Control pre-test: 63.9	Control post-test: 51.23			
<i>Quality of life of children and adolescents with type 1 diabetes in Kuwait</i>	Abdul-Rasoul	2013	Kuwait	Outpatient	Diabetic group: 9.1 (SD 3.7), control	5.37 (SD 2.8)	Prospective	Case-control	Diabetic	Y	Secondary	NK	Paediatric Quality of Life Inventory (PedsQL)	Gender	Girls' mean score: 76.6 (SD)	t test	<0.05	Y
														Boys' mean score: 69.7 (SD)	NK	<0.001	Y	
														Self-efficacy				0.57
														Depression				-0.5
<i>Relationship of self-efficacy and bingeing to adherence to diabetes regimen among adolescents</i>	Littlefield	1992	Canada	Outpatient	15.3 (range 13-18)	5.8 years (SD 3.9 years)	Prospective	Cross-sectional	193	Y	Primary	Cross-sectional	Questionnaire	Self-esteem	0.45	NK	<0.001	Y
														Bingeing (as in, on food)	-0.36	NK	<0.001	Y
														General insulin adherence: Immigrant vs French Native mother	Immigrant mother score: 3.9 (SD 1.1)	ANOVA	<0.01	Y
														Percentage that adjust insulin dose during illness: Immigrant	French native mother score: 4.6 (SD 1.1)			
<i>Risk factors for poor glycemic control in diabetic children in France</i>	Tubiana-Ruff	1995	France	Outpatient	Median: 10 (range 7-13.7 years)	Median: 2 years (range 0.5-11 years)	Prospective	Cross-sectional	165	Y	Primary	Cross-sectional	Questionnaire (Hanson et al., 1992)	Immigrant mothers: 29.2%	ANOVA	<0.001	Y	
														Native French mother: 62%				
<i>Satisfaction and quality of life with premeal inhaled versus injected insulin in adolescents and adults with type 1 diabetes</i>	Testa	2007	USA and Canada	Outpatient	control group: 14.1 (SD 1.7, range 11-17), inhaled insulin group: 13.8 (SD 1.4, range 12-17)	Control group: 6.1 years (SD 3.5 years, range 1-13.6 years). Inhaled insulin group: 5.5 years (SD 3.5 years, range 1-13.7 years)	Prospective	Cohort study	207	Y	Primary	24 weeks	Questionnaire	Method of insulin delivery barriers to adherence	Inhaled insulin score: 74.2 (SD 1.4) S/C insulin score: 67 (SD 1.6)	Pearson (r) and Spearman (rho)	0.001	Y

Study Title	Lead Author	Year	Country	Setting (dropdown of inpatient, outpatient, intensive care, primary care, healthy participants)	Mean Age of Participants (include range or SD if given)	Mean duration of diabetes at start of study	Prospective, Retrospective, not known	Study Design (RCT, Cohort, Case Control, Case report)	Sample (Y/N)	Adherence to insulin therapy assessed	Primary, secondary outcome or not known	Over what time did they assess the patients' adherence (days/weeks/months)	How did they measure adherence?	Factor assessed for association with adherence (please list all captured by study team). Please use a new row for each variable tested for association with adherence	Effect on adherence - how did each factor alter the use of insulin (numerical)	Statistical test	P value	Statistically significant (Y/N)
<i>Self-efficacy as a mediator variable for adolescents' adherence to treatment for insulin-dependent diabetes mellitus</i>	Ott	2000	USA	Outpatient	13.97 (SD 1.76, range 11-18)	5.63 years (SD 3.73 years, range 1.08-15 years)	Prospective	Cross-sectional	161	Y	Primary	cross-sectional (previous 7 days)	Summary of self-care activities (Schafer et al. 1983)	Age	-0.04	Zero order	>0.05	N
														Illness severity	-0.16	Zero order	>0.05	N
														Duration of diabetes	-0.1	Zero order	>0.05	N
														Self-efficacy	0.21	Zero order	<0.01	Y
Diabetes Family Responsibility Questionnaire	0.19	Zero order correlations	<0.05	Y														
Diabetes Family Behaviour: Supportive subscale	0.36	Zero order correlations	<0.005	Y														
Diabetes Family Behaviour: Nonsupportive subscale	-0.29	Zero order correlations	<0.005	Y														
<i>Sleep duration and its impact on adherence in adolescents with type 1 diabetes mellitus</i>	McDonough	2017	USA	Outpatient	15 (SD 1.6, range 12.4-15.2 years)	6.8 years (SD 3.9 years, range 0.8-15.2 years)	Prospective	Cross-sectional	45	Y	Primary	14 days	Total daily insulin boluses and mealtime BOLUS score	Amount of sleep	Every 1 minute increase/decrease in sleep resulted in 1.2% increase/decrease in the total number of daily boluses/20 minutes per	ANOVA	<0.001	Y
														HbA1c	-0.28	Pearson	<0.001	Y
<i>Social competence and parental support as mediators of the link between stress and metabolic control in adolescents with insulin-dependent diabetes mellitus</i>	Hanson	1987	USA	Outpatient	14.5	NK	Prospective	Cross-sectional	104	Y	Primary	Cross-sectional	Self-report and observation (Cerkoney and Hart, 1980 and Schlenk and Hart, 1984)	Stress	-0.08	Pearson	>0.05	N
														Social competence	0.2	Pearson	<0.05	Y
														Parental support	0.32	Pearson	<0.001	Y

Study Title	Lead Author	Year	Country	Setting (dropdown of inpatient, outpatient, intensive care, primary care, healthy participants)	Mean Age of Participants (include range or SD if given)	Mean duration of diabetes at start of study	Prospective, Retrospective, not known	Study Design (RCT, Cohort, Case Control, Case report)	Sample (Y/N)	Adherence to insulin therapy assessed	Primary, secondary outcome or not known	Over what time did they assess the patients' adherence (days/weeks/months)	How did they measure adherence?	Factor assessed for association with adherence (please list all captured by study team). Please use a new row for each variable tested for association with adherence	Effect on adherence - how did each factor alter the use of insulin (numerical)	Statistical test	P value	Statistically significant (Y/N)	
															CSII: 1.81 different sites used (SD 0.82) MDI: 2.81 different sites used (SD 0.9)		NK	NK	
														CSII vs MDI	t test		NK	NK	
														Age	Pearson	MDI: 0.04 CSII: -0.01	0.7 0.99	N N	
														Time since diagnosis	Pearson	MDI: -0.09 CSII: -0.07	0.37 0.49	N N	
														Parental marital status	t test	MDI: NK CSII: NK	0.26 0.89	N N	
														Parental education level	t test	MDI: NK CSII: NK	0.75 0.06	N N	
														Perceived barriers to site rotation	Pearson	MDI: -0.28 CSII: -0.21	0.01 0.06	Y N	
														New sites would be painful	Chi-squared	MDI: 49% CSII: 64%	NK NK	NK NK	
														Comfort with existing routine	Chi-squared	MDI: 54% CSII: 67%	NK NK	NK NK	
														Age	pearson	-0.34	<0.01	Y	
														Perceived Support Scale for Family Environment Scale (FES): Cohesion	pearson	0.11	>0.05	N	
														Diabetes Social Support Questionnaire: frequency	pearson	0.32	<0.01	Y	
														Diabetes Social Support Questionnaire: individualised	pearson	0.2	>0.05	N	
														Management Behaviours of Adolescents (Harris et al., 2000 and La Greca, 1995)					
														Pre-intervention		score: 36.78 (SD 10.12)			
														Post-intervention		score: 37 (SD 10.26)	Pearson and t test	<0.0001	Y
														Diabetes Adaptation Scale - Parent Form					
														Intervention group vs control group (with general adherence)		Post-test: 0.156 3-month follow-up: 0	ANCOVA	0.697 0.997	N N

Study Title	Lead Author	Year	Country	Setting (dropdown of inpatient, outpatient, intensive care, primary care, healthy participants)	Mean Age of Participants (include range or SD if given)	Mean duration of diabetes at start of study	Prospective, Retrospective, not known	Study Design (RCT, Cohort, Case Control, Case report)	Sample (Y/N)	Adherence to insulin therapy assessed (Y/N)	Primary, secondary outcome or not known	Over what time did they assess the patients' adherence (days/weeks/months)	How did they measure adherence?	Factor assessed for association with adherence (please list all captured by study team). Please use a new row for each variable tested for association with adherence	Effect on adherence - how did each factor alter the use of insulin (numerical)	Statistical test	P value	Statistically significant (Y/N)														
<i>The health belief model and adolescents with insulin-dependent diabetes mellitus</i>	Bond	1992	USA	Outpatient	14.2 (SD 2.3, range 10 years)	5.8 years (SD 3.7 years, range 1-16 years)	Prospective	Cross-sectional	56	Y	Primary	Cross-sectional; previous 24 hours	Diabetes Regimen Compliance Questionnaire (DRCQ; Brownlee-Duffeck et al., 1987), Diabetes Self-Care Activities Summary (DSCQ; McCaul, Glasgow and Shafer, 1987) and 3x Child Compliance Telephone Interviews (CTIs; Johnson et al., 1986)	Age	DSCQ: NK CCTI: -0.28	Hierarchical Hierarchical	>0.05 <0.05	N Y														
														Benefits - costs	DRCQ: 0.17 DSCQ: 0.31	Standardised regression Standardised	>0.05 <0.05	N Y														
															Threat	CCTI: -0.05 DRCQ: -0.08 DSCQ: -0.05	Standardised Standardised Standardised	>0.05 >0.05 >0.05	N N N													
																Cues	DRCQ: 0.2 DSCQ: 0.34 CCTI: 0.36	Standardised regression Standardised Standardised	>0.05 <0.01 <0.01	N Y Y												
														Benefits - costs and threat	DRCQ: -0.38 DSCQ: NK CCTI: NK		Standardised Standardised Standardised	<0.01 >0.05 >0.05	Y N N													
															<i>The impact of mothers' sense of empowerment on the metabolic control of their children with juvenile diabetes</i>	Florian	1998	Israel	Outpatient	15.11 (SD 1.7, range 1 years)	6.6 years (SD 3.6 years, range 2-16 years)	Prospective	Cross-sectional	88	Y	Primary	Cross-sectional; previous month	Self-Care Questionnaire (Glasgow et al., 1987)	Mother's sense of empowerment	0.2	Pearson	<0.05
														Mother's age															-0.07	Pearson	>0.05	N
														Mother's education															0.13	Pearson	>0.05	N
														Economic status															-0.14	Pearson	>0.05	N
														Number of children in family															0.03	Pearson	>0.05	N
Age	-0.16	Pearson	>0.05	N																												
Child's gender	-0.24 (worse adherence in	Pearson	<0.05	Y																												
Diabetes duration	-0.19	Pearson	<0.05	Y																												
HbA1c	-0.25	Pearson	<0.01	Y																												
HbA1c	-0.556	Pearson	<0.01	Y																												
<i>The Interactive Effect of Diabetes Family Conflict and Depression on Insulin Bolusing Behaviors for Youth</i>	Maliszewski	2017	USA	Outpatient	13.64 (SD 1.77)	5.88 years (SD 3.15 years)	Prospective	Cross-sectional	91	Y	Primary	Cross-sectional; variable amount of time downloaded	BOLUS scores	Age	-0.286	Pearson	<0.01	Y														
														Mean daily blood glucose	-0.428	Pearson	<0.01	Y														
														Youth depression	-0.28	Pearson	<0.01	Y														
														Diabetes family conflict (parent report)	-0.293	Pearson	<0.01	Y														
														Diabetes family conflict (child report)	-0.166	Pearson	>0.05	N														
														<i>The relationship between negative communication and body image dissatisfaction in adolescent females with type 1 diabetes mellitus</i>	Kichler	2008	USA	Outpatient	14.1 (SD 1.88, range 1 NK)	NK	Prospective	Cross-sectional	75	Y	Primary	Cross-sectional	Self-Care Inventory (SCI; Greco et al., 1990 and La Greca et al., 1988) and Diabetes Self-Management Profile (DSMP; Haris et al., 2000)	BMI SDS	-0.19	NK	>0.05	N
																												Negative communication	-0.39	NK	<0.01	Y
																												Eating Disorders Inventory - Body Dissatisfaction Scale	-0.43	NK	<0.01	Y
																												Eating Attitudes Test 26	-0.45	NK	<0.01	Y
																												HbA1c	-0.54	NK	<0.01	Y
<i>The role of health beliefs in the regimen adherence and metabolic control of adolescents and adults with diabetes mellitus</i>	Brownlee-Duffeck	1987	USA	Outpatient	18 (SD 2.6, range 13-28.9 years)	NK	Prospective	Cross-sectional	54	Y	Primary	Cross-sectional	Diabetes Regimen Adherence Questionnaire (DRAQ)															Age	r= -0.02, b= -0.58	sr squared	>0.05	N
																												Knowledge	r=0.0, b=0.02	sr squared	>0.05	N
																												Health Belief Model (HBM): Sever	r=0, b=0.07	sr squared	>0.05	N
																												HBM: Susceptibility	r=0.01, b=-0.29	sr squared	>0.05	Y
																												HBM: costs	r=0.25, b=-1.19	sr squared	<0.0001	N
														HBM: Benefits	r=0.02, b=0.32	sr squared	>0.05	N														
														HBM: cues to action	r=0, b=-0.43	sr squared	>0.05	N														

Study Title	Lead Author	Year	Country	Setting (dropdown of inpatient, outpatient, intensive care, primary care, healthy participants)	Mean Age of Participants (include range or SD if given)	Mean duration of diabetes at start of study	Prospective, Retrospective, not known	Study Design (RCT, Cohort, Case Control, Case report)	Sample (Y/N)	Adherence to insulin therapy assessed	Primary, secondary outcome or not known	Over what time did they assess the patients' adherence (days/weeks/months)	How did they measure adherence?	Factor assessed for association with adherence (please list all captured by study team). Please use a new row for each variable tested for association with adherence	Effect on adherence - how did each factor alter the use of insulin (numerical)	Statistical test	P value	Statistically significant (Y/N)
<i>Type 1 diabetes among adolescents: Reduced diabetes self-care caused by social fear and fear of hypoglycemia</i>	Di Battista	2009	USA and Canada	Outpatient	15.9 (SD 1.44, range 11-19 years)	6.42 years (SD3.63)	Prospective	Cross-sectional	76	Y	Primary	Cross-sectional	Summary of Diabetes Self-Care Activities Questionnaire (SDSCA)	Social anxiety	Boys: -0.39 Girls: 0.21	Pearson	<0.05	Y
														QoL: Satisfaction	Boys: -0.42 Girls: -0.12		Multiple regression analysis	>0.05
														QoL: Impact	Boys: -0.38 Girls: -0.11	Multiple regression analysis	<0.05	Y
														QoL: Social worry	Boys: -0.3 Girls: 0		Multiple regression analysis	>0.05
														QoL: Diabetes worry	Boys: -0.24 Girls: -0.14	Multiple regression analysis	>0.05	N
														Overall QoL	Boys: -0.44 Girls: -0.09		Multiple regression analysis	>0.05
														HFS: Behaviour	Boys: 0.12 Girls: 0.15	Multiple regression analysis	>0.05	N
														HFS: worry/fear	Boys: -0.5 Girls: -0.02		Multiple regression analysis	<0.01
														Total HFS	Boys: -0.38 Girls: 0.04	Multiple regression analysis	<0.05	Y
														<i>Use of Commonly Available Technologies for Diabetes Information and Self-Management Among Adolescents With Type 1 Diabetes and Their Parents: A Web-Based Survey Study.</i>	Vaala	2015	USA	Outpatient
Age	-0.18 beta	<0.05	Y															
Non-white adolescent	-0.13 beta	>0.05	N															
Duration of diabetes	0.08 beta	>0.05	N															
Uses social networking	0.18 beta	<0.05	Y															
Uses diabetes websites	0.15 beta	<0.05	Y															
Uses diabetes apps	0.12 beta	>0.05	N															
Uses text messaging	0.11 beta	>0.05	N															
Uses meter/pump software	0.15 beta	<0.05	Y															
Adolescent diabetes technology index	0.23 beta	<0.01	Y															
<i>Victimization of youth with type-1 diabetes by teachers: relations with adherence and metabolic control</i>	Peters	2008	USA	Outpatient	12.8 (SD 2.5, range 8-17 years)	NK	Prospective	Cross-sectional	167	Y	Primary	Cross-sectional (previous 3-4 months)	Diabetes Self-Management Profile (Harris et al., 2000)	Teacher victimisation	Total sample: -0.135 Age 8-11: -0.343 Age 12-17: -0.112	NK	>0.05	N
														HbA1c	Total sample: -0.159 Age 8-11: -0.072 Age 12-17: -0.154		>0.05	N
														DSMP subscale: exercise	Total sample: 0.245 Age 8-11: 0.234 Age 12-17: 0.219		<0.01	Y
														DSMP hypoglycaemia subscale: diet	Total sample: 0.403 Age 8-11: 0.407 Age 12-17: 0.388	NK	<0.01	Y
														DSMP subscale: hypoglycaemia management	Total sample: 0.154 Age 8-11: 0.061 Age 12-17: 0.185		>0.05	N
														DSMP subscale: glucose testing	Total sample: 0.309 Age 8-11: 0.176 Age 12-17: 0.3		<0.01	Y
														Total DSMP score	Total sample: 0.65 Age 8-11: 0.667 Age 12-17: 0.629	NK	<0.01	Y

Study Title	Lead Author	Year	Country	Setting (dropdown of inpatient, outpatient, intensive care, primary care, healthy participants)	Mean Age of Participants (include range or SD if given)	Mean duration of diabetes at start of study	Prospective, Retrospective, not known	Study Design (RCT, Cohort, Case Control, Case report)	Sample (Y/N)	Adherence to insulin therapy assessed (Y/N)	Primary, secondary outcome or not known	Over what time did they assess the patients' adherence (days/weeks/months)	How did they measure adherence?	Factor assessed for association with adherence (please list all captured by study team). Please use a new row for each variable tested for association with adherence	Effect on adherence - how did each factor alter the use of insulin (numerical)	Statistical test	P value	Statistically significant (Y/N)	
<i>White Coat Adherence in Pediatric Patients with Type 1 Diabetes Who Use Insulin Pumps</i>	Driscoll	2016	USA	Outpatient	13.15 (SD 3.13, range	7.06 years (SD 3.3 years, range 1.22-15.4 years)	Retrospective	Cross-sectional	98	Y	Primary	Previous 2-3 months	Bolus data downloaded from pumps	Boluses delivered day before clinic visit (designed to assess white coat adherence)	Visit 1: -0.06 Visit 2: -0.096	Linear mixed models	<0.0001	Y	
														Age	Visit 1: -0.271 Visit 2: -0.243		<0.01	Y	
														Boluses delivered day before clinic visit x age	Visit 1: 0.0027 Visit 2: 0.005	Linear mixed models	<0.0001	Y	
																	<0.0001	Y	
<i>French version of a scale evaluating adherence to diabetes regimen in children.</i>	Moret	1995	France	Outpatient	10.2(SD1.9, range 7-13)	3.1 (SD 2,7)	Not Known	Cohort study	165	y	primary	1 month	the insulin adjustment score; questionnaire and 1 month after measurement of biological hypoglycemia and hypoglycemic conditions	Hypoglycaemia	-0.23	pearson correlation	<0.01	Y	
														Age	0.28	pearson correlation	<0.001	Y	
														Age at diagnosis	0.18	pearson correlation	<0.05	Y	
	<i>psychological impact of continuous subcutaneous insuline infusion pump therapy in non-selected newly diagnosed insulin dependent (type1) diabetic children: evaluation after two years of therapy</i>	Slijper	1990	The Netherlands	Outpatient	9 (SD 4) CT(conventional injection therapy): 7 (SD 4)	Not Known	Not Known	Cohort study	34	y	primary	follow up for all children was monthly for 2 years	Questionnaire	CSII vs MDI and intelligence	no significant difference for WISC-R or WIPPSI test (intelligence tests)	wilcoxon mann whitney	ns	No
																CSII patients had better compliance	wilcoxon mann whitney	p<0.05	y
<i>Worries and difficulties identified by young puerto ricans with insulin dependent diabetes mellitus; related to metabolic control, despair, social support and depression symptoms (Difficulties in Puerto Rican youth with diabetes)</i>	Jeannette Rossello	2006	Puerto Rico	Outpatient	8-17 years old (mean age 12.29)	NK	Retrospective	Case control	101	y	Primary	Cross-sectional	Questionnaire	Depressive state in children/teen	0.342	Not specified, frequen	p<0.01	y	
														Dispair or lack of hope	0.429	Not specified, frequen	p<0.01	y	
	Diabetes Care in insulin independent patients: Effects of a program to change parents behaviour	Jose Olivares	1997	Spain	Outpatient	parents 32-50 years (mean age 39.529) children 9-12 years	patients divided in 2 groups (experimental	Prospective	cohort/ RCT	36	y	Secondary	8 weeks	Questionnaire	Therapeutic knowledge	F=87.085, TE=2.709	ANCOVA	p=0.000	y
															shared responsibility children-pa	F=139.054, TE=2.837	ANCOVA	p=0.000	y

Study Title	Lead Author	Year	Country	Setting (dropdown of inpatient, outpatient, intensive care, primary care, healthy participants)	Mean Age of Participants (include range or SD if given)	Mean duration of diabetes at start of study	Prospective, Retrospective, not known	Study Design (RCT, Cohort, Case Control, Case report)	Sample (Y/N)	Adherence to insulin therapy assessed	Primary, secondary outcome or not known	Over what time did they assess the patients' adherence (days/weeks/months)	How did they measure adherence?	Factor assessed for association with adherence (please list all captured by study team). Please use a new row for each variable tested for association with adherence	Effect on adherence - how did each factor alter the use of insulin (numerical)	Statistical test	P value	Statistically significant (Y/N)
<i>Algemene ouder-kindrelatie en diabetesgerelateerde ouder-kindrelatie in de adolescentie: Relatie met glykemische controle en de rol van adherence</i> General parent-child relationship and diabetes-related parent-child relationship in adolescence	van Dongen	2005	Netherla	Outpatient	12.7 (SD 1.6, range 10-14)	2 months (SD 36.4 months, range 4-142 months)	Prospective	Cohort study	53	Y	primary	NK	Insulin required of adherence scale (HBGM also assessed; strongly correlated so added together)	Age	-0.4 NK	<0.01	Y	
														Gender	-0.2 NK	>0.05	N	
														Parent-child relationship	CR: 0.49 PR: 0.38	NK	<0.01	Y
														Conflict	CR: -0.38 PR: -0.39	NK	<0.01	Y
														Child is responsible	CR: -0.3 PR: -0.31	NK	<0.05	Y
														Both are responsible	CR: 0.3 PR: 0.32	NK	<0.05	Y
														Parent is responsible	CR: 0.01 PR: 0.01	NK	>0.05	N

Appendix 2 Data extraction tool. Studies below the red line are foreign language studies and were extracted by native speakers.



Title	Author	Year	Introduction				Methods							Results				Discussion		Other		Total responses reducing risk of bias (/20)		
			1) Were the aims/objectives of the study clear?	2) Was the study design appropriate for the stated aim(s)?	3) Was the sample size justified?	4) Was the population clearly defined? (Is it clear who the research was about?)	5) Was the sample frame taken from an appropriate population base so that it closely represented the target/reference population under	6) Was the selection process likely to select subjects/participants that were representative of the target/reference population under	7) Were measures undertaken to address and categorise non-responders?	8) Were the risk factor and outcome variables measured appropriately to the aims of the study?	9) Were the risk factor and outcome variables measured correctly using instruments/measurements that had been trialled, piloted or published	10) Is it clear what was used to determine statistical significance and/or precision estimates? (eg, p values, CIs)	11) Were the methods (including statistical methods) sufficiently described to enable them to be repeated?	12) Were the basic data adequately described?	13) Does the response rate raise concerns about non-response bias?	14) If appropriate, was information about non-responders described?	15) Were the results internally consistent?	16) Were the results for the analyses described in the methods, presented?	17) Were the authors' discussions and conclusions justified by the results?	18) Were the limitations of the study discussed?	19) Were there any funding sources or conflicts of interest that may affect the authors' interpretation of results?		20) Was ethical approval or consent of participants attained?	
<i>Adolescents' health attitudes and adherence to treatment for insulin-dependent diabetes mellitus</i>	Palardy	1998	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	NK	Yes	18	
<i>Association of insulin-manipulation and psychiatric disorders: A systematic epidemiological evaluation of adolescents with type 1 diabetes in Austria</i>	Berger	2019	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	19	
<i>Associations between major life events and adherence, glycemic control, and psychosocial characteristics in teens with type 1 diabetes.</i>	Commist	2018	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	17	
<i>Comparison of usability and patient preference for the new disposable insulin device solostar versus flexpen, lilly disposable pen, and a prototype pen: an open-label study</i>	Haak	2007	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	No	Yes	Yes	Yes	NK	No	NK	Yes	Yes	No	NK	Yes	13	
<i>Compliance of adolescents with diabetes</i>	Kyngas	2000	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	NK	No	Yes	Yes	Yes	Yes	No	NK	NK	14
<i>Coping styles in youths with insulin-dependent diabetes mellitus</i>	Hanson	1989	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	No	NK	Yes	16
<i>Crisis intervention program in newly diagnosed diabetic children.</i>	Galatzer	1982	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	NK	Yes	18
<i>Development and validity testing of the revised diabetes self-care inventory for children and adolescents</i>	Nakamu	2019	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	17	
<i>Eating patterns in adolescents with type 1 diabetes: Associations with metabolic control, insulin omission, and eating disorder pathology.</i>	Wisting	NK	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	19
<i>Empirical validation for a family-centered model of care</i>	Hanson	1995	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	NK	No	Yes	Yes	Yes	Yes	No	NK	Yes	15
<i>Environmental factors affecting management of type 1 diabetes in children below the age of 10.</i>	Piechow	2017	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	NK	No	Yes	Yes	Yes	Yes	No	NK	Yes	15
<i>Executive functioning, parenting stress, and family factors as predictors of diabetes management in pediatric patients with type 1 diabetes using intensive regimens</i>	Smith	2014	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Yes	NK	NK	16

Title	Author	Year	Methods										Results				Discussion		Other		Total responses reducing risk of bias (/20)		
			1) Were the aims/objectives of the study clear?	2) Was the study design appropriate for the stated aim(s)?	3) Was the sample size justified?	4) Was the target/reference population clearly defined? (Is it clear who the research was about?)	5) Was the sample frame taken from an appropriate population base so that it closely represented the target/reference population under	6) Was the selection process likely to select subjects/participants that were representative of the target/reference population under	7) Were measures undertaken to address and categorise non-responders?	8) Were the risk factor and outcome variables measured appropriately to the aims of the study?	9) Were the risk factor and outcome variables measured correctly using instruments/measurements that had been trialled, piloted or published	10) Is it clear what was used to determine statistical significance and/or precision estimates? (eg, p values, CIs)	11) Were the methods (including statistical methods) sufficiently described to enable them to be repeated?	12) Were the basic data adequately described?	13) Does the response rate raise concerns about non-response bias?	14) If appropriate, was information about non-responders described?	15) Were the results internally consistent?	16) Were the results described in the methods, presented?	17) Were the authors' discussions and conclusions justified by the results?	18) Were the limitations of the study discussed?		19) Were there any funding sources or conflicts of interest that may affect the authors' interpretation of results?	20) Was ethical approval or consent of participants attained?
<i>Father-absent adolescents with insulin-dependent diabetes mellitus: A population at risk?</i>	Hanson	1988	Yes	Yes	No	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	No	No	Yes	16
<i>Hope and mealtime insulin boluses are associated with depressive symptoms and glycemic control in youth with type 1 diabetes mellitus</i>	Calkins-	2018	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	No	Yes	18
<i>I get by with a little help from my family and friends: Adolescents' support for diabetes care</i>	La Greca	1995	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	NK	No	Yes	Yes	Yes	Yes	NK	Yes	16
<i>Illness perceptions and self efficacy beliefs in adolescents and young adults with insulin dependent diabetes mellitus</i>	Griva	2000	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	NK	Yes	19
<i>Impact of family environment and support on adherence, metabolic control, and quality of life in adolescents with diabetes.</i>	Pereira	2008	No	NK	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Yes	NK	No	Yes	Yes	Yes	Yes	NK	Yes	13
<i>Insulin bolusing software: The potential to optimize health outcomes in type 1 diabetes mellitus</i>	Driscoll	2013	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	NK	No	NK	Yes	Yes	Yes	No	Yes	16
<i>Model of associations between psychosocial variables and health-outcome measures of adolescents with IDDM</i>	Hanson	1987	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	NK	No	Yes	Yes	Yes	Yes	No	NK	16
<i>Parent and child perceptions of the management of juvenile diabetes</i>	Allen	1983	Yes	Yes	No	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	NK	No	Yes	Yes	Yes	No	NK	NK	13
<i>Parent-child relationships and the management of insulin-dependent diabetes mellitus</i>	Miller-Johnso	1994	No	NK	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	NK	NK	14
<i>Parental involvement and adolescents' diabetes management: the mediating role of self-efficacy and externalizing and internalizing behaviors.</i>	Berg	2011	No	NK	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	No	Yes	17
<i>Personality traits as predictors of adherence in adolescents with type 1 diabetes</i>	Wheeler	2012	Yes	Yes	No	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	NK	No	NK	Yes	Yes	Yes	NK	Yes	14
<i>Poor adherence to integral daily tasks limits the efficacy of CSII in youth</i>	O'Conne	2011	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	NK	No	NK	Yes	Yes	No	No	Yes	15
<i>Predictors of good adherence of adolescents with diabetes (insulin-dependent diabetes mellitus)</i>	Kyngas	2007	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	NK	No	Yes	Yes	Yes	Yes	NK	Yes	16

Title	Author	Year	Introduction			Methods								Results				Discussion		Other		Total responses reducing risk of bias (/20)	
			1) Were the aims/objectives of the study clear?	2) Was the study design appropriate for the stated aim(s)?	3) Was the sample size justified?	4) Was the target/reference population clearly defined? (Is it clear who the research was about?)	5) Was the sample frame taken from an appropriate population base so that it closely represented the target/reference population under	6) Was the selection process likely to select subjects/participants that were representative of the target/reference population under	7) Were measures undertaken and categorised to address non-responders?	8) Were the risk factor and outcome variables measured appropriate to the aims of the study?	9) Were the risk factor and outcome variables measured correctly using instruments/measurements that had been trialled, piloted or published	10) Is it clear what was used to determine statistical significance and/or precision estimates? (eg, p values, CIs)	11) Were the methods (including statistical methods) sufficiently described to enable them to be repeated?	12) Were the basic data adequately described?	13) Does the response rate raise concerns about non-response bias?	14) If appropriate, was information about non-responders described?	15) Were the results internally consistent?	16) Were the results for the analyses described in the methods, presented?	17) Were the authors' conclusions justified by the results?	18) Were the limitations of the study discussed?	19) Were there any funding sources or conflicts of interest that may affect the authors' interpretation of results?		20) Was ethical approval or consent of participants attained?
<i>The relationship between negative communication and body image dissatisfaction in adolescent females with type 1 diabetes mellitus</i>	Kichler	2008	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	NK	No	Yes	Yes	Yes	Yes	NK	Yes	15
<i>The role of health beliefs in the regimen adherence and metabolic control of adolescents and adults with diabetes mellitus</i>	Brownle	1987	No	NK	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	NK	Yes	17
<i>Type 1 diabetes among adolescents: Reduced diabetes self-care caused by social fear and fear of hypoglycemia</i>	Di Battis	2009	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	NK	No	Yes	Yes	Yes	Yes	NK	Yes	16
<i>Use of Commonly Available Technologies for Diabetes Information and Self-Management Among Adolescents With Type 1 Diabetes and Their Parents: A Web-Based Survey Study.</i>	Vaala	2015	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	17
<i>Victimization of youth with type-1 diabetes by teachers: relations with adherence and metabolic</i>	Peters	2008	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	NK	No	Yes	Yes	Yes	Yes	No	Yes	17
<i>White Coat Adherence in Pediatric Patients with Type 1 Diabetes Who Use Insulin Pumps</i>	Driscoll	2016	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	No	No	NK	Yes	Yes	Yes	No	Yes	17

Title	Author	Year	Introduction			Methods							Results				Discussion		Other		Total responses reducing risk of bias (/20)		
			1) Were the aims/objectives of the study clear?	2) Was the study design appropriate for the stated aim(s)?	3) Was the sample size justified?	4) Was the target/reference population clearly defined? (Is it clear who the research was about?)	5) Was the sample frame taken from an appropriate population base so that it closely represented the target/reference population under	6) Was the selection process likely to select subjects/participants that were representative of the target/reference population under	7) Were measures undertaken to address and categorise non-responders?	8) Were the risk factor and outcome variables measured appropriate to the aims of the study?	9) Were the risk factor and outcome variables measured correctly using instruments/measurements that had been trialled, piloted or published	10) Is it clear what was used to determine statistical significance and/or precision estimates? (eg, p values, CIs)	11) Were the methods (including statistical methods) sufficiently described to enable them to be repeated?	12) Were the basic data adequately described?	13) Does the response rate raise concerns about non-response bias?	14) If appropriate, was information about non-responders described?	15) Were the results internally consistent?	16) Were the results for the analyses described in the methods, presented?	17) Were the authors' discussions and conclusions justified by the results?	18) Were the limitations of the study discussed?		19) Were there any funding sources or conflicts of interest that may affect the authors' interpretation of results?	20) Was ethical approval or consent of participants attained?
<i>Prevalence of intentional under- and overdosing of insulin in children and adolescents with type 1 diabetes</i>	Schober	2011	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	NK	No	NK	Yes	Yes	Yes	NK	Yes	15
<i>Psychometric evaluation of the adherence in diabetes questionnaire</i>	Kristens	2012	No	NK	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Yes		18
<i>Relationship of self-efficacy and binge to adherence to diabetes regimen among adolescents</i>	Littlefield	1992	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	NK	No	Yes	Yes	Yes	Yes	NK	Yes		16
<i>Risk factors for poor glycemic control in diabetic children in France.</i>	Tubiana	1995	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	No	Yes	NK	No	Yes	Yes	Yes	Yes	NK	Yes		15
<i>Self-efficacy as a mediator variable for adolescents' adherence to treatment for insulin-dependent diabetes mellitus</i>	Ott	2000	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	NK	No	Yes	Yes	Yes	Yes	NK	Yes		16
<i>Sleep duration and its impact on adherence in adolescents with type 1 diabetes mellitus</i>	McDonoi	2017	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	NK	Yes		17
<i>Social competence and parental support as mediators of the link between stress and metabolic control in adolescents with insulin-dependent diabetes mellitus</i>	Hanson	1987	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	No	NK	Yes		16
<i>Survey of insulin site rotation in youth with type 1 diabetes mellitus.</i>	Patton	2010	No	NK	Yes	Yes	Yes	No	Yes	No	Yes	Yes	Yes	No	No	NK	Yes	Yes	Yes	No	Yes		14
<i>The Diabetes Social Support Questionnaire-Family Version: Evaluating adolescents' diabetes-specific support from family members</i>	La Greca	2002	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	No	No	Yes	No	No	Yes	Yes	Yes	Yes	No	Yes		16
<i>The Effect of Family-centered Care on Management of Blood Glucose Levels in Adolescents with Diabetes.</i>	Cheragh	2015	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	NK	No	Yes	Yes	Yes	Yes	No	Yes		17
<i>The health belief model and adolescents with insulin-dependent diabetes mellitus</i>	Bond	1992	Yes	Yes	Yes	Yes	No	No	No	Yes	Yes	Yes	Yes	NK	No	Yes	Yes	Yes	No	NK	NK		12
<i>The impact of mothers' sense of empowerment on the metabolic control of their children with juvenile diabetes</i>	Florian	1998	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	NK	No	Yes	Yes	Yes	No	NK	Yes		15
<i>The Interactive Effect of Diabetes Family Conflict and Depression on Insulin Bolusing Behaviors for Youth</i>	Maliszew	2017	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	NK	No	Yes	Yes	Yes	Yes	No	Yes		17

Appendix 3 Appraisal Tool for Cross-Sectional Studies (AXIS) and results for all cross-sectional studies.

Domain	Question	Options	Star awarded?
<b>Selection</b>	1) Is the case definition adequate?	a) Yes, with independent validation	Yes
		b) Yes, e.g.- record linkage or based on self-reports	No
		c) No description	No
	2) Representativeness of the cases.	a) Consecutive or obviously representative series of cases	Yes
		b) Potential for selection biases or not stated	No
	3) Selection of controls.	a) Community controls	Yes
		b) Hospital controls	No
		c) No description	No
	4) Definition of controls.	a) No history of disease (endpoint)	Yes
		b) No description of source	No
<b>Comparability</b>	1) Comparability of cases and controls on the basis of the design or analysis.	a) Study controls for most important factor	Yes
		b) Study controls for any additional factor	Yes
<b>Exposure</b>	1) Ascertainment of exposure.	a) Secure record (e.g.- surgical record)	Yes
		b) Structured interview where blind to case/control status	Yes
		c) Interview not blinded to case/control status	No
		d) Written self-report or medical record only	No
		e) No description	No
	2) Same method of ascertainment for cases and controls.	a) Yes	Yes
		b) No	No
	3) Non-response rate.	a) Same rate for both groups	Yes
		b) Non-respondents described.	No
		c) Rate different and no designation.	No

*Appendix 4 Newcastle-Ottawa Scale for bias assessments of case-control studies.*

Title	Author	Year	NOS Case-control Bias Assesment: Selection (Answers and star rating /4)	NOS Case-control Bias Assesment: Comparability (star rating /2)	NOS Case-control Bias Assesment: Exposure (Answers and star rating /3)	Total star rating /9
<i>Pathways from emotional adjustment to glycemic control in youths with diabetes in Hong Kong</i>	Stewart	2000	1) a. 2) a. 3) a. 4) a. ****	**	1) a. 2) a. 3) a. ***	9
<i>Quality of life of children and adolescents with type 1 diabetes in Kuwait.</i>	Abdul-Rasoul	2013	1) a. 2) a. 3) a. 4) a. ****	**	1) a. 2) a. 3) a. ***	9

*Appendix 5 Completed case-control study Newcastle-Ottawa scale bias assessments.*

Domain	Question	Options	Star awarded?
<b>Selection</b>	1) Representativeness of the exposed cohort.	a) Truly representative of the average cohort in the community	Yes
		b) Somewhat representative of the average cohort in the community	Yes
		c) Selected group of users, e.g.- nurses, volunteers	No
		d) No description of the derivation of the cohort	No
	2) Selection of the non-exposed cohort.	a) Drawn from the same community as the exposed cohort	Yes
		b) Drawn from a different source	No
		c) No description of the derivation of the non-exposed cohort	No
	3) Ascertainment of exposure.	a) Secure record (e.g.- surgical records)	Yes
		b) Structured interview	Yes
		c) Written self-report	No
		d) No description	No
	4) Demonstration that the outcome of interest was not present at the start of the study.	a) Yes	Yes
b) No		No	
<b>Comparability</b>	1) Comparability of cohorts on the basis of the design or analysis.	a) Study controls for most important factor	Yes
		b) Study controls for any additional factor	Yes
<b>Outcome</b>	1) Assessment of outcome.	a) Independent blind assessment	Yes
		b) Record linkage	Yes
		c) Self-report	No
		d) No description	No
		e) No description	No
	2) Was follow-up long enough for outcomes to occur?	a) Yes	Yes
		b) No	No
	3) Adequacy of follow-up of cohorts.	a) Complete follow-up; all subjects accounted for	Yes
		b) Subjects lost to follow-up unlikely to introduce bias; small number lost to follow-up or description provided of those lost	Yes
		c) Follow up rate low enough to potentially result in bias and no description of those lost	No
		d) No statement	No

Appendix 6 Newcastle-Ottawa scale for bias assessments of cohort studies.

Title	Author	Year	NOS Cohort: Selection. Answers and star rating (/4 stars)	NOS Cohort: Comparability (/2 stars)	NOS Cohort: Outcome answers and star rating (/3 stars)	NOS Total (/9 stars)
<i>Adherence among children and adolescents with insulin-dependent diabetes mellitus over a four-year longitudinal follow-up: I. The influence of patient coping and</i>	Jacobson	1990	1) a. 2) b. 3) c. 4) a. ****	**	1) c. 2) a. 3) d. *	6
<i>Adherence among children and adolescents with insulin-dependent diabetes mellitus over a four-year longitudinal follow-up: II. Immediate and long-term linkages with</i>	Hauser	1990	1) b. 2) a. 3) c. 4) a. ****	**	1) c. 2) a. 3) b. **	7
<i>Adherence to IDDM regimens: relationship to psychosocial variables and metabolic control.</i>	Schafer	1983	1) b. 2) a. 3) c. 4) a. ****	*	1) c. 2) a. 3) d. *	5
<i>Adherence to Insulin Pump Behaviors in Young Children with Type 1 Diabetes Mellitus</i>	Patton	2017	1) b. 2) a. 3) a. 4) a. ****	*	1) b. 2) a. 3) b. **	8
<i>Adherence to insulin treatment in children with type I diabetes mellitus at a hospital in Malaysia</i>	Ying	2017	1) a. 2) a. 3) a. 4) a. ****	/	1) b. 2) a. 3) b. **	7
<i>Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus</i>	Morris	1997	1) a. 2) a. 3) a. 4) a. ****	**	1) b. 2) a. 3) d. **	8
<i>Adherence-health status relationships in childhood diabetes</i>	Johnson	1990	1) b. 2) a. 3) a. 4) a. ****	*	1) b. 2) a. 3) b. ***	8
<i>Assessing family sharing of diabetes responsibilities.</i>	Anderson	1990	1) a. 2) a. 3) b. 4) a. ****	**	1) c. 2) a. d. **	7
<i>Benefits of using the I-port system on insulin-treated patients</i>	Khan	2019	1) b. 2) a. 3) b. 4) a. ****	**	1) c. 2) a. 3) d. *	7
<i>Brief report: Maternal posttraumatic stress symptoms are related to adherence to their child's diabetes treatment regimen.</i>	Horsch	2014	1) b. 2) a. 3) b. 4) a. ****	*	1) c. 2) a. 3) d. *	6
<i>Brief report: Parent's health literacy among high-risk adolescents with insulin dependent diabetes</i>	Janisse	2010	1) b. 2) a. 3) b. 4) a. ****	**	1) c. 2) a. 3) b. **	8
<i>Depressive symptoms, daily stress, and adherence in late adolescents with type 1 diabetes.</i>	Baucom	2015	1) a. 2) a. 3) c. d) a. ****	**	1) c. 2) a. 3) d. *	6



Title	Author	Year	NOS Cohort: Selection. Answers and star rating (/4 stars)	NOS Cohort: Comparability (/2 stars)	NOS Cohort: Outcome answers and star rating (/3 stars)	NOS Total (/9 stars)
<i>Engagement with a Text-Messaging Intervention Improves Adherence in Adolescents with Type 1 Diabetes: Brief Report.</i>	Zhang	2018	1) b. 2) a. 3) a. 4) a. ****	**	1) b. 2) a. 3) b. ***	9
<i>Health-risk behaviors and type 1 diabetes outcomes in the transition from late adolescence to early emerging adulthood</i>	Lee Tracy	2019	1) a. 2) a. 3) c. 4) a. ***	*	1) a. 2) a. 3) d. **	6
<i>Illness representations predict adherence in adolescents and young adults with type 1 diabetes</i>	McGrady	2014	1) b. 2) a. 3) c. 4) a. ***	**	1) c. 2) a. 3) b. **	7
<i>Longitudinal associations of maternal depressive symptoms, maternal involvement, and diabetes management across adolescence.</i>	Wiebe	2011	1) b. 2) a. 3) c. 4) a. ***	*	1) c. 2) b. 3) d. *	5
<i>Psychologic predictors of compliance in children with recent onset of diabetes mellitus</i>	Jacobson	1987	1) a. 2) a. 3) c. 4) a. ***	**	1) c. 2) a. 3) d. *	6
<i>Psychometric evaluation of the adherence in diabetes questionnaire</i>	Kristensen	2012	1) a. 2) a. 3) c. 4) a. ***	**	1)	
<i>Satisfaction and quality of life with premeal inhaled versus injected insulin in adolescents and adults with type 1 diabetes</i>	Testa	2007	1) b. 2) a. 3) a. 4) a. ****	**	1) c. 2) a. 3) d. *	7

Appendix 7 Completed cohort study Newcastle-Ottawa Scale bias assessments.

Domain	Questions	Howells, 2002	Franklin, 2006	Glaser, 2004	Gregory, 2011	Mendez, 1997	Abolfotouh, 2011	Jones, 2002
<b>Domain 1: Randomisation process</b>	1.1) Was the allocation sequence random?	Y	Y	Y	Y	NI	N	Y
	1.2) Was the allocation sequence concealed until participants were enrolled and assigned to interventions?	Y	PY	PY	PY	NI	PN	PY
	1.3) Did baseline differences between intervention groups suggest a problem with the randomisation process?	PN	N	PN	PN	N	N	PN
	Overall risk of bias for this domain	Low	Low	Low	Low	Some concerns	High	Low
<b>Domain 2: Deviation from intended interventions</b>	2.1) Were participants aware of their assigned intervention during the trial?	PY	PY	PY	PY	PY	PY	PY

Domain	Questions	Howells, 2002	Franklin, 2006	Glaser, 2004	Gregory, 2011	Mendez, 1997	Abolfotouh, 2011	Jones, 2002
	2.2) Were carers and people delivering the interventions aware of participants' assigned intervention during the trial?	Y	Y	PY	PY	PY	Y	PY
	2.3) If Y/PY/NI to 2.1 or 2.2: Were there deviations from the intended intervention that arose because of the experimental context?	PN	PN	PN	PN	PN	PY	PN
	2.4) If Y/PY to 2.3: Were these deviations likely to have affected the outcome?	N/A	N/A	N/A	N/A	N/A	PN	N/A
	2.5) If Y/PY/NI to 2.4: Were these deviations from intended intervention balanced between groups?	N/A	N/A	N/A	N/A	N/A	N/A	N/A
	2.6) Was an appropriate analysis used to estimate the effect of assignment to intervention?	Y	Y	Y	PY	PY	PY	PY

Domain	Questions	Howells, 2002	Franklin, 2006	Glaser, 2004	Gregory, 2011	Mendez, 1997	Abolfotouh, 2011	Jones, 2002
	2.7) If N/PN/NI to 2.6: Was there potential for a substantial impact (on the result) of the failure to analyse participants in the group to which they were randomized?	N/A	N/A	N/A	N/A	N/A	N/A	N/A
	Overall risk of bias for this domain	High	Low	Low	Low	Low	Some concerns	Low
<b>Domain 3: Missing outcome data</b>	3.1) Were data for this outcome available for all, or nearly all, participants randomised?	Y	Y	PN	Y	PY	NI	y
	3.2) If N/PN/NI to 3.1: is there evidence that the result was not biased by missing outcome data?	N/A	N/A	PN	N/A	N/A	PY	N/A
	3.3) If N/PN to 3.2: could missingness in the outcome depend on its true value?	N/A	N/A	PN	N/A	N/A	N/A	N/A
	3.4) If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value?	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Domain	Questions	Howells, 2002	Franklin, 2006	Glaser, 2004	Gregory, 2011	Mendez, 1997	Abolfotouh, 2011	Jones, 2002
	Overall risk of bias for this domain	Low	Low	Low	Low	Low	Low	Low
<b>Domain 4: Measurement of the outcome</b>	4.1) Was the method of measuring the outcome inappropriate?	PN	PN	PN	PN	PN	PN	PN
	4.2) Could measurement or ascertainment of the outcome have differed between intervention groups?	PN	PN	PN	PN	PN	PN	PN
	4.3) If N/PN/NI to 4.1 and 4.2: Were outcome assessors aware of the intervention received by study participants?	PY	PY	PY	PY	PY	PY	PY
	4.4) If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received?	PY	PY	PN	PN	PY	PN	PN

Domain	Questions	Howells, 2002	Franklin, 2006	Glaser, 2004	Gregory, 2011	Mendez, 1997	Abolfotouh, 2011	Jones, 2002
	4.5) If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received?	PN	PN	N/A	N/A	PN	N/A	N/A
	Overall risk of bias for this domain	Some concerns	Some concerns	Low	Low	Some concerns	Low	Low
<b>Domain 5: Selection of the reported result</b>	5.1) Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before unblinded outcome data were available for analysis?	Y	PY	Y	Y	PY	Y	Y
	5.2) Is the numerical result being assessed likely to have been selected on the basis of the results from multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?	Y	Y	Y	PN	PY	PY	PN

Domain	Questions	Howells, 2002	Franklin, 2006	Glaser, 2004	Gregory, 2011	Mendez, 1997	Abolfotouh, 2011	Jones, 2002
	5.3) Is the numerical result being assessed likely to have been selected on the basis of the results from multiple eligible analyses of the data?	PY	PY	PY	PN	PY	PY	PN
	Overall risk of bias for this domain	High	High	High	Low	High	High	Low
<b>Overall risk of bias</b>		High	Some concerns	Some concerns	Low	High	High	Low

Appendix 8 Completed Cochrane risk of bias for randomised trials tool (RoB 2) for RCTs included in systematic review. Legend; Y: yes, PY: probably yes, NI: no information, PN: probably no, N: no, N/A: not applicable.

Result Number and Title	Excluded by/included	First Exclusion Criteria Met
1. <i>"I Don't Want Them to Feel Different": A Mixed Methods Study of Parents' Beliefs and Dietary Management Strategies for Their Young Children with Type 1 Diabetes Mellitus.</i>	Title	Intervention: not related to insulin treatment
2. <i>"Sweet Talk": Text Messaging Support for Intensive Insulin Therapy for Young People with Diabetes</i>	Full Text	Outcome: not related to insulin treatment adherence
4. <i>"Symptom-based insulin adjustment for glucose normalization" (SIGN) algorithm: a pilot study.</i>	Title	Outcome: not related to insulin treatment adherence
5. <i>'Diabulima' through the lens of social media: a qualitative review and analysis of online blogs by people with Type 1 diabetes mellitus and eating disorders.</i>	Title	Outcome: not related to insulin treatment adherence
6. <i>'It's not for me'-patterns of glycaemia in youth who discontinue CSII</i>	Abstract	Wrong study type (review, conference abstract etc.)
7. <i>640g minimed system effectiveness in children and adolescents with type 1 diabetes: Education plus technology ensure higher %time in target range (70-160 mg/dl)</i>	Title	Intervention: not related to insulin treatment
8. <i>[Analysis of the quality of primary therapeutic-preventive care rendered to patients with type I diabetes mellitus].</i>	Title	Outcome: not related to insulin treatment adherence
9. <i>[Basal bolus therapy in adolescent diabetic patients].</i>	Abstract	Outcome: not related to insulin treatment adherence
10. <i>[Clinical evaluation of glycohemoglobin and serum glycoproteins using affinity chromatography in children with type I diabetes mellitus].</i>	Title	Outcome: not related to insulin treatment adherence
11. <i>[Compliance of children and adolescents with type 1 diabetes (juvenile diabetes mellitus)].</i>		



<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
13. <i>[Compliance of young diabetic patients with therapeutic regimens and participation by the family].</i>		
14. <i>[Current and future care for diabetes in children: from insulin to immunotherapy].</i>	Abstract	Wrong study type (review, conference abstract etc.)
15. <i>[Current aspects in therapy of insulin-dependent diabetes mellitus in children and adolescents].</i>	Full Text	Wrong study type (review, conference abstract etc.)
16. <i>[Daytime flexible application of Insulin degludec in patients with type 1 diabetes or type 2 diabetes].</i>	Abstract	Outcome: not related to insulin treatment adherence
18. <i>[Development and outcome of motivational support during inpatient education of insulin-dependent diabetic patients--a pilot project].</i>	Full Text	Population: not children (adults/foetuses)
19. <i>[Diabetes mellitus and cellular immunity].</i>	Title	Outcome: not related to insulin treatment adherence
20. <i>[Diet composition along the evolution of type 1 diabetes mellitus].</i>	Title	Outcome: not related to insulin treatment adherence
21. <i>[Evaluation of a program for the care of the diabetic. A 40-month continuity study].</i>	Abstract	Population: not children (adults/foetuses)
22. <i>[Exploration of left ventricular function in insulin-dependent diabetics (relation with retinopathy)].</i>	Title	Outcome: not related to insulin treatment adherence
23. <i>[French version and validation of a scale evaluating compliance in diabetic children].</i>	Included	
24. <i>[Glibenclamide instead of insulin: a new chance for MODY 3 type diabetes patients: case report].</i>	Title	Population: do not have T1DM
26. <i>[How I assess ... home glycemic control in diabetic patients].</i>	Title	Outcome: not related to insulin treatment adherence
27. <i>[Hypoglycemia provoked by clandestine injections of insulin in the diabetic child].</i>	Title	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
28. <i>[Insulin pump treatment in children and adolescents with type 1 diabetes].</i>	Abstract	Wrong study type (review, conference abstract etc.)
29. <i>[Intensified conventional insulin therapy. The long-term successes and reasons for failure of this therapeutic concept].</i>	Full Text	Population: not children (adults/foetuses)
31. <i>[Intensive insulin therapy in adolescents with type 1 diabetes mellitus: initial experiences with a semiautomatic insulin injection device (the insulin pen)].</i>		
32. <i>[Juvenile onset diabetes: the effect of education for metabolic control].</i>	Abstract	Outcome: not related to insulin treatment adherence
34. <i>[Mauriac syndrome--a rare complication of type 1 diabetes mellitus].</i>	Title	Outcome: not related to insulin treatment adherence
35. <i>[Modern methods for controlling type-1 diabetes?].</i>	Title	Outcome: not related to insulin treatment adherence
36. <i>[Needs of schoolchildren with type 1 diabetes in Extremadura: Family perceptions].</i>	Abstract	Outcome: not related to insulin treatment adherence
37. <i>[New aspects of the diet in type 1 diabetes mellitus].</i>	Title	Intervention: not related to insulin treatment
38. <i>[Predictors of treatment adherence in children with type 1 diabetes mellitus].</i>	Full Text	Wrong study type (review, conference abstract etc.)
39. <i>[Psychological aspects of treatment compliance in the insulin- dependent diabetic child].</i>		
40. <i>[Psychological factors associated to patient's treatment compliance in Chilean diabetic teenagers].</i>		
41. <i>[Quality of diabetes care in Norwegian general practice].</i>	Title	Outcome: not related to insulin treatment adherence
42. <i>[Self-monitoring blood glucose in type 2 diabetes: for whom? And why? Which proofs?].</i>	Title	Population: do not have T1DM

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
43. <i>[Self-monitoring of blood glucose in type 2 diabetic patients. What could we propose according to their treatment?]</i> .	Title	Population: do not have T1DM
44. <i>[The Aide to Juvenile Diabetes Association: its role in the management and education of patients with insulin-dependent diabetes]</i> .	Title	Outcome: not related to insulin treatment adherence
45. <i>[The selection of insulin and adjustment of the dosage in diabetic children and adolescents: personal experiences]</i> .	Abstract	Outcome: not related to insulin treatment adherence
47. <i>[The usage of the personal insulin pump for treatment of a 7 week infant with neonatal diabetes mellitus]</i> .	Title	Outcome: not related to insulin treatment adherence
48. <i>[Therapeutic education regarding type 1 diabetes (DM1)]</i> .	Abstract	Outcome: not related to insulin treatment adherence
49. <i>[Treatment of young patients with type 1 diabetes in an adult diabetes clinic]</i> .	Title	Population: not children (adults/foetuses)
50. <i>[Why is that the response to treatment of type 1 diabetes is not improving?]</i> .	Abstract	Wrong study type (review, conference abstract etc.)
51. <i>A 3-year prospective study of parent-child communication in early adolescents with type 1 diabetes: relationship to adherence and glyceimic control.</i>	Full Text	Outcome: not related to insulin treatment adherence
52. <i>A biopsychosocial model of glyceimic control in diabetes: stress, coping and regimen adherence.</i>	Abstract	Population: not children (adults/foetuses)
53. <i>A case report of a 14 year old female with a known history of type 1 diabetes mellitus who developed tracheal stenosis as a result of prolonged intubation from diabetic ketoacidosis and subsequently developed acute pancreatitis</i>	Title	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>54. A clinical pilot to assess improvement in health related quality of life (QOL), treatment satisfaction, and glycemic control in adolescents with type 2 diabetes (T2DM) using continuous subcutaneous insulin injection therapy (CSII)</i>	Title	Population: do not have T1DM
<i>55. A comparison of IDeg + IAsp versus IDet + IAsp in subjects with type 1 diabetes: subgroup analysis of Japanese subjects.</i>	Abstract	Population: not children (adults/foetuses)
<i>56. A Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes Mellitus.</i>	Title	Population: not children (adults/foetuses)
<i>57. A comparison of the use of premixed insulins in pen-injectors with conventional patient-mixed insulin treatment in children and adolescents with IDDM. Is there a decreased risk of night hypoglycemia?</i>	Title	Outcome: not related to insulin treatment adherence
<i>58. A computer insulin titration protocol is associated with a reduction of hypoglycemia in the PIC U</i>	Title	Outcome: not related to insulin treatment adherence
<i>59. A discrete choice experiment evaluation of patients' preferences for different risk, benefit, and delivery attributes of insulin therapy for diabetes management.</i>	Full Text	Population: not children (adults/foetuses)
<i>60. A focus on blood glucose monitoring: relation to glycemic control and determinants of frequency.</i>	Title	Intervention: not related to insulin treatment
<i>61. A group approach to the management of diabetes in adolescents and young adults</i>	Abstract	Population: not children (adults/foetuses)

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
62. <i>A hypnotherapeutic approach to the improvement of compliance in adolescent diabetics.</i>		
63. <i>A Large Difference in Dose Timing of Basal Insulin Introduces Risk of Hypoglycemia and Overweight: A Cross-Sectional Study.</i>	Title	Outcome: not related to insulin treatment adherence
64. <i>A longitudinal analysis of adherence and health status in childhood diabetes</i>	Included	
65. <i>A model for promoting adolescents' adherence to treatment for type 1 diabetes mellitus</i>	Full Text	Wrong study type (review, conference abstract etc.)
66. <i>A multi-disciplinary education process related to the discharging of children from hospital when the child has been diagnosed with type 1 diabetes--a qualitative study.</i>	Abstract	Outcome: not related to insulin treatment adherence
67. <i>A Multidisciplinary Evaluation of a Virtually Supervised Home-Based High-Intensity Interval Training Intervention in People With Type 1 Diabetes.</i>	Abstract	Population: not children (adults/foetuses)
69. <i>A multivariate model exploring the predictive value of demographic, adolescent, and family factors on glycemic control in adolescents with type 1 diabetes.</i>	Full Text	Outcome: not related to insulin treatment adherence
70. <i>A multivariate model of demographic and psychosocial predictors of HBA1c in adolescents with type 1 diabetes</i>	Abstract	Wrong study type (review, conference abstract etc.)
71. <i>A new indwelling catheter, I-PORT advance, to improve adherence to basal-bolus treatment in children and adolescents with type 1 diabetes: A randomized, crossover pilot study comparing glycemic control and satisfaction</i>	Abstract	Wrong study type (review, conference abstract etc.)

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>72. A new paediatric diabetes knowledge test - M-WIKAD development and factor analysis</i>	Title	Outcome: not related to insulin treatment adherence
<i>73. A novel method for measuring patients' adherence to insulin dosing guidelines: introducing indicators of adherence</i>	Included	
<i>74. A novel tool to predict youth who will show recommended usage of diabetes technologies.</i>	Title	Outcome: not related to insulin treatment adherence
<i>75. A pilot study of factors associated with glycaemic control in adults with Type 1 diabetes mellitus on insulin pump therapy.</i>	Title	Population: not children (adults/foetuses)
<i>76. A prime example of high compliance</i>	Abstract	Population: do not have T1DM
<i>77. A profile of self-care behaviors in emerging adults with type 1 diabetes.</i>	Title	Population: not children (adults/foetuses)
<i>78. A prototype of a new noninvasive device to detect nocturnal hypoglycemia in adolescents with type 1 diabetes--a pilot study.</i>	Title	Outcome: not related to insulin treatment adherence
<i>79. A qualitative study exploring patients' experiences regarding insulin pump use.</i>	Abstract	Population: not children (adults/foetuses)
<i>80. A randomized clinical trial aimed at preventing poor psychosocial and glycemic outcomes in teens with type 1 diabetes (T1D).</i>	Full Text	Outcome: not related to insulin treatment adherence
<i>81. A randomized control trial of the effect of negotiated telephone support on glycaemic control in young people with Type 1 diabetes</i>	Included	
<i>83. A randomized controlled trial of Sweet Talk, a text-messaging system to support young people with diabetes</i>	Included	

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>85. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.</i>	Title	Outcome: not related to insulin treatment adherence
<i>87. A randomized trial of regular standardized telephone contact by a diabetes nurse educator in adolescents with poor diabetes control.</i>	Full Text	Outcome: not related to insulin treatment adherence
<i>88. A randomized, crossover pilot study comparing glycemic control and satisfaction with an indwelling catheter (i-port advance) for insulin administration in children and adolescents with type 1 diabetes on basal-bolus treatment*</i>	Full Text	Wrong study type (review, conference abstract etc.)
<i>89. A rare complication of T1DM in a female teenager: Mauriac syndrome?</i>	Title	Outcome: not related to insulin treatment adherence
<i>90. A study of type 1 diabetes mellitus from South India</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>91. A systematic review of non-genetic predictors and genetic factors of glycosylated haemoglobin in type 1 diabetes one year after diagnosis.</i>	Title	Outcome: not related to insulin treatment adherence
<i>92. A Systematic Review of Patients' Perspectives on the Subcutaneous Route of Medication Administration</i>	Title	Wrong study type (review, conference abstract etc.)
<i>93. A thematic approach to enhance clinical content in a cell and tissue biology course</i>	Title	Outcome: not related to insulin treatment adherence
<i>94. Abnormal left ventricular diastolic function during cold presser test in uncomplicated insulin-dependent diabetes mellitus</i>	Title	Outcome: not related to insulin treatment adherence
<i>95. Accelerated complications in Type 2 diabetes mellitus: the need for greater awareness and earlier detection.</i>	Title	Population: do not have T1DM

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>96. Accuracy and preference assessment of prefilled insulin pen versus vial and syringe with diabetes patients, caregivers and healthcare professionals.</i>	Abstract	Population: not children (adults/foetuses)
<i>97. Accuracy of blood glucose estimates in adolescents with diabetes mellitus</i>	Title	Outcome: not related to insulin treatment adherence
<i>98. Accuracy of Blood Glucose Meters for Self-Monitoring Affects Glucose Control and Hypoglycemia Rate in Children and Adolescents with Type 1 Diabetes</i>	Title	Outcome: not related to insulin treatment adherence
<i>100. Accuracy of insulin pump therapy usage in pediatric patients with type 1 diabetes</i>	Title	Outcome: not related to insulin treatment adherence
<i>101. Achievement of internationally established metabolic goals in Spanish paediatric patients with type 1 diabetes</i>	Title	Outcome: not related to insulin treatment adherence
<i>102. Achievement of metabolic control among children and adolescents with type 1 diabetes in Spain</i>	Title	Outcome: not related to insulin treatment adherence
<i>103. Achievement of metabolic control goals set by the American Diabetes Association and the International Society for Pediatric and Adolescent Diabetes in pediatric patients with type 1 diabetes from Spain</i>	Title	Outcome: not related to insulin treatment adherence
<i>105. Achieving glycemic control: cornerstone in the treatment of patients with multiple metabolic risk factors.</i>	Title	Outcome: not related to insulin treatment adherence
<i>106. Achieving optimal diabetic control in adolescence: the continuing enigma.</i>	Title	Outcome: not related to insulin treatment adherence
<i>107. Acid peptic disease in children with type 1 diabetes mellitus: A complicating relationship</i>	Title	Outcome: not related to insulin treatment adherence



Result Number and Title	Excluded by/included	First Exclusion Criteria Met
108. <i>Acute Hyperglycemia Associated with Psychotic Symptoms in a Patient with Type 1 Diabetes Mellitus: A Case Report.</i>	Title	Outcome: not related to insulin treatment adherence
109. <i>Acute painful neuropathy (insulin neuritis) - Case report</i>	Title	Outcome: not related to insulin treatment adherence
110. ADAPTATION EN LANGUE FRANCAISE ET VALIDATION D'UNE ECHELLE MESURANT L'ADHESION AU TRAITEMENT DES ENFANTS DIABETIQUES French version of a scale evaluating adherence to diabetes regimen in children	Abstract	Outcome: not related to insulin treatment adherence
111. <i>Adequate prescribing of medication does not necessarily translate into good control of diabetes mellitus.</i>	Abstract	Outcome: not related to insulin treatment adherence
112. <i>Adesao ao tratamento de diabetes mellitus tipo 1 atendidos em um programa especializado em Porto Alegre</i> Adherence to treatment in diabetes mellitus type 1 treated in a specialized program in Porto Alegre	Included	
113. <i>Adherence among children and adolescents with insulin-dependent diabetes mellitus over a four-year longitudinal follow-up: I. The influence of patient coping and adjustment</i>	Included	
114. <i>Adherence among children and adolescents with insulin-dependent diabetes mellitus over a four-year longitudinal follow-up: II. Immediate and long-term linkages with the family milieu</i>	Included	
115. <i>Adherence among Saudi adolescents with type 1 diabetes: A qualitative study</i>	Abstract	Wrong study type (review, conference abstract etc.)
116. <i>Adherence behavior among adolescents with type I insulin-dependent diabetes mellitus: The role of cognitive appraisal processes</i>	Full Text	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>117. Adherence behaviors in research protocols: comparison of two interventions</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>118. Adherence behaviours in Taiwanese children and adolescents with type 1 diabetes mellitus.</i>	Full Text	Outcome: not related to insulin treatment adherence
<i>119. Adherence challenges in the management of type 1 diabetes in adolescents: prevention and intervention.</i>	Full Text	Wrong study type (review, conference abstract etc.)
<i>121. Adherence in adults with type 1 diabetes mellitus correlates with treatment satisfaction but not with adverse events.</i>	Title	Population: not children (adults/foetuses)
<i>122. Adherence is suboptimal in adolescents with type 1 diabetes participating in a clinical trial</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>123. Adherence to a pediatric diabetic ketoacidosis protocol in children presenting to a tertiary care hospital</i>	Title	Outcome: not related to insulin treatment adherence
<i>124. Adherence to blood glucose monitoring in children and young people with type 1 diabetes on insulin pump therapy in a teaching hospital</i>	Title	Outcome: not related to insulin treatment adherence
<i>125. Adherence to clinic visits is not improved by insulin use in metformin-treated children and teens with type 2 diabetes</i>	Title	Population: do not have T1DM
<i>126. Adherence to clinical care guidelines for cystic fibrosis-related diabetes in 659 German/Austrian patients</i>	Title	Population: do not have T1DM
<i>127. Adherence to diabetes care in children and adolescents with type 1 diabetes mellitus in Spain: Results from the chrystal study</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>128. Adherence to Diet in Youth with Type 1 Diabetes</i>	Title	Outcome: not related to insulin treatment adherence
<i>131. Adherence to guidelines in the treatment of diabetic ketoacidosis in children: A nationwide survey</i>	Title	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>132. Adherence to IDDM regimens: relationship to psychosocial variables and metabolic control.</i>	Included	
<i>133. Adherence To Insulin In Singaporean Pediatric Type 1 Diabetes Patients And Its Association With Glycemic Control And Healthcare Utilization</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>134. Adherence to Insulin Pen Therapy Is Associated with Reduction in Healthcare Costs Among Patients with Type 2 Diabetes Mellitus.</i>	Title	Population: do not have T1DM
<i>135. Adherence to insulin pump behaviors among young children with type 1 diabetes (T1D): Opportunities for intervention</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>136. Adherence to Insulin Pump Behaviors in Young Children with Type 1 Diabetes Mellitus</i>	Included	
<i>137. Adherence to insulin pump behaviors in young children with type 1 diabetes mellitus: Opportunities for intervention</i>		
<i>138. Adherence to insulin pump treatment declines with increasing age in adolescents with type 1 diabetes mellitus</i>	Full Text	Outcome: not related to insulin treatment adherence
<i>139. Adherence to insulin therapeutic regimens in patients with type 1 diabetes. A nationwide survey in Brazil.</i>	Full Text	Population: not children (adults/foetuses)
<i>140. Adherence to insulin therapeutic regims in patients with type 1 diabetes. A nationwide survey in brazil-Comment on Gomes et al.</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>141. Adherence to insulin treatment in children with type I diabetes mellitus at a hospital in Malaysia</i>	Included	
<i>142. Adherence to insulin treatment in diabetes: can it be improved?</i>	Full Text	Wrong study type (review, conference abstract etc.)

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>143. Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus</i>	Included	
<i>144. Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus. The DARTS/MEMO Collaboration. Diabetes Audit and Research in Tayside Scotland. Medicines Monitoring Unit.</i>		
<i>145. Adherence to medical regimens</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>146. Adherence to metformin is reduced during school holidays and weekends in children with type 1 diabetes participating in a randomised controlled trial</i>	Title	Outcome: not related to insulin treatment adherence
<i>147. Adherence to pediatric diabetic ketoacidosis guidelines by community emergency departments' providers</i>	Title	Outcome: not related to insulin treatment adherence
<i>148. Adherence to physical activity in young people with Type 1 diabetes</i>	Title	Outcome: not related to insulin treatment adherence
<i>150. Adherence to self-care and glycaemic control among people with insulin-dependent diabetes mellitus</i>	Full Text	Population: not children (adults/foetuses)
<i>151. Adherence to the ISPAD guidelines 2009 in acute management of diabetic ketoacidosis in children and adolescents in Austria</i>	Title	Outcome: not related to insulin treatment adherence
<i>152. Adherence to the Warsaw School of Pump Therapy and using of different types of boluses for meals in children and adolescent with type 1 diabetes</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>153. Adherence-health status relationships in childhood diabetes</i>	Included	

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
154. <i>Adherencia al tratamiento en adolescentes diabeticos tipo 1 chilenos: Una aproximacion psicologica</i> <i>Psychological factors associated to patient's treatment compliance in Chilean diabetic teenagers</i>	Full Text	Outcome: not related to insulin treatment adherence
155. <i>Adolescent adherence in type 1 diabetes</i>	Included	
157. <i>Adolescent non-adherence reveals a genetic cause for diabetes</i>	Abstract	Population: do not have T1DM
159. <i>Adolescent psychosocial development and adherence to treatment for insulin-dependent diabetes mellitus</i>	Abstract	Wrong study type (review, conference abstract etc.)
160. <i>Adolescent use of insulin and patient-controlled analgesia pump technology: A 10-year food and drug administration retrospective study of adverse events</i>	Abstract	Outcome: not related to insulin treatment adherence
161. <i>Adolescents with diabetes and high HbA1c - A neurodevelopmental perspective</i>	Title	Outcome: not related to insulin treatment adherence
162. <i>Adolescents with diabetes: Attitude towards the disease and psychosocial impact</i>	Abstract	Outcome: not related to insulin treatment adherence
163. <i>Adolescents with diabetes: Effects of personal and social factors on risk, health, and illness management behaviors</i>	Abstract	Wrong study type (review, conference abstract etc.)
164. <i>Adolescents' and their parents' views on the acceptability and design of a new diabetes education programme: a focus group analysis.</i>	Abstract	Outcome: not related to insulin treatment adherence
165. <i>Adolescents' health attitudes and adherence to treatment for insulin-dependent diabetes mellitus</i>	Included	

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>166. Adolescents, parents and physicians: a comparison of perspectives on type 1 diabetes self-care.</i>	Full Text	Outcome: not related to insulin treatment adherence
<i>167. Adults with type 1 diabetes eat a high-fat atherogenic diet that is associated with coronary artery calcium.</i>	Title	Population: not children (adults/foetuses)
<i>168. Advances in pharmacological treatment of type 1 diabetes during pregnancy.</i>	Title	Population: not children (adults/foetuses)
<i>169. Advances in transdermal insulin delivery.</i>	Title	Outcome: not related to insulin treatment adherence
<i>170. Adverse events in intensively treated children and adolescents with type 1 diabetes.</i>	Title	Outcome: not related to insulin treatment adherence
<i>171. Adverse lipid and inflammatory changes in young nondiabetic first-degree relatives of type 1-diabetic patients</i>	Title	Outcome: not related to insulin treatment adherence
<i>172. Algemene ouder-kindrelatie en diabetesgerelateerde ouder-kindrelatie in de adolescentie: Relatie met glykemische controle en de rol van adherence</i> <i>General parent-child relationship and diabetes-related parent-child relationship in adolescence</i>	Included	
<i>173. Alpha-lipoic acid may improve the clinical, endocrine and metabolic features of polycystic ovary syndrome through an insulin-sensitizing effect and an antioxidant action</i>	Title	Population: do not have T1DM
<i>174. Ambulatory 24-hour fast using flexible insulin therapy in patients with type 1 diabetes.</i>	Title	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>175. An analysis of "no effect of insulin pen with memory function on glycemic control in a patient cohort with poorly controlled type 1 diabetes: a randomized open-label study".</i>	Full Text	Wrong study type (review, conference abstract etc.)
<i>176. An analysis on the factors associated with reuse of insulin pen needles in type 2 diabetic patients in China</i>	Title	Population: do not have T1DM
<i>177. An annual review questionnaire in children and young people with type 1 diabetes</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>178. An approach to prevention of recurrent diabetic ketoacidosis in the pediatric population</i>	Title	Outcome: not related to insulin treatment adherence
<i>179. An audit of insulin usage and insulin injection practices in a large Indian cohort</i>	Abstract	Population: do not have T1DM
<i>180. An audit of the dietary intake of Australian children with type 1 diabetes</i>	Title	Outcome: not related to insulin treatment adherence
<i>181. An evaluation of patient preference for an alternative insulin delivery system compared to standard vial and syringe.</i>	Abstract	Population: not children (adults/foetuses)
<i>182. An exploratory randomised controlled trial using short messaging service to facilitate insulin administration in young adults with type 1 diabetes</i>	Title	Population: not children (adults/foetuses)
<i>184. An intervention to promote family teamwork in diabetes management tasks: Relationships among parental involvement, adherence to blood glucose monitoring, and glycemic control in young adolescents with type 1 diabetes</i>	Title	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
185. <i>Analiz kachestva pervichnoi lechebno-profilakticheskoi pomoshchi bol'nym sakharnym diabetom I tipa</i> Analysis of the quality of primary therapeutic-preventive care rendered to patients with type I diabetes mellitus	Title	Outcome: not related to insulin treatment adherence
186. <i>Analysis of the NovoPen Echo for the delivery of insulin: a comparison of usability, functionality, and preference among pediatric subjects, their parents, and health care professionals</i>	Abstract	Outcome: not related to insulin treatment adherence
188. <i>Analysis of use of an automated bolus calculator reduces fear of hypoglycemia and improves confidence in dosage accuracy in type 1 diabetes mellitus patients treated with multiple daily insulin injections.</i>	Full Text	Wrong study type (review, conference abstract etc.)
189. <i>Analyzing the Potential of Advanced Insulin Dosing Strategies in Patients With Type 2 Diabetes: Results From a Hybrid In Silico Study.</i>	Title	Population: do not have T1DM
190. <i>Anorexia nervosa and bulimia in diabetics</i>	Full Text	Population: not children (adults/foetuses)
191. <i>Antiphospholipid syndrome in children</i>	Title	Population: do not have T1DM
192. <i>Anxiety symptoms in adolescents with type 1 diabetes: association with blood glucose monitoring and glycemic control.</i>	Title	Outcome: not related to insulin treatment adherence
193. <i>Análisis discriminante de la adhesión al tratamiento en la diabetes mellitus insulinodependiente</i>	Full Text	Population: not children (adults/foetuses)
194. <i>Aortic compliance measurements using Doppler ultrasound: In vivo biochemical correlates</i>	Title	Population: do not have T1DM



<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>195. Application of novel dual wave meal bolus and its impact on glycated hemoglobin A1c level in children with type 1 diabetes</i>	Title	Outcome: not related to insulin treatment adherence
<i>197. Approach to the obese adolescent with new-onset diabetes</i>	Title	Outcome: not related to insulin treatment adherence
<i>199. Are clinical or metabolic variables useful to distinguish between an infant of a diabetic mother and simple macrosomia of the newborn?</i>	Title	Outcome: not related to insulin treatment adherence
<i>200. Are families of children with type 1 DM ready for televisits?</i>	Title	Outcome: not related to insulin treatment adherence
<i>201. Are paediatric patients attending their annual diabetic retinopathy screening?</i>	Title	Outcome: not related to insulin treatment adherence
<i>202. Are we using current up-to-date evidence in the delivery and documentation of sick day management education to children and adolescents with type 1 diabetes?</i>	Title	Outcome: not related to insulin treatment adherence
<i>203. Arterial stiffness as measure of cardiovascular risk in lean and obese adolescents and adolescents with type 1 diabetes</i>	Title	Outcome: not related to insulin treatment adherence
<i>204. Arterial wall thickening and stiffening in children and adolescents with type 1 diabetes.</i>	Title	Outcome: not related to insulin treatment adherence
<i>205. ASPECTS PSYCHOLOGIQUES DE LA COMPLIANCE AU TRAITEMENT CHEZ L'ENFANT DIABETIQUE INSULINODEPENDANT</i> <i>Psychologic aspects of compliance with therapy in children with insulin-dependent diabetes mellitus</i>		
<i>206. Assessing diabetes support in adolescents: factor structure of the Modified Diabetes Social Support Questionnaire (M-DSSQ-Family).</i>	Abstract	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>207. Assessing family sharing of diabetes responsibilities.</i>	Included	
<i>208. Assessing the Impact of Excessive Gestational Weight Gain Among Women With Type 1 Diabetes on Overweight/Obesity in Their Adolescent and Young Adult Offspring: A Pilot Study.</i>	Title	Population: not children (adults/foetuses)
<i>209. Assessing treatment barriers in young adults with type 1 diabetes.</i>	Title	Population: not children (adults/foetuses)
<i>210. Assessment of adherence and healthcare costs of insulin device (FlexPen) versus conventional vial/syringe</i>	Full Text	Population: not children (adults/foetuses)
<i>211. Assessment of patient-reported outcomes of insulin pen devices versus conventional vial and syringe.</i>	Full Text	Wrong study type (review, conference abstract etc.)
<i>213. Assessment of quality of life in children with peanut allergy</i>	Title	Population: do not have T1DM
<i>214. Associated factors with the control of type 1 diabetes mellitus</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>215. Association between carotid intima-media thickness, buccodental status, and glycemic control in pediatric type 1 diabetes</i>	Title	Outcome: not related to insulin treatment adherence
<i>217. Association between food insecurity and glycemic control among youth with type 1 diabetes in Haiti</i>	Title	Outcome: not related to insulin treatment adherence
<i>218. Association of HbA1c to BOLUS Scores among Youths with Type 1 Diabetes</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>220. Association of insulin-manipulation and psychiatric disorders: A systematic epidemiological evaluation of adolescents with type 1 diabetes in Austria</i>	Included	
<i>221. Associations between family members' perceptions of the health care system and the health of youths with insulin-dependent diabetes mellitus</i>	Title	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>222. Associations between major life events and adherence, glycemic control, and psychosocial characteristics in teens with type 1 diabetes.</i>	Included	
<i>223. Attitudes towards insulin pump therapy among adolescents and young people</i>	Full Text	Population: not children (adults/foetuses)
<i>225. Attributions of teacher reactions to diabetes self-care behaviors</i>	Included	
<i>226. Audit of DKA management in Wellington New Zealand 2005-2013</i>	Title	Outcome: not related to insulin treatment adherence
<i>227. Audit of screening and confirmation of diagnosis of coeliac disease in type 1 diabetes patients</i>	Title	Outcome: not related to insulin treatment adherence
<i>228. Audit of the use of integrated care pathway in the management of diabetic Keto acidosis in children</i>	Title	Outcome: not related to insulin treatment adherence
<i>229. Back to school and normality after lung transplantation in childhood and the need for psycho-social interventions</i>	Title	Population: do not have T1DM
<i>230. Bariatric surgery for severe obesity in two adolescents with type 1 diabetes</i>	Title	Outcome: not related to insulin treatment adherence
<i>232. Barriers to care in the adult patient with cystic fibrosis-related diabetes</i>	Title	Population: not children (adults/foetuses)
<i>233. Barriers to effective management of type 2 diabetes in primary care : qualitative systematic review.</i>	Title	Population: do not have T1DM
<i>234. Barriers to regimen adherence among persons with insulin-dependent diabetes.</i>	Full Text	Population: not children (adults/foetuses)
<i>235. Behavior therapy for families of adolescents with diabetes: Effects on directly observed family interactions</i>	Included	
<i>236. Behavioral Family Systems Therapy for adolescents with diabetes</i>	Abstract	Wrong study type (review, conference abstract etc.)

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>237. Behaviours, thoughts and perceptions around mealtime insulin usage and wastage among people with type 1 and type 2 diabetes mellitus: A cross-sectional survey study.</i>	Abstract	Population: not children (adults/foetuses)
<i>238. Benefits of an insulin dosage calculation device for adolescents with type 1 diabetes mellitus</i>	Included	
<i>240. Benefits of using the I-port system on insulin-treated patients</i>	Included	
<i>241. Beta-cell autoimmunity in pediatric celiac disease: the case for routine screening?</i>	Title	Outcome: not related to insulin treatment adherence
<i>243. Betreuung von Kindern und Jugendlichen mit Diabetes mellitus Treatment of children and adolescents with diabetes mellitus</i>	Full Text	Wrong study type (review, conference abstract etc.)
<i>244. Bias in food intake reporting in children and adolescents with type 1 diabetes: the role of body size, age and gender.</i>	Title	Outcome: not related to insulin treatment adherence
<i>245. Bicentric evaluation of a teaching and treatment programme for type 1 (insulin-dependent) diabetic patients: improvement of metabolic control and other measures of diabetes care for up to 22 months.</i>	Full Text	Population: not children (adults/foetuses)
<i>246. Biomedical predictors of consistent continuous glucose monitoring in youth with type 1 diabetes</i>	Title	Outcome: not related to insulin treatment adherence
<i>247. Biopsychosocial Factors Associated With Satisfaction and Sustained Use of Artificial Pancreas Technology and Its Components: a Call to the Technology Field.</i>	Full Text	Wrong study type (review, conference abstract etc.)
<i>248. Blood glucose control and compliance of diabetic children</i>	Full Text	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>249. Blood glucose monitoring and glycemic control in adolescents with type 1 diabetes: meter downloads versus self-report.</i>	Title	Outcome: not related to insulin treatment adherence
<i>250. Blood glucose monitoring by diabetic adolescents: compliance and metabolic control</i>	Title	Outcome: not related to insulin treatment adherence
<i>251. Blood glucose monitoring: Which is better: Continuous real-time or episodic real-time on demand? CON</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>252. Blood glucose self-monitoring in type 2 diabetes: a randomised controlled trial</i>	Title	Population: do not have T1DM
<i>253. Blood glucose testing by drivers with diabetes: A survey of glucose meter users</i>	Title	Population: not children (adults/foetuses)
<i>254. Blood or urine glucose-based insulin therapy and control of glycemia. Computer-simulation study.</i>	Title	Outcome: not related to insulin treatment adherence
<i>255. Blood pressure lowering for the prevention and treatment of diabetic kidney disease.</i>	Title	Outcome: not related to insulin treatment adherence
<i>256. Body relationship as a predictor of self-care, physical health, and psychological well-being in adolescents with type 1 diabetes</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>257. Bolus calculator and wirelessly communicated blood glucose measurement effectively reduce hypoglycaemia in type 1 diabetic children - randomized controlled trial.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>258. Brazilian multicenter study for the evaluation of patients' satisfaction of blood glucose self-monitoring with BGStar blood glucose meter in insulinized patients with diabetes mellitus type 1 and 2</i>	Title	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
259. <i>Brief report: Maternal posttraumatic stress symptoms are related to adherence to their child's diabetes treatment regimen.</i>	Included	
260. <i>Brief report: Parent's health literacy among high-risk adolescents with insulin dependent diabetes</i>	Included	
261. <i>Budget Impact of Long-Acting Insulin Analogues: The Case in Brazil.</i>	Title	Outcome: not related to insulin treatment adherence
262. <i>Burden of Cardiovascular Risk Factors Over Time and Arterial Stiffness in Youth With Type 1 Diabetes Mellitus: The SEARCH for Diabetes in Youth Study.</i>	Title	Outcome: not related to insulin treatment adherence
263. <i>Burden of thiamine deficiency among children presented with diabetic ketoacidosis</i>	Title	Outcome: not related to insulin treatment adherence
264. <i>Can a computer game improve adherence to treatment in children with type 1 diabetes?</i>	Abstract	Wrong study type (review, conference abstract etc.)
265. <i>Can integrated technology improve self-care behavior in youth with type 1 diabetes? A randomized crossover trial of automated pump function.</i>	Abstract	Outcome: not related to insulin treatment adherence
266. <i>Características da dieta nas diferentes fases da evolução do diabetes melito Tipo 1</i> <i>Diet composition along the evolution of Type 1 diabetes mellitus</i>	Title	Outcome: not related to insulin treatment adherence
267. <i>Carbohydrate counting accuracy and blood glucose variability in adults with type 1 diabetes.</i>	Title	Outcome: not related to insulin treatment adherence
268. <i>Carbohydrate counting from onset of diabetes reduced insulin requirements but increased weight in children and adolescents</i>	Title	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>269. Carbohydrate Counting in Children and Adolescents with Type 1 Diabetes.</i>	Title	Outcome: not related to insulin treatment adherence
<i>270. Carbohydrate management</i>	Title	Outcome: not related to insulin treatment adherence
<i>271. Cardiac and Vascular Function in Adolescents and Young Adults with Type 1 Diabetes</i>	Title	Outcome: not related to insulin treatment adherence
<i>273. Cardiometabolic risk in pediatric survivors of childhood cancer</i>	Title	Population: do not have T1DM
<i>274. Cardiometabolic risk in survivors of childhood cancer who received hematopoietic cell transplant (HCT)</i>	Title	Population: do not have T1DM
<i>275. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial.</i>	Title	Outcome: not related to insulin treatment adherence
<i>276. Cardiovascular disease risk in young people with type 1 diabetes.</i>	Title	Outcome: not related to insulin treatment adherence
<i>278. Care of adolescents and young adults with diabetes - much more than transitional care: a personal view.</i>	Abstract	Population: not children (adults/foetuses)
<i>279. Care of adolescents with type 2 diabetes across the North West London pediatric diabetes network</i>	Title	Population: do not have T1DM
<i>280. Care plans: Part of improving ability to self care</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>281. Caregiver reports of provider recommended frequency of blood glucose monitoring and actual testing frequency for youth with type 1 diabetes.</i>	Title	Outcome: not related to insulin treatment adherence
<i>282. Case report: Rare form of diabetes mellitus type 1 in adolescent patient</i>	Title	Outcome: not related to insulin treatment adherence
<i>283. Case series of neuropathic symptoms in 3 adolescent females with diabetes mellitus</i>	Title	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
284. <i>Celiac disease arthropathy and autoimmunity study</i>	Title	Population: do not have T1DM
285. <i>Cell Based Therapy for Type 1 Diabetes: Should We Take Hyperglycemia Into Account?</i>	Title	Outcome: not related to insulin treatment adherence
286. <i>Challenges in using insulin pumps in pediatrics : AAA self report by families</i>	Abstract	Wrong study type (review, conference abstract etc.)
287. <i>Challenges of Diabetes Management in Toddlers</i>	Abstract	Outcome: not related to insulin treatment adherence
288. <i>Changes in treatment adherence and glyceimic control during the transition to adolescence in type 1 diabetes.</i>	Full Text	Outcome: not related to insulin treatment adherence
289. <i>Changes in type 1 diabetes health indicators from high school to college.</i>	Title	Outcome: not related to insulin treatment adherence
290. <i>Characteristics of adolescents with type 1 diabetes who exhibit adverse outcomes.</i>	Abstract	Outcome: not related to insulin treatment adherence
291. <i>Characteristics of diabetic ketoacidosis in Chinese adults and adolescents -- a teaching hospital-based analysis.</i>	Title	Outcome: not related to insulin treatment adherence
292. <i>Characteristics of pediatric diabetic ketoacidosis patients in Saudi Arabia</i>	Abstract	Outcome: not related to insulin treatment adherence
293. <i>Characterization of metabolic responders on CSII treatment amongst children and adolescents in Denmark from 2007 to 2013</i>	Title	Outcome: not related to insulin treatment adherence
295. <i>Chat line for adolescents with type 1 diabetes: A useful tool to improve coping with diabetes: A 2-year follow-up study</i>	Full Text	Outcome: not related to insulin treatment adherence
297. <i>Children and adolescents living with diabetes and celiac disease.</i>	Abstract	Outcome: not related to insulin treatment adherence
298. <i>Children as partners with adults in their medical care.</i>	Full Text	Outcome: not related to insulin treatment adherence



<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>299. Children with coeliac disease and insulin dependent diabetes mellitus - Growth, diabetes control and dietary intake</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>300. Chronic diseases of childhood: Assessing compliance with complex medical regimens</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>301. Clinical and economic outcomes among patients with diabetes mellitus initiating insulin glargine pen versus vial</i>	Abstract	Population: not children (adults/foetuses)
<i>302. Clinical case: Berardinelli-seip syndrome in a 5 month old child</i>	Title	Outcome: not related to insulin treatment adherence
<i>303. Clinical characteristics and management of patients with type 1 diabetes-a national population-based spanish study (SED1)</i>	Abstract	Population: not children (adults/foetuses)
<i>304. Clinical characteristics of non-insulin-dependent diabetes mellitus among southwestern American Indian youths</i>	Title	Population: do not have T1DM
<i>305. Clinical Efficacy of Two Different Methods to Initiate Sensor-Augmented Insulin Pumps: A Randomized Controlled Trial.</i>	Abstract	Population: not children (adults/foetuses)
<i>306. Clinical practice factors that define insulin pump readiness</i>	Title	Outcome: not related to insulin treatment adherence
<i>307. Clinical predictors of mucormycosis in children with type 1 diabetes mellitus.</i>	Title	Outcome: not related to insulin treatment adherence
<i>308. Clinical profile and outcome of children with diabetic ketoacidosis: Type 1 diabetes mellitus a real challenge for low income Nation</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>309. Clinical profile and outcome of type 1 diabetes mellitus in tertiary care center of Eastern Nepal</i>	Abstract	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>310. Clinical profile and outcomes of paediatric patients with diabetic ketoacidosis at a tertiary care hospital in Pakistan</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>311. Clinical profile of type 1 diabetes mellitus in children referred to a tertiary care centre</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>312. Clinical Use of Continuous Glucose Monitoring in Adults with Type 1 Diabetes.</i>	Title	Population: not children (adults/foetuses)
<i>313. Clinical utility of serologic testing for celiac disease in asymptomatic patients: an evidence-based analysis.</i>	Title	Population: do not have T1DM
<i>314. Clinical, para-clinical and outcomes of diabetes ketoacidosis in Vietnam national hospital pediatrics</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>315. Closing the loop in poor control</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>316. Clustering of coronary heart disease risk factors among obese children</i>	Title	Outcome: not related to insulin treatment adherence
<i>317. Coated pellets with controlled glucose release in treatment of children with diabetes</i>	Title	Outcome: not related to insulin treatment adherence
<i>318. Cognitive and behavioral determinants of compliance in diabetics</i>	Full Text	Population: not children (adults/foetuses)
<i>319. Cognitive-behavioral therapy for the treatment of depression and adherence in patients with type 1 diabetes: pilot data and feasibility.</i>	Full Text	Population: not children (adults/foetuses)
<i>320. Comparing medical utilization between insulin pen and vial users within a pediatric medicaid accountable care organization</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>321. Comparing social learning and family systems correlates of adaptation in youths with IDDM</i>	Abstract	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
322. <i>Comparison of insulin detemir in a twice daily insulin regimen versus a three times daily insulin regimen in children with type 1 diabetes: A randomized controlled trial</i>	Abstract	Wrong study type (review, conference abstract etc.)
323. <i>Comparison of insulin regimens and administration modalities in pregnancy complicated by diabetes</i>	Title	Population: not children (adults/foetuses)
324. <i>Comparison of medication adherence in diabetes mellitus patients on human versus analogue insulins</i>	Abstract	Population: not children (adults/foetuses)
325. <i>Comparison of quality of life in adolescents with Type 1 diabetes using different treatment modalities; Continuous subcutaneous insulin infusion (insulin pumps), twice daily injections or multiple insulin injections</i>	Abstract	Wrong study type (review, conference abstract etc.)
326. <i>Comparison of usability and patient preference for the new disposable insulin device solostar versus flexpen, lilly disposable pen, and a prototype pen: an open-label study</i>	Included	
327. <i>Compliance and administration methods in management of type 1 diabetes.</i>	Full Text	Wrong study type (review, conference abstract etc.)
329. <i>Compliance bei Kindern und Jugendlichen mit Typ-1-Diabetes (juvener Diabetes mellitus) Compliance of children and adolescents with type 1 diabetes (juvenile diabetes mellitus)</i>	Full Text	Outcome: not related to insulin treatment adherence
330. <i>Compliance of adolescents with diabetes</i>	Included	
331. <i>Compliance of young diabetics with health regimens</i>	Full Text	Outcome: not related to insulin treatment adherence
332. <i>Compliance to treatment among children with type 1 diabetes mellitus: Experience in Abakaliki</i>	Abstract	Wrong study type (review, conference abstract etc.)

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>333. Compliance with complex medical regimens: Assessing daily management of childhood diabetes</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>334. Compliance with dietary prescriptions in children and adolescents with insulin-dependent diabetes mellitus</i>	Title	Outcome: not related to insulin treatment adherence
<i>335. Compliance with gluten free diet (GFD) is associated with better glycemic control in children with type 1 diabetes (T1D)</i>	Title	Outcome: not related to insulin treatment adherence
<i>336. Compliance with gluten-free diet has a positive influence on glycemic control in children with celiac disease and type 1 diabetes</i>	Title	Outcome: not related to insulin treatment adherence
<i>337. Comprehensive assessment of long-term therapeutic adherence and recurrent pain in children and adolescents</i>	Full Text	Outcome: not related to insulin treatment adherence
<i>338. Computerized knowledge management in diabetes care</i>	Title	Outcome: not related to insulin treatment adherence
<i>339. Condition-related predictors of successful transition from paediatric to adult care among adolescents with Type 1 diabetes.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>340. Consequences of delayed pump infusion line change in patients with type 1 diabetes mellitus treated with continuous subcutaneous insulin infusion.</i>	Title	Outcome: not related to insulin treatment adherence
<i>342. Considerations for diabetes: treatment with insulin pen devices.</i>	Full Text	Wrong study type (review, conference abstract etc.)
<i>343. Continuous Glucose Monitoring (CGM) Adherence in Youth with Type 1 Diabetes: Associations with Biomedical and Psychosocial Variables</i>	Title	Outcome: not related to insulin treatment adherence
<i>344. Continuous Glucose Monitoring Adherence: Lessons from a Clinical Trial to Predict Outpatient Behavior</i>	Title	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
346. <i>Continuous glucose monitoring and pumps.</i>	Abstract	Outcome: not related to insulin treatment adherence
347. <i>Continuous glucose monitoring interventions in toddlers with type 1 diabetes (T1D)</i>	Abstract	Outcome: not related to insulin treatment adherence
348. <i>Continuous glucose monitoring systems for type 1 diabetes mellitus.</i>	Abstract	Outcome: not related to insulin treatment adherence
350. <i>Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections: The GOLD Randomized Clinical Trial.</i>	Title	Population: not children (adults/foetuses)
351. <i>Continuous subcutaneous insulin infusion ("Insulin Pump") in pediatric patients with type 1 diabetes: Experience in a Chilean state hospital</i>	Abstract	Outcome: not related to insulin treatment adherence
352. <i>Continuous subcutaneous insulin infusion (CSII)</i>	Full Text	Wrong study type (review, conference abstract etc.)
353. <i>Continuous subcutaneous insulin infusion (insulin pump) therapy can be safely used in the hospital in select patients.</i>	Full Text	Population: not children (adults/foetuses)
354. <i>Continuous subcutaneous insulin infusion in Italy: third national survey.</i>	Abstract	Outcome: not related to insulin treatment adherence
355. <i>Control of type 2 diabetes mellitus among general practitioners in private practice in nine countries of Latin America</i>	Title	Population: do not have T1DM
356. <i>Coping styles in youths with insulin-dependent diabetes mellitus</i>	Included	
357. <i>Correlates of insulin injection omission.</i>	Abstract	Population: not children (adults/foetuses)
358. <i>Correlates of medication adherence in the TODAY cohort of youth with type 2 diabetes</i>	Title	Population: do not have T1DM
359. <i>Costs associated with long-acting insulin analogues in patients with diabetes.</i>	Title	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>360. Could clinical parameters at initiation of continuous glucose monitoring (CGM) predict efficacy on HbA1c in type 1 diabetes (T1D) pediatric patients at 3 months? Preliminary results in a prospective study of 141 patients (Start-In!)</i>	Title	Outcome: not related to insulin treatment adherence
<i>361. CoYoT1 Clinic: Home Telemedicine Increases Young Adult Engagement in Diabetes Care.</i>	Title	Population: not children (adults/foetuses)
<i>362. Crisis intervention program in newly diagnosed diabetic children.</i>	Included	
<i>363. Cross-cultural adaption and psychometric properties of the Chinese version of the Diabetes Behavior Rating Scale: a pilot study</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>364. Current Diagnosis and Treatment, and Clinical Challenges in the Management of Lipodystrophy Syndromes in Children and Youth</i>	Abstract	Population: do not have T1DM
<i>365. Cyclical cushing's disease in an adolescent with type 1 diabetes</i>	Title	Outcome: not related to insulin treatment adherence
<i>366. Cytoadherence of lymphocytes from type 1 diabetic subjects to insulin-secreting cells. Marker of anti-beta-cell cellular immunity.</i>	Title	Outcome: not related to insulin treatment adherence
<i>367. D-buddy peer support for better health outcomes in adolescents with diabetes mellitus</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>368. Daily insulin requirement of children and adolescents with type 1 diabetes: Effect of age, gender, body mass index and mode of therapy</i>	Title	Outcome: not related to insulin treatment adherence
<i>370. Das diabetische kind auf der notfallstationThe diabetic child and adolescent in the emergency room</i>	Abstract	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>371. Day-to-day consistency in amount and source of carbohydrate intake associated with improved blood glucose control in type 1 diabetes.</i>	Title	Outcome: not related to insulin treatment adherence
<i>373. Decision-making in diabetes mellitus type 1.</i>	Full Text	Wrong study type (review, conference abstract etc.)
<i>374. Defective erythrocyte C3b receptor function associated with low serum complement (C3, C4) concentrations in insulin-dependent diabetes mellitus.</i>	Title	Outcome: not related to insulin treatment adherence
<i>375. Depression among adults with diabetes in Jordan: risk factors and relationship to blood sugar control.</i>	Title	Population: not children (adults/foetuses)
<i>376. Depression and suicidal ideation in adolescents with type 1 diabetes mellitus</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>377. Depression-related hyperglycemia in type 1 diabetes: a mediational approach.</i>	Full Text	Population: not children (adults/foetuses)
<i>378. Depressive symptoms and glycemic control in adolescents with type 1 diabetes: mediational role of blood glucose monitoring.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>379. Depressive symptoms in type 1 diabetic children with poor and excellent metabolic control</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>380. Depressive symptoms, daily stress, and adherence in late adolescents with type 1 diabetes.</i>	Included	
<i>381. Depressive symptoms, depression-related cognitions, and diabetes care in adolescence</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>382. Design, construction, and implementation of an online platform for patients with type 1 diabetes: EncoDiab.</i>	Abstract	Population: not children (adults/foetuses)

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
383. <i>Detecting intentional insulin omission for weight loss in girls with type 1 diabetes mellitus.</i>	Included	
384. <i>Determinacion continua de glucosa sistema glucoday. En ninos adolescentes con diabetes tipo 1[Continuous glucose monitoring using the Glucoday system, in children and adolescents who have type one diabetes]</i>	Abstract	Outcome: not related to insulin treatment adherence
385. <i>Determinants of Glycemic Control among Insulin Treated Diabetic Patients in Southwest Ethiopia: Hospital Based Cross Sectional Study</i>	Title	Outcome: not related to insulin treatment adherence
386. <i>Determinants of outcome of children with type 1 diabetes in Cameroon</i>	Title	Outcome: not related to insulin treatment adherence
387. <i>Determinants of self-monitoring of blood glucose in patients with Type 1 diabetes: a multi-centre study in Brazil.</i>	Title	Outcome: not related to insulin treatment adherence
388. <i>Developing a theoretical maintenance model for disordered eating in Type 1 diabetes.</i>	Title	Outcome: not related to insulin treatment adherence
389. <i>Development and evaluation by a cluster randomised trial of a psychosocial intervention in children and teenagers experiencing diabetes: The DEPICTED study</i>	Included	
391. <i>Development and validity testing of the revised diabetes self-care inventory for children and adolescents</i>	Included	
392. <i>Development of a New Measure for Assessing Insulin Delivery Device Satisfaction in Patients with Type 1 and Type 2 Diabetes.</i>	Abstract	Population: not children (adults/foetuses)
393. <i>Development of an Insulin-Prescribing Chart for Paediatric Diabetes</i>	Abstract	Outcome: not related to insulin treatment adherence
394. <i>Developmental effects of type 1 diabetes</i>	Title	Outcome: not related to insulin treatment adherence



Result Number and Title	Excluded by/included	First Exclusion Criteria Met
395. <i>Developmental influences on adolescent health</i>	Title	Population: do not have T1DM
396. <i>Dextran-b-poly(lactide-co-glycolide) polymersome for oral delivery of insulin: In vitro and in vivo evaluation.</i>	Title	Outcome: not related to insulin treatment adherence
397. <i>Diabeetikonuoren hoitoon sitoutuminen ja perheen toimivuus nuoren itsensa arvioimana Compliance of young diabetic patients with therapeutic regimens and participation by the family</i>	Full Text	Outcome: not related to insulin treatment adherence
398. <i>DIABEO App Software and Telemedicine Versus Usual Follow-Up in the Treatment of Diabetic Patients: Protocol for the TELESAGE Randomized Controlled Trial.</i>	Abstract	Outcome: not related to insulin treatment adherence
399. <i>Diabete di tipo 1 in eta pediatrica all'esordio: Casistica ospedaliera Italiana raccolta mediante network Childhood type 1 diabetes at onset: Network for collection of case records in Italian hospitals</i>	Title	Outcome: not related to insulin treatment adherence
400. <i>Diabetes Control and Adherence in Adolescence.</i>	Full Text	Wrong study type (review, conference abstract etc.)
401. <i>Diabetes Control and Complications Trial (DCCT): results of feasibility study. The DCCT Research Group.</i>	Title	Outcome: not related to insulin treatment adherence
402. <i>Diabetes control did not worsen after insulin pump discontinuation in non-compliant adolescents with type 1 diabetes</i>	Abstract	Outcome: not related to insulin treatment adherence
403. <i>Diabetes in childhood</i>	Abstract	Wrong study type (review, conference abstract etc.)
404. <i>Diabetes in Japan: a review of disease burden and approaches to treatment.</i>	Title	Outcome: not related to insulin treatment adherence
405. <i>Diabetes knowledge in preadolescents with type 1 diabetes</i>	Abstract	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
406. <i>Diabetes melito do tipo 2 na infancia e adolescencia: Revisao da literatura</i> Type 2 diabetes in children and adolescents: Literature review	Title	Population: do not have T1DM
407. <i>Diabetes mellitus as a model of psychosomatic and somatopsychic interrelationships.</i>	Title	Outcome: not related to insulin treatment adherence
408. <i>Diabetes mellitus at a rural hospital in northwestern Tanzania</i>	Abstract	Outcome: not related to insulin treatment adherence
409. <i>Diabetes mellitus in the transition to adulthood: adjustment, self-care, and health status</i>	Abstract	Population: not children (adults/foetuses)
410. <i>Diabetes mellitus type 1 in patient with medium-chain acyl-coenzyme a dehydrogenase deficiency</i>	Abstract	Outcome: not related to insulin treatment adherence
411. <i>Diabetes mellitus.</i>	Abstract	Outcome: not related to insulin treatment adherence
412. <i>Diabetes regimen behaviors. Predicting adherence</i>	Full Text	Population: not children (adults/foetuses)
413. <i>Diabetes resilience: Psychometric properties of a measure for preadolescents with type 1 diabetes</i>	Abstract	Outcome: not related to insulin treatment adherence
414. <i>Diabetes technology and the human factor.</i>	Abstract	Wrong study type (review, conference abstract etc.)
415. <i>Diabetes technology in adolescents and young adults</i>	Abstract	Wrong study type (review, conference abstract etc.)
416. <i>Diabetes-specific risk taking-psychometric properties of a measure for adolescents with type 1 diabetes (T1D)</i>	Abstract	Wrong study type (review, conference abstract etc.)
417. <i>Diabetic care provision and glycemic control in a pediatrics diabetic clinic: An audit</i>	Abstract	Outcome: not related to insulin treatment adherence
418. <i>Diabetic control in adolescents</i>	Abstract	Population: not children (adults/foetuses)
419. <i>Diabetic ketoacidosis complicating pregnancy.</i>	Title	Population: not children (adults/foetuses)
420. <i>Diabetic ketoacidosis in a patient with islet cell transplant</i>	Title	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>421. Diabetic ketoacidosis in an adolescent and young adult population in the UK in 2014: National survey comparison of the management in adult and paediatric settings</i>	Title	Outcome: not related to insulin treatment adherence
<i>422. Diabetic ketoacidosis in the setting of HNF1A-maturity onset diabetes of the young.</i>	Title	Outcome: not related to insulin treatment adherence
<i>423. Diabetic ketoacidosis with acute renal failure and rhabdomyolysis: A case presentation and review of literature</i>	Title	Outcome: not related to insulin treatment adherence
<i>424. Diabetic ketoacidosis, determinants and mortality rate in Sudanese children with type 1 diabetes mellitus</i>	Title	Outcome: not related to insulin treatment adherence
<i>425. Diabetic ketoacidosis--a study of 33 episodes</i>	Title	Outcome: not related to insulin treatment adherence
<i>426. Diabetic ketoacidosis: risk factors and management strategies.</i>	Title	Outcome: not related to insulin treatment adherence
<i>427. Diabetic mellitus type 1 in patient with beta major thalassemia (case report)</i>	Title	Outcome: not related to insulin treatment adherence
<i>428. Diabulimia: how eating disorders can affect adolescents with diabetes</i>	Full Text	Wrong study type (review, conference abstract etc.)
<i>430. Diagnosis and management of hyperglycemic emergencies.</i>	Title	Outcome: not related to insulin treatment adherence
<i>431. Diagnosis and management of type 2 diabetes in youth in North Queensland and the Northern Territory: A health professional survey</i>	Title	Population: do not have T1DM
<i>432. Diazoxide in children with obesity after hypothalamic-pituitary lesions: A randomized, placebo-controlled trial</i>	Title	Population: do not have T1DM
<i>433. Diet and the diabetic patient.</i>	Title	Outcome: not related to insulin treatment adherence
<i>434. Diet therapy among young diabetics in the Philippines.</i>	Title	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
435. <i>Diet-related knowledge, skill, and adherence among children with insulin-dependent diabetes mellitus</i>	Title	Outcome: not related to insulin treatment adherence
436. <i>Dietary adherence and associated glycemic control in families of young children with type 1 diabetes.</i>	Title	Outcome: not related to insulin treatment adherence
437. <i>Dietary Adherence and Mealtime Behaviors in Young Children with Type 1 Diabetes on Intensive Insulin Therapy</i>	Title	Outcome: not related to insulin treatment adherence
439. <i>Dietary behaviors predict glycemic control in youth with type 1 diabetes.</i>	Title	Outcome: not related to insulin treatment adherence
440. <i>Dietary compliance among insulin-dependent diabetics.</i>	Title	Outcome: not related to insulin treatment adherence
441. <i>Dietary intake and risk of non-severe hypoglycemia in adolescents with type 1 diabetes.</i>	Title	Outcome: not related to insulin treatment adherence
442. <i>Dietary survey of diabetics</i>	Title	Outcome: not related to insulin treatment adherence
443. <i>Differences between bulimia nervosa and binge-eating disorder in females with type 1 diabetes: the important role of insulin omission.</i>	Full Text	Population: not children (adults/foetuses)
444. <i>Differences in family mealtime interactions between young children with type 1 diabetes and controls: implications for behavioral intervention.</i>	Abstract	Outcome: not related to insulin treatment adherence
445. <i>Differences in long-term metabolic control and BMI in children with type 1 diabetes on insulin pumps stratified by age and sex</i>	Title	Outcome: not related to insulin treatment adherence
446. <i>Differences in the metabolism of postprandial lipoproteins after a high-monounsaturated-fat versus a high-carbohydrate diet in patients with type 1 diabetes mellitus.</i>	Title	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
447. <i>Different health behaviours and clinical factors associated with bone mineral density and bone turnover in premenopausal women with and without type 1 diabetes.</i>	Title	Outcome: not related to insulin treatment adherence
448. <i>Dificultades y preocupaciones identificadas por jóvenes puertorriqueños/as con diabetes mellitus insulino-dependiente (IDDM): su relación con control metabólico, desesperanza, apoyo social y sintomatología depresiva</i> <i>Difficulties and concerns identified by Puerto Rican youth with insulin-dependent diabetes mellitus (IDDM): their relationship with metabolic control, hopelessness, social support, and depressive symptoms</i>	Included	
449. <i>Discontinuation of insulin pump treatment in children, adolescents, and young adults. A multicenter analysis based on the DPV database in Germany and Austria.</i>	Title	Outcome: not related to insulin treatment adherence
450. <i>Discordant diabetes family responsibility sharing is associated with increased diabetes family conflict in youth with type 1 diabetes (T1D)</i>	Abstract	Wrong study type (review, conference abstract etc.)
451. <i>Discriminación de niveles de glucosa en sangre en diabéticos insulino-dependientes mediante señales externas y perfiles glucémicos</i>	Abstract	Outcome: not related to insulin treatment adherence
452. <i>Discriminant analysis of treatment adherence in insulin-dependent diabetes mellitus</i>	Full Text	Population: not children (adults/foetuses)
453. <i>Disease burden in young adults with Type 2 diabetes: A retrospective study</i>	Title	Population: not children (adults/foetuses)

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>454. Disease management in the young diabetic patient: glucose monitoring, coping skills, and treatment strategies.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>455. Disease management programs for patients with type 2 diabetes mellitus in Germany: a longitudinal population-based descriptive study</i>	Title	Population: do not have T1DM
<i>456. Dismissing attachment and outcome in diabetes: The mediating role of coping</i>	Full Text	Population: not children (adults/foetuses)
<i>457. Disordered Eating Behaviors Are Not Increased by an Intervention to Improve Diet Quality but Are Associated With Poorer Glycemic Control Among Youth With Type 1 Diabetes.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>458. Disposable insulin syringe reuse and aseptic practices in diabetic patients</i>	Title	Outcome: not related to insulin treatment adherence
<i>459. DKA management and outcomes</i>	Title	Outcome: not related to insulin treatment adherence
<i>460. Do European people with type 1 diabetes consume a high atherogenic diet? 7-year follow-up of the EURODIAB Prospective Complications Study.</i>	Title	Outcome: not related to insulin treatment adherence
<i>461. Do fat and protein need insulin? The complex food counting in meal-bolus calculation</i>	Title	Outcome: not related to insulin treatment adherence
<i>462. Do youth with type 1 diabetes exercise safely? A focus on patient practices and glycemic outcomes.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>463. Does high blood glucose mean more insulin? Type 1 diabetes management in children and adolescents</i>	Title	Outcome: not related to insulin treatment adherence
<i>465. Does parental perception of their child's quality of life and diabetes knowledge matter in relation to improving glycaemic control?</i>	Abstract	Wrong study type (review, conference abstract etc.)

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>466. Does patient behavior or access factors have the largest influence on screening in type 1 diabetes?</i>	Title	Outcome: not related to insulin treatment adherence
<i>467. Does self-efficacy mediate the cross-sectional relationship between perceived quality of health care and self-management of diabetes? Results from Diabetes MILES - Australia.</i>	Abstract	Population: not children (adults/foetuses)
<i>468. Durability of insulin pump use in pediatric patients with type 1 diabetes</i>	Full Text	Outcome: not related to insulin treatment adherence
<i>470. Dynamic regulation of plasma matrix metalloproteinases in human diabetic ketoacidosis</i>	Title	Outcome: not related to insulin treatment adherence
<i>472. Early age at menarche: a risk factor for overweight or obesity in patients with type 1 diabetes living in urban areas?</i>	Title	Outcome: not related to insulin treatment adherence
<i>473. Early diabetic nephropathy in a pediatric renal transplant recipient leading to end stage renal disease</i>	Title	Outcome: not related to insulin treatment adherence
<i>474. Early feeding and risk of type 1 diabetes: Experiences from the Trial to Reduce Insulin-dependent diabetes mellitus in the Genetically at Risk (TRIGR)</i>	Title	Outcome: not related to insulin treatment adherence
<i>476. Early identification of monogenic diabetes: Implications on medical treatment and genetic counselling for an adolescent girl with MODY3</i>	Title	Population: do not have T1DM
<i>477. Early infant feeding and risk of developing type 1 diabetes associated autoantibodies</i>	Title	Outcome: not related to insulin treatment adherence
<i>479. Early onset type 2 diabetes mellitus in a Saudi child misdiagnosed as type 1 diabetic: A case report.</i>	Title	Population: do not have T1DM

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>480. Early pharmacokinetic and pharmacodynamic effects of mixing lispro with glargine insulin: Results of glucose clamp studies in youth with type 1 diabetes</i>	Title	Outcome: not related to insulin treatment adherence
<i>482. Early presentation of type 2 diabetes in Mexican-American youth</i>	Title	Population: do not have T1DM
<i>484. Early risk factors for nonadherence in pediatric type 1 diabetes: a review of the recent literature.</i>	Title	Wrong study type (review, conference abstract etc.)
<i>486. Early signs of atherosclerosis in diabetic children on intensive insulin treatment: A population-based study</i>	Title	Outcome: not related to insulin treatment adherence
<i>488. Eating disorders in adolescents with type 1 and type 2 diabetes mellitus: Prevalence and adherence to the regimen</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>489. Eating habits, body weight, and insulin misuse. A longitudinal study of teenagers and young adults with type 1 diabetes.</i>	Abstract	Population: not children (adults/foetuses)
<i>490. Eating patterns in adolescents with type 1 diabetes: Associations with metabolic control, insulin omission, and eating disorder pathology.</i>	Included	
<i>491. Education and care in schooled diabetic children and adolescents</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>493. Educational program for patients with type-1 diabetes mellitus receiving free monthly supplies of insulin improves knowledge and attitude, but not adherence.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>494. Educational social games embedded in a telemonitoring tool for children with type 1 diabetes: A preliminary paper</i>	Abstract	Outcome: not related to insulin treatment adherence



<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>495. Educational strategies on insulin therapy for young people with diabetes mellitus: Systematic review</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>496. Effect of dietary compliance on metabolic control in insulin-dependent diabetics</i>	Title	Outcome: not related to insulin treatment adherence
<i>497. Effect of fasting during Ramadan on different metabolic parameters and quality of life in type 1 diabetic patients</i>	Title	Outcome: not related to insulin treatment adherence
<i>498. Effect of gluten-free diet and adherence on growth and diabetic control in diabetics with coeliac disease</i>	Title	Outcome: not related to insulin treatment adherence
<i>500. Effect of health beliefs among physicians, families, and children with insulin-dependent diabetes mellitus on treatment adherence and metabolic control</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>501. Effect of metformin on vascular function in children with type 1 diabetes: A 12-month randomized controlled trial</i>	Title	Outcome: not related to insulin treatment adherence
<i>502. Effect of therapy with insulin glargine (lantus) on glycemic control in toddlers, children, and adolescents with diabetes.</i>	Title	Outcome: not related to insulin treatment adherence
<i>503. Effectiveness of a tailored medical support to overcome the barriers to education, treatment and good metabolic control in children with type-1 diabetes from ethnic minorities.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>504. Effectiveness of lactobacillus reuteri oral administration on periodontal disease in children and adolescents with type 1 diabetes</i>	Title	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>505. Effectiveness of multiple daily injection or continuous infusion of insulin on children at different courses of T1DM</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>506. Effectiveness of sensor-augmented pump therapy in children and adolescents with type 1 diabetes in the STAR 3 study.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>507. Effectiveness of the sensor augmented pump in managing type 1 diabetes mellitus</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>508. Effects of a behavioral intervention on treatment adherence and stress management in adolescents with IDDM</i>	Included	
<i>509. Effects of cognitive behavioural group training (CBGT) in adult patients with poorly controlled insulin-dependent (type 1) diabetes: a pilot study.</i>	Title	Population: not children (adults/foetuses)
<i>510. Effects of diabetes em movimento community-based exercise program on body composition in patients with type 2 diabetes</i>	Title	Population: do not have T1DM
<i>511. Effects of enhanced conventional therapy on metabolic control in children with insulin-dependent diabetes mellitus</i>	Title	Outcome: not related to insulin treatment adherence
<i>512. Effects of Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb12 on beta-cell function in children with newly diagnosed type 1 diabetes: A pilot study</i>	Title	Outcome: not related to insulin treatment adherence
<i>513. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension.</i>	Title	Outcome: not related to insulin treatment adherence

Result Number and Title	Excluded by/included	First Exclusion Criteria Met
<i>514. Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes--a protocol for a randomised, double-blind, placebo-controlled study: the Lira-1 study.</i>	Title	Outcome: not related to insulin treatment adherence
<i>516. Efficacy of Humalog injections before an afternoon meal and their acceptance by children and adolescents with Type 1 diabetes</i>	Full Text	Outcome: not related to insulin treatment adherence
<i>518. Efficacy of Metformin Treatment with Respect to Weight Reduction in Children and Adults with Obesity: A Systematic Review</i>	Title	Population: do not have T1DM
<i>519. Efficacy of sensor-augmented insulin pump with predictive low glucose suspension: A multicentre clinical experience in adults and children in Spain</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>520. Efficacy of Thrice-daily versus Twice-daily Insulin Regimens on Glycohemoglobin (Hb A1c) in Type 1 Diabetes Mellitus: A Randomized Controlled Trial.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>521. Efficacy without barriers to insulin therapy: lessons from the BEGIN trial programme.</i>	Full Text	Population: not children (adults/foetuses)
<i>522. Efficacy, safety and acceptability of the new pen needle 33G?x?4?mm. AGO 01 study.</i>	Title	Outcome: not related to insulin treatment adherence
<i>523. Efficacy, safety and acceptability of the new pen needle 34G?x?3.5?mm: a crossover randomized non-inferiority trial; AGO 02 study.</i>	Title	Outcome: not related to insulin treatment adherence
<i>524. El cuidado de la diabetes mellitus insulino-dependiente: Efectos de un programa de modificación de conducta en padres</i>	Included	

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>525. Elimination of dietary gluten does not reduce titers of type 1 diabetes-associated autoantibodies in high-risk subjects.</i>	Title	Outcome: not related to insulin treatment adherence
<i>526. Emotions and compliance in diabetic children</i>	Full Text	Wrong study type (review, conference abstract etc.)
<i>527. Empirical validation for a family-centered model of care</i>	Included	
<i>528. Endothelial cell-binding properties of lymphocytes infiltrated into human diabetic pancreas: Implications for pathogenesis of IDDM</i>	Title	Outcome: not related to insulin treatment adherence
<i>529. Endurance athletes and type 1 diabetes.</i>	Title	Outcome: not related to insulin treatment adherence
<i>530. Engagement with a Text-Messaging Intervention Improves Adherence in Adolescents with Type 1 Diabetes: Brief Report.</i>	Included	
<i>531. Engaging hispanic adolescents with type 2 diabetes or obesity in personalized exercise</i>	Title	Population: do not have T1DM
<i>532. Entred-Ado study: Health, education and risk behaviours of adolescents with diabetes</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>533. Environmental factors affecting management of type 1 diabetes in children below the age of 10.</i>	Included	
<i>534. Epidemiology and chelation therapy effects on glucose homeostasis in thalassaemic patients</i>	Title	Population: do not have T1DM
<i>535. Establishing a baseline for patients with type 1 diabetes who wear medical identification</i>	Title	Outcome: not related to insulin treatment adherence
<i>536. Estimation of secondary effect parameters in glycaemic dynamics using accumulating data from a virtual type 1 diabetic patient.</i>	Title	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
537. <i>Evaluacion de un programa de atencion al diabetico. Estudio de continuidad a 40 meses</i> Evaluation of a program for the care of the diabetic. A 40-month continuity study	Title	Outcome: not related to insulin treatment adherence
538. <i>Evaluating the carbohydrate counting method related to blood glucose monitoring habits in type 1 diabetes mellitus patients</i>	Title	Outcome: not related to insulin treatment adherence
539. <i>Evaluating the impact of an insulin pump discontinuation action plan on patient or caregiver confidence and anxiety</i>	Abstract	Outcome: not related to insulin treatment adherence
540. <i>Evaluation of left ventricular diastolic function in insulin dependent diabetic children by M-mode and Doppler echocardiography</i>	Title	Outcome: not related to insulin treatment adherence
542. <i>Evaluation of the Adherence to Continuous Glucose Monitoring in the Management of Type 1 Diabetes Patients on Sensor-Augmented Pump Therapy: The SENLOCOR Study.</i>	Title	Outcome: not related to insulin treatment adherence
544. <i>Evaluation of the Carbohydrate, Insulin Collaborative Education (CHOICE) programme for young people with Type 1 diabetes</i>	Abstract	Outcome: not related to insulin treatment adherence
545. <i>Evaluation of the efficacy and tolerability of acarbose in patients with diabetes mellitus : a postmarketing surveillance study.</i>	Title	Outcome: not related to insulin treatment adherence
546. <i>Evaluation of the juniorSTAR half-unit insulin pen in young people with type 1 diabetes - user perspectives</i>	Included	

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>548. Evaluation of the knowledge and skills on self-monitoring blood glucose in patients and caregivers of patients with diabetes mellitus type 1</i>	Title	Outcome: not related to insulin treatment adherence
<i>549. Evaluation of the treatment of diabetic ketoacidosis in the medical intensive care unit</i>	Title	Outcome: not related to insulin treatment adherence
<i>550. Evaluation of treatment adherence in type 1 diabetes: A novel approach</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>552. Evidence for early stage atherosclerosis and low grade inflammation in diabetic children on intensive insulin treatment: A population based study</i>	Title	Outcome: not related to insulin treatment adherence
<i>553. Evolution of the diabetic diet: Fats and fallacies.</i>	Title	Outcome: not related to insulin treatment adherence
<i>554. Examining concurrent validity of the mealtime BOLUS score with common psychosocial correlates of adherence in youth</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>555. Executive functioning, parenting stress, and family factors as predictors of diabetes management in pediatric patients with type 1 diabetes using intensive regimens</i>	Included	
<i>556. Exercise capacity in healthy pubertal children in comparison with type 1 diabetic pubertal children</i>	Title	Outcome: not related to insulin treatment adherence
<i>557. Exercise equipment and diabetes.</i>	Title	Outcome: not related to insulin treatment adherence
<i>558. Exercise therapy: prevention and treatment of disease</i>	Title	Outcome: not related to insulin treatment adherence
<i>559. Exercise to preserve beta cell function in recent-onset type 1 diabetes mellitus (EXTOD)--a study protocol for a pilot randomized controlled trial.</i>	Title	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>560. Exercise to preserve <math>\beta</math>-cell function in recent-onset Type 1 diabetes mellitus (EXTOD) - a randomized controlled pilot trial.</i>	Title	Outcome: not related to insulin treatment adherence
<i>561. Exercise training and glycemic control in adolescents with poorly controlled type 1 diabetes mellitus.</i>	Title	Outcome: not related to insulin treatment adherence
<i>562. Experience with the Enlite sensor in a multicenter pediatric study.</i>	Title	Outcome: not related to insulin treatment adherence
<i>563. Experiences and real life management of insulin pump therapy in adults with type 1 diabetes.</i>	Title	Population: not children (adults/foetuses)
<i>564. Experiences in diabetes management: Interviews with children with type 2 diabetes and their caregivers</i>	Title	Population: do not have T1DM
<i>565. Experimental cannabidiol treatment reduces early pancreatic inflammation in type 1 diabetes.</i>	Title	Outcome: not related to insulin treatment adherence
<i>566. Expert Study: Utility of an Automated Bolus Advisor System in Patients with Type 1 Diabetes Treated with Multiple Daily Injections of Insulin-A Crossover Study.</i>	Full Text	Population: not children (adults/foetuses)
<i>567. Explanatory style in parents and insulin-dependent diabetic children in relation to depressive symptoms, compliance and metabolic control</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>568. Exploring factors influencing HbA1c and psychosocial outcomes in people with type 1 diabetes after training in advanced carbohydrate counting.</i>	Full Text	Population: not children (adults/foetuses)
<i>569. Exploring the motivations behind misreporting self-measured blood glucose in adolescents with type 1 diabetes - a qualitative study</i>	Abstract	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
571. <i>Expressed emotion and warmth: Extending the EE contrast to insulin-dependent diabetes mellitus</i>	Full Text	Outcome: not related to insulin treatment adherence
572. <i>Extremely elevated triglyceride blood concentration as a presentation of type 2 diabetes mellitus (T2DM) in childhood obesity</i>	Title	Population: do not have T1DM
573. <i>Exubera(®) (inhaled insulin): an evidence-based review of its effectiveness in the management of diabetes.</i>	Title	Outcome: not related to insulin treatment adherence
574. <i>Facteurs liés à l'évolution des connaissances du diabète de l'enfance à l'adolescence</i> <i>Factors associated with change in diabetes knowledge from childhood to adolescence</i>	Abstract	Outcome: not related to insulin treatment adherence
575. <i>Factitious self-manipulation of the external insulin pump in adolescents with Type 1 diabetes.</i>	Full Text	Wrong study type (review, conference abstract etc.)
576. <i>Factores Psicológicos y Sociales Asociados a la Adherencia al Tratamiento en Adolescentes Diabéticos Tipo 1</i>		
577. <i>Factors associated to adherence to blood glucose self-monitoring in patients with diabetes treated with insulin. The dapa study.</i>	Title	Outcome: not related to insulin treatment adherence
578. <i>Factors associated with adherence to continuous subcutaneous insulin infusion in pediatric diabetes</i>	Abstract	Outcome: not related to insulin treatment adherence
580. <i>Factors associated with adherence to diabetes care recommendations among children and adolescents with type 1 diabetes: A facility-based study in two urban diabetes clinics in Uganda</i>		



<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>581. Factors associated with glycaemic control in children and adolescents with type 1 diabetes mellitus at a tertiary-care center in Thailand: A retrospective observational study</i>	Title	Outcome: not related to insulin treatment adherence
<i>584. Factors associated with glycaemic control: A cross-sectional nationwide study in 2,579 french children with type 1 diabetes</i>	Title	Outcome: not related to insulin treatment adherence
<i>585. Factors associated with having eye examinations in persons with diabetes</i>	Title	Outcome: not related to insulin treatment adherence
<i>586. Factors associated with high levels of glycated haemoglobin in patients with type 1 diabetes: a multicentre study in Brazil.</i>	Title	Outcome: not related to insulin treatment adherence
<i>587. Factors associated with increased risk of insulin pump discontinuation in pediatric patients with type 1 diabetes.</i>	Full Text	Outcome: not related to insulin treatment adherence
<i>588. Factors associated with non-adherence to insulin in patients with type 1 diabetes.</i>	Full Text	Population: not children (adults/foetuses)
<i>590. Factors associated with shared decision-making in pediatric type 1 diabetes: The search for diabetes in youth study</i>	Title	Outcome: not related to insulin treatment adherence
<i>591. Factors influencing the quality of glycaemic control in children and adolescents with type 1 diabetes, after five years of full and equal access of self-monitoring supplies</i>	Title	Outcome: not related to insulin treatment adherence
<i>592. Factors related to CSII compliance</i>	Full Text	Population: not children (adults/foetuses)
<i>593. Failure to achieve target glycaemic control on continuous subcutaneous insulin infusion (CSII) - Is passive pumping to blame?</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>594. Familial idiopathic oedema in prepubertal children: A new syndrome</i>	Title	Population: do not have T1DM

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>595. Family and disease management in young type 1 diabetic patients.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>596. Family conflict, adherence, and glycaemic control in youth with short duration Type 1 diabetes.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>597. Family factors involved in insulin-dependent diabetes mellitus: Metabolic control and compliance</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>598. Family physicians' and general practitioners' approaches to drug management of diabetic hypertension in primary care</i>	Title	Outcome: not related to insulin treatment adherence
<i>599. Family-based behavior therapy for diabetic adolescents</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>600. Faster pharmacokinetics and increased patient acceptance of intradermal insulin delivery using a single hollow microneedle in children and adolescents with type 1 diabetes</i>	Included	
<i>602. Father-absent adolescents with insulin-dependent diabetes mellitus: A population at risk?</i>	Included	
<i>603. Fatores associados a auto-aplicacao da insulina nos usuarios com diabetes mellitus acompanhados pela Estrategia Saude da Familia Factors associated with insulin self-administration by diabetes mellitus patients in the Family Health Strategy</i>	Full Text	Population: not children (adults/foetuses)
<i>604. Fear of driving license withdrawal in patients with insulin-treated diabetes mellitus negatively influences their decision to report severe hypoglycemic events to physicians.</i>	Abstract	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>605. Fear of hypoglycemia in adults with type 1 diabetes: impact of therapeutic advances and strategies for prevention - a review.</i>	Title	Population: not children (adults/foetuses)
<i>606. Fear of hypoglycemia in type 1 diabetes managed by continuous subcutaneous insulin infusion: is it associated with poor glycaemic control?</i>	Full Text	Population: not children (adults/foetuses)
<i>607. Feasibility of a mobile phone-based data service for functional insulin treatment of type 1 diabetes mellitus patients.</i>	Abstract	Population: not children (adults/foetuses)
<i>608. Feasibility of an online intervention (STAK-D) to promote physical activity in children with type 1 diabetes: Protocol for a randomised controlled trial</i>	Title	Outcome: not related to insulin treatment adherence
<i>609. Feasibility of genetic and immunological prediction of Type 1 diabetes in a population-based birth cohort</i>	Title	Outcome: not related to insulin treatment adherence
<i>610. First 20 months' experience with use of mefformin for type 2 diabetes in a large health maintenance organization</i>	Title	Population: do not have T1DM
<i>611. Flexible insulin dosing improves health-related quality-of-life (HRQoL): a time trade-off survey.</i>	Full Text	Population: not children (adults/foetuses)
<i>613. Frequency and motives of blood glucose self-monitoring in type 1 diabetes.</i>	Title	Outcome: not related to insulin treatment adherence
<i>614. Frequency and reasons for CSII discontinuation in children and young patients with T1DM</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>615. Frequency of blood glucose monitoring in relation to glycaemic control: observational study with diabetes database.</i>	Title	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>616. Frequency of blood glucose testing in well educated patients with diabetes mellitus type 1: how often is enough?</i>	Title	Outcome: not related to insulin treatment adherence
<i>617. Frequency of diabetic keto-acidosis in children with cystic fibrosis related diabetes</i>	Title	Population: do not have T1DM
<i>618. Frequency of mealtime insulin bolus as a proxy measure of adherence for children and youths with type 1 diabetes mellitus</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>620. Frequency of mealtime insulin bolus predicts glycosylated hemoglobin in youths with type 1 diabetes</i>	Title	Outcome: not related to insulin treatment adherence
<i>622. Frequency of Missed Insulin Boluses in Type 1 Diabetes and Its Impact on Diabetes Control.</i>	Title	Outcome: not related to insulin treatment adherence
<i>623. Function of the growth hormone-insulin-like growth factor I axis in the profoundly growth-retarded diabetic child: Evidence for defective target organ responsiveness in the mauriac syndrome</i>	Title	Outcome: not related to insulin treatment adherence
<i>624. Functional and psychosocial ramifications of type 1 diabetes mellitus in pediatric endocrinology</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>625. Fungal esophagitis in a child with insulin diabetes dependent mellitus</i>	Title	Outcome: not related to insulin treatment adherence
<i>626. Further examination of a structured adherence interview of diabetes for children, adolescents, and parents</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>627. Generic and disease-specific quality of life in adolescents with type 1 diabetes: comparison to age-matched healthy peers.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>628. Gluten-free diet in children with recent-onset type 1 diabetes without coeliac disease: A 12-month intervention trial</i>	Title	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
629. <i>Gluten-free diet in newly diagnosed children with type 1 diabetes</i>	Title	Outcome: not related to insulin treatment adherence
630. <i>Glycaemic control and associated factors in a population of children and adolescents living with type 1 diabetes in Cameroon</i>	Title	Outcome: not related to insulin treatment adherence
631. <i>Glycaemic control in a type 1 diabetes clinic for younger adults.</i>	Title	Population: not children (adults/foetuses)
632. <i>Glycaemic control in type 1 diabetes mellitus among children and adolescents in a resource limited setting in Dar es Salaam - Tanzania.</i>	Abstract	Outcome: not related to insulin treatment adherence
634. <i>Glycaemic control of insulin-dependent diabetes mellitus in Sudan: Influence of insulin shortage</i>	Included	
635. <i>Glycaemic control of Type 1 diabetes in clinical practice early in the 21st century: an international comparison.</i>	Title	Outcome: not related to insulin treatment adherence
636. <i>Glycemic and lactate thresholds during incremental effort test in pubertal children with type 1 diabetes compared with healthy controls</i>	Title	Outcome: not related to insulin treatment adherence
637. <i>Glycemic control and associated factors among type 2 diabetic patients at Shanan Gibe Hospital, Southwest Ethiopia</i>	Title	Population: do not have T1DM
638. <i>Glycemic control and correlates in a group of sub Saharan type 1 diabetes adolescents.</i>	Title	Outcome: not related to insulin treatment adherence
639. <i>Glycemic control and executive function in adolescents with type 1 diabetes (T1d)</i>	Abstract	Wrong study type (review, conference abstract etc.)
640. <i>Glycemic control in adult type 1 diabetes patients from a brazilian country city: comparison between a multidisciplinary and a routine endocrinological approach.</i>	Title	Population: not children (adults/foetuses)

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>641. Glycemic control with metformin or insulin therapy in adolescents with type 2 diabetes mellitus</i>	Title	Population: do not have T1DM
<i>642. Glycemic management using simple continuous subcutaneous insulin infusion in patients with type 2 diabetes</i>	Title	Population: do not have T1DM
<i>643. Glycemic outcomes and system adherence between age groups in pediatric subjects using a hybrid closed-loop pump</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>644. Glycemic variability: A peril of modern insulin therapy among youths with type 1 diabetes?</i>	Title	Outcome: not related to insulin treatment adherence
<i>645. Glycosylated hemoglobin feedback profile as one behavioral strategy for improving adherence to long-term regimens: Insulin dependent diabetes mellitus</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>646. Good adherence to the Mediterranean diet reduces the risk for NASH and diabetes in pediatric patients with obesity: The results of an Italian Study</i>	Title	Outcome: not related to insulin treatment adherence
<i>647. Good cop, bad cop: quality of parental involvement in type 1 diabetes management in youth.</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>648. Growth and body composition in type 1 diabetes mellitus.</i>	Title	Outcome: not related to insulin treatment adherence
<i>650. Growth monitoring in management of T1DM children from low-socioeconomic status</i>	Title	Outcome: not related to insulin treatment adherence
<i>651. Health status, regimen adherence, and psychosocial functioning of minority youth with type 2 diabetes</i>	Title	Population: do not have T1DM
<i>652. Health-related quality of life (HRQOL) and its associated factors in children with Type 1 Diabetes Mellitus (T1DM)</i>	Abstract	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>653. Health-related quality of life and its associated factors in children with type 1 diabetes mellitus</i>		
<i>654. Health-Related Stigma in Young Adults With Type 1 Diabetes Mellitus.</i>	Title	Population: not children (adults/foetuses)
<i>655. Health-risk behaviors and type 1 diabetes outcomes in the transition from late adolescence to early emerging adulthood</i>	Included	
<i>656. Healthcare costs and adherence associated with human regular U-500 versus high-dose U-100 insulin in patients with diabetes.</i>	Full Text	Population: not children (adults/foetuses)
<i>657. Helicobacter pylori infection and insulin requirement among children with type 1 diabetes mellitus</i>	Title	Outcome: not related to insulin treatment adherence
<i>659. Help 'difficult' adolescents with type 1 diabetes to improve metabolic control: The peter pan project</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>660. Hepatic glycogenosis, a rare cause of hepatomegaly and abnormal liver enzymes in type 1 diabetes mellitus: A case report</i>	Title	Outcome: not related to insulin treatment adherence
<i>661. High inpatient variability of calcineurin inhibitor levels is associated with post-transplant diabetes mellitus in pediatric kidney transplant</i>	Title	Population: do not have T1DM
<i>662. High-risk youth with diabetes need home-based behavioral interventions</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>663. Home-based behavioral health intervention: Use of a telehealth model to address poor adherence to type-1 diabetes medical regimens</i>	Full Text	Outcome: not related to insulin treatment adherence
<i>665. Home-based management can achieve intensification cost-effectively in type 1 diabetes</i>	Full Text	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>666. Hope and mealtime insulin boluses are associated with depressive symptoms and glycemic control in youth with type 1 diabetes mellitus</i>	Included	
<i>667. Hospitalization of diabetics 12-30 years of age in Kuwait: Patients' characteristics, and frequency and reasons for admission</i>	Title	Outcome: not related to insulin treatment adherence
<i>668. How diabetes specialists treat their own diabetes: findings from a study of the AADE and ADA membership.</i>	Title	Population: not children (adults/foetuses)
<i>669. How do we educate young people to balance carbohydrate intake with adjustments of insulin?</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>670. How effective are trained dogs at alerting their owners to changes in blood glycaemic levels?: Variations in performance of glycaemia alert dogs.</i>	Title	Outcome: not related to insulin treatment adherence
<i>671. How much do forgotten insulin injections matter to hemoglobin a1c in people with diabetes? A simulation study.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>672. How poorer quality of life in adolescence predicts subsequent type 1 diabetes management and control.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>673. How useful are serum IGF-I measurements for managing GH replacement therapy in adults and children?</i>	Title	Outcome: not related to insulin treatment adherence
<i>674. Huge transient elevation of liver enzymes during diabetic ketoacidosis</i>	Title	Outcome: not related to insulin treatment adherence
<i>675. Human Factors and Data Logging Processes With the Use of Advanced Technology for Adults With Type 1 Diabetes: Systematic Integrative Review.</i>	Title	Population: not children (adults/foetuses)
<i>676. Human factors associated with continuous glucose monitor use in patients with diabetes: A systematic review</i>	Title	Outcome: not related to insulin treatment adherence



<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
677. <i>Hydrolyzed infant formula and early beta-cell autoimmunity</i>	Title	Outcome: not related to insulin treatment adherence
678. <i>Hyperglycaemia and metabolic syndrome: Not always synonymous of T2D</i>	Title	Outcome: not related to insulin treatment adherence
679. <i>Hyperglycaemic emergencies are a common problem</i>	Title	Outcome: not related to insulin treatment adherence
680. <i>Hypoglycaemia and counterregulation during childhood.</i>	Title	Outcome: not related to insulin treatment adherence
682. <i>Hypoglycaemia and driving in people with insulin-treated diabetes: adherence to recommendations for avoidance.</i>	Title	Outcome: not related to insulin treatment adherence
683. <i>Hypoglycaemia in type 1 diabetes: technological treatments, their limitations and the place of psychology.</i>	Abstract	Outcome: not related to insulin treatment adherence
684. <i>Hypoglycemia and ketoacidosis with insulin pump therapy in children and adolescents</i>	Abstract	Outcome: not related to insulin treatment adherence
685. <i>Hypoglycemia unawareness is associated with reduced adherence to therapeutic decisions in patients with type 1 diabetes: evidence from a clinical audit.</i>	Full Text	Population: not children (adults/foetuses)
686. <i>Hypoglycemic episodes in an adolescent with diabetes type 1: A case report and a review of the literature</i>	Title	Outcome: not related to insulin treatment adherence
687. <i>Hypothalamic obesity: Pathogenesis and natural history</i>	Title	Population: do not have T1DM
688. <i>I get by with a little help from my family and friends: Adolescents' support for diabetes care</i>	Included	
689. <i>I know, so i do! Relationship between literacy and metabolic control in patients with type i diabetes</i>	Abstract	Wrong study type (review, conference abstract etc.)

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>690. Identification of clinically relevant dysglycemia phenotypes based on continuous glucose monitoring data from youth with type 1 diabetes and elevated hemoglobin A1c</i>	Title	Outcome: not related to insulin treatment adherence
<i>691. Identifying and preventing eating disorders in youth with diabetes</i>	Title	Outcome: not related to insulin treatment adherence
<i>692. Identity and treatment adherence in predominantly ethnic minority teens and young adults with type 1 diabetes</i>	Full Text	Outcome: not related to insulin treatment adherence
<i>693. Illness perceptions and self efficacy beliefs in adolescents and young adults with insulin dependent diabetes mellitus</i>	Included	
<i>694. Illness representations and glycemic control in adolescents with type 1 diabetes</i>	Title	Outcome: not related to insulin treatment adherence
<i>695. Illness representations predict adherence in adolescents and young adults with type 1 diabetes</i>	Included	
<i>697. Illness specific self-esteem in adolescents with type 1 diabetes</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>698. Illness-Specific Risk-Taking in Adolescence: A Missing Piece of the Nonadherence Puzzle for Youth With Type 1 Diabetes?</i>	Full Text	Wrong study type (review, conference abstract etc.)
<i>699. Immediate management of diabetic ketoacidosis (DKA) in the emergency department (ED): What needs improvement?</i>	Title	Outcome: not related to insulin treatment adherence
<i>700. Immune responses to an encapsulated allogeneic islet beta-cell line in diabetic NOD mice.</i>	Title	Outcome: not related to insulin treatment adherence
<i>701. Immunotherapy-based strategies for the treatment of autoimmune diabetes: searching for the cure.</i>	Title	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>702. Impact of a high-monounsaturated-fat diet on lipid profile in subjects with type 1 diabetes.</i>	Title	Outcome: not related to insulin treatment adherence
<i>703. Impact of a serious videogame designed for flexible insulin therapy on the knowledge and behaviors of children with type 1 diabetes: The LUDIDIAB pilot study</i>	Full Text	Outcome: not related to insulin treatment adherence
<i>705. Impact of ambulatory, family-focused teamwork intervention on glycemic control in youth with type 1 diabetes.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>706. Impact of combination therapy with dulaglutide and SGLT2i on vascular age, an indicator of cardiovascular risk, in Indian adults with type 2 diabetes: A real-world study</i>	Title	Population: not children (adults/foetuses)
<i>707. Impact of disease-management programs on metabolic control in patients with type 1 diabetes mellitus</i>	Title	Outcome: not related to insulin treatment adherence
<i>708. Impact of elective hospital admissions on glycaemic control in adolescents with poorly controlled type 1 diabetes.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>709. Impact of family environment and support on adherence, metabolic control, and quality of life in adolescents with diabetes.</i>	Included	
<i>710. Impact of family factors on metabolic control and on regimen adherence in type 1 diabetes among Hispanic and African-American adolescents</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>711. Impact of long-term use of eHealth systems in adolescents with type 1 diabetes treated with sensor-augmented pump therapy</i>	Full Text	Outcome: not related to insulin treatment adherence
<i>713. Impact of nutrition on type 1 diabetes management and outcomes</i>	Title	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
714. <i>Impact of patient education on diabetic distress &amp; clinical outcomes in type II diabetes mellitus patients</i>	Title	Population: do not have T1DM
715. <i>Impact of psychology services in an integrated pediatric endocrinology clinic</i>	Abstract	Wrong study type (review, conference abstract etc.)
716. <i>Impact of SMBG on control of diabetes as measured by HbA1. 3-yr Survey of a juvenile IDDM clinic</i>	Title	Outcome: not related to insulin treatment adherence
717. <i>Impact of telemedicine in managing type 1 diabetes among school-age children and adolescents: an integrative review.</i>	Abstract	Outcome: not related to insulin treatment adherence
718. <i>Impact of type 1 diabetes mellitus and celiac disease on nutrition and quality of life.</i>	Title	Outcome: not related to insulin treatment adherence
719. <i>Impacto psicosocial de la diabetes mellitus tipo 1 en niños, adolescentes y sus familias. Revisión de la literatura</i> <i>Psychosocial impact of type 1 diabetes mellitus in children, adolescents and their families. Literature review</i>	Title	Wrong study type (review, conference abstract etc.)
720. <i>Impaired absorption and omission of insulin: a novel method of detection using the diabetes advisory system computer model.</i>	Abstract	Population: not children (adults/foetuses)
721. <i>Impaired awareness of hypoglycemia in children and adolescents with type 1 diabetes mellitus in north of Jordan</i>	Title	Outcome: not related to insulin treatment adherence
722. <i>Impaired left-ventricular function in insulin-dependent diabetic patients with increased urinary albumin excretion.</i>	Title	Outcome: not related to insulin treatment adherence
723. <i>Implementation of a multicomponent process to obtain informed consent in the Diabetes Control and Complications Trial. The DCCT Research Group.</i>	Title	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
724. <i>Implementation of treatment protocols in the diabetes control and complications trial</i>	Title	Outcome: not related to insulin treatment adherence
725. <i>Implementing a pathway for the investigation of Cystic Fibrosis-Related Diabetes in a paediatric cystic fibrosis clinic</i>	Title	Population: do not have T1DM
726. <i>Importancia de los sistemas de informacion en programas de salud publica: bases de datos de pacientes diabeticos[Importance of the information systems in public health programs: diabetic patients databases]</i>	Title	Outcome: not related to insulin treatment adherence
727. <i>Important determinants of diabetes control in insulin pump therapy in patients with type 1 diabetes mellitus</i>	Abstract	Outcome: not related to insulin treatment adherence
729. <i>Improper Insulin Compliance May Lead to Hepatomegaly and Elevated Hepatic Enzymes in Type 1 Diabetic Patients [7]</i>	Full Text	Outcome: not related to insulin treatment adherence
730. <i>Improper insulin compliance may lead to hepatomegaly and elevated hepatic enzymes in type 1 diabetic patients: Response to Yu and Howard [8]</i>	Abstract	Wrong study type (review, conference abstract etc.)
731. <i>Improved BMI in long-term tube-fed pediatric patients with use of a clinic survey</i>	Title	Population: do not have T1DM
732. <i>Improved glycemic control and acute complications among children with type 1 diabetes mellitus in Moshi, Tanzania.</i>	Title	Outcome: not related to insulin treatment adherence
733. <i>Improvement of diabetic control and acceptability of a three-injection insulin regimen in diabetic adolescents: A multicenter controlled study</i>	Abstract	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>734. Improvement of the compliance with blood glucose monitoring in young insulin-dependent diabetes mellitus patients by the Sensorlink(TM) system</i>	Title	Outcome: not related to insulin treatment adherence
<i>735. Improving adherence to blood glucose testing in insulin-dependent diabetic children</i>	Title	Outcome: not related to insulin treatment adherence
<i>736. Improving care for pediatric diabetic ketoacidosis</i>	Title	Outcome: not related to insulin treatment adherence
<i>737. Improving children's compliance with diabetes management</i>	Full Text	Wrong study type (review, conference abstract etc.)
<i>738. Improving compliance with exercise in adolescents with insulin-dependent diabetes mellitus: results of a self-motivated home exercise program.</i>	Title	Outcome: not related to insulin treatment adherence
<i>739. In adult patients with type 1 diabetes healthy lifestyle associates with a better cardiometabolic profile.</i>	Title	Population: not children (adults/foetuses)
<i>740. In pursuit of excellence in diabetes care: trends in insulin delivery.</i>	Full Text	Outcome: not related to insulin treatment adherence
<i>741. In situ simulation-based study to determine adherence to pediatric diabetic ketoacidosis management guidelines</i>	Title	Outcome: not related to insulin treatment adherence
<i>742. In vitro-generation of surrogate islets from adult stem cells.</i>	Title	Outcome: not related to insulin treatment adherence
<i>744. In vivo microscopy of murine islets of Langerhans: increased adhesion of transferred lymphocytes to islets depends on macrophage-derived cytokines in a model of organ-specific insulinitis.</i>	Title	Outcome: not related to insulin treatment adherence
<i>745. In-home nighttime predictive low glucose suspend experience in children and adults with type 1 diabetes.</i>	Full Text	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>746. Incidence and prevalence of insulin-dependent diabetes mellitus in the zero- to 19-years' age-group in Sydney</i>	Title	Outcome: not related to insulin treatment adherence
<i>747. Incidence of symptomatic mild hypoglycaemic events: A prospective study in adult patients with insulin-treated diabetes mellitus using a portable microcomputer-based data-logger</i>	Title	Population: not children (adults/foetuses)
<i>748. Incorporating Long-Acting Insulin Glargine into the UVA/ Padova Type 1 Diabetes Simulator for In Silico Testing of MDI Therapies.</i>	Title	Outcome: not related to insulin treatment adherence
<i>749. Increasing the adherence of diabetic adolescents.</i>	Full Text	Population: not children (adults/foetuses)
<i>750. Individualized growth hormone therapy in children: Advances beyond weight-based dosing</i>	Title	Population: do not have T1DM
<i>751. Influence of food consumption in glycemic control and the cardiometabolic risk of children and adolescents with diabetes mellitus type 1</i>	Title	Outcome: not related to insulin treatment adherence
<i>752. Influence of imaginative teaching of diet on compliance and metabolic control in insulin dependent diabetes.</i>	Title	Outcome: not related to insulin treatment adherence
<i>753. Influence of intensive education coupled with counseling on glycosylated hemoglobin levels and other parameters of diabetes control in pediatric patients with type 1 diabetes mellitus in India</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>754. Inhaled human insulin.</i>	Title	Outcome: not related to insulin treatment adherence
<i>755. Inhaled insulin in diabetes mellitus.</i>	Title	Outcome: not related to insulin treatment adherence
<i>757. Inhaled insulin: overview of a novel route of insulin administration.</i>	Title	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
758. <i>Inhaled therapy: A commercial success but a therapeutic embarrassment. Are we seeing the first signs of change? &lt;&lt; plus ca change, plus c'est la meme chose &gt;&gt;</i>	Title	Outcome: not related to insulin treatment adherence
759. <i>Injection distress, quality of life and treatment adherence in a sample of youth with type 1 diabetes</i>	Abstract	Wrong study type (review, conference abstract etc.)
760. <i>Insights into the percutaneous penetration of antidiabetic agents.</i>	Abstract	Outcome: not related to insulin treatment adherence
761. <i>Institution of basal-bolus therapy at diagnosis for children with type 1 diabetes mellitus.</i>	Abstract	Outcome: not related to insulin treatment adherence
762. <i>Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study.</i>	Full Text	Population: not children (adults/foetuses)
763. <i>Insulin adherence in patients with diabetes: Risk factors for injection omission</i>	Full Text	Population: not children (adults/foetuses)
764. <i>Insulin administration and the impacts of forgetting a dose.</i>	Abstract	Population: not children (adults/foetuses)
766. <i>Insulin allergy can be successfully managed by a systematic approach</i>	Title	Outcome: not related to insulin treatment adherence
767. <i>Insulin bolus dose calculator: A web app to create an insulin dose spreadsheet</i>	Abstract	Wrong study type (review, conference abstract etc.)
768. <i>Insulin bolusing software: The potential to optimize health outcomes in type 1 diabetes mellitus</i>	Included	
770. <i>Insulin delivery by injection in children and adolescents with diabetes</i>	Abstract	Wrong study type (review, conference abstract etc.)
772. <i>Insulin delivery using hollow microneedles in children with type 1 diabetes</i>	Abstract	Wrong study type (review, conference abstract etc.)
773. <i>Insulin dependent diabetes mellitus: Regimen adherence in children and young people</i>		



<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
774. <i>Insulin detemir in a twice daily insulin regimen versus a three times daily insulin regimen in the treatment of type 1 diabetes in children: A pilot randomized controlled trial</i>	Full Text	Outcome: not related to insulin treatment adherence
776. <i>Insulin for children, education for the life</i>	Abstract	Wrong study type (review, conference abstract etc.)
777. <i>Insulin glargine 300 U/mL in the management of diabetes: clinical utility and patient perspectives.</i>	Abstract	Outcome: not related to insulin treatment adherence
778. <i>Insulin Injection Technique Questionnaire: results of an international study comparing Brazil, Latin America and World data.</i>	Full Text	Population: not children (adults/foetuses)
779. <i>Insulin manipulation as an indicator of psychiatric comorbidity in children and adolescents with type 1 diabetes mellitus</i>	Abstract	Wrong study type (review, conference abstract etc.)
780. <i>Insulin omission in women with IDDM</i>	Full Text	Population: not children (adults/foetuses)
781. <i>Insulin pen use and diabetes treatment goals: A study from Iran STEPS 2016 survey</i>	Abstract	Population: not children (adults/foetuses)
782. <i>Insulin Pump Adherence Behaviors Do Not Correlate With Glycemic Variability Among Youth With Type 1 Diabetes (T1D).</i>	Full Text	Outcome: not related to insulin treatment adherence
783. <i>Insulin pump at the onset of type 1 diabetes: An expensive toy or a wise choice?</i>	Abstract	Outcome: not related to insulin treatment adherence
784. <i>Insulin Pump Combined with Flash Glucose Monitoring: A Therapeutic Option to Improve Glycemic Control in Severely Nonadherent Patients with Type 1 Diabetes.</i>	Full Text	Population: not children (adults/foetuses)
785. <i>Insulin pump therapy - Practical aspects</i>	Abstract	Outcome: not related to insulin treatment adherence
786. <i>Insulin Pump Therapy for Type 1 Diabetes</i>	Abstract	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>787. Insulin pump therapy in Type 1 pediatric patients: Now and into the year 2000</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>788. Insulin pump use in young adolescents with type 1 diabetes: A descriptive study</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>790. Insulin Pumps in Type 1 Diabetes with Mental Disorders: Real-Life Clinical Data Indicate Discrepancies to Recommendations.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>791. Insulin resistance: Policy plan to address burning issue by NGO from rural India</i>	Title	Outcome: not related to insulin treatment adherence
<i>792. Insulin therapy during diabetic ketoacidosis in children</i>	Title	Outcome: not related to insulin treatment adherence
<i>793. Insulin therapy in Europe.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>794. Insulin therapy in type 2 diabetes for physicians and practitioners.</i>	Title	Population: do not have T1DM
<i>795. Insulin therapy regimens in paediatric age</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>796. Insulin withholding for weight control in women with diabetes</i>	Full Text	Population: not children (adults/foetuses)
<i>797. Insulin-coated gold nanoparticles as a new concept for personalized and adjustable glucose regulation.</i>	Title	Outcome: not related to insulin treatment adherence
<i>798. Insulin-dependent diabetes mellitus in childhood</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>799. Insulin-induced oedema in a patient with diabetes mellitus complicated by ketoacidosis</i>	Title	Outcome: not related to insulin treatment adherence
<i>801. Insulin-treated diabetes patients with fear of self-injecting or fear of self-testing: psychological comorbidity and general well-being.</i>	Abstract	Population: not children (adults/foetuses)
<i>802. Integrated insulin pump therapy with continuous glucose monitoring for improved adherence: technology update.</i>	Abstract	Population: not children (adults/foetuses)

Result Number and Title	Excluded by/included	First Exclusion Criteria Met
803. <i>Intensive diabetes education program and multidisciplinary team approach in management of newly diagnosed type 1 diabetes mellitus: a greater patient benefit, experience at Siriraj Hospital.</i>	Abstract	Outcome: not related to insulin treatment adherence
804. <i>INTENSIVIERTE INSULIN-THERAPIE BEI ADOLESZENTEN MIT DIABETES MELLITUS TYP I: ERSTE ERFABRUNGEN MIT DEM HALBAUTOMATISCHEN INSULIN-INJEKTIONSGERAT (INSULIN-PEN) Intensified insulin therapy in adolescents with type I diabetes mellitus: First experience with insulin pen</i>	Full Text	Population: not children (adults/foetuses)
805. <i>INTENSIVIERTE KONVENTIONELLE INSULINTHERAPIE. LANGZEITERFOLGE UND GRUNDE FUR DAS VERSAGEN DIESES THERAPIEKONZEPTES Intensified conventional insulin treatment: Long-term results and reasons for failure of this treatment concept</i>	Abstract	Outcome: not related to insulin treatment adherence
806. <i>Interaction of pubertal development and metabolic control in 1303 adolescents with diabetes mellitus type 1</i>	Title	Outcome: not related to insulin treatment adherence
807. <i>Interdisciplinary education group in type 1 diabetes</i>	Abstract	Wrong study type (review, conference abstract etc.)
808. <i>Interim report on the effective intraperitoneal therapy of insulin-dependent diabetes mellitus in pet dogs using "Neo-Islets," aggregates of adipose stem and pancreatic islet cells (INAD 012-776).</i>	Title	Population: not humans
809. <i>Intermittent hypoxia maintains glycemia in streptozotocin-induced diabetic rats.</i>	Title	Population: not humans

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>810. Interplay between Type 1 Diabetes Mellitus and Celiac Disease: Implications in Treatment.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>811. INTERPRET, an international report on routine practice of sensor-augmented pump therapy: Results from the 6 months interim analysis of the pediatric population</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>812. INTERPRET, an international report on routine practice of sensorenabled pump therapy: Result from the 6 months interim analysis</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>813. Intervention needed to optimize insulin pump use</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>814. Interventions with adherence-promoting components in pediatric type 1 diabetes: meta-analysis of their impact on glycemic control.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>815. Intrinsic motivation in minority youths with type 1 diabetes</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>816. Is compliance with diabetes retinopathy (DR) screening associated with achievement of therapeutic goals in youth with type 1 diabetes (T1DM)?</i>	Title	Outcome: not related to insulin treatment adherence
<i>817. Is continuous glucose monitoring (CGM) for everyone? To whom should CGM be prescribed and how?</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>818. Is everything new necessarily better? The pros and cons of new technology</i>	Title	Outcome: not related to insulin treatment adherence
<i>819. Is insulin pump therapy effective in Type 1 diabetes?</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>820. Is it useful to propose insulin pump at the onset of type 1 diabetes mellitus (T1DM)?</i>	Abstract	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
821. <i>Is living a dolce vita with diabetes possible?-metabolic control and quality of life in patients treated with 640G system</i>	Abstract	Wrong study type (review, conference abstract etc.)
822. <i>Is the frequency of self-monitoring of blood glucose related to long-term metabolic control? Multicenter analysis including 24,500 patients from 191 centers in Germany and Austria.</i>	Title	Outcome: not related to insulin treatment adherence
823. <i>ISPAD and its role in the management of diabetes in the young in the Indian subcontinent and the Far East</i>	Title	Outcome: not related to insulin treatment adherence
824. <i>Italian multicentre study of intensive therapy with insulin lispro in 1184 patients with Type 1 diabetes.</i>	Abstract	Outcome: not related to insulin treatment adherence
825. <i>Juvenile diabetes</i>	Abstract	Wrong study type (review, conference abstract etc.)
826. <i>Juvenile insulin dependent diabetes control, a reflection on patient satisfaction and their awareness in a peripheral hospital</i>	Abstract	Wrong study type (review, conference abstract etc.)
827. <i>Key considerations when repositioning a known drug for inhalation therapy</i>	Title	Outcome: not related to insulin treatment adherence
828. <i>La retinopathie diabétique du sujet jeune: l'Enfant et l'adolescent</i> Diabetic retinopathy in children and adolescents	Title	Outcome: not related to insulin treatment adherence
829. <i>Labour productivity effects of prescribed medicines for chronically ill workers</i>	Abstract	Population: not children (adults/foetuses)
830. <i>Lactobacillus reuteri oral administration improves periodontal disease in children and adolescents with type 1 diabetes</i>	Title	Outcome: not related to insulin treatment adherence
831. <i>Learned helplessness in diabetic youths</i>	Full Text	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>832. Left ventricular mass and arterial compliance: relation to coronary heart disease and its risk factors in South Indian adults.</i>	Title	Population: not children (adults/foetuses)
<i>833. Lessons learned from a pilot RCT of simultaneous versus delayed initiation of continuous glucose monitoring in children and adolescents with type 1 diabetes starting insulin pump therapy</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>835. Lifestyle and cardiometabolic risk in adults with type 1 diabetes: a review.</i>	Title	Population: not children (adults/foetuses)
<i>836. Lipoatrophy in a girl after switching insulin analog injection to a pump</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>837. Lived experience of diabetes among older, rural people</i>	Title	Population: not children (adults/foetuses)
<i>838. Locus of control beliefs predicting oral and diabetes health behavior and health status</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>839. Long term experiences with a computerized diabetes management and glucose monitoring system in insulin-dependent diabetic patients</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>840. Long-Term Adherence to Automated Bolus Calculators.</i>	Full Text	Population: not children (adults/foetuses)
<i>841. Long-term benefits of continuous subcutaneous insulin infusion in children with Type 1 diabetes: A 4-year follow-up</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>843. Long-Term Efficacy and Safety of Sensor Augmented Insulin Pump Therapy with Low-Glucose Suspend Feature in Patients with Type 1 Diabetes.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>844. Long-term glycaemic control achieved in young insulin-dependent diabetics</i>	Title	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>845. Long-term metformin treatment in adolescents with obesity and insulin resistance, results of an open label extension study</i>	Title	Population: do not have T1DM
<i>846. Long-term outcomes of continuous glucose monitoring in young children with type 1 diabetes undergoing insulin pump therapy: A retrospective evaluation</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>847. Longitudinal associations of maternal depressive symptoms, maternal involvement, and diabetes management across adolescence.</i>	Included	
<i>848. Low Carbohydrate and Low-Fat Diets: What We Don't Know and Why we Should Know It.</i>	Title	Outcome: not related to insulin treatment adherence
<i>849. Low carbohydrate diet in type 1 diabetes, long-term improvement and adherence: A clinical audit.</i>	Title	Outcome: not related to insulin treatment adherence
<i>850. Low discomfort and pain associated with intensified insulin therapy in children and adolescents.</i>	Full Text	Outcome: not related to insulin treatment adherence
<i>851. Lower executive functioning associated with greater diabetes-specific risk-taking in adolescents with type 1 diabetes</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>852. Lower plasma insulin levels during overnight closed-loop in school children with type 1 diabetes: Potential advantage? A randomized cross-over trial.</i>	Title	Outcome: not related to insulin treatment adherence
<i>853. Making Insulin Accessible: Does Inhaled Insulin Fill an Unmet Need?</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>854. Management and outcomes in paediatric ketoacidosis-West Midlands experience</i>	Title	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>855. Management of children with type 1 diabetes during illness: a national survey.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>856. Management of cystic fibrosis related diabetes: A survey of UK cystic fibrosis centers</i>	Title	Population: do not have T1DM
<i>857. Management of diabetes in Morocco: results of the International Diabetes Management Practices Study (IDMPS) - wave 5.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>858. Management of diabetic ketoacidosis in children and adolescents.</i>	Title	Outcome: not related to insulin treatment adherence
<i>860. Management of diabetic ketoacidosis in limited resource setting</i>	Title	Outcome: not related to insulin treatment adherence
<i>861. Management of juvenile diabetes</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>862. Management of ketosis-prone type 2 diabetes mellitus.</i>	Title	Population: do not have T1DM
<i>863. Management of third-trimester diabetic pregnancies with the use of continuous subcutaneous insulin infusion therapy: a pilot study.</i>	Abstract	Population: not children (adults/foetuses)
<i>864. Managing diabetic ketoacidosis: Keeping with the programme</i>	Title	Outcome: not related to insulin treatment adherence
<i>865. Managing insulin-dependent diabetes mellitus in adolescence: A developmental perspective</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>866. Managing psychosocial issues in a family with diabetes</i>	Full Text	Wrong study type (review, conference abstract etc.)
<i>867. Managing special occasions and fasts</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>868. Maternal depressive symptoms and disease care behaviors in youths with type 1 diabetes: A mediational model</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>869. Mauriac syndrome: A case report</i>	Title	Outcome: not related to insulin treatment adherence
<i>870. Mauriac syndrome: A rare differential diagnosis of abnormal liver tests in diabetic patients</i>	Title	Outcome: not related to insulin treatment adherence



<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
871. <i>Mauriac Syndrome: A Rare Hepatic Glycogenosis in Poorly Controlled Type 1 Diabetes.</i>	Title	Outcome: not related to insulin treatment adherence
872. <i>Mauriac syndrome: Still exists and haunts us from time to time. A case series</i>	Title	Outcome: not related to insulin treatment adherence
873. <i>Mauriac's syndrome: An uncommon and old complication of type 1 diabetes mellitus</i>	Title	Outcome: not related to insulin treatment adherence
874. <i>May gender influence the quality of life in children and adolescents with type 1 diabetes?</i>	Abstract	Outcome: not related to insulin treatment adherence
875. <i>Mealtime insulin bolus adherence and glycemic control in adolescents on insulin pump therapy</i>	Abstract	Outcome: not related to insulin treatment adherence
876. <i>Measures of Adherence and Challenges in Using Glucometer Data in Youth with Type 1 Diabetes: Rethinking the Value of Self-Report.</i>	Abstract	Outcome: not related to insulin treatment adherence
877. <i>Measuring illness management behaviors on intensive insulin regimens: A revision of the twenty-four hour recall interview</i>	Abstract	Outcome: not related to insulin treatment adherence
878. <i>Medication adherence and economic problem among patients with type 1 diabetes in Central Java Province , Indonesia</i>	Abstract	Wrong study type (review, conference abstract etc.)
879. <i>Metabolic control and compliance with self-monitoring of blood glucose in adolescents and young adults with type 1 diabetes: Results of the I-NewTrend randomized clinical trial</i>	Title	Outcome: not related to insulin treatment adherence
880. <i>Metabolic control and diet in Finnish diabetic adolescents</i>	Title	Outcome: not related to insulin treatment adherence
881. <i>Metabolic control and treatment patterns in patients with type 1 diabetes in Castilla-La Mancha: the DIAbetes tipo 1 in Castilla La Mancha study.</i>	Title	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>882. Metabolic control in adolescents with diabetes: An examination of systemic variables</i>	Title	Outcome: not related to insulin treatment adherence
<i>883. Metabolic control in children and adolescents with insulin-dependent diabetes mellitus</i>	Title	Outcome: not related to insulin treatment adherence
<i>884. Metabolic control in emerging adults with type 1 diabetes</i>	Title	Population: not children (adults/foetuses)
<i>885. Metabolic outcomes in overweight adults according to birth weight and overweight onset</i>	Title	Population: not children (adults/foetuses)
<i>886. Metabolische hepatopathie bei einem 16-jährigen jungen mit diabetes mellitus: Eine diagnostische und therapeutische herausforderung</i> <i>Metabolic hepatopathy in a 16 year old boy with diabetes. A diagnostic and therapeutic challenge</i>	Title	Outcome: not related to insulin treatment adherence
<i>887. Metformin as additional therapy in adolescents with poorly controlled type 1 diabetes: randomised placebo-controlled trial with aspects on insulin sensitivity.</i>	Title	Outcome: not related to insulin treatment adherence
<i>888. Metformin improves vascular function in children and adolescents with type 1 diabetes: The adelaide metformin RCT trial</i>	Title	Outcome: not related to insulin treatment adherence
<i>889. Metformin in adults with type 1 diabetes: Design and methods of REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL): An international multicentre trial.</i>	Title	Population: not children (adults/foetuses)
<i>890. Metformin levels and adherence in children and adolescents with type 1 diabetes enrolled in a 12 month randomised controlled trial</i>	Title	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>891. Methods for insulin delivery and glucose monitoring in diabetes: summary of a comparative effectiveness review</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>892. Methods for Insulin Delivery and Glucose Monitoring: Comparative Effectiveness</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>893. Microalbuminuria in diabetes mellitus - Efficacy of a new screening method in comparison with timed overnight urine collection</i>	Title	Outcome: not related to insulin treatment adherence
<i>894. MicroRNAs and histone deacetylase inhibition-mediated protection against inflammatory <math>\beta</math>-cell damage.</i>	Title	Outcome: not related to insulin treatment adherence
<i>895. Mindfulness-based Group Intervention for an Adolescent Girl at Risk for Type 2 Diabetes: A Case Report</i>	Title	Population: do not have T1DM
<i>896. Missed insulin boluses for snacks in youth with type 1 diabetes.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>897. Missed Medical Appointments and Disease Control in Children With Type 1 Diabetes.</i>	Full Text	Outcome: not related to insulin treatment adherence
<i>898. Mixing rapid-acting insulin analogues with insulin glargine in children with type 1 diabetes mellitus.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>899. Mobile Momentary Assessment and Biobehavioral Feedback for Adolescents with Type 1 Diabetes: Feasibility and Engagement Patterns.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>900. Mobile phone support is associated with reduced ketoacidosis in young adults.</i>	Title	Population: not children (adults/foetuses)
<i>901. Model of associations between psychosocial variables and health-outcome measures of adolescents with IDDM</i>	Included	

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
902. <i>Modern clinical management helps reducing the impact of type 1 diabetes in children</i>	Abstract	Outcome: not related to insulin treatment adherence
904. <i>MODERNE ASPEKTE DER THERAPIE DES INSULINABHANGIGEN DIABETES MELLITUS BEI KINDERN UND JUGENDLICHEN</i> <i>Modern aspects of therapy in insulin-dependent diabetes mellitus in children and adolescents</i>	Abstract	Wrong study type (review, conference abstract etc.)
905. <i>MODY2 and type 1 diabetes in a pediatric patient who developed DKA</i>	Title	Outcome: not related to insulin treatment adherence
906. <i>Momentary Predictors of Insulin Restriction Among Adults With Type 1 Diabetes and Eating Disorder Symptomatology.</i>	Title	Population: not children (adults/foetuses)
907. <i>Momentary sampling using personal digital assistants (PDAs) to assess adherence in teens with type 1 diabetes (T1D): Feasibility, burden and acceptability</i>	Abstract	Outcome: not related to insulin treatment adherence
908. <i>Morbidity and mortality of diabetic ketoacidosis with and without insulin pump care.</i>	Abstract	Outcome: not related to insulin treatment adherence
910. <i>Motor vehicle accidents during episodes of hypoglycaemia--case reports and lessons to be learnt.</i>	Title	Outcome: not related to insulin treatment adherence
911. <i>Moving Into Action: Informing Policy and Strengthening Healthcare Systems in Asia Pacific</i>	Title	Outcome: not related to insulin treatment adherence
912. <i>Multicenter closed-loop/hybrid meal bolus insulin delivery with type 1 diabetes.</i>	Abstract	Outcome: not related to insulin treatment adherence
913. <i>Multicentre study on prevalence of endocrine complications in thalassaemia major</i>	Title	Population: do not have T1DM

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>914. Multicentre study on prevalence of endocrine complications in thalassaemia major. Italian Working Group on Endocrine Complications in Non-endocrine Diseases.</i>	Title	Population: do not have T1DM
<i>915. Multidisciplinary care on type 1 diabetics: "ADINF doce vida Nova Friburgo" project</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>916. Multidisciplinary treatment of pediatric obesity</i>	Title	Population: do not have T1DM
<i>917. Multifamily group problem-solving intervention for adherence challenges in pediatric insulin-dependent diabetes</i>	Full Text	Outcome: not related to insulin treatment adherence
<i>918. Multivariate assessment of adherence and glycemic control in youth with type 1 diabetes</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>919. Neurog3 misexpression unravels mouse pancreatic ductal cell plasticity.</i>	Title	Population: not humans
<i>920. New concepts in diabetes: how multihormonal regulation can improve glycemic control.</i>	Title	Outcome: not related to insulin treatment adherence
<i>921. New insights in CF-related diabetes</i>	Title	Population: do not have T1DM
<i>922. New insulins and quality of life.</i>	Full Text	Wrong study type (review, conference abstract etc.)
<i>923. New onset type 1 diabetes in the pediatric population of a second level hospital: 12 years' review and evaluation of recent treatment and connection between hospitals</i>	Title	Outcome: not related to insulin treatment adherence
<i>924. New paradigms for growth hormone therapy in children</i>	Title	Population: do not have T1DM
<i>925. New technologies for promoting hypoglycaemia self-management in type 1 diabetic children</i>	Title	Outcome: not related to insulin treatment adherence
<i>926. Nicotinamide protected first-phase insulin response (FPIR) and prevented clinical disease in first-degree relatives of type-1 diabetics</i>	Title	Population: do not have T1DM

Result Number and Title	Excluded by/included	First Exclusion Criteria Met
928. <i>No effect of insulin pen with memory function on glycemic control in a patient cohort with poorly controlled type 1 diabetes: A randomized open-label study</i>	Full Text	Population: not children (adults/foetuses)
930. <i>No effect of the FitFor2 exercise programme on blood glucose, insulin senesitivity, and birthweight in pregnant women who were overweight and at risk for gestational diabetes : results of a randomised controlled trial.</i>	Title	Population: do not have T1DM
931. <i>Non-compliance of insulin pump users; questionnaire and case reports</i>	Abstract	Outcome: not related to insulin treatment adherence
932. <i>Non-insulin-dependent diabetes mellitus in Indian children in Manitoba</i>	Title	Population: do not have T1DM
933. <i>Nonadherence to insulin therapy in low-income, type 2 diabetic patients.</i>	Title	Population: do not have T1DM
934. <i>Noncommunicable disease management in resource-poor settings: a primary care model from rural South Africa.</i>	Title	Outcome: not related to insulin treatment adherence
935. <i>Normalizing blood glucose levels in children with type 1 diabetes: Mystery motivators used within the context of behavioral consultation models</i>	Abstract	Wrong study type (review, conference abstract etc.)
936. <i>NOUVELLES TECHNIQUES D'ADMINISTRATION DE L'INSULINE LES MULTI-INJECTIONS A L'AIDE DE STYLOS INJECTEURS</i> <i>New techniques of insulin administration: Multiple injections by means of injection pens</i>	Full Text	Outcome: not related to insulin treatment adherence
937. <i>Novel therapies in the management of type 1 diabetes mellitus.</i>	Abstract	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>938. NovoPen Echo™ for the delivery of insulin in paediatric patients: A comparison of usability, functionality and preference among patients, their parents and healthcare professionals</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>939. Numerical and clinical precision of continuous glucose monitoring in Colombian patients treated with insulin infusion pump with automated suspension in hypoglycemia.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>940. Nutritional management of children and adolescents with insulin-dependent diabetes mellitus: A review by the Diabetes Care and Education dietetic practice group</i>	Title	Outcome: not related to insulin treatment adherence
<i>941. Objectively Measured Adherence in Adolescents With Type 1 Diabetes on Multiple Daily Injections and Insulin Pump Therapy</i>	Full Text	Outcome: not related to insulin treatment adherence
<i>942. Observational study of diabetes management in type 1 diabetic school-age children during holiday versus school days</i>	Full Text	Outcome: not related to insulin treatment adherence
<i>944. OcobeHHocT HcyHoTepa p caxapHoM dabeTe 1 Ta y deTe odpocTkoB, oyayux yukokopTkodb Characteristics of insulin therapy of diabetes mellitus type 1 in children and adolescents receiving glucocorticoids</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>945. Optimal pump settings differ according to age and insulin dose</i>	Title	Outcome: not related to insulin treatment adherence
<i>946. Optimal Use of Diabetes Devices: Clinician Perspectives on Barriers and Adherence to Device Use.</i>	Full Text	Population: not children (adults/foetuses)
<i>947. Optimization of insulin treatment in children</i>	Full Text	Wrong study type (review, conference abstract etc.)

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
948. <i>Optimizing insulin pump therapy: a quality improvement project.</i>	Abstract	Outcome: not related to insulin treatment adherence
949. <i>Optimum bolus wizard settings in insulin pumps in children with Type 1 diabetes</i>	Abstract	Outcome: not related to insulin treatment adherence
950. <i>Oral glucose tolerance testing: A quality improvement initiative to increase adherence</i>	Title	Population: do not have T1DM
951. <i>Oral hypoglycemic glibenclamide: Can it be a substitute to insulin in the management of gestational diabetes mellitus? a comparative study</i>	Title	Population: do not have T1DM
952. <i>Oral insulin: an update.</i>	Title	Outcome: not related to insulin treatment adherence
953. <i>Our initial experience with insulin pump treatment</i>	Abstract	Outcome: not related to insulin treatment adherence
954. <i>Outcomes of a rural model of extended adolescent diabetes care to mid 20s without transition to adult services</i>	Title	Population: not children (adults/foetuses)
955. <i>Outcomes of admissions with diabetic ketoacidosis (DKA) compared to the national British Society of Paediatric Endocrinology and Diabetes (BSPED) guidelines</i>	Title	Outcome: not related to insulin treatment adherence
956. <i>Outpatient-to-inpatient transition of insulin pump therapy: successes and continuing challenges.</i>	Abstract	Population: not children (adults/foetuses)
957. <i>Outside-hospital assistance for children and adolescents with type 1 diabetes mellitus</i>	Title	Outcome: not related to insulin treatment adherence
959. <i>Overcoming the challenges in the nutritional management of toddlers with diabetes</i>	Abstract	Wrong study type (review, conference abstract etc.)
960. <i>Paediatric diabetes in Tanzania: Problems and perspectives</i>	Abstract	Wrong study type (review, conference abstract etc.)
961. <i>Paediatric diabetes: achieving practical, effective insulin therapy in type 1 and type 2 diabetes.</i>	Abstract	Outcome: not related to insulin treatment adherence



<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
962. <i>Paediatric non-ketotic hyperglycaemic hemichorea-hemiballismus.</i>	Title	Population: do not have T1DM
963. <i>Pancreatic islet transplantation.</i>	Title	Outcome: not related to insulin treatment adherence
964. <i>Pancreatic stem cells: a therapeutic agent that may offer the best approach for curing type 1 diabetes.</i>	Title	Outcome: not related to insulin treatment adherence
965. <i>Parent and child perceptions of the management of juvenile diabetes</i>	Included	
966. <i>Parent-child relationships and the management of insulin-dependent diabetes mellitus</i>	Included	
967. <i>Parental expectations about their involvement in diabetes management: Reliability and validity of the outcome expectations of parental involvement (OEPI) scale</i>	Abstract	Outcome: not related to insulin treatment adherence
968. <i>Parental involvement and adolescents' diabetes management: the mediating role of self-efficacy and externalizing and internalizing behaviors.</i>	Included	
969. <i>Parental involvement buffers associations between pump duration and metabolic control among adolescents with type 1 diabetes.</i>	Abstract	Outcome: not related to insulin treatment adherence
970. <i>Parental involvement in diabetes management tasks: Relationships to blood glucose monitoring adherence and metabolic control in young adolescents with insulin-dependent diabetes mellitus</i>	Title	Outcome: not related to insulin treatment adherence
971. <i>Parental involvement in regimen responsibilities: Implications for the adherence behaviors and psychosocial adjustment of adolescents with insulin-dependent diabetes mellitus</i>	Abstract	Wrong study type (review, conference abstract etc.)

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>972. Parental stress response within a family context: Association with diabetic control in adolescents with IDDM</i>	Full Text	Outcome: not related to insulin treatment adherence
<i>973. Parent-child relationships and insulin-dependent diabetes mellitus: Observational ratings of clinically relevant dimensions</i>	Full Text	Outcome: not related to insulin treatment adherence
<i>974. Participant and parent experiences in the oral insulin study of the Diabetes Prevention Trial for Type 1 Diabetes</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>976. Participant and parent experiences in the parenteral insulin arm of the diabetes prevention trial for type 1 diabetes</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>978. Participant characteristics and study features associated with high retention rates in a longitudinal investigation of type 1 diabetes mellitus.</i>	Title	Outcome: not related to insulin treatment adherence
<i>979. Pathways from emotional adjustment to glycemic control in youths with diabetes in Hong Kong</i>	Included	
<i>980. Patient education and compliance in non-insulin dependent diabetes mellitus</i>	Title	Population: do not have T1DM
<i>981. Patient Perspectives on Nurse-led Consultations Within a Pilot Structured Transition Program for Young Adults Moving From an Academic Tertiary Setting to Community-based Type 1 Diabetes Care</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>982. Patient perspectives on peer support for adults with type 1 diabetes: a need for diabetes-specific social capital.</i>	Title	Population: not children (adults/foetuses)
<i>983. Patient perspectives on personalized glucose advisory systems for type 1 diabetes management.</i>	Abstract	Population: not children (adults/foetuses)

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
984. <i>Patient recruitment in paediatric clinical trials</i>	Title	Population: do not have T1DM
985. <i>Patient safety and minimizing risk with insulin administration - role of insulin degludec.</i>	Title	Outcome: not related to insulin treatment adherence
986. <i>Patient with MSUD presenting with diabetic ketoacidosis</i>	Title	Outcome: not related to insulin treatment adherence
987. <i>Patients with poorly controlled diabetes in primary care: healthcare clinicians' beliefs and attitudes</i>	Title	Outcome: not related to insulin treatment adherence
988. <i>Patients' empowerment, physicians' perceptions, and achievement of therapeutic goals in patients with type 1 and type 2 diabetes mellitus in Mexico.</i>	Abstract	Outcome: not related to insulin treatment adherence
989. <i>Patterns of adherence to diabetes vision care guidelines: baseline findings from the Diabetic Retinopathy Awareness Program.</i>	Title	Outcome: not related to insulin treatment adherence
990. <i>Pediatric diabetes management in Appalachian Kentucky: adherence of primary care physicians to ADA guidelines</i>	Title	Outcome: not related to insulin treatment adherence
992. <i>Peptic ulcer disease in youths with insulin-dependent diabetes mellitus: a prospective study.</i>	Title	Outcome: not related to insulin treatment adherence
993. <i>Perceived peer support and diabetes management from adolescence into early emerging adulthood.</i>	Full Text	Outcome: not related to insulin treatment adherence
994. <i>Perceptions and experiences of using automated bolus advisors amongst people with type 1 diabetes: a longitudinal qualitative investigation.</i>	Abstract	Outcome: not related to insulin treatment adherence
995. <i>Percutaneous transhepatic pancreatic islet cell transplantation in type 1 diabetes mellitus: radiologic aspects.</i>	Title	Outcome: not related to insulin treatment adherence

Result Number and Title	Excluded by/included	First Exclusion Criteria Met
996. <i>Perfil clinico de ninos con cetoacidosis diabetica en una unidad de paciente critico</i> <i>Clinical profile of children with diabetic ketoacidosis in a critical care unit</i>	Title	Outcome: not related to insulin treatment adherence
997. <i>Persistent effects of a pedagogical device targeted at prevention of severe hypoglycaemia: a randomized, controlled study.</i>	Abstract	Outcome: not related to insulin treatment adherence
998. <i>Personal continuous glucose monitoring (CGM) in diabetes management: review of the literature and implementation for practical use.</i>	Title	Outcome: not related to insulin treatment adherence
1000. <i>Personality traits as predictors of adherence in adolescents with type 1 diabetes</i>	Included	
1001. <i>Personalized medicine switching from insulin to sulfonylurea in permanent neonatal diabetes mellitus dictated by a novel activating ABCC8 mutation</i>	Title	Outcome: not related to insulin treatment adherence
1002. <i>Perspectives of patients with type 1 or insulin-treated type 2 diabetes on self-monitoring of blood glucose: a qualitative study.</i>	Title	Outcome: not related to insulin treatment adherence
1003. <i>Pharmaceutical care of an adolescent with type 1 diabetes.</i>	Abstract	Outcome: not related to insulin treatment adherence
1004. <i>Pharmacokinetic Properties of Liraglutide as Adjunct to Insulin in Subjects with Type 1 Diabetes Mellitus.</i>	Title	Outcome: not related to insulin treatment adherence
1005. <i>Pharmazeutische Betreuung von Jugendlichen mit Diabetes mellitus Typ 1</i> <i>Zeit fur "Diabetes Stewardship"? Diabetes Stewardship - Pharmaceutical care of adolescents with type 1 diabetes mellitus provided by community pharmacists</i>	Full Text	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>1006. Physical activity and sedentary behavior levels in children and adolescents with type 1 diabetes using insulin pump or injection therapy - The importance of parental activity profile.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1007. Physical activity intensity and type 2 diabetes risk in overweight youth: A randomized trial</i>	Title	Population: do not have T1DM
<i>1008. Physical activity intensity and type 2 diabetes risk in overweight youth: The power trial, a randomized, controlled trial</i>	Title	Population: do not have T1DM
<i>1009. Pilot study of self-measurement of blood glucose using the Dextrostix-Eyetone system for juvenile-onset diabetes.</i>	Title	Outcome: not related to insulin treatment adherence
<i>1010. Polymer-Based Nanoparticle Strategies for Insulin Delivery.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1011. Poor adherence in adolescents with type 1 diabetes associated with distress, fear of hypoglycemia, and executive functioning</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>1012. Poor adherence to integral daily tasks limits the efficacy of CSII in youth</i>	Included	
<i>1014. Poor home compliance in brittle diabetes</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1015. Post-Graduate education program for dieticians - Medical nutrition therapy in diabetes</i>	Title	Outcome: not related to insulin treatment adherence
<i>1016. Post-transplant diabetes mellitus (PTDM) in pediatric renal transplant recipient</i>	Title	Population: do not have T1DM
<i>1017. Postpartum physiology, psychology and paediatric study-P4 study</i>	Title	Population: do not have T1DM
<i>1018. Potential beneficial effects of a gluten-free diet in newly diagnosed children with type 1 diabetes: a pilot study.</i>	Title	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>1019. Potential reno-protective effects of a gluten-free diet in type 1 diabetes.</i>	Title	Outcome: not related to insulin treatment adherence
<i>1020. Precipitating factors of diabetic ketoacidosis at a public hospital in a middle-income country.</i>	Title	Outcome: not related to insulin treatment adherence
<i>1022. Predicting adolescent adjustment to diabetes mellitus from locus of control and optimism</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>1023. Predictors and treatment outcome of hyperglycemic emergencies at Jimma University Specialized Hospital, southwest Ethiopia</i>	Title	Outcome: not related to insulin treatment adherence
<i>1025. Predictors of deteriorations in diabetes management and control in adolescents with type 1 diabetes.</i>	Title	Outcome: not related to insulin treatment adherence
<i>1026. Predictors of glucose control in children and adolescents with type 1 diabetes: results of a cross-sectional study in Cameroon</i>	Title	Outcome: not related to insulin treatment adherence
<i>1027. Predictors of glycemic control and diabetes-related costs among type 2 diabetes patients initiating therapy with liraglutide in the United States.</i>	Title	Population: do not have T1DM
<i>1028. Predictors of good adherence of adolescents with diabetes (insulin-dependent diabetes mellitus)</i>	Included	
<i>1029. Predictors of metabolic control at one year in a population of pediatric patients with type 2 diabetes mellitus: A retrospective study</i>	Title	Population: do not have T1DM
<i>1030. Predictors of parental monitoring of diabetes care in a high-risk sample</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>1031. Predictors of response to insulin therapy in youth with poorly-controlled type 2 diabetes in the TODAY trial</i>	Title	Population: do not have T1DM

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>1032. Predictors of study completion and withdrawal in a randomized clinical trial of a pediatric diabetes adherence intervention.</i>	Title	Outcome: not related to insulin treatment adherence
<i>1033. Preprandial versus postprandial blood glucose monitoring in type 1 diabetic pregnancy: a randomized controlled clinical trial.</i>	Title	Outcome: not related to insulin treatment adherence
<i>1034. Presente e futuro della terapia insulinica nel bambino e adolescente con diabete mellito di tipo 1 Insulin therapy in children and adolescents with T1DM - What's here and what's to come</i>	Full Text	Wrong study type (review, conference abstract etc.)
<i>1035. Prevalence and management of patients with type 1 diabetes and autism spectrum disorder</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>1036. Prevalence of diabetic eye disease in an inner city population: The Liverpool Diabetic Eye Study</i>	Title	Outcome: not related to insulin treatment adherence
<i>1037. Prevalence of endocrine complications and short stature in patients with thalassaemia major: A multicenter study by the Thalassaemia International Federation (TIF)</i>	Title	Population: do not have T1DM
<i>1038. Prevalence of injection-meal interval usage and its association with variables of metabolic control in patients with Type 1 and Type 2 diabetes.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1039. Prevalence of intentional under- and overdosing of insulin in children and adolescents with type 1 diabetes</i>	Included	
<i>1041. Prevalence of intentional under- and overdosing of insulin in diabetic children and adolescents</i>		

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>1042. Primary dietary intervention study to reduce the risk of islet autoimmunity in children at increased risk for type 1 diabetes</i>	Title	Outcome: not related to insulin treatment adherence
<i>1043. Primary dietary intervention study to reduce the risk of islet autoimmunity in children at increased risk for type 1 diabetes: the BABYDIET study.</i>	Title	Outcome: not related to insulin treatment adherence
<i>1044. Problem solving and diabetes regimen adherence by children and adolescents with IDDM in social pressure situations: A reflection of normal development</i>	Full Text	Outcome: not related to insulin treatment adherence
<i>1045. Profile of internection of pediatric patients with diabetes mellitus type 1 in a reference service in Rio de Janeiro</i>	Title	Outcome: not related to insulin treatment adherence
<i>1046. Prolonged use of continuous glucose monitors in children with type 1 diabetes on continuous subcutaneous insulin infusion or intensive multiple-daily injection therapy.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1047. Proposed clinical application for tuning fuzzy logic controller of artificial pancreas utilizing a personalization factor</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1048. Prospects for smoking cessation among people with insulin-dependent diabetes.</i>	Title	Outcome: not related to insulin treatment adherence
<i>1049. Protocol for Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetes Cases (The MAG1C trial): a randomised, double-blinded, placebo-controlled trial.</i>	Title	Outcome: not related to insulin treatment adherence
<i>1050. Psychiatric illness and family support in children and adolescents hospitalized with diabetic ketoacidosis</i>	Abstract	Wrong study type (review, conference abstract etc.)



<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>1051. Psychiatric illness and family support in children and adolescents with diabetic ketoacidosis: A controlled study</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1052. Psycho-social aspects of children and adolescents with diabetes.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1053. Psychoanalytic formulation and treatment: Chronic metabolic disturbance in insulin-dependent diabetes mellitus</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>1054. Psychologic predictors of compliance in children with recent onset of diabetes mellitus</i>	Included	
<i>1055. Psychological and demographic correlates of glycaemic control in adult patients with type 1 diabetes.</i>	Title	Population: not children (adults/foetuses)
<i>1057. Psychological aspects of childhood diabetes</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1058. Psychological aspects of continuous glucose monitoring in pediatric type 1 diabetes.</i>	Title	Outcome: not related to insulin treatment adherence
<i>1059. Psychological barriers to optimal insulin therapy: more concerns in adolescent females than males.</i>	Full Text	Outcome: not related to insulin treatment adherence
<i>1060. Psychological factors associated with diabetes self-management among adolescents with Type 1 diabetes: A systematic review</i>	Title	Wrong study type (review, conference abstract etc.)
<i>1061. Psychological functioning among mothers of children with insulin-dependent diabetes mellitus: A longitudinal study</i>	Full Text	Outcome: not related to insulin treatment adherence
<i>1062. Psychological impact of continuous subcutaneous insulin infusion pump therapy in non-selected newly diagnosed insulin dependent (type 1) diabetic children: evaluation after two years of therapy.</i>	Included	

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>1064. Psychological responses to the needle-free injection of insulin with the disposable front-end Medi-Jector (MJ-6)</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>1065. Psychometric analysis of the Spanish and Catalan versions of the Diabetes Self-Care inventory-revised version questionnaire.</i>	Abstract	Population: not children (adults/foetuses)
<i>1066. Psychometric evaluation of the adherence in diabetes questionnaire</i>	Included	
<i>1068. Psychometric properties of a diabetes resilience measure for adolescents</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>1069. Psychometric properties of the preschool diabetes behavior checklist</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>1070. Psychopathology and continuous subcutaneous insulin infusion in type 1 diabetes.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1071. Psychosocial adaptation following the diagnosis of insulin-dependent diabetes mellitus: An intervention</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1072. Psychosocial and psychopathologic influences on management and control of insulin-dependent diabetes</i>	Full Text	Population: not children (adults/foetuses)
<i>1073. Psychosocial aspects of xenotransplantation: survey in adolescent recipients of porcine islet cells.</i>	Title	Outcome: not related to insulin treatment adherence
<i>1074. Psychosocial correlates of glycemic control: the Pittsburgh Epidemiology of Diabetes Complications (EDC) Study.</i>	Title	Outcome: not related to insulin treatment adherence
<i>1075. Psychosocial determinants of regimen adherence behaviors in adolescents with type I insulin-dependent diabetes mellitus: Individual cognitive factors, social factors, and perceived barriers to adherence</i>	Abstract	Wrong study type (review, conference abstract etc.)

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>1076. Psychosocial factors associated with use of continuous glucose monitoring.</i>	Title	Outcome: not related to insulin treatment adherence
<i>1077. Psychosocial predictors of adherence and metabolic control in adolescents with insulin-dependent diabetes mellitus</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>1078. Psychosocial problems in adolescents with type 1 diabetes mellitus.</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>1080. Psychosocial profile, glycemic control and well being in poverty associated type 1 diabetes mellitus [T1DM] adolescents in India</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>1081. Psyllium supplementation improves parameters of the metabolic syndrome: A randomized, participant-blinded, placebo controlled, crossover trial</i>	Title	Population: do not have T1DM
<i>1082. Puberty in CF</i>	Title	Population: do not have T1DM
<i>1083. Pulmonary function in insulin-dependent diabetes mellitus with limited joint mobility.</i>	Title	Outcome: not related to insulin treatment adherence
<i>1084. Pump settings in different age groups</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>1085. Pumpers, skypers, surfers and texters: Technology to improve the management of diabetes in teenagers</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1086. Quality of life and diabetes knowledge of young persons with type 1 diabetes: Influence of treatment modalities and demographics</i>	Full Text	Outcome: not related to insulin treatment adherence
<i>1088. Quality of life and glycemic control in adolescents with type 1 diabetes and the impact of an education intervention</i>	Included	
<i>1090. Quality of life and new devices in the management of type 1 diabetes in children and adolescents.</i>	Abstract	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>1091. Quality of life in children with diabetes and celiac disease: minimal impact of the 'double diagnosis'.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1092. Quality of life in insulin users measured by ITR-QOL</i>	Full Text	Population: not children (adults/foetuses)
<i>1093. Quality of Life in Type 1 Diabetes and Celiac Disease: Role of the Gluten-Free Diet</i>	Title	Outcome: not related to insulin treatment adherence
<i>1094. Quality of life of children and adolescents with type 1 diabetes in Kuwait.</i>	Included	
<i>1095. Quality of life related to health in adolescents with type 1 diabetes</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>1096. Quality of life, perceived difficulties in adherence to a diabetes regimen, and blood glucose control.</i>	Full Text	Population: not children (adults/foetuses)
<i>1097. Quality of the parent-child interaction in young children with type 1 diabetes mellitus: study protocol.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1098. Race and sex differences in metabolic control of adolescents with IDDM: A function of psychosocial variables?</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1099. Randomised placebo-controlled trial of human recombinant insulin-like growth factor I plus intensive insulin therapy in adolescents with insulin-dependent diabetes mellitus</i>	Title	Outcome: not related to insulin treatment adherence
<i>1100. Randomized, controlled trial of behavior therapy for families of adolescents with insulin-dependent diabetes mellitus</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1101. Rare, acute complications in children with diabetes mellitus type 1</i>	Title	Outcome: not related to insulin treatment adherence
<i>1102. Real world management of pregestational diabetes not achieving glycemic control for many patients in the UK</i>	Title	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>1103. Real-time continuous glucose monitoring in children and adolescents</i>	Title	Outcome: not related to insulin treatment adherence
<i>1105. Reasons for the discontinuation of therapy of personal insulin pump in children with type 1 diabetes.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1106. Recent challenges in insulin delivery systems: a review.</i>	Title	Wrong study type (review, conference abstract etc.)
<i>1107. Recent Updates on Novel Approaches in Insulin Drug Delivery: A Review of Challenges and Pharmaceutical Implications.</i>	Title	Wrong study type (review, conference abstract etc.)
<i>1108. Recommendations for the use of sensor-augmented pumps with predictive low-glucose suspend features in children: The importance of education.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1109. Recurrent diabetic ketoacidosis-like symptoms and factitious hyperglycemia as a Munchausen syndrome in diabetes mellitus type 1: A case report</i>	Title	Outcome: not related to insulin treatment adherence
<i>1110. Recurrent Hypertriglyceridemic Pancreatitis (HTGP); and the Use of Insulin Drip as Treatment.</i>	Title	Population: do not have T1DM
<i>1111. Redesigning an intensive insulin service for patients with type 1 diabetes: a patient consultation exercise.</i>	Abstract	Population: not children (adults/foetuses)
<i>1112. Reduction in severe hypoglycaemia in paediatric type 1 diabetes during the first year of continuous glucose monitoring: Real-world data from the DPV registry</i>	Title	Outcome: not related to insulin treatment adherence
<i>1113. Reduction of protein intake decreases glomerular filtration rate in young type 1 (insulin-dependent) diabetic patients mainly in hyperfiltering patients.</i>	Title	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>1114. Reemergence of a rare syndrome: Mauriac syndrome</i>	Title	Outcome: not related to insulin treatment adherence
<i>1115. Relation of different measures of psychological characteristics to oral health habits, diabetes adherence and related clinical variables among diabetic patients</i>	Full Text	Population: not children (adults/foetuses)
<i>1116. Relation of serum leptin and insulin-like growth factor-1 levels to intima-media thickness and functions of common carotid artery in children and adolescents with type 1 diabetes</i>	Title	Outcome: not related to insulin treatment adherence
<i>1118. Relationship between age at menarche and cardiovascular risk factors in women with type 1 diabetes</i>	Title	Outcome: not related to insulin treatment adherence
<i>1119. Relationship between blood glucose levels and manic episodes in a patient with bipolar-I disorder: Presentation of a case</i>	Title	Population: do not have T1DM
<i>1120. Relationship between disinhibition and metabolic control in adolescents with type 1 diabetes</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1121. Relationship between food consumption and glycemic control of adolescents with type 1 diabetes</i>	Title	Outcome: not related to insulin treatment adherence
<i>1122. Relationship between glycemic control, ethnicity and socioeconomic status in Hispanic and white non-Hispanic youths with type 1 diabetes mellitus.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1123. Relationship between health locus of control, health value, and social support and compliance of persons with diabetes mellitus.</i>	Full Text	Population: not children (adults/foetuses)
<i>1124. Relationship of self-efficacy and bingeing to adherence to diabetes regimen among adolescents</i>	Included	

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
1125. <i>Relationship of the patient age and intensity of type 2 diabetes treatment</i>	Title	Population: do not have T1DM
1126. <i>Relationships between goals and health outcomes in children and adolescents with insulin-dependent diabetes mellitus</i>	Abstract	Outcome: not related to insulin treatment adherence
1127. <i>Relationships between quality of life, family factors, adherence, and glycemic control in pediatric patients with Type 1 diabetes mellitus</i>	Abstract	Wrong study type (review, conference abstract etc.)
1128. <i>Reliability of reporting of self-monitoring of blood glucose in pregnant women.</i>	Title	Population: do not have T1DM
1129. <i>Research on social support in adolescents with IDDM: a critical review</i>	Title	Wrong study type (review, conference abstract etc.)
1130. <i>Response to comment on Gomes et al. Adherence to insulin therapeutic regimens in patients with type 1 diabetes. A nationwide survey in Brazil. Diabetes Res Clin Pract. 2016;120:47-55.</i>	Full Text	Wrong study type (review, conference abstract etc.)
1131. <i>Responsibility for the type 1 diabetes regimen and fear of hypoglycemia in adolescents who use insulin pumps and their parents</i>	Abstract	Outcome: not related to insulin treatment adherence
1132. <i>Reversal of type 2 diabetes in youth who adhere to a very-low-energy diet: a pilot study</i>	Title	Population: do not have T1DM
1133. <i>Reversible steatohepatitis in a young boy with brittle type 1 diabetes mellitus: Mauriac syndrome</i>	Title	Outcome: not related to insulin treatment adherence
1135. <i>Review and update of insulin dependent diabetes mellitus.</i>	Title	Wrong study type (review, conference abstract etc.)
1136. <i>Review of genetic diabetes in an irish paediatric diabetes centre</i>	Title	Population: do not have T1DM
1137. <i>Revisit of a rare complication of type 1 diabetes mellitus: Mauriac syndrome</i>	Title	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>1138. Rhino-orbital-cerebral mucormycosis: a lethal complication of body dysmorphic disorder.</i>	Title	Population: do not have T1DM
<i>1139. Rising incidence and challenges of childhood diabetes. A mini review.</i>	Title	Wrong study type (review, conference abstract etc.)
<i>1141. Risk factors and predictors of uncontrolled hyperglycemia and diabetic ketoacidosis in children and adolescents with type 1 diabetes mellitus in Jeddah, western Saudi Arabia</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1143. Risk factors for poor glycemic control in diabetic children in France.</i>	Included	
<i>1144. Risk factors for poor glycemic control in diabetic children in France: Immigrant versus nonimmigrant mothers</i>		
<i>1145. Risk factors for recurrent admissions with diabetic ketoacidosis: a case-control observational study.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1146. Risk Factors for Recurrent Diabetic Ketoacidosis in Adults With Type 1 Diabetes.</i>	Title	Population: not children (adults/foetuses)
<i>1147. Risk factors of eating disorders in adolescents with type 1 diabetes</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>1148. Risk factors of recurrent diabetic ketoacidosis among type 1 diabetes mellitus children in Dr. Hasan Sadikin General Hospital</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1149. Role of Social Factors in Glycemic Control Among African American Children and Adolescents with Type 1 Diabetes.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1150. Root cause analysis of diabetic ketoacidosis and its complications: A developing country experience</i>	Abstract	Outcome: not related to insulin treatment adherence



<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>1151. Salient characteristics of youth with type 1 diabetes initiating continuous glucose monitoring</i>	Title	Outcome: not related to insulin treatment adherence
<i>1153. Satisfaction and quality of life with premeal inhaled versus injected insulin in adolescents and adults with type 1 diabetes</i>	Included	
<i>1155. School adherence with guidelines for children with diabetes</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1156. Screening for diabetes mellitus in patients with a history of gestational diabetes mellitus: A comparison of practice patterns and adherence to the recommended guidelines in community teaching hospitals</i>	Title	Population: do not have T1DM
<i>1157. Self-administered diabetes self-management profile-short form (DSMP-SF): A user-friendly adherence screener for youth with T1D</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1158. Self-care behaviors and glycemic control in type 1 diabetes.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1159. Self-care behaviors in insulin-dependent diabetes: Evaluative tools and their associations with glycemic control</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1160. Self-care behaviour, treatment satisfaction and quality of life in people on intensive insulin treatment.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1161. Self-disclosure and peer support in adolescents with insulin-dependent diabetes mellitus</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1162. Self-efficacy as a common variable in oral health behavior and diabetes adherence</i>	Full Text	Population: not children (adults/foetuses)

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>1163. Self-efficacy as a mediator variable for adolescents' adherence to treatment for insulin-dependent diabetes mellitus</i>	Included	
<i>1164. Self-efficacy scale for Brazilians with type 1 diabetes.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1165. Self-esteem as a characteristic of adherence to diabetes and dental self-care regimens</i>	Full Text	Population: not children (adults/foetuses)
<i>1166. Self-Management Behaviors in Adults on Insulin Pump Therapy.</i>	Title	Population: not children (adults/foetuses)
<i>1167. Self-monitored blood glucose: a common pitfall.</i>	Title	Outcome: not related to insulin treatment adherence
<i>1168. Self-monitoring adherence to physical activity in children and adolescents with type 1 diabetes.</i>	Title	Outcome: not related to insulin treatment adherence
<i>1170. Self-monitoring of blood glucose (SMBG) in youth with poorly controlled type 2 diabetes (T2D) in the today study</i>	Title	Population: do not have T1DM
<i>1171. Self-monitoring of blood glucose among patients with diabetes in Jordan: Perception, adherence, and influential factors</i>	Title	Outcome: not related to insulin treatment adherence
<i>1172. Self-monitoring of blood glucose and insulin dose alteration in type 1 diabetes mellitus</i>	Full Text	Population: not children (adults/foetuses)
<i>1174. Self-monitoring of blood glucose in youth-onset type 2 diabetes: Results from the ToDay study</i>	Title	Population: do not have T1DM
<i>1175. Self-monitoring of blood glucose levels and glycemic control: the Northern California Kaiser Permanente Diabetes registry.</i>	Title	Outcome: not related to insulin treatment adherence
<i>1176. Self-reported compliance with diabetes self-management during pregnancy.</i>	Abstract	Population: not children (adults/foetuses)

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>1177. Sensor augmented pump therapy from onset of type 1 diabetes: Late follow-up results of the Pediatric ONSET Study</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1178. Sensor-augmented insulin pump therapy: results of the first randomized treat-to-target study.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1179. Sensor-augmented pump and multiple daily injection therapy in the United States and Canada: post-hoc analysis of a randomized controlled trial.</i>	Abstract	Population: not children (adults/foetuses)
<i>1180. Sertraline induced acute pancreatitis in a diabetic adolescent?</i>	Title	Outcome: not related to insulin treatment adherence
<i>1181. Serum C-peptide assay of patients with hyperglycemic emergencies at the Lagos State University Teaching Hospital (LASUTH), Ikeja</i>	Title	Outcome: not related to insulin treatment adherence
<i>1182. Severe diabetic papillopathy mimicking non-arteritic anterior ischemic optic neuropathy (NAION) in a young patient.</i>	Title	Outcome: not related to insulin treatment adherence
<i>1183. Severe Growth Failure and Poorly Controlled Type 1 Diabetes Mellitus in a 7-Year-Old Girl: Mauriac Syndrome.</i>	Title	Outcome: not related to insulin treatment adherence
<i>1184. Severe hypertriglyceridemia in 3 adolescents with type 2 diabetes mellitus and all treated with L-asparaginase</i>	Title	Population: do not have T1DM
<i>1185. Severe hypoglycemia in IDDM children</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1186. Shared decision making between adolescents with type 1 diabetes and physicians</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>1187. Short-term effects of a low carbohydrate diet on glycaemic variables and cardiovascular risk markers in patients with type 1 diabetes: A randomized open-label crossover trial.</i>	Title	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>1188. Should we mix lispro with glargine? removing the guesswork by euglycemic clamp studies</i>	Title	Outcome: not related to insulin treatment adherence
<i>1189. Simulation of diabetic eye disease to compare screening policies.</i>	Title	Outcome: not related to insulin treatment adherence
<i>1190. Simultaneous vs delayed initiation of Real-Time Continuous Glucose Monitoring (RT-CGM) in children and adolescents with established type 1 diabetes starting insulin pump therapy: A pilot study</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1191. Situational obstacles to adherence for adolescents with diabetes</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1192. Six months of gluten-free diet do not influence autoantibody titers, but improve insulin secretion in subjects at high risk for type 1 diabetes</i>	Title	Outcome: not related to insulin treatment adherence
<i>1194. Six months of gluten-free diet lowers insulin requirement but does not influence residual betacell capacity in children with recent T1D onset</i>	Title	Outcome: not related to insulin treatment adherence
<i>1195. Sleep duration and its impact on adherence in adolescents with type 1 diabetes mellitus</i>	Included	
<i>1197. Sleep in children with type 1 diabetes and their parents in the T1D Exchange</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1198. Sleepovers and diabetic ketoacidosis: A cross sectional chart review of DKA admissions in established patients with type 1 diabetes</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>1199. Social competence and parental support as mediators of the link between stress and metabolic control in adolescents with insulin-dependent diabetes mellitus</i>	Included	

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>1200. Social learning intervention to promote metabolic control in type 1 diabetes mellitus: pilot experiment results.</i>	Full Text	Outcome: not related to insulin treatment adherence
<i>1201. Socio-economic, demographic, and clinical correlates of poor glycaemic control within insulin regimens among children with Type 1 diabetes: the SEARCH for Diabetes in Youth Study</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1202. Sociodemographic and psychosocial factors associated with continuous subcutaneous insulin infusion in adolescents with type 1 diabetes.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1203. Sponsorship for adolescents with diabetes</i>	Title	Outcome: not related to insulin treatment adherence
<i>1204. Spontaneous complete remission of type 1 diabetes mellitus in an adult - review and case report.</i>	Title	Population: not children (adults/foetuses)
<i>1205. Stabilization of glycemic control and improved quality of life using a shared medical appointment model in adolescents with type 1 diabetes in suboptimal control.</i>	Included	
<i>1206. Strategies to improve insulin adherence in adolescents with type 1 diabetes</i>	Full Text	Outcome: not related to insulin treatment adherence
<i>1208. Strengths, risk factors, and resilient outcomes in adolescents with type 1 diabetes (T1D): Results from diabetes MILES Youth-Australia</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1209. Stressful Life Events in Young Adults With Type 1 Diabetes in the U.S. T1D Exchange Clinic Registry</i>	Title	Population: not children (adults/foetuses)
<i>1210. Study medication adherence and outcomes in the TODAY cohort of youth with type 2 diabetes (T2D)</i>	Title	Population: do not have T1DM

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>1211. Study on pregnancy outcomes in patients with prepubertal onset of type 1 diabetes</i>	Title	Outcome: not related to insulin treatment adherence
<i>1212. Subcutaneous rapid-acting insulin analogues for diabetic ketoacidosis</i>	Title	Outcome: not related to insulin treatment adherence
<i>1214. Successful switching of multiple dose insulin to oral agents after mixedmeal tolerance test in patient with childhood-onset diabetes</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1215. Sulfonylurea treatment in a celiac girl with neonatal diabetes (KCNJ11 R201H): Impact of low compliance to the gluten free diet</i>	Title	Outcome: not related to insulin treatment adherence
<i>1216. Support as a crucial predictor of good compliance of adolescents with a chronic disease</i>	Full Text	Outcome: not related to insulin treatment adherence
<i>1217. Supported telemonitoring and glycemic control in people with type 2 diabetes : the Telescot diabetes pragmatic multicenter randomized controlled trial.</i>	Title	Population: do not have T1DM
<i>1218. Supportive and nonsupportive family behaviors: relationships to adherence and metabolic control in persons with type 1 diabetes.</i>	Full Text	Outcome: not related to insulin treatment adherence
<i>1219. Surreptitious insulin overdosing in adolescents with type 1 diabetes.</i>	Included	
<i>1220. Survey of antiobesity drug prescribing for obese children and young people in UK primary care</i>	Title	Population: do not have T1DM
<i>1221. Survey of insulin site rotation in youth with type 1 diabetes mellitus.</i>	Included	
<i>1222. Sustained CGM use in low income youth following insurance coverage</i>	Title	Outcome: not related to insulin treatment adherence
<i>1223. SWEET: Developing centers of excellence (CoR)</i>	Title	Outcome: not related to insulin treatment adherence

Result Number and Title	Excluded by/included	First Exclusion Criteria Met
1224. <i>Systematic desensitization in the treatment of needle phobias for children with diabetes</i>	Full Text	Wrong study type (review, conference abstract etc.)
1225. <i>Systematic Review of the Cost Effectiveness of Insulin Analogues in Type 1 and Type 2 Diabetes Mellitus.</i>	Title	Outcome: not related to insulin treatment adherence
1226. <i>Tamoxifen suppresses pancreatic <math>\beta</math>-cell proliferation in mice.</i>	Title	Population: not humans
1227. <i>Targeting optimal metabolic parameters in type 1 diabetes mellitus and coeliac disease: An extra challenge</i>	Title	Outcome: not related to insulin treatment adherence
1228. <i>Teaching children with diabetes about adequate dietary choices</i>	Title	Outcome: not related to insulin treatment adherence
1230. <i>Technical determinants of diabetes control in insulin pump therapy in children and adolescents</i>	Abstract	Outcome: not related to insulin treatment adherence
1231. <i>Teen power: Group intervention for poorly adherent teens with insulin-treated diabetes mellitus and their families</i>	Abstract	Wrong study type (review, conference abstract etc.)
1232. <i>Teenagers with diabetes--management challenges</i>	Abstract	Outcome: not related to insulin treatment adherence
1234. <i>Telemedicine and type 1 diabetes: is technology per se sufficient to improve glycaemic control?</i>	Abstract	Outcome: not related to insulin treatment adherence
1235. <i>Ten years' evaluation of diet, anthropometry, and physical exercise adherence after islet allotransplantation.</i>	Title	Outcome: not related to insulin treatment adherence
1236. <i>Tender hepatomegaly and abnormal pattern of hepatic steatosis in non-compliant adolescents with poorly controlled type 1 diabetes mellitus</i>	Abstract	Outcome: not related to insulin treatment adherence
1237. <i>The 600-step program for type 1 diabetes self-management in youth: the magnitude of the self-management task.</i>	Full Text	Wrong study type (review, conference abstract etc.)

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>1239. The advantages of bolus advisor for automatic calculation of preprandial insulin requirements in patients with type 1 diabetes</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>1240. The Audit of Diabetes-Dependent Quality of Life 19 (ADDQoL): feasibility, reliability and validity in a population-based sample of Australian adults</i>	Title	Population: not children (adults/foetuses)
<i>1241. The barriers against initiating insulin therapy among patients with diabetes living in Yazd, Iran</i>	Title	Outcome: not related to insulin treatment adherence
<i>1242. The basal to total insulin ratio in outpatients with diabetes on basal-bolus regimen.</i>	Title	Outcome: not related to insulin treatment adherence
<i>1243. The burden of severe hypoglycemia in type 1 diabetes.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1244. The challenging years: Surviving adolescence</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>1245. The Choice Should Be Yours: Diabetes-Related Distress by Insulin Delivery Method for People with Type 1 Diabetes.</i>	Abstract	Population: not children (adults/foetuses)
<i>1246. The contribution of art therapy in poorly controlled youth with type 1 diabetes mellitus</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1248. The contribution of hope and affectivity to diabetes-related disability: An exploratory study</i>	Title	Outcome: not related to insulin treatment adherence
<i>1249. The course of glucose intolerance in children with cystic fibrosis: a retrospective study - preliminary report</i>	Title	Population: do not have T1DM
<i>1250. The current status of treatment-related severe hypoglycemia in Japanese patients with diabetes mellitus: a report from the committee on a survey of severe hypoglycemia in the Japan Diabetes Society.</i>	Title	Outcome: not related to insulin treatment adherence



<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>1251. The daily (Daily Automated Intensive Log for Youth) trial: A wireless, portable system to improve adherence and glycaemic control in youth with diabetes</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1252. The Diabetes Social Support Questionnaire-Family Version: Evaluating adolescents' diabetes-specific support from family members</i>	Included	
<i>1254. The diabetic ketoacidosis</i>	Title	Outcome: not related to insulin treatment adherence
<i>1255. The diet in children with diabetes mellitus (DM)</i>	Title	Outcome: not related to insulin treatment adherence
<i>1256. The Effect of Family-centered Care on Management of Blood Glucose Levels in Adolescents with Diabetes.</i>	Included	
<i>1257. The effect of limited and strategic blood glucose monitoring on metabolic control in an indian type 1 diabetes clinic</i>	Title	Outcome: not related to insulin treatment adherence
<i>1258. The effect of metformin in overweight patients with type 1 diabetes and poor metabolic control.</i>	Title	Outcome: not related to insulin treatment adherence
<i>1259. The effect of nutritional status on the endocrine system: Endocrinologist's role in approaching malnutrition in young adults with cystic fibrosis</i>	Title	Population: do not have T1DM
<i>1260. The effect of peer support in adults with insulin pump-treated type 1 diabetes: a pilot study of a flexible and participatory intervention.</i>	Title	Population: not children (adults/foetuses)
<i>1261. The effect of the Talking Diabetes consulting skills intervention on glycaemic control and quality of life in children with type 1 diabetes: Cluster randomised controlled trial (DEPICTED study)</i>	Full Text	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>1263. The effect of whole body vibration training on insulin sensitivity in overweight adolescents: A randomized controlled trial</i>	Title	Population: do not have T1DM
<i>1264. The effectiveness of a daily practice clinical weight management program on cardiometabolic risk in obese children</i>	Title	Population: do not have T1DM
<i>1265. The effectiveness of Internet-based blood glucose monitoring system on improving diabetes control in adolescents with type 1 diabetes.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1266. The Effects of Mental Stress on Non-insulin-dependent Diabetes: Determining the Relationship Between Catecholamine and Adrenergic Signals from Stress, Anxiety, and Depression on the Physiological Changes in the Pancreatic Hormone Secretion.</i>	Title	Population: do not have T1DM
<i>1267. The effects of parent education on adherence and metabolic control of children with insulin-dependent diabetes mellitus</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>1268. The effects of psychosocial factors on control and compliance with diabetes treatment regimens in a sample of children with insulin-dependent diabetes mellitus</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>1269. The effects of targeting improvements in urine glucose on metabolic control in children with insulin dependent diabetes</i>	Title	Outcome: not related to insulin treatment adherence
<i>1270. The effects of weight status on treatment outcomes in a randomized clinical trial of multisystemic therapy for adolescents with type 1 diabetes and chronically poor metabolic control</i>	Title	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>1272. The efficacy and safety of growth hormone (GH) treatment used for children born small for gestational age (SGA) between 1991-2011: The experience of a regional centre</i>	Title	Population: do not have T1DM
<i>1273. The efficacy of intensive individual play therapy for children diagnosed with insulin-dependent diabetes mellitus</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>1274. The efficacy of intensive individual play therapy for chronically ill children</i>	Included	
<i>1275. The efficiency of telemedicine to optimize metabolic control in patients with type 1 diabetes mellitus: Telemed study.</i>	Abstract	Population: not children (adults/foetuses)
<i>1276. The egg or the chicken? Further data on whether good compliance to multi-injection insulin therapy should be a criterion for insulin pump therapy, or does insulin pump therapy improve compliance?</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>1277. The egg or the chicken? Should good compliance to multi-injection insulin therapy be a criterion for insulin pump therapy, or does insulin pump therapy improve compliance?</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>1278. The establishment of a new national network leads to quality improvement in childhood diabetes: Implementation of the ISPAD Guidelines</i>	Title	Outcome: not related to insulin treatment adherence
<i>1280. The feasibility of peer mentoring to improve adherence in adolescents and young adults with type 1 diabetes</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1281. The focus is on the families: Racial differences in parents' perception of diabetes care</i>	Abstract	Wrong study type (review, conference abstract etc.)

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>1282. The health and lifestyles of adolescents with type 1 diabetes in Portugal</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1283. The health belief model and adolescents with insulin-dependent diabetes mellitus</i>	Included	
<i>1284. The impact of adherence to the nutritional education on glycemic control and quality of life in children and adolescents with type 1 diabetes mellitus</i>	Title	Outcome: not related to insulin treatment adherence
<i>1285. The impact of ethnicity, educational and economic status on the prescription of insulin therapeutic regimens and on glycemic control in patients with type 1 diabetes. A nationwide study in Brazil.</i>	Title	Outcome: not related to insulin treatment adherence
<i>1286. The impact of family functioning on treatment adherence and metabolic control for adolescents with poorly controlled type 1 diabetes</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>1287. The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study.</i>	Title	Outcome: not related to insulin treatment adherence
<i>1288. The impact of mothers' sense of empowerment on the metabolic control of their children with juvenile diabetes</i>	Included	
<i>1289. The Impact of Patient-Centered Medical Homes on Quality of Care and Medication Adherence in Patients with Diabetes Mellitus</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1290. The impact of physiological, therapeutic and psychosocial variables on glycemic control in youth with type 1 diabetes mellitus</i>	Abstract	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>1292. The Impact of Self-Monitoring Blood Glucose Adherence On Glycemic Goal Attainment in an Indigent Population, With Pharmacy Assistance.</i>	Title	Outcome: not related to insulin treatment adherence
<i>1293. The impact of sensor-augmented insulin pump (SAP) therapy on quality of life (QOL) in children and adolescents with type 1 diabetes (T1D) and their parents</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>1294. The impact of sleep on adherence behaviors in adolescents with type 1 diabetes mellitus</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>1295. The Impact of Technology on Current Diabetes Management.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1297. The influence of patient variables on insulin total daily dose in paediatric inpatients with new onset type 1 diabetes mellitus.</i>	Title	Outcome: not related to insulin treatment adherence
<i>1298. The influence of process, structure and policy on HbA1c levels in treatment of children and adolescents with type 1 diabetes</i>	Title	Outcome: not related to insulin treatment adherence
<i>1301. The Interactive Effect of Diabetes Family Conflict and Depression on Insulin Bolusing Behaviors for Youth</i>	Included	
<i>1302. The International Diabetes Closed-Loop Study: Testing Artificial Pancreas Component Interoperability</i>	Title	Outcome: not related to insulin treatment adherence
<i>1303. The International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes--chapter 3: Pig islet product manufacturing and release testing.</i>	Title	Population: not humans

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>1304. The JDRF CCTN CGM TIME Trial: Timing of Initiation of continuous glucose Monitoring in Established pediatric type 1 diabetes: Study protocol, recruitment and baseline characteristics</i>	Title	Outcome: not related to insulin treatment adherence
<i>1306. The lived experiences of young people (13-16 years) with Type 1 diabetes mellitus and their parents--a qualitative phenomenological study.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1307. The multinational second Diabetes, Attitudes, Wishes and Needs study: results of the French survey.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1308. The natural history of brittle diabetes.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1309. The onset of a chronic disease as a traumatic psychic experience: A psychodynamic survey on type 1 diabetes in young patients</i>	Full Text	Outcome: not related to insulin treatment adherence
<i>1310. The patient-doctor relationship and metabolic control in patients with type 1 (insulin-dependent) diabetes mellitus.</i>	Abstract	Population: not children (adults/foetuses)
<i>1311. The psychology of the adolescent with chronic disease: What to learn from the diabete</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>1312. The relationship among independence, diet adherence, and ego identity in adolescents with insulin-dependent diabetes mellitus</i>	Title	Outcome: not related to insulin treatment adherence
<i>1313. The relationship between adherence behaviors and metabolic control in childhood diabetes</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1314. The relationship between carbohydrate and the mealtime insulin dose in type 1 diabetes.</i>	Title	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>1315. The relationship between diabetes self-management and metabolic control in youth with type 1 diabetes: an integrative review.</i>	Title	Wrong study type (review, conference abstract etc.)
<i>1316. The relationship between maternal fear of hypoglycaemia and adherence in children with type-1 diabetes.</i>	Full Text	Outcome: not related to insulin treatment adherence
<i>1317. The relationship between negative communication and body image dissatisfaction in adolescent females with type 1 diabetes mellitus</i>	Included	
<i>1319. The relationship between primary care physicians' adherence to guidelines for the treatment of diabetes and patient satisfaction : findings from a pilot study.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1320. The relationship between psychological stress and insulin-dependent diabetic blood glucose control: preliminary investigations</i>	Abstract	Population: not children (adults/foetuses)
<i>1321. The Relationship between Self-Management and Glycemic Control in a Cohort of Children with Type 1 and Type 2 Diabetes.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1322. The relationship of stress and coping to regimen adherence and glycemic control of diabetes</i>	Abstract	Population: not children (adults/foetuses)
<i>1323. The rise of technology in diabetes care. Not all that is new is necessarily better.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1324. The role of coping with disease in adherence to treatment regimen and disease control in type 1 and insulin treated type 2 diabetes mellitus.</i>	Abstract	Population: not children (adults/foetuses)

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>1325. The role of diet behaviors in achieving improved glycemic control in intensively treated patients in the diabetes control and complications trial</i>	Title	Outcome: not related to insulin treatment adherence
<i>1326. The role of family environment and treatment adherence in the metabolic control of children with type 1 diabetes: A meta-analysis</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>1327. The role of health beliefs in the regimen adherence and metabolic control of adolescents and adults with diabetes mellitus</i>	Included	
<i>1328. The role of marital distress, parental and child depression, family functioning and health care behaviors in treatment adherence and metabolic control among adolescents with diabetes</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>1329. The Role of Peers for Diabetes Management in Adolescents and Emerging Adults With Type 1 Diabetes: A Longitudinal Study.</i>	Full Text	Population: not children (adults/foetuses)
<i>1330. The role of self-monitoring of blood glucose in the routine management of children with insulin-dependent diabetes mellitus</i>	Title	Outcome: not related to insulin treatment adherence
<i>1331. The screening and diagnosis of cystic fibrosis-related diabetes in the United Kingdom</i>	Title	Population: do not have T1DM
<i>1332. The self-regulation of health behavior in children with insulin-dependent diabetes mellitus</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>1333. The short-term results of intensive insulin therapy in preadolescent children with type-1 diabetes</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1334. The state of young adults with juvenile onset diabetes.</i>	Title	Population: not children (adults/foetuses)



<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>1335. The structure of parental involvement and relations to disease management for youth with type 1 diabetes.</i>	Included	
<i>1336. The theory of reasoned action in describing tooth brushing, dental caries and diabetes adherence among diabetic patients</i>	Full Text	Population: not children (adults/foetuses)
<i>1337. The Type 1 Diabetes-Resistance Locus Idd22 Controls Trafficking of Autoreactive CTLs into the Pancreatic Islets of NOD Mice.</i>	Title	Population: not humans
<i>1338. The unusual presentation and challenges in managing thyroid storm with concomitant diabetic ketoacidosis</i>	Title	Outcome: not related to insulin treatment adherence
<i>1339. The ups and downs of low-carbohydrate diets in the management of Type 1 diabetes: a review of clinical outcomes.</i>	Title	Outcome: not related to insulin treatment adherence
<i>1340. The use of a CoolSense device to lower pain sensation during finger pricking while measuring blood glucose in diabetes patients--a randomized placebo.</i>	Abstract	Population: not children (adults/foetuses)
<i>1341. The use of computers in the control of diabetes in children and adolescents.</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>1342. The use of insulin pump therapy in adolescents</i>	Full Text	Outcome: not related to insulin treatment adherence
<i>1343. The use of premixed 30/70 insulin in high risk youth with type 1 diabetes: A quality audit</i>	Title	Outcome: not related to insulin treatment adherence
<i>1344. The utility of natriuretic peptides as novel cardiovascular biomarkers in girls with Turner syndrome: Comparison of findings to obese children and adolescents</i>	Title	Population: do not have T1DM
<i>1345. There is a bright future in the management of diabetes in children in resource limited countries</i>	Title	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>1346. Thyroiditis as a silent cause of hyperglycaemia in type 1 diabetes</i>	Title	Outcome: not related to insulin treatment adherence
<i>1347. Tiempo de exposicion al gluten y marcadores de riesgo de diabetes mellitus insulino dependiente en pacientes celiacosRisk markers for insulin-dependent diabetes mellitus and duration of exposure to gluten in celiac patients</i>	Title	Outcome: not related to insulin treatment adherence
<i>1348. Time of Day When Type 1 Diabetes Patients With Eating Disorder Symptoms Most Commonly Restrict Insulin.</i>	Abstract	Population: not children (adults/foetuses)
<i>1349. Time to failure of oral therapy in children with type 2 diabetes: A single center retrospective chart review</i>	Title	Population: do not have T1DM
<i>1350. Timing of initiation of continuous glucose monitoring (CGM) in established pediatric diabetes (The CGM TIME trial)</i>	Title	Outcome: not related to insulin treatment adherence
<i>1351. Timing of Meal Insulin and Its Relation to Adherence to Therapy in Type 1 Diabetes</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1352. Tip 1 diyabetli cocuklarda glisemik kontrolu etkileyen faktorlerFactors influencing glycemic control in children with type 1 diabetes</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1353. To evaluate various precipitating factors for diabetic ketoacidosis</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1354. To study the clinical profile of children admitted with diabetic ketoacidosis in a Tertiary Hospital in India</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1355. To study the efficacy of intervention strategies on features of metabolic syndrome in asian urban adolescent girls with pcos</i>	Title	Population: do not have T1DM

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>1356. To whatsapp or not to whatsapp? what could be done with new social media to manage type 1 diabetes in adolescents</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>1357. Too sweet for too long?</i>	Abstract	Population: do not have T1DM
<i>1358. Total body irradiation (TBI) increases cardio-metabolic risk and induces carotid vascular stiffness in survivors after hematopoietic cell transplant (HCT) for childhood hematologic malignancies</i>	Title	Population: do not have T1DM
<i>1359. Transition instead of transfer for drug treatment in adolescent diabetes type 1</i>	Title	Outcome: not related to insulin treatment adherence
<i>1360. Translation and validation of the diabetes self-management profile (DSMP) in Brazilian Portuguese language: First instrument to assess type 1 diabetes self-management in a Brazilian pediatric population</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1361. Treatment of osteopenia in children with insulin-dependent diabetes mellitus: The effect of 1alpha-hydroxyvitamin D3</i>	Title	Outcome: not related to insulin treatment adherence
<i>1362. Treatment of type 1 diabetes with insulin lispro during Ramadan.</i>	Full Text	Population: not children (adults/foetuses)
<i>1364. Treatment of type 2 diabetes in a Hispanic population of South Florida - Economic analysis</i>	Title	Population: do not have T1DM
<i>1365. Treatment of type 2 diabetes mellitus in children and adolescents</i>	Title	Population: do not have T1DM
<i>1366. Trends in cannabis use among patients with diabetes- the national survey on drug use and health, 2005-2017</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1367. Trends in cardiovascular risk factor management in type 1 diabetes by sex.</i>	Title	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>1368. Trends in health-related quality of life among adolescents with type 1 diabetes mellitus in Saudi Arabia</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>1369. Twin studies in diabetes mellitus.</i>	Title	Outcome: not related to insulin treatment adherence
<i>1370. Two cases of diabetic ketoacidosis in HNF1A-MODY linked to severe dehydration: Is it time to change the diagnostic criteria for MODY?</i>	Title	Population: do not have T1DM
<i>1371. Type 1 diabetes among adolescents: Reduced diabetes self-care caused by social fear and fear of hypoglycemia</i>	Included	
<i>1373. Type 1 diabetes and prolonged fasting</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1375. Type 1 diabetes mellitus</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>1376. Type 1 diabetes mellitus and pregnancy.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1377. Type 1 diabetes mellitus and sickle cell disease: A case series of pediatric patients at rainbow babies &amp; children's hospital</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1378. Type 1 diabetes mellitus: Metabolic control before and after puberty</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>1379. Type 1 diabetes structured education: What are the core self-management behaviours?</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1380. Type 1 diabetes, sickle thalassaemia in a toddler, case report in Saudi Arabia</i>	Title	Outcome: not related to insulin treatment adherence
<i>1381. Type 2 diabetes mellitus in children and adolescents.</i>	Title	Population: do not have T1DM
<i>1382. Type 2 diabetes mellitus is becoming the most common type of diabetes in school children</i>	Title	Population: do not have T1DM
<i>1383. Type 1 diabetes mellitus in toddlers</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1384. UCD School of Medicine and Medical Science, SMMS, Summer Student Research Awards 2013, SSRA</i>	Title	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>1385. UK service level audit of insulin pump therapy in paediatrics.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1386. Uncontrolled hypertension in type 1 diabetes: assessment of patients' desires about treatment and improvement of blood pressure control by a structured treatment and teaching programme.</i>	Title	Outcome: not related to insulin treatment adherence
<i>1388. Uncovering undetected hypoglycemic events.</i>	Title	Outcome: not related to insulin treatment adherence
<i>1389. Underestimated impact of non-severe nocturnal hypoglycaemic events (NHEs) on patients' functioning and well being</i>	Title	Outcome: not related to insulin treatment adherence
<i>1390. Understanding your diabetic patient.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1391. Undiagnosed coeliac disease and risk of autoimmune disorders in subjects with type 1 diabetes mellitus</i>	Title	Outcome: not related to insulin treatment adherence
<i>1392. Unstable type 1 diabetes in adolescence</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1393. Updated and revised diabetes family conflict scale</i>	Full Text	Outcome: not related to insulin treatment adherence
<i>1395. Uptake of a novel tool to adjust insulin boluses, based on CGM trend arrows and insulin sensitivity (trend arrow adjustment tool); In children with type 1 diabetes, who are using insulin pump therapy and continuous glucose monitoring</i>	Abstract	Wrong study type (review, conference abstract etc.)
<i>1396. Urine alpha-Glutathione S-Transferase, systemic inflammation and arterial function in juvenile type 1 diabetes</i>	Title	Outcome: not related to insulin treatment adherence
<i>1398. Use and discontinuation of continuous subcutaneous insulin infusion and continuous glucose monitoring in paediatric patients with type 1 diabetes: Rates and causes</i>	Abstract	Wrong study type (review, conference abstract etc.)

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>1399. Use of a glucose-controlled insulin infusion system in children and adolescents with insulin-dependent diabetes.</i>	Full Text	Outcome: not related to insulin treatment adherence
<i>1400. Use of an automated bolus calculator reduces fear of hypoglycemia and improves confidence in dosage accuracy in patients with type 1 diabetes mellitus treated with multiple daily insulin injections</i>	Full Text	Outcome: not related to insulin treatment adherence
<i>1402. Use of an insulin pen with memory is not enough to give better glycaemic control</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1403. Use of an integrated strip-free blood glucose monitoring system increases frequency of self-monitoring and improves glycemic control: Results from the ExAct study.</i>	Title	Outcome: not related to insulin treatment adherence
<i>1404. Use of Commonly Available Technologies for Diabetes Information and Self-Management Among Adolescents With Type 1 Diabetes and Their Parents: A Web-Based Survey Study.</i>	Included	
<i>1405. Use of continuous glucose monitoring, computerized therapy recommendations, and automated data processing in a pediatric trial of tight glycemic control</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1406. Use of continuous subcutaneous insulin infusion (insulin pump) therapy in the hospital: a review of one institution's experience.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1407. Use of FGM as a clinical tool in type 1 diabetes young adults</i>	Title	Outcome: not related to insulin treatment adherence
<i>1408. Use of insulin pump therapy at nighttime only for children 7-10 years of age with type 1 diabetes</i>	Abstract	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
<i>1410. Use of multisystemic therapy to improve regimen adherence among adolescents with type 1 diabetes in chronic poor metabolic control: a randomized controlled trial.</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1411. Use of nutrition therapy in the management of diabetes mellitus.</i>	Title	Outcome: not related to insulin treatment adherence
<i>1412. Use of the real-time continuous glucose monitor at initiation of insulin pump therapy in children and adolescents</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1413. Using a primary nurse manager to implement DCCT recommendations in a large pediatric program.</i>	Title	Outcome: not related to insulin treatment adherence
<i>1414. Using an injection port helps improve metabolic control and compliance to a strict basal-bolus regimen in children and adolescents with type 1 diabetes.</i>	Full Text	Wrong study type (review, conference abstract etc.)
<i>1415. Using behavioral interventions to assist children with type 1 diabetes manage blood glucose levels</i>	Full Text	Outcome: not related to insulin treatment adherence
<i>1416. Using gamification to encourage blood glucose testing in children with Type 1 diabetes</i>	Title	Outcome: not related to insulin treatment adherence
<i>1417. Using insulin pump with a remote control system in patients with diabetes improves glyemic control and enhances patient satisfaction</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1418. Using mobile phones to measure adolescent diabetes adherence</i>	Abstract	Outcome: not related to insulin treatment adherence
<i>1420. Using spatio-temporal surveillance data to test the infectious environment of children before type 1 diabetes diagnosis.</i>	Title	Outcome: not related to insulin treatment adherence

<b>Result Number and Title</b>	<b>Excluded by/included</b>	<b>First Exclusion Criteria Met</b>
1421. <i>Using the Internet-based upload blood glucose monitoring and therapy management system in patients with type 1 diabetes.</i>	Title	Outcome: not related to insulin treatment adherence
1422. <i>USO DI INSULINE PREMISCELATE NEL TRATTAMENTO DEL BAMBINO DIABETICO</i> <i>Use of premixed insulins in the management of children with type 1 diabetes</i>	Title	Outcome: not related to insulin treatment adherence
1423. <i>Vaccination adherence to influenza, pneumococcal and hepatitis B virus in adult type 1 diabetes mellitus patients.</i>	Title	Population: not children (adults/foetuses)
1424. <i>Validation of a contemporary adherence measure for children with Type 1 diabetes: The Diabetes Management Questionnaire</i>	Abstract	Outcome: not related to insulin treatment adherence
1426. <i>Validation of a diabetes self-care measure for parents of children with type 1 diabetes</i>	Abstract	Outcome: not related to insulin treatment adherence
1427. <i>Validation of a diabetes-specific quality-of-life scale for patients with type 1 diabetes.</i>	Full Text	Population: not children (adults/foetuses)
1428. <i>Validation of an abbreviated adherence measure in youth with type 1 diabetes (T1D)</i>	Abstract	Wrong study type (review, conference abstract etc.)
1429. <i>Validation of the diabetes self management profile-self report form: Measure of adolescent adherence</i>	Abstract	Wrong study type (review, conference abstract etc.)
1430. <i>Value of serum 1,5-anhydroglucitol measurements in childhood obesity in the continuum of diabetes</i>	Title	Population: do not have T1DM
1431. <i>Variations in the quality and sustainability of long-term glycaemic control with continuous subcutaneous insulin infusion.</i>	Title	Outcome: not related to insulin treatment adherence
1432. <i>Vessel wall properties of large arteries in uncomplicated IDDM</i>	Title	Outcome: not related to insulin treatment adherence



Result Number and Title	Excluded by/included	First Exclusion Criteria Met
1433. <i>Victimization of youth with type-1 diabetes by teachers: relations with adherence and metabolic control</i>	Included	
1435. <i>Virtual reality and interactive gaming technology for obese and diabetic children: is military medical technology applicable?</i>	Abstract	Outcome: not related to insulin treatment adherence
1436. <i>Visceral fat, independent of total-body adiposity, is associated with cardiovascular risk factors, insulin resistance, and vascular dysfunction among children and adolescents</i>	Title	Population: do not have T1DM
1437. <i>Web-based diabetes education and coping skills training</i>	Abstract	Outcome: not related to insulin treatment adherence
1438. <i>Weight gain associated with intensive therapy in the diabetes control and complications trial. The DCCT Research Group.</i>	Full Text	Outcome: not related to insulin treatment adherence
1439. <i>What do professionals recommend regarding the frequency of self-monitoring of blood glucose?</i>	Title	Outcome: not related to insulin treatment adherence
1440. <i>What's new in the psychosomatics of insulin-dependent diabetes mellitus</i>	Abstract	Wrong study type (review, conference abstract etc.)
1441. <i>When to treat a diabetic patient using an external insulin pump. Expert consensus. Société francophone du diabète (ex ALFEDIAM) 2009.</i>	Title	Outcome: not related to insulin treatment adherence
1442. <i>White Coat Adherence in Pediatric Patients with Type 1 Diabetes Who Use Insulin Pumps</i>	Included	
1444. <i>White Coat Adherence Occurs in Adolescents with Type 1 Diabetes Receiving Intervention to Improve Insulin Pump Adherence Behaviors</i>		

Result Number and Title	Excluded by/included	First Exclusion Criteria Met
1445. <i>Who participates in research on adherence to treatment in insulin-dependent diabetes mellitus? Implications and recommendations for research.</i>	Abstract	Outcome: not related to insulin treatment adherence
1446. <i>Wilson disease and metabolic syndrome: Is there a link?</i>	Title	Population: do not have T1DM
1447. <i>WITHDRAWN: Inhaled insulin in diabetes mellitus.</i>	Abstract	Wrong study type (review, conference abstract etc.)
1448. <i>Wolfram (DIDMOAD) syndrome: A multidisciplinary clinical study in nine Turkish patients and review of the literature</i>	Title	Outcome: not related to insulin treatment adherence
1449. <i>Występowanie celiakii oraz chorób autoimmunologicznych tarczycy u dzieci i młodzieży z cukrzycą typu 1 z regionu Dolnego Śląska</i> <i>The incidence of celiac disease and autoimmune thyroid diseases in children and adolescents with diabetes type 1 from Lower Silesia</i>	Title	Outcome: not related to insulin treatment adherence
1450. <i>Yineleyen diyabetik ketoasidoz benzeri belirtiler ve yapay hiperglisemi, diyabet tip 1 ve munchausen sendromu birlikteligi: Olgu sunumu</i> <i>Recurrent diabetic ketoacidosis-like symptoms and factitious hyperglycemia as a munchausen syndrome in diabetes mellitus type 1: A case report</i>	Title	Outcome: not related to insulin treatment adherence
1451. <i>Young children's subjective reports about their diabetes mellitus: a validation of the Diabetes Pictorial Scale</i>	Title	Outcome: not related to insulin treatment adherence
1452. <i>Young patients with type 1 diabetes poorly controlled and poorly compliant with self-monitoring of blood glucose: can technology help? Results of the i-NewTrend randomized clinical trial</i>	Title	Outcome: not related to insulin treatment adherence

*Appendix 9 All studies found from database searching and if they were included or reasons for exclusion. Studies that have been left blank were either duplicates seen elsewhere in the table (often alternative language versions) or had been included as far as the full text screen but did not have a full text available.*

Search Number	Database	Search Term	Number of Results
1	EMBASE	exp "INSULIN DEPENDENT DIABETES MELLITUS"/ OR exp "DIABETES MELLITUS"/	913 724
2	EMBASE	("type 1 diabetes").ti,ab	59 601
3	EMBASE	(1 OR 2)	916 691
4	EMBASE	(insulin).ti,ab	458 125
5	EMBASE	(3 AND 4)	201 771
6	EMBASE	(adherence).ti,ab	169 529
7	EMBASE	(compliance).ti,ab	175 573
8	EMBASE	(6 OR 7)	331 482
9	EMBASE	(5 AND 8)	4 406
10	EMBASE	9 [Human age groups Infant to one year OR Child unspecified age OR Preschool Child 1 to 6 years OR School Child 7 to 12 years OR Adolescent 13 to 17 years]	727
11	HMIC	exp "INSULIN DEPENDENT DIABETES MELLITUS"/ OR exp "DIABETES MELLITUS"/	2 892
12	HMIC	("type 1 diabetes").ti,ab	168
13	HMIC	(11 OR 12)	2 907
14	HMIC	(insulin).ti,ab	645
15	HMIC	(13 AND 14)	371
16	HMIC	(adherence).ti,ab	1 474

17	HMIC	(compliance).ti,ab	2 256
18	HMIC	(16 OR 17)	3 603
19	HMIC	(15 AND 18)	21
21	Medline	exp "DIABETES MELLITUS, TYPE 1"/	73 975
22	Medline	("type 1 diabetes").ti,ab	37 576
23	Medline	(21 OR 22)	85 036
24	Medline	(insulin).ti,ab	345 339
25	Medline	(23 AND 24)	34 757
26	Medline	(adherence).ti,ab	110 853
27	Medline	(compliance).ti,ab	109 996
28	Medline	(26 OR 27)	214 135
29	Medline	(25 AND 28)	711
50	Medline	29 [Human age groups Infant OR Child,preschool OR Child OR Adolescent]	342
31	PsycINFO	exp "DIABETES MELLITUS"/	8 102
32	PsycINFO	("type 1 diabetes").ti,ab	1 868
33	PsycINFO	(31 OR 32)	9 281
34	PsycINFO	(insulin).ti,ab	10 647
35	PsycINFO	(33 AND 34)	2 050
36	PsycINFO	(adherence).ti,ab	27 143
37	PsycINFO	(compliance).ti,ab	22 868
38	PsycINFO	(36 OR 37)	48 566
39	PsycINFO	(35 AND 38)	234
51	PsycINFO	39 [Human age groups Childhood birth-12 Yrs OR Neonatal birth-1 Mo OR Infancy 2-23 Mo OR Preschool Age	124

		2-5 Yrs OR School Age 6-12 Yrs OR Adolescence 13-17 Yrs]	
<b>41</b>	PubMed	("type 1 diabetes" OR "insulin dependent diabetes" OR "juvenile onset diabetes").ti,ab	38 798
<b>42</b>	PubMed	("type 1 diabetes").ti,ab	38 519
<b>43</b>	PubMed	(41 OR 42)	39 798
<b>44</b>	PubMed	(insulin).ti,ab	404 899
<b>45</b>	PubMed	(43 AND 44)	17 502
<b>46</b>	PubMed	(adherence).ti,ab	152 775
<b>47</b>	PubMed	(compliance).ti,ab	178 118
<b>48</b>	PubMed	(46 OR 47)	288 448
<b>49</b>	PubMed	(45 AND 48)	599

*Appendix 10: Full search strategy used during systematic review. Legend; EMBASE: Excerpta Medica Database, HMIC: Healthcare Management Information Consortium, exp: explode – used within search engine to include the term as well as any more specific terms associated with it.*

# PENDANT study

**A study to establish if there is a relationship between how unwell children and young people are when diagnosed with Type 1 Diabetes, and how well they manage later on**



## Information leaflet for younger participants

IRAS ID 264508  
PENDANT Study – Patient Information Leaflet for Younger Children



### What will happen to the information collected about me?

The information will help us learn more about how well children and families can manage after a child (like you) has been told they have diabetes. The information collected will be stored at the hospital for 10 years.

### Do I have to take part?

No. If you are not happy then your doctor will keep looking after you

IRAS ID 264508  
PENDANT Study – Patient Information Leaflet for Younger Children

### What is this about?

We want to get you and your family's help. We don't yet understand how much your new condition (Diabetes) has changed your life. Or how it has changed your family's life. We want to ask some questions to learn about this.



### Why you?

You have recently found out that you have Type 1 Diabetes, and will

as normal. If you are not sure, we can arrange for someone to talk to you and answer any questions you have.

### Can I change my mind?

Yes, this is not a problem. Just tell the nurse or doctor.



### Who is doing this research?

Doctors at Alder Hey, and scientists at the University of Liverpool. Part of the study is being done by a

be followed up by the team at Alder Hey.

### What will the study involve?

We would like to ask you and your family some questions about how you are all feeling. These questions will take about 40 minutes, which is about the length of a lesson in school.

### What will happen next?

We will ask you and your family (if they are present) to agree to take part (consent). If you are happy to do this, then we will ask the questions. If you want to take part, but can't today, we could phone your family up another time.

V3.0, 25<sup>th</sup> October 2019

medical student from the University of Liverpool, who has taken an extra year in their studies to do the research. The student is also based here at Alder Hey and is supported closely by the doctors and scientists.

### Who do I ask about this?

Your family will have been given lots of information. If you or they are not sure, the doctor or nurse who gave you this information leaflet can tell you more



V3.0, 25<sup>th</sup> October 2019

# PENDANT study

**A study to establish if there is a relationship between how unwell children and young people are when diagnosed with Type 1 Diabetes, and how well they manage later on**



## Information leaflet for older participants

IRAS ID 264508  
PENDANT Study – Patient Information Leaflet for Older Patients

tell the researcher. We have clinical psychologists within our team that you might find helpful.

The information we collect may help us to improve the service we deliver to our newly diagnosed patients and help to inform a future screening protocol.

### How will we use information about you?

We will need to use information from you and your medical records for this research project.

This information will include your hospital number, name and contact details. People will use this information to do the research or to check your records to make sure that the research is being done properly.

People who do not need to know who you are will not be able to see your name or contact details. Your data will have a code number instead.

We will keep all information about you safe and secure.

Once we have finished the study, we will keep some of the data so we can check the results. We will write our reports in a way that no-one can work out that you took part in the study.

### What are your choices about how your information is used?

- You can stop being part of the study at any time, without giving a reason, but we will keep information about you that we already have.
- We need to manage your records in specific ways for the research to be reliable. This means

IRAS ID 264508  
PENDANT Study – Patient Information Leaflet for Older Patients

### What is this about?

We would like to invite you and your family to take part in our research study, to help understand the effects on patients and families of a new diagnosis of Type 1 Diabetes. This leaflet will help you to understand why the research is being done, and what it will involve.

Our team will go through this information with you and answer any questions you may have.

### What do we know about how well young people manage a Type 1 Diabetes Diagnosis?

For young people diagnosed with Type 1 diabetes and their families, the time around diagnosis can seem confusing and frightening.

There are many different ways of coping, but we do not know a lot about how individual young people, or their families, manage. How much extra stress does this put on them? Do they need any extra help?

### Why have you been asked to take part in this study?

You have recently been diagnosed with Type 1 Diabetes and will be followed up by the team at Alder Hey.

### What will the study involve?

The study involves you and your family completing a series of questionnaires (maximum of 40 minutes) with a member of our team. The questionnaires will focus on the level of stress you and your family have experienced

that we won't be able to let you see or change the data we hold about you.

### Where can you find out more about how your information is used?

You can find out more about how we use your information:

- at [www.hra.nhs.uk/information-about-patients/](http://www.hra.nhs.uk/information-about-patients/)
- by asking one of the research team
- by sending an email to [d.hawcutt@liv.ac.uk](mailto:d.hawcutt@liv.ac.uk), who can put you in contact with the sponsor's Data Protection Officer.

### Do I have to take part?

No. If you are not happy then your doctors will keep looking after you as normal. If you are not sure then we can arrange for someone to talk to you and help you make up your mind.

### Can I change my mind?

Yes, this is not a problem. If you change your mind, you can withdraw from the study at any time without giving reason (up to the point we publish the results).

### Who is doing this research?

This research is being organised by the doctors at Alder Hey Children's Hospital and scientists at the Department of Women's and Children's Health at the University of Liverpool. Part of the study is being undertaken by a medical student from the University of Liverpool, who has taken an extra year in their degree to do a Masters

since diagnosis, how you all coped with this stress, and how the diagnosis has impacted on your quality of life. This will normally be done within the hospital before/after your diabetes clinic appointments. However, if for any reason we are unable to collect this information during this time we may need to contact you by phone or arrange to do a home visit.

### What will happen next?

If you agree to take part in this study, a member of our research team will ask for a parent/guardian to sign a consent form. You may be asked to sign an assent form. We will then arrange a time to see you before/after your diabetes clinic appointments to complete the series of questionnaires.

If you turn 16 while in the study, we will ask if you wish to continue in the study. If you do, you will be asked to sign a consent form for yourself. This is because the law regarding consent changes when you turn 16.

If you are interested, we may ask you again in the future, but you can decide if you wish to take part in future.

### Are there any risks/ benefits to taking part?

The questionnaires will take about 40 minutes extra, in addition to your diabetes clinic appointment. Medical care will be unaffected, but if we do find something that may affect your health, we will discuss this with you.

Some people find talking about an illness distressing. If at any time you (or your family) feel that the actual or perceived distress is too great, please do not hesitate to

V3.0, 25<sup>th</sup> October 2019

degree (an MPhil). The student is closely supported by the doctors and scientists.

As a student project, this research has no specific funding. The sponsor is Alder Hey Children's Hospital.

### Has the study been checked?

Yes. All research that involves NHS patients (like you) must be approved by a Research Ethics Committee before it goes ahead. The Committee is satisfied that your rights will be respected, that any risks have been reduced to a minimum and balanced against possible benefits, and that you have been given sufficient information on which to make an informed decision to take part or not.

### Who do I ask about this?

The doctor or nurse who gave you this information leaflet can discuss the study with you more.

### What if something goes wrong?

If you are unhappy, or have concerns about any aspect of this study, or would like to make a complaint, you should speak to the PALS office on 0151 252 5374, or via email [PALS@alderhey.nhs.uk](mailto:PALS@alderhey.nhs.uk)

Alternatively, you can contact Dr Dan Hawcutt (the researcher in charge of the study) at [d.hawcutt@liv.ac.uk](mailto:d.hawcutt@liv.ac.uk).



V3.0, 25<sup>th</sup> October 2019



# PENDANT study

**A study to establish if there is a relationship between how unwell children and young people are when diagnosed with Type 1 Diabetes, and how well they manage later on**



## Information leaflet for patients competent to consent

IRAS ID 264508

PENDANT Study – Patient Information Leaflet for Patients Competent to Consent

This information will include your hospital number, name, and contact details. People will use this information to do the research or to check your records to make sure that the research is being done properly.

People who do not need to know who you are will not be able to see your name or contact details. Your data will have a code number instead.

We will keep all information about you safe and secure.

Once we have finished the study, we will keep some of the data so we can check the results. We will write our reports in a way that no-one can work out that you took part in the study.

### What are your choices about how your information is used?

- You can stop being part of the study at any time, without giving a reason, but we will keep information about you that we already have.
- We need to manage your records in specific ways for the research to be reliable. This means that we won't be able to let you see or change the data we hold about you.

### Where can you find out more about how your information is used?

You can find out more about how we use your information:

- at [www.hra.nhs.uk/information-about-patients/](http://www.hra.nhs.uk/information-about-patients/)
- by asking one of the research team

IRAS ID 264508

PENDANT Study – Patient Information Leaflet for Patients Competent to Consent

### What is this about?

We would like to invite you to take part in our research study, to help understand the effects on families of a new diagnosis of Type 1 Diabetes. This leaflet will help you to understand why the research is being done, and what it will involve.

Our team will go through this information with you and answer any questions you may have.

### What do we know about how well young people manage a Type 1 Diabetes Diagnosis?

For young people diagnosed with Type 1 diabetes, and their families, the time around diagnosis can seem confusing and frightening.

There are many different ways of coping, but we do not know a lot about how individual young people, or their families, manage. How much extra stress does this put on them? Do they need any extra help?

### Why have you been asked to take part in this study?

You have recently been diagnosed with Type 1 Diabetes and will be followed up by the team at Alder Hey.

### What will the study involve?

The study involves completing a series of questionnaires (maximum of 40 minutes) with a member of our team. The questionnaires will focus on the level of stress you have experienced since diagnosis, how you have coped with this stress, and how the diagnosis has impacted on quality of life. This will normally be done within the

- by sending an email to [d.hawcutt@liv.ac.uk](mailto:d.hawcutt@liv.ac.uk), who can put you in contact with the sponsor's Data Protection Officer.

### Do I have to take part?

No. If you are not happy to take part, then your doctors will keep looking after you as normal. If you are not sure, then we can arrange for someone to talk to you and help you make up your mind.

### Can I change my mind?

Yes, this is not a problem. If you change your mind, you can withdraw from the study at any time without giving reason (up to the point we publish the results).

### Who is doing this research?

This research is being organised by the Doctors at Alder Hey Children's Hospital and Scientists at the Department of Women's and Children's Health at the University of Liverpool. Part of the study is being undertaken by a medical student from the University of Liverpool who has taken an extra year in their degree to do a Masters degree (an MPhil). The student is closely supported by the doctors and scientists.

As a student project, this research has no specific funding. The sponsor is Alder Hey Children's Hospital.

### Has the study been checked?

Yes. All research that involves NHS patients (like you) must be approved by a Research Ethics Committee before it goes ahead. The Committee is satisfied that your rights will be respected, that any risks have been

hospital before/after your diabetes clinic appointments. However, if for any reason we are unable to collect this information during this time we may need to contact you by phone or arrange to do a home visit.

### What will happen next?

If you agree to take part in this study, a member of our research team will ask you to sign a consent form. Once you have consented, we will arrange a time to see you before/after your diabetes clinic appointments to complete the series of questionnaires.

If you are interested, we may ask you again in the future, but you can decide if you wish to take part in future.

### Are there any risks/ benefits to taking part?

The questionnaires will take about 40 minutes extra, in addition to your diabetes clinic appointment. Medical care will be unaffected, but if we do find something that may affect your health, we will discuss this with you.

Some people find talking about an illness distressing. If at any time you feel that the actual or perceived distress is too great, please do not hesitate to tell the researcher. We have clinical psychologists within our team that you might find helpful.

The information we collect may help us to improve the service we deliver to our newly diagnosed patients and help to inform a future screening protocol.

### How will we use information about you?

We will need to use information from you and your medical records for this research project.

V3.0 25<sup>th</sup> October 2019

reduced to a minimum and balanced against possible benefits, and that you have been given sufficient information on which to make an informed decision to take part or not.

### Who do I ask about this?

The doctor or nurse who gave you this information leaflet can discuss the study with you more.

### What if something goes wrong?

If you are unhappy, or have concerns about any aspect of this study, or would like to make a complaint, you should speak to the PALS office on 0151 252 5374, or via email [PALS@alderhey.nhs.uk](mailto:PALS@alderhey.nhs.uk)

Alternatively, you can contact Dr Dan Hawcutt (the researcher in charge of the study) at [d.hawcutt@liv.ac.uk](mailto:d.hawcutt@liv.ac.uk).



V3.0 25<sup>th</sup> October 2019

**Partner Organisations:**

Health Research Authority, England  
 NHS Research Scotland  
 HSC Research & Development, Public Health Agency, Northern Ireland

NIHR Clinical Research Network, England  
 NISCHR Permissions Co-ordinating Unit, Wales

**2. Summary of amendment(s)**

This template **must only** be used to notify NHS/HSC R&D office(s) of amendments, which are **NOT** categorised as Substantial Amendments.  
**If you need to notify a Substantial Amendment to your study then you **MUST** use the appropriate Substantial Amendment form in IRAS.**

No.	Brief description of amendment <i>(please enter each separate amendment in a new row)</i>	Amendment applies to <i>(delete/ list as appropriate)</i>		List relevant supporting document(s), including version numbers <i>(please ensure all referenced supporting documents are submitted with this form)</i>		R&D category of amendment <i>(category A, B, C) For office use only</i>
		Nation	Sites	Document	Version	
1	<p>A discrepancy in the protocol has been identified that we wish to remove. The inclusion criteria state (correctly) that we wish to only recruit children and young people who have been diagnosed in the last three months.</p> <p>Most patients only have one clinic appointment within the first three months, but some are seen more rapidly and have a second (or even third). The outcomes measures for this study relate to psychological trauma following diagnosis, and we are keen to use the appointment nearest 3 months from diagnosis. <u>Therefore</u> we wish to alter the text on page 8 from “first outpatient appointment” to “outpatient appointment within 3 months of diagnosis”. Please see updated protocol that accompanies this application.</p>	England	All sites or list affected sites	Protocol	2.0	
		Northern Ireland	All sites or list affected sites			
		Scotland	All sites or list affected sites			
		Wales	All sites or list affected sites			
2						
3						
4						
5						

[Add further rows as required]

Appendix 14 Submitted ethical amendment number 1.

**Partner Organisations:**

Health Research Authority, England  
 NHS Research Scotland  
 HSC Research & Development, Public Health Agency, Northern Ireland

NIHR Clinical Research Network, England  
 NISCHR Permissions Co-ordinating Unit, Wales

**2. Summary of amendment(s)**

This template **must only** be used to notify NHS/HSC R&D office(s) of amendments, which are **NOT** categorised as Substantial Amendments.  
**If you need to notify a Substantial Amendment to your [study](#) then you MUST use the appropriate Substantial Amendment form in IRAS.**

No.	Brief description of amendment <i>(please enter each separate amendment in a new row)</i>	Amendment applies to <i>(delete/ list as appropriate)</i>		List relevant supporting document(s), including version numbers <i>(please ensure all referenced supporting documents are submitted with this form)</i>		R&D category of amendment <i>(category A, B, C) For office use only</i>
		Nation	Sites	Document	Version	
1	<p>It has been noted that many dyads are willing to complete the questionnaires but are unable to take the extra time at the clinic appointments to complete them due to work/school/childcare commitments. On page 8 in v2.0 of our study protocol, we stated that families unable to complete the questionnaires on the day would be offered the opportunity to complete them over the phone. However, our early impressions are that the extensive nature of the questionnaires would make them unsuitable for completion by phone.</p> <p>We are of course still keen to capture this group of patients and so have amended the option of a phone call to an option of a home visit by a member of the study team at a mutually convenient time.</p> <p>Any before any home visit, the attending research team member will notify another member of the team who and where they are visiting and will once again notify them once the visit is completed.</p> <p>Please see updated protocol that accompanies this application.</p>	<p>England</p> <p>Northern Ireland</p> <p>Scotland</p> <p>Wales</p>	<p>All sites or list affected sites</p> <p>All sites or list affected sites</p> <p>All sites or list affected sites</p> <p>All sites or list affected sites</p>	<p>Protocol</p>	<p>3.0</p>	
2						
3						
4						

Appendix 15 Submitted ethical amendment 2.